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ABSTRACT
Two longitudinal data sets were individually analysed within this thesis. Data set A was a vital signs 
data set and data set B was a data set of dietary response. Initially, an exploratory data analysis approach 
was used to analyse the data at each univariate time point. Missing data were observed and an approach 
was suggested of estimating some of these missing records. It was found that this missing data only 
affected multivariate test results when the proportion of individuals with missing records was large. 
While using the conventional methods of analysis of the data set as a whole, some authors suggest using 
restrictive covariance structures corresponding to the data, following the assumption of normality. An 
issue that can cause problems with matrix calculations for any multivariate method and therefore 
invalidates the multivariate procedures is if the number of repeated measures is greater than the number 
of individual profiles per group. In this situation there is the problem in assuming a normal distribution 
for the data, which is a major assumption for any multivariate analysis, when this assumption does not 
really hold. The main aim of our research was to devise methods of analysing the whole data set when 
the data is of the form mentioned above and when the assumption of normality fails. Various data 
reduction approaches were suggested for analysing the data in a multivariate manner for this situation. 
The following three approaches were suggested to reduce the number of repeated measurements: (a) 
multivariate summary measures, (b) principal components and (c) averaging the data over groups of time 
points.
Both the principal components and summary measures approaches do not retain the time element and so 
firm conclusions can not be made. Our main contribution, within this thesis, is to illustrate that there are 
ways of reducing the data by still retaining the element of time in some manner. This is by using the 
method of averaging the data over groups of time points. The suggested procedures, of averaging data 
over segments of time, allows the use of the usual multivariate tests and modelling procedures without 
having to meet the assumption of normality or having any constraints on the covariance structure. This 
reduction method leads to more robust tests. Most analysis of variance tests become reduced to Chi- 
squared tests following this type of data reduction approach.
Any statistical analyses were conducted with the aid of SAS 6.10 on VAX and later on 6.12 on UNIX. 
Data set A was the primary data set for analysis purposes.
INTRODUCTION
So far in the literature to date there have been a vast number of methods and applications used in the 
analysis of repeated measures data. The topic of ‘Repeated Measures Data Analysis’ is an expanding 
field and one in which there is a range of both new and old literature. There is also a wide variety of 
varying opinion on the way that repeated measures data should be analysed. Hence, it is not possible to 
compile a summary based on just methods used in literature so far. Instead, our research looks into 
some of the most common methods of analysis of repeated measures data (particularly for longitudinal 
research) which have been suggested until now. We look into some of the available literature in the areas 
of ‘repeated measures’ and ‘profile data’ analysis with particular attention focussed on the sorts of data 
obtained from ‘longitudinal trials’. In our research we will be looking at biomedical data. However, 
repeated measures data can also arise in a wide variety of other contexts. Other research areas include 
agricultural, psychological, economic and social research.
Chapter 1 describes clearly what repeated measures are, shows the general structure of a longitudinal 
data set and suggests ways of obtaining such data. Both an ideal situation and a messy situation are 
described in order to give an idea of the shortcomings of such data. Specifically mentioned are the 
problems of missing data, unscheduled visits, non-balanced data, early dropouts and unequal spacing 
between visits. Ideas are suggested on how to control some of these problems but it must be noted that 
some of these suggestions are not always practical. Details are given on study design used to obtain 
repeated measure data. Through our research we have discovered that there are three general methods of 
collecting any type of data. These are through setting up a designed experiment, conducting a survey or 
with an observational study [40]. All three methods mentioned are very different in their approaches. 
However, the information being gathered using any of these methods would be similar whichever is 
used. The choice of using a particular method is up to the individual carrying out the study or the 
investigator. Factors, which may affect the choice of designs, would be things such as cost, efficiency, 
convenience and availability. It is believed that repeated measures data are usually obtained via some 
type of designed or planned experiment. There are four study designs that specifically lead to the 
measurement of repeated measures datal36]. These are split plot designs, crossover studies, source of 
variability studies and longitudinal studies. A study using any combination of these four designs would 
also yield repeated measures data.
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Chapter 2 reviews some common methods used to analyse repeated measures or particularly longitudinal 
data. Distributional assumptions are also described in this chapter.
Chapter 3 describes the two longitudinal data sets A and B. Data set A was a ‘large’ longitudinal 
unbalanced data set which had three variables (Heart Rate, Systolic Blood Pressure and Diastolic Blood 
Pressure) that were measured for 86 patients who were from 2 centres and were each randomly allocated 
to one of four treatment groups (1 to 4). The three vital signs were each measured at multiple time 
points (at baseline and then over 24 hours at hourly intervals) per individual using an ambulatory 
measurement device. Normal ranges for vital signs and other categories were obtained from National 
Blood Pressure Education Program, JNCV Report and also from private communication with an M.D 
[69]. These categories were used to further classify data set A to obtain a categorical data structure. Data 
set B was a ‘small’ longitudinal balanced data set measured for 24 individuals that were randomly 
allocated to one of three diet groups (1 to 3). The readings were taken at baseline and also at 9 other on 
therapy time points. This data set had no categorical information available. These two data sets A and B 
were each analysed in an appropriate manner.
In the past, it has been recommended to use individual univariate tests at each time point to avoid the 
difficulties associated with multivariate analysis methods due to the fact that they can at times become 
quite tedious or complicated. Nowadays, with computers and computer packages such as SAS and S- 
Plus etc., the issue of problems with computation of multivariate methods is not of so much of a problem 
as it was in the past. In the existing literature many authors I19,30] disregard these univariate methods 
over time, claiming that they are not worth while. This is mainly because of dependence between 
successive measurements and difficulty in interpreting the various individual test results. Only the 
univariate approach of ‘Response Features Analysis’ is a method that is still considered to be worthwhile 
by various authors 119,20,43J. It was therefore decided to use only this univariate approach to summarise 
the data over time.
Initially an exploratory data analysis was conducted on the data and these findings are displayed in 
chapter 4. There was the problem of missing data that was encountered during data analysis. Thirteen of 
the 86 records from data set A and 4 of the 24 records from data set B had at least one missing ‘on 
treatment’ record. Section 4.2 briefly introduces the reader to the area of missing data, suggests some 
commonly used methods and describes an ad-hoc missing data generation process that was devised, to 
deal with the missing data issue, for the purpose of this thesis. The method was applied to data set A to
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obtain a data set that contained 84 records of complete ‘on treatment’ information with 2 patients still 
having missing baseline information. It was felt that data generation was reasonable for data set A since 
it was very large and the time points were close together and there were many time points for each 
patient. It was believed that losing 2 patients worth of data out of 86 records at the start of the study 
would not affect the results that drastically for any univariate or multivariate time dependent methods 
applied to this particular data set. When analysing the smaller data set B, only 4 of 24 individuals had at 
least one missing record. Following the data generation method, there were 22 individuals remaining 
with a full set of records but the data set would now become unbalanced. Since the data set was smaller 
than data set A and the time points were further apart, we were uncertain of whether the data generation 
method would be appropriate for data set B.
In order to get a feel for what was going on with the data and how the data generation method would 
affect any results, both the old data sets (with missing records) and the new data sets (with generated 
observations) were looked at carefully and the results compared. For this reason, even though not first 
planned, separate univariate tests were conducted on the individual time points, using both the original 
(with missing records) and the complete (generated) data sets, as a means of comparing methods only. 
This approach was also applied to the summary measures from the original and the complete data sets 
and these results were also compared. These methods were conducted on both data sets A and B. There 
were no vast differences between the results before and after data replacement. Due to the similarity of 
figures produced before and after data replacement, only those using the data set with missing records 
are displayed, to show the behaviour of the data across or over time.
In analysing both data sets A and B, it was decided to analyse the data using multivariate testing and 
mixed modelling techniques, since this is one of the most efficient methods of dealing with repeated 
measures data. Of the various SAS procedures of conducting multivariate-modelling techniques, there 
are two commonly used procedures in dealing with modelling continuous data. These are Proc GLM 
and the more recent method of Proc MIXED. Details on these and other SAS procedures used in the 
analysis of the data for this thesis are described in section 2.6.
After gaining a general feel for the topic, it was found that when most multivariate repeated measures 
data analysis are conducted, various assumptions (including normality, equal correlation between groups 
and equality of variance) need to be made about the distribution of the data for the tests to be valid.
Even though computing resources allow computation methods, which previously were not possible for
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multivariate analysis of variance, there are still occasions that problems can occur with multivariate 
analysis of variance (MANOVA). A specific case is when there are more repeated measurements than 
the number of individuals within a groupl27,35] and hence normality of the data may not be a reasonable 
assumption. This happens to be the case for both data sets A and B.
The main purpose of our research is to see what happens if the usual assumptions of normality is not 
met. Some methods from the literature, that are used to analyse this form of data, when these general 
assumptions are not valid, are looked at and finally some alternative ideas are suggested to those used in 
practice. A suggestion to overcome this problem as mentioned in the literature, was ‘Response Features 
Analysis’ or the ‘Summary Measures’ (S.M.) approachl24,431. The approach was for one single summary 
measure to represent the whole profile for an individual. This summary measure would then be analysed 
using some univariate testing method such as the parametric analysis of variance (ANOVA) or non- 
parametric Kruskal-Wallis test (for comparing more than two treatments). Chapter 5 describes the 
results obtained from analysing the data using this S.M. approach. The disadvantage is that multivariate 
methodology gets lost in using this procedure.
The approach of dealing with multivariate data with the problem of having more measurements than 
individual profiles has not been greatly focused on in the literature. For this thesis, it is suggested that 
the best method of dealing with the data, so a robust multivariate analyses could still be conducted, was 
a segmentation of the data with data reduction of some kind. Chapter 6 gives details on suggested 
approaches for data reduction in order for a valid multivariate approach to be applied. Three methods of 
data reduction were looked into. One of the methods was an extension of the S.M approach using a set of 
6 summary measures (mean, median, min, max, q l and q3) together to describe each individual profile. 
These data were then analysed in a multivariate rather than univariate fashion. The second approach, 
was an extension of the idea mentioned by Jones and R iceI33] who used P.C.A to reduce the number of 
individual profiles. The approach used in this thesis reduced the number of time points instead of the 
number of individual profiles. The final approach, which was suggested for the purpose of this thesis, 
was to use the mean of every two (for data set A only) or three (for both data sets A and B) observations 
instead of each time. This method yields a data set that still preserves a time element whereas the other 
two methods do not maintain this factor. Multivariate tests were conducted to see whether the three 
approaches give similar results or whether one approach is better than another. All multivariate test 
approaches were conducted on the data before and after data replacement to see if similar results were
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obtained whichever method was applied and whether missing data would be an issue for multivariate 
testing. The multivariate method of Mahalanobis distances was used to test for treatment differences for 
all the above mentioned data sets. The results from each of the multivariate tests were then compared 
and these are shown in chapter 7. Multivariate testing was affected by missing data since records were 
not retained during analysis.
All multivariate mixed modelling procedures were conducted on both the original data before imputing 
missing records and also on the reduced data obtained from the complete data set (after data generation) 
to maintain consistency with the multivariate tests that were previously conducted. It was, however, not 
necessary to work with a complete data set since Proc MIXED is not affected by missing data. The 
procedure was applied to only the reduced data, using the reducing procedure of averaging over 
segments of time, since this was the only reduction approach that retained the element of time as with 
the original data. This allowed a comparison of results before and after data reduction. Chapter 8 shows 
the findings of the mixed modelling approach. Each of the variables after being reduced by averaging in 
groups of three measurements (or two measurements if possible) were modelled using a mixed 
modelling approach after adjusting for baseline reading and time. Individuals were modelled as random 
effects in the models. No conclusions could be drawn about any other reduction methods since time was 
lost in the calculations.
From conclusions described in chapter 9, it was found that the data before and after imputing missing 
information gave similar findings. The best data reduction approach appeared to be the summary 
measures (SM) approach for testing the data and also the grouped mean (method 1) for modelling the 
data. Details of further work are also discussed in this chapter.
In conducting the initial exploratory analysis, there were some problems and issues that were 
encountered. Some of the main issues that led to problems during the analysis of this data set were 
missing observations and imbalance between treatment groups. Missing data was not an issue when it 
came to analysing data in a univariate manner. The problem occurred while conducting any multivariate 
methods (P.C.A. and Mahalanobis Distance) on the data set with missing information, especially if there 
were many individuals with missing data. One of the most up to date approaches of modelling such data 
is using Proc MIXED, since these issues do not tend to be of concern using this technique.
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CHAPTER 1: Repeated Measures Data Structures and Collection
1.0 Introduction
The subject of ‘Repeated Measures Data Design and Analysis’ is a very broad research area. Wishart 
(1938)1621 and Greenhouse and Geisser (1959)[27j conducted some of the earliest research in this field. It 
is only in the recent years (since 1980) that the area has become very popular and the field is still 
growing to this date. Among the various books published in the area, Crowder and Hand [14,30], Diggle, 
Liang and Zeger[18] and Vonesh and Chinchilli[61] are among the most popular and up-to-date ones. All 
of these books were published in the late 1980’s to mid 1990’s. These books and references therein will 
give the reader a broader insight into the topic of research and may enlighten as to the variety of both the 
old and new literature available and the various works that have been conducted in this field. There have 
been a variety of works published in the area of ‘Repeated Measures Data’. There is still, however, a 
large potential for other research ideas in the spectrum of research readily available.
Repeated measures data can arise through various experimental designs including spilt-plots, cross-over 
trials and parallel groups design experiments but to name a few [36]. For the purpose of this thesis, only 
repeated measures data from a longitudinal setting will be focused on. The terms ‘Longitudinal Data’ or 
‘Repeated Measures Data’ will be used interchangeably to refer to the data used during analysis.
The present chapter introduces the reader to repeated measures data structures and collection. The 
structure of specifically a longitudinal data set in both an ideal and a messy situation are described in 
section 1.1. Some of the shortcomings of repeated measures data, as described in section 1.2, include 
the problems of missing data, unscheduled visits, non-balanced data, early dropouts and unequal spacing 
between visits. Another issue, which is to be the main area of focus for this thesis, is when the repeated 
measures are large compared to the number of individuals on whom they are measured[27,35]. Ideas are 
suggested on how to control some of these problems but it must be noted that some of these suggestions 
may not sometimes be applicable. Section 1.3 gives details and examples of study designs used to 
obtain repeated measure data. Section 1.4 explains the main reasons for collecting this type of data and 
mentions some questions that may be asked during the data analysis stage. An overview of this chapter 
is given in section 1.5.
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1.1 Repeated Measures Data Structures
This chapter is intended to give the reader an introduction to repeated measures data structures.
Below is a description of what repeated measures data actually are and how these types of data are 
obtained. Repeated measures data are multiple recordings of an observational unit or the same dependent 
variable, (e.g. blood pressure, heart rates or some other measurement), which are taken for each of a 
number of individual experimental or primary sampling units (e.g. patients, subjects or some other 
individuals). The experimental units are randomly selected to represent various strata or are randomly 
assigned to levels of a grouping factor (e.g. therapy, treatment or some other group). In other words, an 
individual can either be allocated to one of several groups or can fall into one of a number of naturally 
occurring groups. The responses that are being measured under the various conditions are the 
observational units and these can be taken (or measured) at various points in space or time. In our 
research, we will be looking at biomedical data. However, repeated measures data can also arise in a 
wide variety of other contexts or research areas such as agricultural, psychological, economic and social 
research.
Initially an important thing to remember is that ‘Repeated Measures’ are the type of data, not the design 
of experiment, which is a mistake that is often made. The terminology that is often used to explain the 
set of multivariate repeated measures data for an individual unit is an individuals profile. This can be 
seen more clearly in the diagram below which shows data collected in a longitudinal manner in an ideal 
situation.
Example 1: An Ideal Situation:
R e p e a t e d  R e a d in g s  o f  t h e  S a m e  R e s p o n s e  V a r ia b l e  
Group 1
Unit 1 X X X X X X X X X X
Unit 2 X X  X X X  X X X X  X
Group 2
Unit 3 X X X X X X X X X X
Unit 4 X X X X X X X X X Xi 1---------1---------1-------- 1---------r -------1---------1---------j---------1
tl h  t3 U ts t$ t7 tg t9 tjo
Times of Readings (Days)
Here, is a simple example where there are four individuals each randomly allocated to one o f two groups 
1 and 2 (i=l, 2). Hence, each group includes two individuals (j=l, 2) and ten readings are measured on
each of these individuals at the same time points (k=l to 10). The ten time points are equally spaced 
apart. There are no missine data in this example and the data are balanced between groups. Hence this 
is repeated measures data from a ‘balanced complete longitudinal’ design. The general notation for any 
individual observation using the information from above would be Yjjk. So, for example, the individual 
observation unit 3 at time 3 from group 2 would be shown by Y213.
Note: As can be seen in the example above, in an ideal world it would be preferable for each sampling 
unit to have measurements at the same times and also for there to be equal spacing between each pair of 
response measurements or readings. Another thing that is preferable is the complete collection of data. 
However it is not always possible in most real situations for us to meet all the criteria mentioned above 
while collecting data and there usually tends to be a shortcoming in at least one of the conditions 
mentioned above. The diagram below shows some of these shortcomings in a clearer fashion for 
longitudinal data collected in a messy situation.
Example 2: A Messy Situation
Group 1
Unit 1 X X X X X X X  X X X
Unit 2 X X X X X X X X X
Group 2
Unit 3 X X X X X X X
Unit 4 X X X X X X X X X X



















Times of Readings (Days)
1.2 Problems With Data Structures
Data structure problems can lead to problems during analysis. Some of these problems are mentioned 
below and are illustrated in Example 2 above:
a) Unequally spaced time points between measurements.
In the situation above, the design is such that the data measurement is not at equally spaced time points, 
The main reason for this could be due to the fact that measurements can only be taken at certain times 
because of external or environmental factors. An example would be if it were known, before the study 
began, that there were specific times that the outcomes of interest would occur and these would be the 
time points where special attention would be given. The problem of unequally spaced time points can
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also occur in a designed experiment with equally spaced time points when there are unscheduled visits. 
The main difference is that for the designed experiment the additional set of information could always be 
dropped for analysis purposes. However, if the study was set up to measure data at unscheduled visits 
this could not be done. It must be noted, however, that it is not always practical to set up an 
experimental design with equal spaced time points, especially if the variable being measured is only 
available at certain times. In this case, an appropriate method of analysing the data would be using a 
time series approach.
b) Unscheduled visits.
There is one extra reading for unit 4 that is measured at an unscheduled visit between t5 and t$. This 
would mainly be due to the availability of the sampling unit. For example, a patient knows that he or 
she can not make their next appointment and therefore turns up early to tell the doctor of the situation. 
The doctor still takes measurements in the hope that the data can be used. Even though it is not 
planned, it is sometimes believed that partial data is better than no data at all. If the study were a 
designed experiment with equal spacing between measurements, there would be justification in 
removing any additional data especially when they were unscheduled measurements. For a design that 
has unequal spacing between measurements the process of removing additional data would not be 
justifiable. This data should then be analysed as a data series again using time series techniques.
c) Incomplete / Missing data at scheduled visits.
Sampling units 2, 3 and 4 all have missing readings that were supposed to be measured at scheduled 
visits. The main reasons for this could be that the equipment being used to measure the data fails or that 
the sampling unit might not be able to make the scheduled appointment. Both a designed experiment or 
a study that is not designed could yield missing data and it is believed that this is something that can not 
readily be controlled whatever the design is. Having one missing record for a patient would force the 
whole observation to be dropped when most multivariate methods are applied to the data. This means 
that a lot of useful data is wasted. The solution in this case is to generate these missing data in some 
way, if possible.
d) Unbalanced data between groups.
It can be seen that group 2 has one more patient than group 1. This is an issue that causes problems in 
some analyses. The main way that this problem can be solved is by conducting a designed experiment. 
However, it must be noted that this problem can not be eliminated in all designed experiments since
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there are times that patients drop out of a study directly after randomisation and hence there are different 
numbers of observations in each treatment group. It is believed that a designed experiment may have 
greater control over this issue than any other type of study. Depending on the size of the study and the 
numbers of patients within different groups, it is suggested that the data set could be made to balance by 
randomly dropping the extra data. Note that, this suggestion is only deemed to be appropriate if the data 
set is large enough as the loss of a small number of observations is not expected to affect the results 
greatly. For example, if there were either 21 or 22 individuals in each of 4 treatment groups and if the 
data set was forcibly balanced, for both treatment groups and centre, then one would end up with 20 
individuals in each treatment group.
e) Early Termination
As for unit 5, a patient can drop out of the study before the scheduled time of completion. This means 
that the sampling unit does not have a full set of records. This is an issue that can not be controlled 
based on the design of the study. These observations would generally be dropped from any usual 
multivariate analysis on the data.
Another problem, which is to be a part of the main focus for this research, is as follows:
f) Number of Individuals are less than the Number of R.M.
When the number of repeated measures is greater than the number of individuals then there are problems 
in calculating the sums of squares (SS) and degrees of freedom (df) while conducting multivariate 
ANOVA [27]. When p is large compared to the number of residual df, a singular variance-covariance 
matrix is estimated and this in turn means that the MANOVA test statistic can not be defined [35J.
A practical argument for explicit modelling of the covariance structure, as was stated by Diggle, Liang 
and Zeger[18] concerns the number (p) of repeated measurements per experimental unit. It was observed 
that when p is large, the objection to estimating p (p+l)/2 parameters in the covariance structure gains 
force since this expression is of the order of p2. In extreme cases, p can also exceed the available 
replications.
A different problem also arises if the number of individuals is not considerably greater than the number 
of repeated measures. In this case, in most situations, the assumption of normality or having tests as in 
the case of normal distributions would not be reasonably valid. Hence a suggestion would be to reduce 
the number of repeated measurements in some intuitive manner in order to have the validity of the model 
with desired properties [see 2.1.1 and 2.1.2]. This provides more robust statistical tests. At this stage, a
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reasonable question may be: ‘Would all of the many repeated measures be of relevance or could a fewer 
number of measurements give the same results as all observations?’
1.3 Obtaining Repeated Measures Data 
1.3.1: Data Collection
Generally, most data sets are obtained by one of the following three methodsl40]. All three types of data 
collection mentioned are very different but they all use very similar statistical notation in that they all 
have ‘factor’, ‘level’ and ‘effect’:
A) Designed Experiments
As the name suggests, a designed experiment is planned or designed before the study takes place. 
Example:
Experimental units (patients) are randomly assigned to one o f four groups (drugs 1-4). After 
the experimental units are assigned to their groups, responses (heart rates) are measured.
For this designed experiment, therapy would be a ‘factor’, and each drug would be a ‘level’ within the 
factor. Each level would have an ‘effect’ on heart rate. So applying any one of the drugs has an effect on 
the heart rate of the patient.
B) Sample Surveys
A survey design is a plan that is used to collect data on the sampling units but treatments are not applied 
to these units. The sampling units are usually people and they already have certain pre-existing 
attributes e.g. age or qualifications. The data to be measured could be a variable such as salary and this 
can be determined for each individual sampling unit.
Example:
A survey could be taken on a set of individuals to see how individual salaries behave based on 
qualifications.
For this survey, qualifications would be the ‘factor’, and each ‘level’ (A, B) of the factor would have an 
‘effect’ on salary. Note, a particular qualification would not cause the level of the salary but people with 
qualification A may tend to have a larger or lower salary than people with qualification B.
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C) Observational Studies
The sampling units here already exist before data is collected and they are not from a planned study. 
Example:
Patients visiting a doctor’s office at the time of visit have their weights measured and they are 
categorised into groups based on this information. The blood is then tested for levels of 
cholesterol.
For this observational study, weight would be the ‘factor’ and each weight measurement would be a 
‘level’ of the factor. Differences in the cholesterol level between the diagnostic groups would be 
‘effects’ of the factor levels.
1.3.1.1 Choice of Data Collection Method: In General.
A question now is ‘which type of design should be used in general?’ It is usual for the experimenter to 
go with the most convenient method of data collection based on certain external factors that can not be 
controlled. The person conducting the study should decide based on the following factors before they 
begin data collection:
1. The aim of the project.
A survey could be looking into specifically a small population, such as of an ethnic origin, since it is 
of interest. This, in turn, could lead to a smaller sample size than one would actually prefer and so 
could lead to problems with data analysis. If the study is observational in nature, then the 
investigator has no choice than to go with what is available. A designed experiment is usually the 
best way of controlling the data obtained.
2. The cost of the project.
If fewer financial resources are available than are required, this could again influence the amount of 
data collected. A designed experiment is often more expensive to run than an observational study or 
a survey.
The points mentioned here may be obvious but can often get overlooked. The aim would be to set up a 
design, which captures exactly what the experimenter wants, before starting to collect the data. If the 
data can be obtained through a designed experiment, then this is recommended since it is believed that 
this would reduce some of the problems associated with data analysis after the data has been gathered.
13
1.3.1.2 Choice of Data Collection Method: For Repeated Measures Data.
Specifically with regards to longitudinal data, two important issues that lead to problems with data 
analysis are of missing data and early termination. Neither problem can be controlled by study design. 
Conducting a designed experiment or survey can usually control the problems of unequal spacing 
between time points and unscheduled visits. This is not true when the variable being measured is 
restricted to certain times of measurement, as in an observational study or a study of convenience, where 
there would be no solution to this problem. Unbalanced data can be controlled if a balanced study 
design is conducted with no dropouts.
Hence, it is suggested that the best way of obtaining repeated measures data, that in the end will be 
easier to analyse, is to obtain the data using a designed experiment or survey. A number of factors need 
to be taken into account when collecting data such as the aim, cost and efficiency. A designed 
experiment or survey does not control factors such as malfunction of a machine used to measure the 
variable of interest, early termination from the study or other environmental factors. It should be noted 
that once it is decided to obtain the repeated measurements for a particular variable then the data design 
usually ends up falling into the category of a ‘designed experiment’. This is the case whichever initial 
method was used to classify the observational units into experimental groups. There is usually some sort 
of planning in the process of collecting repeated measures data. It should be noted that the data sets that 
are to be used for this thesis are from designed experiments.
There are various standard designs for experiments that fall into the category of a “designed experiment” 
and a detailed explanation of these can be found in various texts. Due to time constraints, further details 
of designed experiments will not be given in this thesis. The reader can refer to any books with 
‘Experimental Designs’ or ‘Designed Experiments’ in the title and any references therein [12,44,641. 
Further details are given below on the designs used to obtain repeated measures data in particular.
1.3.2: Designs Used to Obtain Repeated Measures Data
Many different designs can be used to obtain repeated measures data. Experimentation and collection of 
repeated measures data are very important since the collection of such data particularly allow 
comparisons of treatment effects over time. There are a wide variety of study designs that can lead to 
the collection of repeated measures information. Of these, the four most important study designs are 
longitudinal, source of variability, crossover, and split-plot studies. A combination of any two or more 
of these methods can also give us repeated measures data. For all study designs mentioned, every
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individual unit is observed under two or more conditions. Koch 1361 gives a good overview together with 
references for all four designs with some examples of each and also some statistical methods and 
applications particularly in reference to split-plot designs. The advantages and disadvantages of each 
design and similarities and differences between them are also mentioned.
We will begin by giving a brief example of each of the four designs with a brief overview of similarities 
between the design structures and any important points of discussion. The main body of the report will, 
however, focus on repeated measures from a longitudinal study, and the analysis of such data.
A) Split-Plot Experiments:
Example:
Sixty-four laboratory rats are randomly divided into four groups o f 16. Each group o f 16 is 
assigned to a block o f 4 cages (with 4 rats in each cage). Four dietary calcium sources are 
randomly assigned to the four cages within each block. Four rats are assigned to each cage. 
Four implants (A, B, C ,D) are randomly assigned. [Littell [701].
Split-plot designs have differences compared with other designs in that they have more than just one 
stage of randomisation. Subjects are initially randomly assigned to treatment groups or selected from 
strata. Conditions are then randomly allocated within these groups or strata.
Treatment groups can be based on a single factor or on a cross-classification of two or more factors. 
They can be assigned to whole plots based on a completely randomised, a randomised complete blocks 
or a type of incomplete blocks design. Conditions can similarly be assigned to split-plots.
These designs are commonly used in agricultural experimentation, where the subjects are whole plots or 
fields within which split-plots are the observational units.
B) Cross-Over (or Change-Over) Designs:
Example:
Each subject is randomly assigned to either sequence AB or sequence BA. Responses to each 
successive treatment are measured for an allocated period. The conditions are the time 
periods and treatment and also the proceeding treatment.
The subjects within a crossover design are randomly assigned to treatment groups or are selected from 
strata. They are randomly assigned with alternate treatment sequences. One could seek here estimation 
of time, location or treatment effects etc.
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For a cross over study, the previous treatment can influence the response on a particular treatment and so 
a carry over or residual effect may occur. If it is known that the extent of carry over is more than 
negligible then some sort of adjustment is needed. It has been suggested that sequences should be 
devised to allow estimation of location, treatment and carry-over effects. This at times can be hard to 
implement. An alternative design where each subject gets only one treatment eliminates this problem.
C) Source of Variability Studies
These studies identify the amount of variability between responses attributed to each component of the 
sampling process or measurement process.
Example:
The assessment o f variability associated with clusters o f households and interviewers. This is 
to be done in a survey o f socio-economic variables. A random sample o f288 clusters of 8 
households is randomly divided into 3 sets (A, B and C) o f 96 clusters. 24 interviewers are 
randomly assigned to each set o f clusters. Each assignment in the protocol is made at 
random. In set A each interviewer is assigned 4 clusters and obtains responses from all 8 
households within each cluster. Within group B, each o f 12 pairs o f 2 interviewers is assigned 
to 8 clusters. Each pair of interviewers is then assigned 4 households from each cluster. For 
group C, 6 blocks of 4 interviewers are formed. Each block is assigned 16 clusters. Each 
interviewer within the group o f 4 is then assigned 2 households from each o f the 16 
clusters [361.
Studies of source of variability can deal with fixed and random components of measurements. Their 
structure varies and can be anything from very straightforward to very complex.
D) Longitudinal Studies:
For longitudinal studies, the observational units for subjects are associated, rather than assigned 
randomly, with the conditions. The association is usually through space or time. Longitudinal study 
designs are specifically parallel groups of subjects, which can be either randomly assigned to treatments 
or randomly selected from strata or both.
Example:
A much-cited example in the literature is o f the experiment on the control o f intestinal 
parasites in cattle. Cattle ingest roundworm larvae during the grazing season (from spring to 
autumn). The larvae have developed from eggs previously deposited on the pasture in the
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faeces o f infected cattle. Once an animal is infected it is deprived o f nutrients and its 
immunity to other diseases is lowered. This then can greatly affect the cattle’s growth. In 
order to monitor the effect of a treatment on the disease, the observations need to be measured 
through out the grazing season. In an experiment to compare two methods A and B for 
controlling the disease, 60 animals were randomly assigned to two treatment groups each of 
size 30. The animals were put out to pasture at the beginning o f the grazing season and the 
members o f each group received one o f the two treatments. The weight o f each animal was 
recorded 11 times to the nearest kg. The first 10 observations were made at biweekly intervals 
and the last measurement was made at a weekly interval. [Kenward{35]].
The cattle are the subjects and the successive time intervals are the observational conditions. The 
experimental unit being measured is weight. Many designs can be classed as being longitudinal in 
nature and, as already mentioned above, this thesis focuses mainly on this type of design.
1.3.2.1 Discussion of Designs Used to Obtain Repeated Measurements
For longitudinal, split-plot and crossover designs, the subjects are randomly assigned to or are selected 
from strata. Both longitudinal and crossover trials have similar concepts since individual subject 
responses are measured at many points. Split-plot studies are slightly different since the researcher has a 
control over the variability of influencing factors between conditions by controlling the whole plot units. 
Designs can be conducted to control carry-over effects, but designing a study can be complicated and 
expensive. Since both split-plot and crossover designs have conditions assigned to periods, they both 
have similar pros and cons.
Advantages here are:
1) Designs require fewer subjects so costs can be reduced. They are also simple to conduct.
2) Comparisons between within subject treatment conditions and interaction effects can be accurately 
estimated.
Disadvantages are:
1) If carry over effect is not accounted for the results can be biased.
2) Greater cost or effort is required for the administration of split plots experiments to ensure each
condition only affects the split-plot to which it was assigned.
An important part in the analysis of longitudinal studies concerns the amount of data being gathered (e.g. 
the time intervals). Increasing the amount of data can increase the information. However, the cost and
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effort of gathering more information also increases if not collected and processed automatically. The 
selected design usually leads to the required information based on resources. Take caution, however, 
that obtaining too many time points of data can later lead to problems at the time of data analysisl27,35].
1.4 Aims of Any Repeated Measures Data Collection and Analysis
The general aim of collecting any repeated measures data is to get an idea of how each variable being 
measured is behaving ‘as a whole’ over space (or time). The method of conducting repeated measures 
analysis varies among researchers and it is generally proposed that this could be done in either a 
univariate or multivariate fashion depending on the assumptions being made just prior to the time of 
analysis. Generally, during any analysis there are always some initial questions that need to be asked 
regarding the data set being looked into. Examples of some relevant questions would be:
1. Do some patients have specifically more abnormal readings than others?
2. Are there any differences between the distributions of treatment groups over time? If so, when 
do these differences occur?
3. Are there any vast changes from baseline (pre-treatment records)?
The purpose of the analysis would be to answer the most appropriate questions asked in the most 
feasible manner.
1.5 Overview
Repeated measures data are the type of data not the design of study. Various study designs can be used 
to obtain repeated measures data including longitudinal, crossover and split-plot experiments1361. 
Longitudinal data analysis is only a small sub-section of the larger general topic of repeated measures 
data analysis. However, for the purpose of this thesis, any further mention of repeated measures data 
analysis will be in reference to longitudinal data sets only.
The next chapter will focus on some of the statistical methods that are commonly used to analyse 
longitudinal data sets. In the past, computer packages were unavailable to analyse large longitudinal data 
sets and hence simpler methods were selected to analyse such data. Nowadays, with the advance of 
computers and the availability of statistical software such as SAS, computational analysis is not quite so 
difficult and so more complicated mixed modelling methods are used. Some of the old and new 
approaches of analysis are touched upon if considered appropriate, even though they are not used to 
analyse the observed data sets for this thesis. Some general requirements/assumptions for analysis 
purposes are also addressed.
CHAPTER 2: Data Analysis and Assumptions
2.0 Introduction
The aim of the present chapter is to give some background into some of the analysis methods that are 
commonly used to analyse a set of continuous multivariate observations in time or a longitudinal data 
set. We will review as much of the available literature as possible and summarise this information in an 
appropriate manner.
Categorical data methods for repeated measures data is a topic in its own right and there are various 
publications in this area. This is not of concern for the primary analysis, hence, we will not be going 
into the details of any of the categorical data approaches. We will only touch on some categorical data 
methods if considered appropriate. See Stokes et a l 1571 for a list of references related to categorical data 
analysis methods only.
If a longitudinal data set is created via multiple measurements of a particular variable in time, the data 
set could have a layout containing:
(1) A baseline measurement (pre-study) of the variable and various measurements thereafter.
(2) All observations could occur on-study.
(3) Other variables (covariates) could also be measured and there could be either varying as within-unit 
factors or between-unit factors.
(4) There could be either one study group or many study groups being tested.
The concept, which will be used here in considering a longitudinal design study, is that each individual 
is assigned to only one study group. There are various methods of analysing such data. The data can 
initially be analysed in a univariate format by testing the behaviour at each time point individually or in 
a multivariate format by testing the behaviour at all time points together. The initial thing is to decide 
the purpose of the analysis:
(1) To test for general group differences.
(2) To test for profile differences.
(3) To model the data using either a linear/non-linear approach.
The aim of the analysis of our data would be to look for study group differences based on external 
factors. Some useful SAS commands will be given in this section.
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2.1 Assumptions about the Distribution of the Data.
2.1.1: General Assumptions
All statistical methods of analysis have some underlying theory regarding the F distribution. Some 
underlying assumptions need to be met in order for the F distribution and, hence, the F-test to be valid. 
The most important of these are the assumptions of:
a) Normality.
b) Homogeneity (or equality of variance between groups).
c) Mutual independence or more generally equal correlation’s between groups.
Note that in practice it is not always possible for all three of these conditions to be met precisely. Even 
when these conditions, or when assumptions of asymptotic tests relative to these models, are met 
approximately, one could still draw reasonable conclusions via F-tests. Parametric approaches require 
an assumption of the underlying distribution of the data such as normality. Estimation and testing are 
based on the assumptions that are made about the distribution of the data. Non-parametric methods do 
not make such distributional assumptions about the data. The main advantages of non-parametric 
methods are that inferences tend to be general and the methods can be used when the distribution is 
unknown or the parametric assumptions are invalid. The main disadvantages on the other hand, are that 
the approaches are less powerful than parametric ones when the assumptions are not met. However, 
most of the time, the loss in power is not large enough to make much of a difference. The most 
powerful non-parametric approach is the Manzel-Haenzel approach, which can generally be used in 
place of most other non-parametric methods[58].
2.1.2: Normality
The most stringent condition that is required for any parametric approaches is that of normality.
If it is known that the data are not normal in nature (if the data is skewed), then a log or some other 
transform of the data is usually recommended before carrying out any further parametric analyses[7,8l  
Paik[47] suggested using a parametric variance estimation approach for non-normal repeated measures 
data. Univariate normality is easy to test for using Proc Univariate in SAS with the NORMAL option. 
Here, the following hypothesis is usually tested:
Ho: The data is normal.
Multivariate normality is not as straightforward to test for. Usual methods to test for multivariate 
normality would be to conduct a regression analysis and to analyse the residuals and hence make
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assumptions about the distribution of the data based on the distribution of the residuals. Some 
researchers assume multivariate normality without testing and specify conditions for the variance- 
covariance matrix. If after transformations, normality is still not achieved, then one could explore the 
possibility of using a non-parametric approach to analyse the data. In the case where j (the number of 
individuals) is much larger than p (the number of repeated measures) then the approach of assuming 
asymptotic normality can be taken, as the asymptotic tests in that case behave essentially as in the case 
of normal populations. Initially we will provide an example of a bivariate non-normal distribution with 
normal marginals and zero correlation. This is done using a general construction.
Initially, we consider two independent random variables X and Y having the probability density 
functions f  (x), x e (-00,00) and g (y), y 6 (-00,00) respectively. Here the marginal densities are assumed to 
satisfy the following condition:
f(x),g(y) >'&a > 0, where a  is a positive constant and x and y are points in the interval (a,b). [1]
Due to there being independence, the bivariate joint density of X,Y is the product of the marginals. 
Hence, it is given by f(x)g(y), x 8 (-00,00) , y 8 (-00,00).
A second situation is to consider two uncorrelated dependent random variables X* and Y* with a 
bivariate joint density function h(x,y) defined clearly below:






Line parallel to y-axis
line parallel to x-axis
x+y=c, with c varying
Figure B above, shows the construction described in Figure A after adding three lines.
We define here:
f (x)g(y) + a  if (x, y) is the area shown by dots 
h(x, y) = - f  (x)g(y) - a  if (x, y) is the area shown by lines 
f (x)g(y) if (x, y) is elsewhere.
It can be seen from the symmetry in the picture in Figure B above, that the deviations ( a ) from the
density values f(x)g(y) corresponding to (X,Y) on the lines shown cancel out. Hence, the marginal 
densities of X*,Y* and X*+Y* are the same as those of X, Y and X +Y respectively.
If the bivariate vector (X*,Y*) is taken to be a random vector with density h(x,y) 
and the bivariate vector (X,Y) is taken to be a random vector with density f(x)g(y) 
as described above, then it follows from all the information above that:
a) X* is distributed as X,
b) Y* is distributed as Y
c) X*+Y* is distributed as X+Y.
Since X*, Y* and X*+Y* have the same distribution as X, Y and X+Y respectively, the corresponding 
moments are also the same. We will now consider only the second moments.
If X and Y have the distribution such that E(X2) < °° and E(Y2) < ®°, then
E((X* + Y*))2 = E(X*2)+2E(X*Y*)+E(Y*2) [2a]
E((X+Y)2) = E(X2) + 2E(XY) + E(Y2) [2b]
and E(X*r) = E(Xr), [3a]
E(Y*r) = E(Yr), i=l,2. [3b]
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From [2a], [2b], [3a] and [3b], it follows that 
E(XY) = E(X*Y*)
Since
cov(X,Y) = E(XY) -  E(X)E(Y)
= E(X*Y*) -  E(X*) E(Y*) = cov(X*,Y*) [4]
and X and Y are independent implying Cov(X,Y)=0, the covariance between X* and Y* equals zero and 
X* and Y* are therefore uncorrelated. ,
However, from the construction, it follows that the joint density of X* and Y* does not correspond to 
that of independent R.V.’s , implying that they are dependent R.V’s. This is because the marginal 
densities of X* and Y* are f(x) and g(y) respectively and there are some areas in Figure A where h(x,y)
*  f(x)g(y).
By taking f(x) and g(y) to be normal, we can produce a bivariate distribution for which the random 
variables are uncorrelated but dependent. This also implies that even though the marginals here are 
normal, the bivariate distribution is not normal. For bivariate normal, uncorrelatedness implies 
independence. Since we have in our case R.V is that are uncorrelated but dependent, it follows that their 
joint distribution is not bivariate normal.
If we take (Xi,...Xp) with (X!,X2) distributed as (X*,Y*) and (X2,...XP) as normal and independent of 
(Xi,X2), then we have a p-dimensional non normal random vector with normal marginals having zero 
correlations.
If we are not looking for the new random variables that are not uncorrelated, we get a slightly simpler 
construction of a bivariate distribution that is not normal, but has normal marginals; for an alternative 
construction of this, see below:
Consider the situation of independent random variables X and Y having probability density functions: 
f(x), x 8 (-00,00) and g(y), y 8 (-00,00) respectively.
Here the marginal densities are assumed to satisfy the conditions as before in [1].
Next consider two dependent random variables X* and Y* with the bivariate joint density function 
h(x,y). This is defined after Figure C and D:
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line parallel tc/the y-axis
line parallel to the x-axis
Define now h(x,y) such that:
f  (x)g(y) + a  if  (x, y) is in the area shown by dots 
h(x, y) = • f  (x)g(y) - a  if  (x, y) is in the area shown by lines 
f(x )g (y ) elsewhere.
We can now see that the marginal distributions of X* and Y* have densities f(x) and g(y) respectively. 
If we take f(x) and g(y) to be normal, then it follows that h is the density of a bivariate non-normal 
distribution with normal marginals. Also, now (X!,X2,...X P) can be taken as a vector as defined before, 
but, with (X*,Y*) as in the present construction. Incidentally, the vector obtained from the previous 
construction has Xj’s to be uncorrelated and marginally normal, and in the present construction we have 
Xi’s to be just normal.
Note: following the insertion of the lines in Figure D the deviations from the densities relative to X and 




From the above construction, it is clear that even when we get the respective samples at the various time 
points to be from a normal distribution, it does not follow collectively that the normal distribution 
assumption usually taken for “Repeated Measures Data Analysis” is met. A way of testing for 
multivariate normality would be the recommendation of some approximate techniques.
There is a characterisation of the multivariate normal distribution that a vector (Xi,...Xp) is multivariate 
normal if and only if every linear combination of X^.-.Xp are univariate normal [See Theorem 2.6.2 in 
Anderson (1958)l3aI]. Since any multivariate normal distribution is determined by the corresponding
moments (i.e. by E(X!k l  Xp kp) with k l  kp as non negative integers) it is possible to have a
slightly improved version of the result just stated. The improved version is that a vector (Xi,...Xp) is
multivariate normal if and only if m f1Xi+ + m^Xp is univariate normal for each positive integer
m,, i=l,2....P.
This is so especially because the moments are determined by E{exp(Zmi’Xj)}.
Following this, one could suggest an appropriate technique to test normality as follows:
Choose a sufficiently large number N and test univariate normality of m ^ X ^  m^Xp for integers
m j,.. ..mp =1,2, N. If we have positive conclusions for most of the linear combinations, then it is
reasonable to expect (X!,...XP) to be approximately normal.
To test for multivariate normality, one could also devise alternative techniques.
If X i,.. .,Xn is a reasonably large sample from a population, then, provided n > 3 and E|Xr| < °o, we have 
that E (XXj/n|(X ! -XXj/n))=constant. [5]
If and only if X /s  are normal [see Kagan, Linnik and Rao1341 for the result by Ramachandran and Rao]. 
The result is also valid in the case when Xr's are vectors, and hence one could use this property to test 
for MVN. The test could be devised as follows:
Divide the sample on the p-component vector into smaller samples of equal sizes. Denote XX/n and 
Xi -  SX /n corresponding to these smaller samples (of sizes > 3) by Uh and U2i respectively. Hence, the 
MV normality of Xi, ...X n can be seen to be equivalent to:
E(Ui j|U2i)=constant.
Thus, the problem reduces to that of testing a linear regression. To solve the problem, one could take the 
number of sub samples to be as large as possible to have the test to be approximately valid.
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Incidentally, to go from the Ramchandran and Rao (R-R) characterization of the normal distribution in 
the univariate case to that for the M.V. case, we can use the characterization given in Theorem 2.6.2 of 
AndersonI3a] concerning M.V. normality referred to earlier.
Test in this case only the equations that the conditional expectations of the linear combinations of the 
components of Uu with coefficients mf1, given linear combinations of the components of U2i with 
coefficients nf1 (where m; and nj are positive integers).
An adhoc approach for analysing the Repeated Measures data is to assume that different units are 
independent and that within each treatment group have an identical distribution. With appropriate 
changes to the data sets, one could apply the asymptotic theory relative to parametric tests such as 
Hotelling’s T2, Mahalanobis D2 or likelihood ratio tests to test hypothesis relative to mean vectors or 
appropriate non-parametric tests for the hypothesies that various treatment groups have the same 
distribution. The tests applied are obviously more robust, when n is large.
Suppose the sample sizes nj and n2 are large and the Hotelling T2 is given by:
T2 = _2!£2_(xffl -x<2>)'S-'(x® -x< 2>) i>! + n 2
(with obvious notational alterations) as mentioned on page 109 in AndersonI3a]. Then even when the 
two populations are not normal, under the hypothesis that the mean vectors of the two populations are 
equal, we have the distribution of T2 to be approximately the same as that of Y ' I Y  where Y ~ N (0 ,
2 ) .  Here the Central Limit Theorem (CL) is being assumed together with the assumption of the 
populations having the same covariance matrix.
This follows because asymptotically, S = 2, and under H0,
JH52-(xW _*»))
n i + n 2
is distributed as Y, where Y is as defined here.
From a well known result on quadratic forms it follows that the distribution of Y ' 2 Y is %2 with p df. 
(Theorem 3.3.3 on p54 of AndersonI3a]). Thus even when the two populations are not assumed to be 
normal, the null distribution of T2 becomes a approximately %p2. Incidentally, Hotelling’s T2 is a 
constant multiple of Mahalanobi’s D2, which is given by:
D2 = (x(1) -  x^2))'S-1 (x(1) - x (2)).
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For a normal model under H0,
ni + n2 -  p - l ^
p(n1+ n 2- 2 ) T ~ F(p,n, + n 2 - p - 1 ) .
Indeed in view of the C.L Theorem, it follows that the tests used are asymptotically the same as those 
relative to the normal distributions as long as p (the number of components of the vector) is small 
compared to ni and n2. or more generally ni + n2. (Note that T2, that is a constant multiple of D2, has its 
asymptotic null distributions to be xp2). This remark also applies to the likelihood ratio test or non- 
parametric tests for testing that the mean vector relative to the treatment groups are the same as long as p 
and the number of groups is not large compared to sample sizes for the groups involved.
In particular, in the case of the vector of 6 components of summary statistics, we can reasonably assume 
p (i.e. 6) is small compared to the nj,n2=24 and use T2 or D2 as an approximate test statistic, giving 
approximately a Chi-squared test.
Incidentally, if the whole vector is normal, then the components of the vector are normal, though the 
converse of this result as shown by our constructions is not valid.
In our analysis, if we find that the normality assumption is not met at some time points then it follows 
that the multivariate normality assumption for the data may not be reasonable. One could then look for 
ways to make asymptotic (more robust) tests applicable to our data.
The idea is then to reduce the number of repeated measures to a much smaller number so as to satisfy the 
condition that the number of individuals is considerably larger than the number of repeated measures, 
making asymptotic tests applicable. Under this situation there is no loss of generality in assuming that 
the data sets for units are from individual normal distributions.
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2.2 Methods of Analysis 
2.2.1: Plotting the Data.
An initial approach in conducting any type of analysis is to carry out some kind of exploratory data 
analysis (E.D.A.). We can begin by graphically displaying the data at each time point as follows:
1. Individual profile plots can be displayed together on one plot.
This type of plot can often become very clustered especially if there are too many individuals in the 
study. The following two graphs eliminate this issue.
2. Box plots show distribution of the data at each time point.
3. The group means at each time point with standard errors can be displayed together on one plot.
4. The summary statistics such as mean, median, minimum and maximum at each time point can also 
be displayed over time.
All plots above display the individual repeated measurements of data separately.
Data can also be summarised for all time points together by following the approach of the ‘Response 
Features Analysis’ mentioned in 2.2.2. Here each individual will have a set of single variables that each 
represents all the data as a whole (e.g. mean, median, minimum etc.). This information can then be 
summarised graphically as follows.
5. The data can be plotted as a histogram.
Each observation could be categorised as abnormal/normal and these results could be totalled over the 
whole study for each patient.
6. A scatter plot of the number of abnormal findings for each patient could be displayed.
The relationship between time points is often of concern. This can be displayed graphically as follows:
7. Correlograms are a common way to visually display correlations between the various repeated 
measurements for the data.
2.2.2: Response Features Analysis.
A recent approach called ‘Response Features Analysis’ or ‘Summary Measures (S.M.) Approach’ is to 
summarise or characterise the profile data for an individual into one or may be more summary 
measurements. This approach is pretty easy compared to some of the other analysis methods, that are 
commonly used to deal with repeated measures data. The summary measure needs to be chosen prior to 
data analysis and also should be useful in answering the question for the purpose of the analysis. After 
finding the summary measure, the approach is to analyse this data using some univariate approaches to
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find out whether there are any treatment differences. It is possible, however, that more than one measure 
is required to best describe or summarise individual characteristics. In this case, a multivariate analysis 
approach would be required. There are various summary measures that can be used and the choice very 
much depends on the purpose of the analysis conducted. Some authors have used this approach to 
analyse repeated measures data, claiming that it has advantages over most of the other suggested 
methods l19,20]. Matthews et a l [431 gave a list of potential summary measures that could be used to 
conduct a response profile analysis. Summary measures could be any ‘on-treatment’ summary such as 
an individual summary statistic (mean, median, min, max etc.) or any other measure incorporating the 
pre-treatment or baseline data as well as the ‘on-treatment’ information (e.g. change in mean from 
baseline). Possible disadvantages with this approach are its loss of error degrees of freedom and 
differences in numbers of observations used to calculate the summary measures as discussed by Hand 
and CrowderI30].
2.2.3: Profile Analysis
The analysis conducted on the data set of individual profiles (or multivariate observations in time) is 
known as a profile analysis. The main aim of any profile analysis is to test for differences in levels or 
shapes between the various group profiles 127,301 by looking for ‘time effects’ and ‘group effects’ and 
‘interaction effects’ through multivariate methods of testing. Some common questions that are used to 
answer these issues are:
1) Are the profiles parallel in appearance (or do they have the same shape)? If not, then this would be 
an indication of an ‘interaction by group and time’.
2) Are the profiles all flat (or do the k variables being measured have the same mean)? If not, then 
the indicating would be a ‘time effect’.
3) Do the group mean profiles have the same level? If not, then this would indicate a ‘group effect’. 
The aim would be to initially test for an interaction and if none exist, then the individual covariates are 
analysed as individual effects. The data can be summarised via either linear or non-linear modelling. 
2.2.4: Time Series Methods
If the number of repeated measurements are large or there are longitudinal measurements that are 
unequally spaced in time, then time series methods could provide alternative approaches 13b’11]. Time 
series methods 191 are not considered in this thesis.
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2.2.5: Survival Methods
If the data include follow-up studies for the time to an event such as death or a disease of interest then 
suggestions have been made that the data can be analysed using survival analysis techniques [59,63]. An 
approach could be taken to analyse the time to incidence data using Kaplan-Meier estimates and plot the 
cumulative survival estimates using Proc LIFETEST in SAS. The Wilcoxon test is appropriate for 
testing if most events occur at the beginning of the time range of interest and the Log Rank test is useful 
for testing events that don’t occur until later.
The Kaplan-Meier estimate is given by:
where k takes values 1.. ..p and n; is the number of patients with no abnormal reading before t* and d; 
is the number of patients with first abnormal reading at tj.
The equation above is the product of the estimated probabilities of surviving up to the time point ti, when 
t lied in the interval tk to tk+i.
2.2.6: Handling Missing Data
When analysing any data, there is often the issue of missing data and while collecting repeated measures 
for a variable on an individual it is not unusual to find that there are some missing records. There are 
many techniques that have been devised in the literature to deal with missing data. Commonly used 
techniques for dealing with missing data for repeated measures data are the ‘Last Value Carried Forward 
(LVCF)’ and ‘Group Means’ methods. Various works have been conducted using mainly the LVCF 
method but there is a range of varying opinions as to the circumstances for using this particular 
approach. A recent computer package called ‘SOLAS for missing data Analysis 1.0’ has been 
developed to deal with analysing data with missing records. The package is windows based and deals 
with single imputation methods including ‘LVCF’, ‘Group Means’ and ‘Hot Decking’ as well as 
multiple imputation methods.
There is continuing discussion on the pros and cons of using these and other imputation of generating 
missing data. The most obvious criticism is that the data points are not real and give the investigator a 
false impression. It is very easy to impute missing observations but these methods can often become 
abused if not approached with consideration. The main things that require consideration are the size of 
the data set and the number of missing records.
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Among the several techniques available in the literature on how to deal with and model missing data, 
some methods have been suggested on modelling missing data mechanisms as part of the modell15’41,48, 
661671. These methods will not be applied in the context of this thesis.
2.2.7: Categorical Data Analysis
Longitudinal data can take either a categorical or a continuous form. Categorical data approaches have 
been considered by various authors [13’57,70j. Chi-squared tests or Fishers Exact tests can be conducted to 
test the distribution of any categorical variable e.g. the number of abnormal results for individuals. Other 
methods such as logistic regression could be used to test binary response variables.
The general form of a logistic regression model is:
( \
log p1- p = Po + P1X1 + PnXn
where p is the expected value for the response variable, or probability of having the response. The 
number of explanatory variables is denoted by n. A maximum likelihood (M.L.E.) approach is taken to 
estimate the regression coefficients for a logistic model. The response variables are assumed to have a 
binomial distribution120].
Hence,
 '^ X n
^  1 + exp +^ lXl + ^nZn
If there were categorical data with greater than a binary response variable (e.g. age), an alternative 
approach would be to analyse the variable as a continuous variable. Modelling for categorical data with 
explanatory variables having greater than a dichotomous response could be conducted using the 
CATMOD procedure in SAS without having to create dummy variables as is the case when using Proc 
LOGISTIC in SAS. The main disadvantage over Proc LOGISTIC is the interpretation is not as 
straightforward. Some manipulation of the output is needed before final results can be obtained[57]. 
Methods of multivariate testing of categorical data include GEE (developed by Zeger and Liang 1986). 
The method can be used to conduct regression analysis on repeated categorical (mainly binary/Poisson 
responses) outcomes. There are macros available to conduct a GEE analysis and these are available in 
Stokes et a l I57]. This GEE method is not addressed in the thesis.
31
2.2.8: Other Semi-Parametric, Non-Parametric Approaches
Papers have been written on semi-parametric and non-parametric approaches [2,16,221.
If one is given samples of sizes ni,....nk from k populations, then the non-parametric Kruskal-Wallis 
(K-W) test statistic for testing that the populations are identical is:
where
3(N +1),N(N + 1)
N = i >
i=l
and for each i, R; is the rank sum relative to the observations from the i* population when all the 
observations are ranked in ascending order from 1 to N. The test here is to reject the hypothesis of equal 
distribution if H is greater than or equal to the tabulated value.
For the details of various other tests used in this thesis, we refer the reader to standard statistical 
textbooks and SAS manuals.
2.3 Testing
As can be seen in section 2.2, there are various methods of dealing with repeated measures data and 
most methods fall into one of the following two categories.
1. Univariate Analysis Methods: including ANOVA [21,45].
2. Multivariate Analysis Methods[10J: including MANOVA128,291.
Univariate analysis of variance is a special case of the multivariate analysis of variance approach. Both 
the ANOVA and MANOVA approaches can be used to test for group differences for the analysis of 
balanced, continuous repeated measures data and have been mentioned together by several authors120,11' 
31,401. The main aim of any multivariate or univariate testing is to see whether the groups have the same 
distribution. The following hypothesis is generally tested:
H0: the treatment groups are homogeneous in nature.
Hi: the groups are inhomogeneous.
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2.3.1: Univariate Analysis Methods.
The univariate approach does not account for the factor of time. The aim is to test for differences 
between average group responses. Methods that are usually used to test for differences are the 
parametric t-test (using Proc TTEST) to test between the means for two groups or a 1-way ANOVA 
(using Proc GLM with the RANDOM Statement) for more than 2 groups. If the data is not normal or 
approximately normal then an equivalent non-parametric test (using Proc NPAR1WAY) would be more 
appropriate, though one could still use the parametric tests that are robust here. There are generally two 
methods that could be adopted for this purpose. These are:
a) Univariate testing at each individual time point.
b) Univariate testing on a selected set of single Response Features or Summary Measures (S.M.) 
that best describes the data as mentioned in [2.2.2].
The first approach treats the repeated measures at each time point as individual measurements and each 
time point can then be analysed individually. This method was devised at a time when computing 
resources were limited, and it has many flaws. This is not recommended as a general tool for analysing 
repeated measures data for a number of reasons. A major assumption here is that each individual has 
similar times of measurement and this is definitely not always the case. The approach also assumes no 
relationship or zero correlation between successive measurements, which is also not the case, especially 
if the repeated measures are measured close together in time. The approach does not account for the 
continuous nature of the data e.g. if an individual has a significant differences at time 1,4 and no 
difference at times 2, 3 and 5. There is no information as to the effect from one time on to the next time 
results, and also whether there is an overall difference between groups. Information is also not available 
on when exactly the changes happened over the continuous time scale.
It is also assumed that the data at each individual time point is normally distributed for the purpose of 
modelling the data. This is obviously not always the case, especially if there are more than two 
treatments being looked into. Missing data information is ignored in this approach, so if an individual 
has missing data at times 1,2, only then the loss of information could be biasing the conclusions when 
finally comparing the results found at each of the time points 1 to 5 to draw conclusions. The summary 
measures approach has the main disadvantage of having a loss of degrees of freedom associated with the 
n individuals, whose summary measures are calculated. Advantages are that the missing data are not an 
issue here and they are easy to implement. Also, if there are only a moderate number of summary
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statistics, then, irrespective of their distributions, there is no loss of generality in assuming their 
distributions are normal if we are to apply test procedures relative to normal distributions, that are 
robust.
2.3.2: Multivariate Analysis Methods.
Much of the available literature claims that a univariate approach is not appropriate in most cases while 
analysing repeated measures data since certain factors are not accounted for. These are things such as 
the fact that observations that are closer together tend to have a higher correlation than observation 
further apart in time.
It has been suggested that the MANOVA approach of comparing overall profiles is the only method that 
requires no knowledge of the general form of the profiles prior to analysis [19,30].
Hence it is often suggested that approaching the analysis in a multivariate manner would often be more 
appropriate. The approach here is to analyse all the data for an individual as one measurement. Each 
individual has a p-dimensional vector of repeated measurements at time points ti to tp. Each of the j 
individuals with data measurements has a vector associated with time. The aim is to test for differences 
between group means of these vectors. An ANOVA can be conducted on the vector of measurements by 
treating the multivariate observations per individual as a single measurement. This method is known as 
MANOVA or multivariate analysis of variance. Greenhouse and Geisser[27] claimed that there were 
situations when MANOVA was inappropriate. This was if the sample size or number of j  individual 
vectors (e.g. number of patients) within a treatment group was less than the number of parameters or 
variables available (e.g. number of time points of measurement). The reasoning behind this as 
mentioned by Kenward 1351 was that repeated measured MANOVA can be inefficient if there were more 
repeated measures than residual df, resulting in a singular variance-covariance matrix and the 
calculations of the MANOVA statistic becomes invalid.
Likelihood Ratio (L.R.) tests could also be conducted. Both methods assume multivariate normality or, 
implicitly, the sample size to be large, and test for differences between more than one treatment group. 
The parametric multivariate methods which can be applied are those based on Hotellings T2 or 
equivalently Mahalanobis D2 statistic which are both used to test the equality of means for two 
multivariate populations.
The approaches of testing the data are very similar to the univariate procedures in that either of the 
following methods can be applied:
34
i) All Times for an Individual analysed together as one observation.
ii) A Combination of Summary Measures analysed together as one observation.
The second approach is not very commonly used but its idea is to analyse a few summary measures that 
best describe the data together at one time, possibly appealing to the properties of asymptotic tests 
referred to earlier [section 2.1.2]. These individual summary measures can be analysed together as one 
combined variable for analysis. The statistical tests mentioned above can be applied to analyse this data.
2.4 Modelling
2.4.1: Covariates and Their Effects Within the Model.
Multivariate methods are commonly used to test for group level differences together with any other 
covariates that may be considered to have an effect on the outcome variable of interest. In other words, 
the multivariate approach tests for more than one effect by looking for interactions between the effects 
and also the individual effects of each covariate of concern. If no interaction exists, then only the 
individual effects are tested. Examples of some covariates that are commonly tested are ‘centre’, ‘age’, 
‘gender’, ‘race’ etc in addition to the usual main effect of ‘group’. If no other effects apart from the 
main effect ‘group’ exist and the data are not repeated in time, then the approach would become a 
univariate ANOVA.
In the case of a profile analysis, where time is also a factor, the problem would immediately turn out to 
be multivariate in nature. The general aim for the multivariate analysis approach, as for the profile 
analysis [see section 2.1.3], would be to also test for the effects of ‘time’ in addition to ‘group’. 
Multivariate modelling techniques can usually be conducted on any longitudinal data set in order to 
model the response as a linear or non-linear function of time.
There are differences in the effects of the various covariates mentioned above. These are:
(A) ‘Time’ is repeated on the same individual and the level changes within an individual and also 
varies between individuals.
(B) ‘Centre’ and ‘Age’ can each have one of two structures. The initial idea, which is easier to 
analyse, is to assume that both stay constant within individuals but vary between individuals. 
This is usually the case for an analysis that does not have the factor of time. This is not always 
the case in the real world though, especially in the course of a long-term or longitudinal study, 
where an individual could change centre or get older at each visit. This leads us to the second 
idea that the variables change within an individual and also vary between individuals.
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(C) ‘Gender’, ‘Race’ and in the case of parallel groups randomised longitudinal data sets in
particular ‘Group’, stays constant and never changes for an individual through the course of the 
study. The variables stay constant within individuals but vary between individuals.
The general classifications for independent covariates (factors) in repeated measures settings are:
1) W ithin-unit factors: These covariates are time dependent; they vary within units over time.
2) Between-unit factors: Specifically baseline covariates, which stay constant over time.
2.4.2: Assumptions.
There are various approaches of modelling multivariate data in time. The general method that takes 
precedence over ANOVA is the general linear modelling approach of MANOVA. Analysis is usually 
applied to linear transforms of the data such as means, slopes etc. (using SAS Proc GLM with 
REPEATED statement, assuming that there is compound symmetry between all measurements and that 
the data is balanced). For the multivariate analysis of variance approach mentioned above, the general 
assumption about the variance-covariance structure is that it is a compound symmetric matrix (CS), 
which is one of the conditions required for the F-test to be valid [see section 2.1.1].
per op ... a
The following three conditions must hold in order for the condition of compound symmetry to hold:
1. Equal variance of repeated measures.
2. Each pair of repeated measures have the same correlation p.
3. Also the covariance matrix should be the same for each treatment group.
The usual problem with repeated measures data is that there is typically positive serial correlation 
between all observation for an individual unit. This therefore does not allow for standard analysis 
methods of the raw data since the condition of independence between observations is not met. The 
covariance structure is important in generating a method for the statistical analysis of such dataI26]. The 
main assumption for the model is that treatments are independent of one another. A flexible model for 
the covariance structure containing both complete and general independence, called Gabriels ante- 
dependence structure, was the alternative method that was proposed by Kenward l35]. This was believed 
to be more appropriate for analysing most repeated measures data. Kenward proposed L.R. tests to
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compare profiles. The approach was suggested as a way of analysing experiments where no specific 
features of the profiles were known to be of interest before the results were measured. The structure 
could be established and a test defined for the overall comparison of profiles under the defined anti­
dependence structure. Kenward mentioned that under the condition of general dependence the results 
correspond to that of the standard MANOVA. Some other approaches have been developed to analyse 
serially correlated data, when it is known in advance which features of the profile are of interest or 
which mathematical function could be used to model the data. This is based on the fact that there is a 
correlation between measurements for models such as random coefficient growth curve and mixed 
models. This leads us to the area of ‘mixed modelling methodology’ [section 2.5.2]. Using this method, 
the parametric structure of the covariance matrix must be stated in advance (using SAS Proc MIXED 
with REPEATED statement, when the data is not necessarily balanced). Generally, the individuals 
(patients) yield random effects and the variables (times) or groups (treatments) of measurement have 
fixed effects. Hence the most appropriate method to deal with repeated measures data would be a mixed 
model approach[38,40,56].
2.4.3: Models
The purpose of modelling any data set is to be able to mathematically reproduce the data. Many papers 
and talks have been presented on the various modelling techniques available for repeated measures 
experiments [1,37,39,42,49,60168]. We will specifically concentrate on models for completely randomised 
designs I40,70].
Example:
Considering the example o f heart rate data which is measured fo r patients, in a completely
randomised design, that are each allocated to one o f four treatment groups 1 to 4.
Here treatment is the ‘factor’ and it has four ‘levels’. Let i denote the levels of the factor, j denote the 
number of individuals within each level of the factor and p denote the number of repeated measurements 
on each of the individuals. Each individual has a vector of p repeated measurements at ti to tp.
Hence, generally pj denotes the mean response of patients treated with drug i=l to 4 and a  j denotes the 
effect of drug i where a j  = p; -p. A factor effect can either be random or fixed.
The overall mean response is p.. Let y be the response variable (for a randomly selected patient on drug 
i) which is a random variable and has mean pi and variance a 2. The variable y deviates from the mean pj 
by a random amount 6 which is a random variable with mean 0 and variance a 2.
a. Simple Cell-Means Models:
yi = P i + £i
For this model, the responses for the heart rate on each drug i= l to 4 is obtained by adding the fixed 
mean for the drug and also a random iid error (which is usually assumed to be distributed with N ^ o 2).
b. Simple Factor EffectsModels:
yi = fx + ai + Si
For this model, the responses for the heart rate on each drug i=l to 4 is obtained by adding the overall 
mean and the effects on drug i=l to 4 and also a random iid error (which is usually assumed to be 
distributed with N(0,o2).
c. General Fixed Effects Models:
yy = p  + a  i + Sjj
This model, deals with when each patient is randomly assigned to a therapy. The response for the heart 
rate are determined for each patient on each drug i=l to 4 is obtained by adding the overall mean and the 
effects on drug i=l to 4 and also a random error. In this case, the response for each patient on the same 
drug has random variation among patients Ey. The term By has the same variance for each drug (and is 
usually assumed to be independent normal) but this is not always the case.
The term ‘fixed’ effect refers to the situation when all possible levels of the treatments are represented. 
Using the example at the beginning of this section, the effects are fixed if the four drugs are the only 
possible levels of therapy and therefore the only information from which conclusions or inferences can 
be made. For fixed effects m odel[71], the main purpose is to provide estimates about the group means 
and differences between them.
d. General Random Effects Models:
‘Random’ effects models1251 refer to the situation when the levels of the factor used represents only the 
random sample of a larger set of potential levels. The following structure holds:
yu = ^  + a i + eu
Here p. represents the overall population mean. If drug is a random factor, then a j represents the 
independent random effects of the drug that are random variables with mean 0 and variance Ot2. In this 
case Sy are independent random variables with mean 0 and variance a 2 (usually taken to be normal) and 
hence, the variance of a randomly chosen individuals response is a T2+ cr2.
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e. Mixed Effects Models.
This is a combination of the general random and fixed effects models.
As the name suggests, the model consists of both random and fixed effects. The following expression 
shows the general structure of a mixed model for repeated measures analysis:
y ijk = H + OCi+Yik + Ty + e p  
Here p, would be the grand mean, ocj would represent fixed group effects, Y;k would be the group by time
interaction effects, x y would be mutually independent random effects for subjects within groups and 8yk
would be mutually independent random measurement errors. All x y are identically distributed and so
also are all e yk, and all x y and s yk are mutually independent (usually assumed to be normal with zero
mean).
A generalisation of the model above is when the vectors (yyi, yijP) are mutually independent, and for
each treatment group i, are identically distributed. This is one of the most general parametric models 
and versions of this model will be used in chapter 8, to analyse the data sets used for this thesis.
Other modelling approaches such as survival analysis [section 2.2.5] and logistic regression [section 
2.2.7] approaches can also be investigated to get a better understanding of the data sets.
2.5 Discussion
Researchers have suggested repeated measures analysis methodology that can be anything from 
extremely simple to very complex to implement. Everitt1191 produced a very good review paper of the 
analysis of repeated measures data. The paper summarises some of the suggested most popular methods 
of analysis.
We should note that often complexities in the structure of the data itself could lead to difficulties with 
data analysis. A useful condition is to conduct a balanced complete blocks design when setting up a 
design to collect repeated measures data. Most papers agree that the first thing to do as with any data 
analysis is to get a feel for the data and conduct some sort of initial exploratory data analysis. The best 
way of doing this is to present it in some graphical manner (e.g. correlogram, scatter plot, box-plot, Cl 
and mean plot). Summary measures can also be obtained. Once plots have been produced one can see 
changes on unusual happenings with the data.
A major issue in the analysis of R.M. data is the issue of data distributions being normal and also that 
there is independence and identical distributions between successive time measurements. All methods
mentioned so far are on how to deal with continuous data. The methods of analysing continuous data 
vary. Usual methods of modelling continuous data would be using linear or non-linear models with 
random and/or fixed effects.
The multivariate tests based on the p-dimensional vectors for patients tend to be unreliable especially if 
p is large and the normality assumption is not met. On the other hand, reduced data involving only one 
or two summary measures throw away a vast amount of information, but the test procedures in this case 
tend to be robust and do not heavily depend on the normality assumption. We should therefore use a 
compromise and one of the major contributions of the present thesis is to suggest ways of analysing the 
data based on a reduced set of observations or a set of summary measures so that as much of the overall 
information from the data is retained. We use robust test procedures that do not stringently depend on 
the assumption of normality.
As implied earlier, to arrive at reasonable conclusions even with non-parametric or categorical data, one 
can not allow too many repeated measures, and hence one must find ways of reducing the value of p. Of 
the categorical and non-parametric tests that will be encountered in this thesis we include tests of 
homogeneity for the distribution of the number of abnormal readings in various treatment groups, and 
the Kruskal-Wallis test for investigating whether different treatments perform differently.
One could also undertake more complex investigations, involving categorical data with higher 
dimensional tables and various levels of abnormality, for testing homogeneity for treatments. However, 
this is beyond the scope of the present study.
2.5.1: ANOVA vs. MANOVA
Some early work on profile data analysis was conducted by Greenhouse and Geisser[27] who together 
wrote a social sciences paper on the methodology used to analyse profile data. The paper referred to 
mainly works on univariate ANOVA, MANOVA and other statistical methodology for multivariate 
research[31]. The aim of the paper, even though showing multivariate techniques, was to show that 
ANOVA was the easiest way of dealing with the multivariate data set that was being analysed. The 
authors specifically looked into the how the F statistics could be adjusted according to the assumptions 
being made about the variables of interest. They claimed that the univariate ANOVA approach allowed 
analysis of data that could not be analysed using multivariate methods. Details of when this would be the 
case are given below.
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There has been a great deal of discussion for many years on the issue of whether to use the classical 
univariate analysis of variance (ANOVA) method15,21,231 or the generalised multivariate analysis of 
variance (MANOVA) 128,291 method to analyse such data. There are advantages and disadvantages to 
both methods. The main problem with the univariate approach is that it assumes independence or zero 
correlation between successive measurements. Univariate ANOVA does not account for the fact that 
measurements that are closer together usually tend to be more closely related (highly dependent), leading 
to larger correlations, than those measurements further apart and also for the fact there is variability 
between experimental units.
The main problems with multivariate methods on the other hand are that they are much harder to 
implement than univariate methods. The results are also not reliable if the data is not approximately 
multivariate normal especially if the tests used are non-robust. For repeated measures MANOVA, no 
assumptions are made about the covariance structure of repeated measures and therefore all variance and 
covariance parameters need to be estimated. A typical case when MANOVA techniques would not be 
appropriate would be if the sample size or number of j individual vectors (e.g. number of patients) within 
a treatment group i was less than the number of p parameters or variables available (e.g. number of times 
of measurement)1271. Along similar lines, repeated measured MANOVA can be inefficient if there are 
more repeated measures than residual df since there will be a singular variance-covariance matrix and 
the MANOVA statistic can not be calculated118,351. Multivariate normality is harder to test for than 
univariate normality. For this thesis, a data reduction approach was suggested so that the condition of 
asymptotic normality could then be applied and hence the test results would become valid.
Since the conditions of normality, equal variance and mutual independence or zero correlation were not 
always reasonable, especially if there were more than two treatment groups or schedules to compare 
Greenhouse and Geisser1271 made one assumption about the variables of interest in order to conduct the 
univariate ANOVA. This was that they had a multi-normal distribution with arbitrary variance- 
covariance matrix. The problem of multivariate observations was approached in a general way and it 
was assumed that an individual vector of 1 to p observations for each individual was sampled from a p- 
variate normal distribution with an arbitrary variance-covariance matrix. In other words, the p 
observations were assumed to be jointly normal (i.e. p-variate normal) with no assumptions being made 
about the variance-covariance matrix.
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Block et a l [4] also used the ANOVA approach but they used assumptions of equal variances for all 
variables and also of independence (or equal correlation between variables).
Greenhouse and Geisser extended the work of Box[5,6] on the approximate distributions of F statistics in 
ANOVA for one group to the case of several groups. The df were adjusted for the approximate F tests to 
get more conservative tests which could be used when the variance-covariance matrices differs from 
group to group if the sample size of groups were the same.
2.5.2: Mixed Modelling
The Mixed Modelling approach deals with some of the shortcomings associated with both the ANOVA 
and generalised MANOVA methods. The model would consist of both fixed and random effects that 
would best describe the data. A mixed models method of dealing with repeated measures data would 
need a prior knowledge of the covariance structure before the time of analysis (a priori) in order to fit the 
model.
In the past, the multivariate method of mixed modelling was not a feasible option since it was 
computationally challenging. In recent years, SAS procedure MIXED[52] has been devised to deal with 
this particular type of analysis. A useful reference is the book in the series by SAS user’s [40]. The book 
gives a range of practical methods and techniques to deal with data for mixed modelling and has a 
chapter devoted to repeated measures analysis. The SAS procedure is very extensive in its coverage and 
only a specialised part of its capabilities has been used for this thesis.
Many authors have suggested that the covariance structures play an important role in the modelling of 
any repeated measures profile data. In conducting multivariate analysis using a mixed modelling 
approach, one of the major assumptions is that the correct covariance structure needs to be specified and 
built into the model at the time of analysis in order to get valid results for the d ata l26,46,65]. SAS Proc 
MIXED has a range of possible covariance structures built in as options. The main ones typically 
referred to are the following: ‘UN’ which is the unstructured matrix, ‘CS’ is the compound symmetric 
matrix, AR (1) and AR (1) with a random effect, ‘SIMPLE’ is the simple matrix.
The random effects in the model structure are affected by the fact that measurements closer together in 
time have higher correlations than measurements further apart. This is the reason that the covariance 
structure must be built into the mixed model. If this were not done, invalid results would be obtained. 
The general SAS command used for mixed modelling of repeated measures data is Proc MIXED with 
the REPEATED statement.
42
2.6 SAS Procedures Used
SAS version 6.10 on VMS and later 6.12 on UNIX were used for analysis of the data. Programs 
produced are displayed in Appendix B. SAS manuals can be referred to for all details on any procedures 
mentioned I50‘55]. The main SAS procedures used for analyses are as follows:
Proc UNIVARIATE with normal option: produced univariate normal tests.
Proc MEANS: produced Summary Measures.
Proc FREQ: produced frequencies. The chisq options =*> Chi-squared tests. The exact option=> Fishers 
exact tests for some situations and the cmh option => Mantzel-Haenzel tests.
Proc PRINCOMP: used to conduct the P.C.A. => eigen-values, vectors and principal components.
Proc DISCRIM  with distance option: computes Mahalanobis distances2 between each pair of treatment 
groups.
NOTE: Both PRINCOMP and DISCRIM drop any observations with at least one missing record from 
the analyses.
Proc NPAR1WAY: computes either Wilcoxon (for 2 groups) or Kruskal-Wallis tests (for > than 2 
groups).
Proc GLM: computes both ANOVA and MANOVA. Only ANOVA results are valid when unbalanced 
groups exist. In the case of univariate ANOVA, Proc GLM is advantageous over Proc ANOVA (which 
does not handle unbalanced groups). The MANOVA is not valid with unbalanced groups and 
individuals with missing data are also dropped from the analysis.
Proc MIXED: was specially devised to handle mixed modelling but the procedure can be used in place 
of Proc GLM to analyse multivariate data. The advantage over proc GLM is that it deals with missing 
data and unbalanced data if it is missing completely at random (MCAR).
Proc MIXED and Proc GLM, while trying to conduct similar analyses, use different estimating 
procedures. Proc GLM uses Method Of Moments (MOM) estimation to obtain ratio of means squared 
(F) statistics and Proc MIXED uses Maximum Likelihood (MLE) or restricted residual MLE (REML) 
methods and Wald-type F statistics [40,52,70].
Proc LIFETEST: computes Kaplan-Meier estimates for time to incidence data and also computes 
L.Ratio tests.
Proc LOGISTIC: computes logistic regression odds ratios for binary response variables.
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2.7 Overview
In the previous chapter we have discussed various statistical methods to deal with longitudinal data 
structure analysis. The key methods to analyse continuous data, which will be used further on in this 
thesis, include plotting the data, response features approach and discriminant analysis. The methods 
used for the categorical data include logistic regression and survival analysis techniques.
In the next chapter, we will discuss the data sets used for this thesis and also any problems that were 
encountered during data analysis.
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CHAPTER 3: The Observed Data and Basic Summary Measures.
3.0 Introduction
This chapter introduces the reader to the actual data to be used for analysis. There are two continuous 
data sets A and B. Data set A contains vital sign measurements for 86 patients each randomly allocated 
to one of four treatment groups and two centres. Data set B contains dietary response measurements for 
24 individuals randomly allocated to one of three diets. In addition, data set A is further classified as a 
categorical data set.
The multivariate and univariate structure of each continuous data set and the univariate structure of the 
categorical data set are described in this chapter. Also mentioned are all the univariate summary 
measures obtained from each data set.
Listings 3.1.1 to 3.5, in this chapter, show the data structure of the first few observations of several data 
formats that will be used during the analysis.
3.1 Observed Data Structures
3.1.1: Description of the Observed Data Sets.
There were two repeated measures data sets each having a longitudinal design. These were:
3.1.1.1 Data Set A: A large real data set containing 24 hour Ambulatory Vital Sign Readings.
This was a blinded data set that was provided by SANOFI UK Ltd. (1994).
The design was a parallel groups design. A total of 86 patients were selected from one of two centres (1 
or 2) and the patients within each centre were randomly allocated to one of four treatments (1,2,3 or 4). 
The two covariates in this data set are ‘centre’ and ‘drug’ and both stay constant through the study. 
Baseline measurements of the three independent response variables systolic blood pressure, diastolic 
blood pressure and heart rate were taken for each individual before active therapy was administered. 
Once therapy was administered, readings of the same 3 variables were again measured at 24 separate 
time points using an ambulatory monitoring system that was attached to each individual patient. The 
patients were not balanced between centres or overall treatment groups. On a few occasions the system 
failed and so a set of measurements (at that failed time point) were not available.
NOTE: Things which were unknown about the study were the times of start and stopping the therapy, 
and whether or not there was more than one administration of the therapy during the 24 points of 
measurement. The age of individuals both at baseline and at each time point was also unknown. These
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are all variables that would have been useful to know. It was assumed that these readings were taken 
for 24 hours at equally spaced hourly intervals. Listing 3.1.1 below shows the layout of the univariate 
data set A by displaying some of the vital sign data in a univariate format for one patient (ID=10013).
Listing 3.1.1
Univariate Data Structure: Data Set A (Systolic Blood Pressure (mmHg))
MEASURE DRUG P A T IE N T CENTRE B A SE TIM E VALUE
S B P 2 1 0 0 1 3 1 1 5 4 . 7 8 7 0 1 5 4 . 7 9
S B P 2 1 0 0 1 3 1 1 5 4 . 7 8 7 1 1 6 5 . 7 5
S B P 2 1 0 0 1 3 1 1 5 4 . 7 8 7 2 1 7 1 . 0 0
S B P 2 1 0 0 1 3 1 1 5 4 . 7 8 7 3 1 5 7 . 0 0
S B P 2 1 0 0 1 3 1 1 5 4 . 7 8 7 4 1 5 3 . 7 5
S B P 2 1 0 0 1 3 1 1 5 4 . 7 8 7 5 1 6 0 . 0 0
S B P 2 1 0 0 1 3 1 1 5 4 . 7 8 7 6 1 5 2 . 7 5
S B P 2 1 0 0 1 3 1 1 5 4 . 7 8 7 7 1 6 6 . 2 5
S B P 2 1 0 0 1 3 1
c o n t i n u e d . .
1 5 4 . 7 8 7 2 4 1 4 1 . 2 5
Displayed on the next page in Listing 3.1.2 are the heart rates for three individuals (ID=10001, 10009





















































3.1.1.2 Data Set B: A small randomly generated data set of responses on 3 combinations of therapy.
This data set of a parallel groups design study was randomly generated by Dr. Roy Saunders, SANOFI 
Research, USA (1997). There were 24 individuals and they were randomly allocated to three treatment 
groups. These were diet, diet+drugl, diet+drug2. Treatment was the only covariate of interest for this 
data set. Recordings of the response variable, dietary response was taken at 10 time points. There were 
no other variables measured. The data was a balanced design with 8 individuals in each group. There 
were some missing responses within the data set. Listing 3.2.1 below shows a univariate listing of all of 
the dietary response values for one subject in data set B (ID=1).
Listing 3.2.1
Univariate Data Structure: Data Set B (Dietary Response)
GROUP SU B JE C T B A SE T IM E R E SP O N SE
G r o u p 1 1 1 . 1 2 5 9 8 0 1 . 1 3
G r o u p 1 1 1 . 1 2 5 9 8 1 0 . 9 4
G r o u p 1 1 1 . 1 2 5 9 8 2 0 . 9 8
G r o u p l 1 1 . 1 2 5 9 8 3 0 . 8 7
G r o u p 1 1 1 . 1 2 5 9 8 4 0 . 8 9
G r o u p l 1 1 . 1 2 5 9 8 5 0 . 8 8
G r o u p l 1 1 . 1 2 5 9 8 6 1 . 1 5
G r o u p l 1 1 . 1 2 5 9 8 7 1 . 1 1
G r o u p l 1 1 . 1 2 5 9 8 8 1 . 0 0
G r o u p l 1 1 . 1 2 5 9 8 9 0 . 9 5
c o n t i n u e d .
Listing 3.2.2 shows dietary response data in multivariate format for 5 individuals (ID=1,2,3,4,5) 
in group 1
Listing 3.2.2
GROUP SUBJECT BASE _1 _2 _3 _4 _5 _6 _7 _8 _9
Groupl 1 1.12598 0.94 0.98 0.87 0.89 0.88 1.15 1.11 1.00 0.95
Groupl 2 0.94240 0.78 0.81 0.73 0.84 0.94 0.82 0.89 0.80 0.94
Groupl 3 0.81512 0.74 0.75 0.74 0.92 0.95 • 0.95 0.98 0.77
Groupl 4 0.87353 1.02 0.96 0.83 0.83 1.08 1.02 1.12 1.02 1.04
Groupl 5 1.00571 1.09 1.01 0.90 0.85 0.85 1.04 1.02 1.13 1.01
continued
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3.1.2: About the Observed Data Sets.
j
As can be seen above, permanent SAS files named ‘UNI_1’ (for the univariate structure) and 
‘MULT_1 ’ (for the multivariate structure) were created for both of the original data sets A and B. The 
variable ‘BASE’ was equivalent to the measurements at ‘TIME’=0 and this measurement was the pre­
treatment baseline reading. All other readings that were measured were recorded on-treatment. 
Similarities between data sets A and B were:
a) They were both longitudinal in nature.
b) Both data sets had missing records. Data set A had missing data for 13 of the 86 individuals in 
the study. There were also 2 additional patients with missing baseline data. Data set B had 
missing data for 4 out of 24 individuals in the study. The times and patients with missing data 
are mentioned in section 4.2.
c) Both data sets were unbalanced following the missing data records.
d) Both data sets had less individual profiles in a treatment group than actual number of repeated 
measurements (times) being measured.
There were some obvious differences between the observed data sets:
a) Data set A was ‘large’, whereas data set B was ‘small’.
b) Data set A had 3 variables being measured (HR, SBP and DBP), whereas data set B had only
one variable (dietary response).
c) Data set A had many repeated observations being measured (24 equally spaced time points and 
baseline) and there were many individual profiles (22 or 21) in each of 4 treatment groups. 
However, data set B had only a few observations being measured (10 equally spaced time 
points) and there were a few individual profiles (8) in each of 3 therapy groups.
3.2 Classification of Vital Sign Data
This refers to data set A only since categorical information was unavailable for data set B.
All categorical methods were applied to only the original data set A1 before missing data was generated. 
Data was categorised into 7 groups according to the National High Blood Pressure Education Program, 
JNCV Report medical literature on blood pressure and heart rate normal ranges as displayed in Table
3.1.1 below. It was mentioned within the report, that low blood pressure would not usually be of 
considerable concern for a patient’s health. Except in rare cases a low blood pressure is good for ones 
blood vessels and heart. Abnormally ‘high’ results for blood pressure is known as ‘hypertension’ and
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this is something which is considered serious as the numbers become higher. Systolic blood pressure 
would usually increase due to hunger whereas diastolic blood pressure would remain constant in this 
situation. Low heart rates are usually found in athletic individuals and are not usually of concern. 
Medications that would decrease heart rate would be beta-blockers. Higher pulse rates usually indicate 
some sort of stress on the heart and are something to worry about. Slight increases in heart rate can 
occur if an individual is hungry. Other things that could increase heart rate would be exercise or 
medications such as calcium channel blockers. The ranges are as follows:
Table 3.1.1 
Seven Stage Vital Sign Classifications
Category 
Age : 18 years old over






Low 40-59 80-99 40-59
Normal 60-79 100-129 60-84
High Normal 80-99 130-139 85-89
*High: Stage 1 100-119 140-159 90-99
Stage 2 120-139 160-179 100-109
Stage 3 140-159 180-209 110-119
Stage 4 160 or over 210 or over 120 or over
* Note: High for Blood Pressure would be hypertension. The categories for blood pressure are from the 
National High Blood Pressure Education Program, JNCV Report.
Heart rate information was obtained after consultation with an M.D [69].
The data was further classified into the following 3 groups using the classification above:
Table 3.1.2
Normal. High and Low Vital Sign Classifications.
Category






Low < 60 (Bradycardia) <100 < 60
Normal 60-99 100-139 60-89
High 100 or over (Tachycardia) 140 or over 90 or over *
* Note that the definition used for ‘High’ diastolic blood pressure is based on the old definition by the 
American Heart Association.
The following listing shows the categorical data set structure by displaying some of the observations for 
one patient (ID=10001) following the classifications mentioned above. Here time is displayed in a 
univariate manner.
Listing 3.3
Categorical Data: Original Data ONLY for Data Set A (Vital Signs Data)
DRUG CENTRE PATIENT TIME ABNORMAL CATEGORY LOW HIGH NORMAL
1 1 10001 1 Normal Normal No No Yes
1 1 10001 2 Normal Normal No No Yes
1 1 10001 3 Normal High Normal No No Yes
1 1 10001 4 Normal Normal No No Yes
1 1 10001 24 Normal High Normal No No Yes
1 1 10001 0 Normal Normal 
continued ..
No No Yes
Vital sign categories and ranges were obtained from Tables 3.1.1 and 3.1.2 above. The variable 
‘CATEGORY’ was created by giving each test result a value of 1 to 7 or missing using the normal 
ranges displayed in Table 3.1.1. Since there were far too many categories to conduct any tests, another 
variable ‘ABNORMAL’ was created. This variable had three levels (low, normal and high) together 
with missing data and the ranges used are given in Table 3.1.2 above. In addition, three binary response 
variables (‘LOW’, ‘NORMAL’ and ‘HIGH’) were created for every time point using variable 
‘ABNORMAL’. In each case the variable had a value of 1 for “yes” and 0 “otherwise”. These three 
variables each had a complete set of records for each patient since missing data was given the value 0 
for “no” event. The data set therefore had a total of 24 “yes” or “no” on-treatment response variables 
per individual. These corresponded to the individuals ‘on-treatment’ readings at time 1 to 24. Each 
individual also had a single “yes” or “no” response variable at baseline. Listing 3.3 above shows one 
page of the structure of this categorical data set.
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3.3 Univariate Summary Measures 
3.3.1: Continuous Summary Measures.
Univariate summary measures were obtained for both continuous data sets A and B described above in 
Listings 3.1.1 and 3.2.1 respectively. There were 7 univariate summary measures that were used during 
data analysis. These measures were the mean, median, minimum, maximum, upper and lower quartiles 
as well as the change in mean on-treatment observations from the baseline observation. The formats of 
the data sets of summary measures are displayed below in Listings 3.4.1 and 3.4.2 below for data set A 
and B respectively.
Listing 3.4.1
Summary Measures By Patient and Drug: Data Set A :Heart Rate (beats/miri): Original Data Set
DRUG CENTRE PATIENT MEAN MEDIAN MIN MAX Q1 Q3 BASE CHANGE
1 1 10001 82.1 81.1 67.5 102.0 77.3 87.5 70.1 12.1
1 1 10009 72.8 68.0 56.5 115.0 62.4 78.8 70.8 2.0
1 1 10011 70.2 64.5 57.0 123.0 61.0 74.7 71.2 -1.1
1 1 20017 66.9 67.1 58.0 81.3 63.3 70.8 66.1 0.7
1 2 20028 66.3 64.5 54.0 92.5 61.5 69.1 65.8 0.5
continued .•
Listing 3.4.2
Summary Measures Bv Subject and Dietary Groun:Data Set B (Dietary Response): Original Data
GROUP SUBJECT MEAN MEDIAN MIN MAX Q1 Q3 BASE CHANGE
Groupl 1 1.0 1.0 0.9 1.1 0.9 1.0 1.1 -0.2
Groupl 2 0.8 0.8 0.7 0.9 0.8 0.9 0.9 -0.1
Groupl 3 0.9 0.8 0.7 1.0 0.7 1.0 0.8 0.0
Groupl 4 1.0 1.0 0.8 1.1 1.0 1.0 0.9 0.1
Groupl 5 1.0 1.0 0.9 1.1 0.9 1.0 1.0 0.0
Groupl 6 0.8 0.8 0.6 0.9 0.7 0.9 0.9 -0.1
Groupl 7 0.9 0.9 0.7 1.2 0.8 1.0 1.0 -0.1
Groupl 8 0.9 1.0 0.8 1.1 0.8 1.0 1.1 -0.1
Group2 9 0.7 0.7 0.5 0.9 0.6 0.8 1.1 -0.5
Group2 10 0.8 0.8 0.7 1.0 
continued . .
0.7 0.9 1.1 -0.3
52
3.3.2: Categorical Summary Measures.
The categorical data in Listing 3.3 above was further broken down into univariate summary measures in 
order to be used for analysis. The number of positive ‘on-treatment’ responses, per patient, was tallied 
for each of the three binary variables, ‘LOW’, ‘NORMAL’ and ‘HIGH’, to create the three variables 
‘NL’, ‘NN’ and ‘NH’ respectively. Each individual had a value for each of these variables that could 
range anything from 0 to 24. The three variables could add up to no more than 24, since the sum was 
the number of available ‘on-treatment’ readings.
From reading through the available literature, it became apparent that only ‘HIGH’ results were 
considered to be truly abnormal results. Hence all further categorical analyses were conducted by 
considering only ‘HIGH’ results to be abnormal. Both ‘HALFABN’ and ‘QRTABN’ were similar 
measurements. Both were dichotomous yes/no response variables. The initial variable measured 
whether more than 50% of the results were abnormal and the second variable measured if more than 
75% of results were abnormal.
The frequency of abnormally ‘high’ results per individual are displayed for three individuals 
(ID=10001,10009,10011) in Listing 3.5 below. In the listing below, ‘FREQ’ was missing since it was 
only calculated for systolic and diastolic blood pressure and not for heart rate data. This variable would 
take the values 0-12,13-18 and 19-24 where these are the ranges of number of ‘high’ (abnormal) 
responses per individual. The reason for ‘FREQ’ not being calculated for HR was that the maximum 
number of abnormally ‘high’ HR readings per individual was 6 and hence no comparisons could be 
made between treatment groups. Hence, a second variable ‘FREQ2’ was calculated where the values 
were 0,1-3 and 4-6 respectively.
Listing 3.5
Number of Abnormal Readings Original Data ONLY for Data Set A: Heart Rate Data
DRUG CENTRE PATIENT N HALFABN QRTABN NL NN NH FREQ FREQ2
1 1 10001 24 NO No 0 23 1 • 1-3
1 1 10009 24 No No 3 19 2 • 1-3




The previous chapter describes the structure of the data sets that were analysed for this thesis. There are 
two data sets A and B [section 3.1] and both contain response variables that were continuous in nature. 
The three response variables in data set A can be further classified into categorical variables using 
ranges obtained from the definition for the American Heart Association [section 3.2].
SAS version 6.10 on the VAX mainframe and later SAS 6.12 on a UNIX platform were used to analyse 
the data. Any important SAS programs are displayed in Appendix B.
The following chapter 4 explains the exploratory data analysis (EDA) conducted on the data and any 
univariate statistical tests applied to the data. Also mentioned are problems encountered with the data 
together with any solutions. Each of the three continuous response variables (heart rate (HR), systolic 
blood pressure (SBP) and diastolic blood pressure (DBP)) in data set A, were analysed as separate 
individual outcome variables. Any continuous data analysis methods conducted on the data sets were 
identical for all three of these variables. Both the continuous ambulatory measurements in data sets A 
(Listing 3.1.1 and 3.1.2 above) and the dietary response in data set B (Listing 3.2.1 and 3.2.2 above) 
were each analysed using continuous data analysis methods. In addition, the variables in data set A 
were also analysed as both categorical and continuous variables following a categorical classification.
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CHAPTER 4: Exploratory Data Analysis
4.0 Introduction
The previous chapter introduced the reader to both the univariate and multivariate structures for the two 
continuous longitudinal data sets A and B that were used for study in this thesis. Also suggested were 
various univariate summary measures that could be used to describe the data.
All approaches used were applied to both data sets A (three vital sign variables heart rate, systolic and 
diastolic blood pressures) and B (dietary response) unless otherwise stated. During the analysis, the four 
aforementioned variables were considered to be four independent variables and hence analysed as such. 
Note: Any relevant SAS code required for analysis is given in Appendix B.
Within this chapter, an initial exploratory data analysis was conducted on the original data sets in their 
univariate format, in order to gain initial feeling for how this data was behaving over time.
There was the problem of missing data, which would not affect any univariate methods but would 
definitely have an impact on any future multivariate analysis methods. A generated data set was created 
for analysis purposes by replacing as many of the missing records as possible.
Any univariate plots (Figures 4.1.1 to 4.4.4 below) were produced in order to get an idea of the 
behaviour of the data sets at both baseline (pre-treatment) and at each individual (on-treatment) time 
point. All the univariate plots over time, which were created for the original data sets were also 
produced for the data sets after imputing missing data. It was found that there were not any detectable 
differences in the plots when comparing plots of before and after data imputation. Since there were no 
vast differences between the two sets of figures, as was also the case with the univariate tests, the only 
figures displayed are those produced from the original data sets.
4.1 Profile Plots of the Continuous Data Over Time
Initially, as most of the literature suggests, individual profile plots were plotted to show the behaviour of 
each of the individuals data over time. For both data sets A and B, there were far too many patients in 
the study to be able to distinguish clearly between treatment groups when all the data was plotted on one 
graph. Hence, a separate profile plot was produced below for each of the four treatments (Figures 4.1.1 
to 4.1.3) in data set A or three therapy groups in data set B (Figure 4.1.4). Even after plotting the data in 
this manner, it can be seen that all these plots are still very cluttered and difficult to interpret. The only 
use in these plots is to gain a general feel for how the data is behaving for each individual. It is 
recommended that other types of plots such as box-plot summaries or summary plots such as those
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produced in sections 4.2 and 4.4 respectively be used in place of the individual profile plots while trying 
to interpret the data and distinguish between the behaviour of treatment groups.
4.1.1: Heart Rate (beats/minute):
Figures 4.1.1 A-D below show the individual patient profiles displayed by each respective treatment 
group 1 to 4 for the original heart rate (beats/minute) data.
Even though a separate plot was produced for each treatment group, the figures were still very congested 
and difficult to interpret. By initially eyeballing these four figures the initial thing that was noticed was 
that individuals on drug 4 appeared to have heart rates that were more spread apart than any of the other 
treatment groups. However, when looking at the scale of the plots it was found that drug 2 in fact has a 
greater spread in it’s data and this was only the case due to one supposed outlier at time 22 hours on- 
treatment. However, since this was not determined to be an outlier, the measurement was kept in the 
analysis. There was also one individual that had consistently lower readings than all other individuals 
on drug 2. All treatments appeared to dip at around 14 or 15 hours and then peak at around 23 hours.
FIGURE 4.1.1
Individual Patient Profiles of Heart Rate over Time bv Treatment Group.
Original Data: Before Missing Data Replaced (N=86).
A: Treatment 1 B: Treatment 2
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4.1.2: Systolic Blood Pressure (mmHg):
Figures 4.1.2 A-D below show the individual patient profiles over time displayed by each of four 
respective treatment groups 1 to 4 for the original systolic blood pressure (mmHg) data.
These plots were produced before imputing missing records. Each treatment group was very congested. 
None of the plots have a pattern that can easily be described. The readings for drug 4 were on the whole 
lower than readings for the other three treatments. It can be seen that drug 4 has smaller variation in the 
data as opposed to drug 3. There was a dip in the data around time 22 hours for drug 4. The data for 
drug 4 had a smaller range than all the other three treatments. Drugs 1 and 3 each had one individual 
that appeared to have a set of extremely low readings. These could be outliers but they were not omitted 
from any analyses.
FIGURE 4.1.2
Individual Patient Profiles of Systolic Blood Pressure over Time hv Treatment Group. 
Original Data: Before Missing Data Replaced fN=86).
A : Treatment 1 B : Treatment 2
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4.1.3: Diastolic Blood Pressure (mmHg):
Plots of the individual patient profiles over time were displayed below for diastolic blood pressure by 
treatment groups (Figures 4.1.3 A-D). These plots were produced before imputing missing records. 
Each plot appeared very cluttered. None of the plots have a pattern that could easily be described.
Drug 2 tended to have individuals with slightly larger diastolic blood pressure readings on average than 
any other treatment group.
FIGURE 4.1.3
Individual Patient Profiles of Diastolic Blood Pressure over Time hv Treatment Group. 
Original Data: Before Missing Data Replaced (N=86).
A : Treatment 1 B : Treatment 2
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4.1.4: Dietary Response
Figures 4.1.4 A-C below show the individual patient profiles displayed by each of three respective 
therapies for the dietary response data. From the individual profile plots below, it can be seen that 
therapy 1 is varying a great deal between individual responses. For therapy 2, the observations are 
closer together but there is still some variation at certain times. For therapy 3, the observations are very 
close together with little variation at each time point. There are obvious differences in profiles. Therapy 
3 is very different from the other two therapies.
FIGURE 4.1.4
Individual Patient Profiles of Dietary Response over Time (hours) by Therapy Group: Original 
Data: Before Missing Data Replaced (N=24).
A : Therapy 1 B : Therapy 2
A : Therapy 1 B : Therapy 2
T1ME+1 TOIE+1
C : Therapy 3
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4.2 Missing Data Records Over Time 
4.2.1: Missing Data Patterns
It could be seen from the individual profile plots 4.1.1-4.1.4 above that some of the individuals in both 
studies did not have a complete set of records. Both data sets A and B had missing records, which in 
turn lead to an unbalanced design in both cases. These missing data patterns are described in Tables
4.1.1 and 4.1.2 below for data sets A and B respectively. Data Set A had missing on-treatment records 
for 13 patients and missing baseline records for 2 patients (Table 4.1.1). The same observations were 
missing for all three variables HR, SBP and DBP indicating that the machinery had failed at these 
specific times. Data Set B had missing on-treatment records for 4 patients (Table 4.1.2).
Table 4.1.1
DRUG CENTER PATIENT TIMES W HEN M ISSING GENERATED?
1 1 10011 1 Yes
10034 13 Y es
10050 18,19 Yes
1 2 20034 23 Yes
2 1 10040 3 Yes
2 2 20022 13 Yes
3 1 10031 23 Yes
10038 1,2,3 No, Deleted
3 2 20045 14,18,19,20,21,22 No, Deleted
20039 18,19,20 Yes
4 1 10024 23 Yes
4 2 20021 22,23 Yes
1 2 20048 0 No, Retained
2 1 10033 0 N o, Retained
NOTE: Each individual had missing data for all three vital signs heart rate, systolic and diastolic BP.
Table 4.1.2





TIMES W HEN M ISSING GENERATED?
6 Yes
GROUP 2 16 3 ,4 No, Deleted
GROUP 3 18 8 Yes
22 9 No, Deleted
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4.2.2: Ad-hoc Data Generation Method
Since the main purpose of this thesis was not to deal with missing data but was to look at approaches 
and problems related to the approaches used, it was decided to regenerate the missing data using the ad- 
hoc method devised for the data sets specific to this thesis. It must be noted that this may not be 
appropriate for all data sets and may need to be modified according to the data being looked at. The 
method was as follows:
Initially any patients that fell into the following three categories were deleted:
a) A patient withdrew early or had a missing last observation.
b) A patient’s records did not begin until after time 2.
c) When there was more than 15% missing data within an individual profile.
The following synario was then applied to generate missing data.
1. If the first observation was missing, then the second record was carried back to the first record.
2. If an individual had one missing record, then the two surrounding observations were averaged and 
this value was used.
3. If two consecutive values were missing then the value on the left was bought forward for one value 
and the value on the right was bought backward for the next missing value.
4. If an even number of values were missing, then this number was divided by two and that many 
observations were bought forward and bought backwards.
5. If an odd number of values were missing, then a combination of the two approaches was used. The 
value 1 was subtracted from the number of missing records. The same approach as point 4 above was 
applied to the data. This resulted in one missing record, which was imputed using point 2 above.
4.2.3: Generating Missing Data
Some of the missing data were generated using the ad-hoc method stated in section 4.2.2 above. The 
individuals for whom data were or were not generated are highlighted on Tables 4.1.1 and 4.1.2 above. 
From the process described, the on-treatment-missing records were not generated for 2 individuals 
within both data sets A and B. Hence, following the ad-hoc data generation process, data set A had 84 
complete on-treatment records and had two missing baseline records and data set B had 22 complete on- 
treatment records. Permanent univariate and multivariate data sets were produced on the data after data 
generation as were produced for the original data format. The univariate data sets were called ‘UNI_2’ 
and the multivariate data sets were called ‘MULT_2’.
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4.3 Distribution of the Continuous Data Over Time
Box-plots were produced below for each treatment for both data set A (Figures 4.2.1 to 4.2.3) and B
(Figure 4.2.4). In each case, similar patterns to those for the profile plots were observed. The box plots
each displayed the median, minimum, maximum and quintiles of the data at each univariate time point
per treatment group. The data did not appear to have a normal distribution at each univariate time point
per treatment group. Hence, a non-parametric Kruskal-Wallis approach was taken to test between
treatment groups at each univariate time point. Tables of summary statistics for these plots were
produced for the original data (Tables la-Id, Appendix A) and data sets after imputing the missing
information (Tables 2a-2d, Appendix A). The respective summary statistics in Tables la-Id  are those
values displayed in the box-plots below (Figures 4.2.1-4.2.4). Univariate (Normality and non-
parametric Kruskal-Wallis) tests were conducted on the data and the test results are also displayed.
The hypothesis for the univariate normal test was as follows:
Ho: The data is normally distributed. Hi: The data is non-normal.
This was obtained using the following code in SAS:
PROC UNIVARIATE NORMAL;
VAR VALUE;
B y  D r u g  T im e ; * * D a t a  s e t  A , C h a n g e  D r u g  t o  G r o u p  f o r  D a t a  s e t  B  * * * ;  
r u n ;
The hypothesis for the univariate Wilcoxon (for n=2 groups) or Kruskal-Wallis (for n > 2 groups) tests 
was as follows: H0: There is no difference in treatment.
H,: There is significant evidence to suggest a treatment difference.
This was obtained using the following code in SAS: 
p r o c  N p a r I w a y  WILCOXON;
CLASS TIME;
VAR VALUE;
B y  T im e ; * * D a t a  s e t  A , C h a n g e  D r u g  t o  G r o u p  fo r  D a t a  s e t  B  ***;  
r u n ;
These tests were conducted on both forms of data in order to see whether there were any vast differences
in testing the data univariately after imputing missing data records. Comparisons of test results before
and after imputing missing data are displayed in Tables 4.2.1-4.2.4 below. Notice that in the case of the
univariate tests, the results both before and after imputing data are almost identical. As mentioned
above, the only purpose of analysing times in a univariate manner was to note differences in results
obtained from the data sets before and after data replacement. There were also far too many univariate
tests being conducted and not all groups were normal for all cases. Hence it was decided that parametric
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test procedures based on asymptotic theory (reducing the number p of repeated measures) or non- 
parametric tests approaches would be a more appropriate way of handling this data rather than 
transforming the data for multivariate analyses purposes.
4.3.1: Heart Rate
Box-plots of summary statistics for Heart Rate (beats/minute) by treatment groups are displayed in 
Figures 4.2.1 A-D below.
FIGURE 4.2.1
Box Plot of Distribution of Heart Rate (beats/min) over Time by Treatment Group. 
Original Data: Before Missing Data Replaced (N=86).
A : Treatment 1 B : Treatment 2
C : Treatment 3 D : Treatment 4
Summary statistics with tests for normality at each time point are displayed in Table la  (Appendix A). 
Table 2a (Appendix A) shows this same table for data after imputing missing records. From the tests of 
normality in Table 4.2.1 below, it can be seen that the original data is not normally distributed for drug 1 
at time 15 hours, drug 2 at times 9 and 23 hours and drug 4 at times 7, 8 ,9 ,13 ,15 , 21 and 23 hours. All 
other data time points are normally distributed. These results are identical for the data after imputing 
missing data. In testing for treatment differences at each time point, using non-parametric Kruskal- 
Wallis tests, it was found that there were no treatment differences in the data for both the original data 
and the data after imputing missing data.
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Table 4.2.1
Normal Tests Per Treatment and Non-Parametric Treatment Difference Tests Over Time
P-Values to Compare Before and After Data Generation: Heart Rate (b/m)
Time Dataset Normal Tests For Each Treatment Group K-Wallis
1 2 3 4
Baseline
0
Before 0.288 0.354 0.531 0.348 0.918
After 0.288 0.354 0.280 0.348 0.921
1 Before 0.731 0.762 0.357 0.179 0.906
After 0.749 0.762 0.356 0.179 0.871
2 Before 0.632 0.422 0.531 0.088 0.554
After 0.632 0.422 0.473 0.088 0.543
3 Before 0.402 0.829 0.661 0.144 0.528
After 0.402 0.736 0.497 0.144 0.609
4 Before 0.578 0.936 0.197 0.863 0.554
After 0.578 0.936 0.200 0.863 0.558
5 Before 0.632 0.845 0.973 0.977 0.486
After 0.632 0.845 0.892 0.977 0.508
6 Before 0.238 0.959 0.506 0.897 0.631
After 0.238 0.959 0.628 0.897 0.646
7 Before 0.245 0.177 0.123 <0.001* 0.913
After 0.245 0.177 0.113 <0.001* 0.919
8 Before 0.089 0.734 0.535 0.029* 0.693
After 0.089 0.734 0.461 0.029* 0.677
9 Before 0.082 0.014* 0.505 0.025* 0.894
After 0.082 0.014* 0.554 0.025* 0.922
10 Before 0.143 0.704 0.098 0.608 0.721
After 0.143 0.704 0.097 0.608 0.692
11 Before 0.637 0.884 0.152 0.266 0.846
After 0.637 0.884 0.187 0.266 0.840
12 Before 0.098 0.570 0.751 0.224 0.648
After 0.098 0.570 0.636 0.224 0.643
13 Before 0.648 0.917 0.958 <0.001* 0.977
After 0.516 0.937 0.920 <0.001* 0.995
14 Before 0.815 0.823 0.827 0.182 0.724
After 0.815 0.823 0.984 0.182 0.642
15 Before 0.038* 0.125 0.531 0.016* 0.866
After 0.038* 0.125 0.691 0.016* 0.825
16 Before 0.901 0.490 0.747 0.108 0.843
After 0.901 0.490 0.777 0.108 0.827
17 Before 0.946 0.903 0.690 0.655 0.868
After 0.946 0.903 0.540 0.655 0.848
18 Before 0.475 0.704 0.341 0.862 0.431
After 0.506 0.704 0.330 0.862 0.427
19 Before 0.639 0.656 0.768 0.724 0.855
After 0.645 0.656 0.775 0.724 0.850
20 Before 0.390 0.257 0.525 0.671 0.782
After 0.390 0.257 0.912 0.671 0.784
21 Before 0.082 0.384 0.528 <0.001* 0.254
After 0.082 0.984 0.697 <0.001* 0.269
22 Before 0.568 0.573 0.525 0.112 0.644
After 0.568 0.573 0.301 0.101 0.524
23 Before 0.939 0.006* 0.438 0.024* 0.250
After 0.947 0.006* 0.636 0.036* 0.184
24 Before 0.626 0.299 0.714 0.167 0.141
After 0.626 0.299 0.510 0.167 0.120
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4.3.2: Systolic Blood Pressure (mmHg)
A clearer picture of the behaviour of the data can be observed from the box-plots of the data seen in 
Figures 4.2.2 A-D below. The data appears to be highly skewed at some of the time points and there is a 
great deal of variation in the ranges for the data at each time point.
FIGURE 4.2.2
Box Plot of Distribution of Systolic Blood Pressure over Time by Treatment Group. 
Original Data: Before Missing Data Replaced (N=86).
A: Treatment 1 B : Treatment 2
T1ME+1 (hours)
C : Treatment 3 D : Treatment 4
Summary statistics with tests for normality at each time point are displayed in Table lb  (Appendix A). 
Table 2b (Appendix A) shows this same table for data after imputing missing records. From Table 4.2.2 
below, it can be seen that the original data is not normally distributed for drug 1 at times 16 and 22 
hours, drug 2 at times 20 and 21 hours, drug 3 at times 0,16 and 24 hours and drug 4 at 3 hours. All 
other data time points are normally distributed. These results are almost identical for the data after 
imputing missing data with the exception of for drug 3 at time 24 hours where the data is marginally 
normally distributed. In testing for treatment differences at each time point, it was found that there were 
treatment differences in both the original and imputing data at times 1, 3, 5, 6 ,7 , 8 16,17 ,18 ,19 ,21 ,23  
and 24 hours. Only the non-normal reading (p=0.027) at time 24 hour on drug 3 was later tested to be 
normally distributed following the data generation method (p=0.054). This inconsistency is not serious.
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Table 4.2.2
Normal Tests Per Treatment and Non-Parametric Treatment Difference Tests Over Time 
P-Values to Compare Before and After Data Generation: Systolic BP (mmHg)
Time Dataset Normal Tests For Each Treatment Group K-Wallis
1 2 3 4
Baseline Before 0.968 0.385 0.041* 0.066 0.857
0 After 0.968 0.385 0.029* 0.066 0.866
1 Before 0.794 0.278 0.150 0.808 0.038*
After 0.913 0.278 0.110 0.808 0.022*
2 Before 0.864 0.416 0.425 0.727 0.110
After 0.864 0.416 0.607 0.727 0.111
3 Before 0.374 0.327 0.624 0.025* 0.015*
After 0.374 0.298 0.369 0.025* 0.012*
4 Before 0.633 0.089 0.057 0.426 0.186
After 0.633 0.089 0.058 0.426 0.186
5 Before 0.947 0.990 0.071 0.922 0.033*
After 0.947 0.990 0.141 0.922 0.035*
6 Before 0.149 0.856 0.901 0.752 0.005*
After 0.149 0.856 0.903 0.752 0.006*
7 Before 0.690 0.985 0.335 0.465 0.023*
After 0.690 0.985 0.378 0.465 0.024*
8 Before 0.483 0.214 0.193 0.502 0.039*
After 0.483 0.214 0.201 0.502 0.042*
9 Before 0.786 0.902 0.963 0.815 0.150
After 0.786 0.902 0.972 0.815 0.151
10 Before 0.839 0.449 0.506 0.317 0.054
After 0.839 0.449 0.498 0.317 0.050
11 Before 0.748 0.343 0.986 0.219 0.059
After 0.748 0.343 0.959 0.219 0.058
12 Before 0.538 0.884 0.711 0.264 0.053
After 0.538 0.884 0.358 0.264 0.052
13 Before 0.649 0.473 0.996 0.536 0.120
After 0.715 0.548 0.881 0.536 0.117
14 Before 0.890 0.539 0.421 0.786 0.082
After 0.890 0.539 0.534 0.786 0.084
15 Before 0.935 0.234 0.782 0.139 0.154
After 0.935 0.234 0.884 0.139 0.163
16 Before 0.006* 0.221 0.002* 0.662 0.002*
After 0.006* 0.221 0.002* 0.662 0.002*
17 Before 0.921 0.179 0.690 0.189 0.037*
After 0.921 0.179 0.643 0.189 0.036*
18 Before 0.359 0.492 0.205 0.167 0.049*
After 0.574 0.492 0.063 0.167 0.039*
19 Before 0.056 0.087 0.733 0.838 0.023*
After 0.118 0.087 0.916 0.838 0.033*
20 Before 0.282 0.016* 0.909 0.379 0.199
After 0.282 0.016* 0.840 0.379 0.335
21 Before 0.175 0.034* 0.514 0.464 0.016*
After 0.175 0.034* 0.651 0.464 0.020*
22 Before 0.018* 0.343 0.811 0.922 0.398
After 0.018* 0.343 0.452 0.852 0.491
23 Before 0.430 0.242 0.308 0.455 0.003*
After 0.388 0.242 0.235 0.719 0.007*
24 Before 0.982 0.422 0.027* 0.091 0.041*
After 0.982 0.422 0.054 0.091 0.036*
66
4.3.3: Diastolic Blood Pressure (mmHg)
A clearer picture of the data could be obtained from the box-plots of the data below (Figures 4.2.3A-D). 
The data on drug 3 appeared to have much more variation at each time point than the other treatments.
FIGURE 4.2.3
Box Plot of Distribution of Diastolic Blood Pressure over Time bv Treatment Group: Original 
Data: Before Missing Data Replaced (N=86).
A : Treatment 1 B : Treatment 2
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Summary statistics with tests for normality at each time point are displayed in Table lc (Appendix A). 
Table 2c (Appendix A) shows this same table for data after imputing missing records. From Table 4.2.3 
below, it can be seen that the original data is not normally distributed for drug 1 at times 12 and 16 
hours, drug 2 at times 11, 20 and 23 hours, drug 3 at 23 hours and drug 4 at 14 hours. All other data 
time points are normally distributed. These results are almost identical for the data after imputing 
missing data with the exception of for drug 3 at time 1, normal reading (p=0.078) on drug 3 was later 
tested to be non-normally distributed following the data generation method (p=0.045). This 
inconsistency is nothing to worry about. In testing for treatment differences at each time point, it was 
found that there were treatment differences in both the original data and the data after imputing missing 
data at times 3, 5, 6, 7, 8,10, 11,16 and 21 hours.
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Table 4.2.3
Normal Tests Per Treatment and Non-Parametric Treatment Difference Tests Over Time 
P-Values to Compare Before and After Data Generation: Diastolic BP (mmHg)
Time Dataset Normal Tests For Each Treatment Group K-Wallis
1 2 3 4
Baseline Before 0.995 0.128 0.528 0.425 0.900
0 After 0.995 0.128 0.663 0.425 0.894
1 Before 0.799 0.964 0.078 0.540 0.173
After 0.728 0.964 0.045* 0.540 0.118
2 Before 0.536 0.859 0.689 0.981 0.145
After 0.536 0.859 0.709 0.981 0.164
3 Before 0.061 0.699 0.378 0.305 0.019*
After 0.061 0.658 0.323 0.305 0.020*
4 Before 0.475 0.992 0.461 0.200 0.062
After 0.475 0.992 0.525 0.200 0.065
5 Before 0.094 0.068 0.427 0.594 0.035*
After 0.094 0.068 0.402 0.594 0.030*
6 Before 0.497 0.091 0.450 0.695 0.017*
After 0.497 0.091 0.641 0.695 0.016*
7 Before 0.621 0.408 0.721 0.244 0.019*
After 0.621 0.408 0.666 0.244 0.015*
8 Before 0.513 0.227 0.833 0.099 0.004*
After 0.513 0.227 0.969 0.099 0.003*
9 Before 0.664 0.821 0.610 0.446 0.673
After 0.664 0.821 0.587 0.446 0.633
10 Before 0.503 0.338 0.061 0.545 0.019*
After 0.503 0.338 0.076 0.545 0.019*
11 Before 0.496 0.045* 0.347 0.743 0.033*
After 0.496 0.045* 0.277 0.743 0.031*
12 Before 0.030* 0.299 0.599 0.676 0.204
After 0.030* 0.299 0.312 0.676 0.293
13 Before 0.415 0.810 0.366 0.415 0.276
After 0.267 0.761 0.621 0.415 0.279
14 Before 0.538 0.166 0.166 0.017* 0.521
After 0.538 0.166 0.222 0.017* 0.474
15 Before 0.248 0.602 0.060 0.810 0.095
After 0.248 0.602 0.197 0.810 0.090
16 Before 0.011* 0.691 0.809 0.626 0.006*
After 0.011* 0.691 0.695 0.626 0.008*
17 Before 0.143 0.752 0.831 0.928 0.070
After 0.143 0.752 0.680 0.928 0.073
18 Before 0.400 0.521 0.320 0.060 0.151
After 0.295 0.521 0.405 0.060 0.147
19 Before 0.330 0.213 0.962 0.998 0.216
After 0.225 0.213 0.659 0.998 0.214
20 Before 0.340 0.025* 0.748 0.244 0.327
After 0.340 0.025* 0.701 0.244 0.459
21 Before 0.111 0.480 0.897 0.071 0.018*
After 0.111 0.480 0.612 0.071 0.020*
22 Before 0.294 0.539 0.946 0.656 0.882
After 0.294 0.539 0.461 0.653 0.810
23 Before 0.660 0.032* 0.015* 0.789 0.430
After 0.666 0.032* 0.022* 0.878 0.530
24 Before 0.499 0.472 0.786 0.151 0.156
After 0.499 0.472 0.902 0.151 0.128
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4.3.4: Dietary Response
Dietary response can be seen more clearly in the box plots below (Figures 4.2.4 A-C) that show both 
the variations in the data and also the distribution of the data at each time point. Therapy 3 is a function 
that is decreasing with time.
FIGURE 4.2.4
Boxplot of Distribution of Dietary Response over Time (hours) by Therapy group. 
Original Data: Before Missing Data Replaced (N=24).
A : Therapy 1 B : Therapy 2
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Summary statistics with tests for normality at each time point are displayed in Table Id (Appendix A). 
Table 2d (Appendix A) shows this same table for data after imputing missing records. From Table 4.2.4 
below, it can be seen that the original data is not normally distributed for therapy 3 at time 6. All other 
data time points are normally distributed. These results are almost identical for the data after imputing 
missing data with the exception of for therapy 3 at time 3 where the data are also not normally 
distributed. In testing for treatment differences at each time point, it was found that there were 
treatment differences in both the original data and the data after imputing missing data at times 2, 3,4, 




Normal Tests Per Treatment and Non-Parametric Treatment Difference Tests Over Time
P-Values to Compare Before and After Data Generation: Dietary Response
Time Dataset Normal Tests For Each Therapy K-Wallis
1 2 3
Baseline Before 0.835 0.744 0.664 0.539
0 After 0.835 0.359 0.749 0.495
1 Before 0.952 0.992 0.335 0.077
After 0.952 0.975 0.562 0.090
2 Before 0.350 0.372 0.887 0.009*
After 0.350 0.412 0.835 0.013*
3 Before 0.795 0.109 0.103 0.010*
After 0.795 0.109 0.028* 0.004*
4 Before 0.231 0.665 0.815 0.007*
After 0.231 0.665 0.557 0.011*
5 Before 0.866 0.856 0.786 <0.001*
After 0.866 0.856 0.782 <0.001*
6 Before 0.069 0.844 0.032* <0.001*
After 0.170 0.912 0.023* <0.001*
7 Before 0.277 0.373 0.151 <0.001*
After 0.277 0.261 0.127 <0.001*
8 Before 0.844 0.755 0.729 <0.001*
After 0.844 0.961 0.777 <0.001*
9 Before 0.074 0.399 0.755 <0.001*
After 0.074 0.334 0.755 <0.001*
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4.4 Plots of Summary Statistic by Treatment over Time
Since it was of interest to see what the mean, median, maximum and minimum profiles looked like, 
appropriate profile plots were produced to show the differences between treatment or therapy group. 
Figures 4.3.1-4.3.4 below, show the plots for the respective summary statistics for heart rate, systolic 
BP, diastolic BP and dietary response respectively and Tables la-Id  (Appendix A) show the actual 
summary statistics used in these plots. A commonly used plot of the mean response profile over time 
together with standard error bars was then produced for each variable in data sets A and B and these are 
displayed below in Figures 4.4.1-4.4.4 respectively. These plots gives a better idea of the behaviour of 
the data over time compared with the picture previously provided by the individual profile plots in 
Figures 4.1.1-4.1.4 above. The median plots (Figures 4.3.1 B -4.3.4 B) show the difference in treatment 
or therapy at each time point clearly on one figure (corresponding to the Kruskal-Wallis test results from 
Tables la-Id  - Appendix A).
4.4.1: Heart Rate (beats/minute)
FIGURES 4.3.1
Plots of Summary Response Profiles over Time by Treatment GroupFor Heart Rate(b/m): 
Original Data Before Missing Data Replaced (N=86).







































There were no obvious treatment differences in the mean heart rate over time since the mean responses 
were very close together (Figure 4.3.1A). The median results (Figure 4.3.IB) appeared to be very 
similar for all four treatments apart from the fact that there were slightly higher results for drug 3 and 
lower results for drug 1 at around times 7 to 10 hours on treatment. Drug 1 had considerably larger 
median levels than the other treatment groups at time 23. Both the minimum and maximum plots over 
time (Figures 4.3.1C and 4.3.ID respectively) varied randomly after ignoring the two outlying readings 
at time 11 and 23 for the minimum plot and at times 9 and 23 on the maximum plot. All figures 
mentioned above gave some idea of the behaviour of the data over time.
From the mean and standard error plot in Figure 4.4.1 below, it can be seen that all standard error bars 
crossed indicating no significant differences between readings from one time point to the next. The 
average data peaked at two times, namely at 11 and 23 hours on-treatment.
FIGURE 4.4.1
Mean and Standard Error Plot for Original Heart Rate Data (beats/min) Over Time By 
Treatment Before Missing Data Replaced.
Figure 4.4.1
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4.4.2: Systolic Blood Pressure (mmHg)
From observing the mean and median plots over time (Figures 4.3.2A and 4.3.2B) it can be seen that the 
mean data stays pretty constant over time until around 14 hours where it suddenly drops. It then levels 
off at between 16 to 21 hours after which time it increases to peak at time 23 hours. For the median data, 
similar patterns exist in the data but there are far more fluctuations between each of the individual time 
points. Both the minimum and maximum response (Figures 4.3.2C and 4.3.2D) vary considerably over 
time between each individual time point. There is no obvious pattern to the data apart from the dip in 
the data around time 14 hours and peak around 23 hours. It can be seen that drug 4 has the lowest 
mean, median and maximum response overall and after 17 hours the minimum response is also lowest 
for drug 4. Drug 1 has the highest mean and median response at most of the observed time points.
FIGURES 4.3.2
Plots of Summary Response Profiles over Time bv Treatment Group for Systolic BP (mmHg) 
Original Data Before Missing Data Replaced (N=86).

































The mean and SE plot in Figure 4.4.2 below gave a clearer picture of the behaviour of the data than for 
the individual profile plots (Figure 4.1.2 above). Drug 4 appeared to have lower mean systolic BP than 




Mean and Standard Error Plot for Original Systolic Blood Pressure (mmHg) Over Time Bv 
Treatment Before Missing Data Replaced.
Figure 4.4.2
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4.4.3: Diastolic Blood Pressure (mmHg)
FIGURES 4.3.3
Plots of Summary Response Profiles over Time by Treatment Group for Diastolic BP (mmHg)
A: Mean









5 6 7 8 9 9  11 e  O H 19 C 17 R 6  to  21 22 23 24
TIME (hours)





03 8 5555 “ <5  45
40 0 1 2 3 4 5 6 7 8 9 10 11 V  13 *  15 16 17 9  19 20 21 22 23 24
TIME (hours)2 • • • 3 *-
3X
IU 00







0 1 8 9 O 11 12 O 14 *5 «  17 18 O 20 21 22 23 24
TIME (hours)
74
From observing the mean and median plots over time (Figures 4.3.3A and 4.3.3B) it could be seen that 
they had similar patterns over time. The mean and median data was constant over time until around 6 
hours where it suddenly dropped slightly and then increased again at time 7 hours. The data peaked at 
11 hours and then gradually decreased until a plateau was reached from time 16 to 21. After this time 
the readings increased until they peaked at 23 hours and then began to decrease.
Both the minimum and maximum response (Figures 4.3.3C and 4.3.3D) over time varied considerably 
between each individual time point and there was no obvious pattern to the data apart from a dip at 
around 19 hours. It could be seen that drug 4 had the lowest mean, median, minimum and maximum 
response after 16 hours. The average data seemed almost constant over time until time 6 hours where it 
dropped slightly. The average readings decreased considerably between 12 to 23 hours (Figure 4.4.3).
FIGURE 4.4.3
Mean and Standard Error Plot for Original Diastolic Blood Pressure (mmHg) Over Time By 
Treatment Before Missing Data Replaced.
Figure 4.4.3
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4.4.4: Dietary Response
The median plot in Figure 4.3.4B is similar to the mean plot in Figure 4.3.4A. The median response for 
group 2 varies slightly more than the mean response. The minimum and maximum responses over time 
are displayed in Figures 4.3.4C and 4.3.4D. The minimum plot is similar in appearance to the median 
plot. The mean and SE plot (Figure 4.4.4 below) shows that therapy 1 has a much larger mean response 




Plots of Summary Response Profiles over Time bv Treatment Group for Dietary Data 
Original Data Before Missing Data Replaced (N=86).
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FIGURE 4.4.4
Mean and Standard Error Plot for Original Dietary Data Over Time Bv Treatment Before
Missing Data Replaced.
Figure 4.4.4
Mean Response and 95% Cl for Dietary Response
<d 10' co c: oQ_COa>CC 0.8-
co •*—> a>a 0.6 -
0.4 4
0 1 2 3 4 5 6 7 98
Time
GROUP ------- 1  2 --------------3
76
4.5 Distribution of Continuous Overall Data Per Group
Box-plots were produced for each outcome variable by treatment/therapy, assuming that there was 
independence between every measurement for each subject. In other words, the repeated data per 
individual were not considered. Hence, time was not considered here and it was therefore assumed that 
the p=l to 24 univariate time points per individual were p separate individuals. The plots both before and 
after data replacement were similar and hence only plots before replacement are displayed below. Note 
that the only reason for taking this approach was as a rough visualisation guide to find out how the 
overall data was behaving when the factors of time, centre, baseline measurement and subject were 
ignored. Further statistical methods were not conducted using this approach.
4.5.1: Heart Rate (beats/minute) 
FIGURE 4.5.1
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From the box-plot, Figure 4.5.1 above, the median data appear to be similar for all four treatment groups. 
Drug 2 appears to have the greatest variation in heart rate measurements. The highest overall heart rate 
measurement occurred on drug 2.
4.5.2: Systolic Blood Pressure (mmHg)
From the box-plot, Figure 4.5.2 below, the median systolic BP on drug 1 seems slightly higher than on 
any other drug and the median systolic BP on drug 4 seems slightly lower on any other drug. The lowest 
overall response for systolic blood pressure occurs on drug 4.
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FIGURE 4.5.2
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4.5.3: Diastolic Blood Pressure (mmHg)
FIGURE 4.5.3
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From the box-plot, Figure 4.5.3 above, the median results on drugs 3 and 4 appear to be lower than the 
median results on drugs 1 and 2. Drug 4 appears to have the greatest variation in diastolic blood pressure 
readings and also appears to contain the lowest overall response. Drug 2 contains the largest response.
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4.5.4: Dietary Response
From the box-plot, Figure 4.5.4 below, the median response is largest for therapy 1 and lowest for 
therapy 3. Therapy 3 also appears to have a skewed distribution.
FIGURE 4.5.4
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4.6 Categorical Approach: Frequency of Abnormally High Results At Each Time.
A categorical approach was only applied to data set A. All data was classified into one of 7 categories 
according to Table 3.1.1 [section 3.2]. Since there were far too many categories to be able to distinguish 
clearly between groups, the data was further categorised into three levels of high, low or normal (Table
3.1.2 [section 3.2]) for heart rate, systolic and diastolic BP respectively. Listing 3.3 [section 3.2] 
provides the structure of this data set. Only the ‘high’ results were considered to be abnormal and these 
data were then analysed.
A frequency table of the number of abnormally ‘high’ results at each time point per treatment group was 
produced for each variable. The results are displayed in Tables 12a-12c (Appendix A) for the three 
respective variables (heart rate, systolic and diastolic blood pressure) being analysed. Univariate tests 
were conducted to test for treatment differences for the number of high results at each univariate time 
point. Chi-squared tests and when inappropriate (if the expected cell count was less than 5%) Fishers 
exact tests were conducted to test for the relationship between the abnormal readings at each time point 
with treatment. All p-values are also displayed in Tables 12a to 12c (Appendix A).
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As with the continuous data analysis approach, the method of analysing the data at each univariate time 
point is not of much use for the same reasons. The main reason against using the univariate time point 
approach is that having a difference at a particular time point does not explain the picture of the data as a 
whole. This analysis was conducted as a means of describing the data only.
4.6.1: Heart Rate (beats/minute)
No significant treatment differences were detected at any time point for the occurrence of abnormally 
‘high’ heart rates (p>0.119). See Table 12a (Appendix A). These findings correspond to those from all 
the previous analyses in this chapter. Namely from the Kruskal-Wallis test at each univariate time point. 
The frequency of individuals with abnormally ‘high’ heart rate results was very low per treatment group 
at each time point. There were no occurrences of abnormally ‘high’ results at times 0,1, 2 ,4 , 17,18,19 
and 20 and there were no more than 7 individuals with an abnormality at any single time point (time 23). 
4.6.2: Systolic Blood Pressure (mmHg):
See Table 12b (Appendix A) for the frequency of occurrence of abnormally ‘high’ results and the Chi- 
squared test results per time point. Significant treatment differences were detected at 6, 8,16 and 23 
hours (p<0.019) for the occurrence of abnormally ‘high’ systolic BP readings. Differences at all these 
time points were also found using the univariate Kruskal-Wallis tests that were conducted on the data.
In all cases, drug 4 had lower occurrence of ‘high’ results than the other treatment group. At earlier 
times, 6 and 8 hours, drug 1 had greater frequency of abnormality and at later times, 16 and 23 hours, 
drug 2 had higher abnormality. In each case drug 4 had lower readings than the other drugs being 
studied.
4.6.3: Diastolic Blood Pressure (mmHg)
Table 12c (Appendix A) gives the frequency of abnormally ‘high’ results and Chi-squared test results. 
Significant treatment differences were detected at only 6 hours (p=0.004) for the occurrence of 
abnormally ‘high’ diastolic BP readings. A treatment difference was also picked up at time 6 hours for 
the median response using the Kruskal-Wallis test. Drug 1 had greater frequency of occurrence of 
abnormally ‘high’ readings and drug 3 had fewer occurrences than any other treatment at time 6 hours.
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4.7 Overview
All plots in sections 4.1,4.3 and 4.4 were produced to get a clear idea of the behaviour of the data at 
both baseline (pre-treatment) and at each individual (on-treatment) time point. Univariate profile plots 
are not very useful in summarising the data and hence, univariate box-plots or summary measures over 
time are considered to be the best way of displaying and summarising the data points.
From the box-plots over time (Figures 4.2.1-4.2.4 [section 4.2]) and univariate normal tests (Tables
4.2.1 to 4.2.4 [section 4.2] and Tables la -ld  (Appendix A)) it can be seen, for all the variables being 
investigated, that there was not always a consistency in the distribution of the data across time. For this 
reason, it was decided to use asymptotic or non-parametric approaches to analyse the data when testing 
for treatment differences at each time point. Most of the time points of data per treatment group or 
therapy, however, were normally distributed according to the box-plots and normality tests. This 
statement can be confirmed by looking at the similarity of the mean and median plots over time. Testing 
for treatment differences per time point is not of any use since the data is not described as a whole 
element. This type of univariate data analysis is only useful for getting an idea of the behaviour of the 
data across time. Here, the only purpose for comparing treatment/therapy groups at each univariate time 
point (Kruskal-Wallis tests), was to be able to compare the data both before and after imputing missing 
records. The actual results of the tests were not of much importance in this situation.
It was found that the data before and after imputing missing data gave basically similar results for both 
the normality tests, the tests of comparing treatment groups and also the plots of summary statistics, 
box-plots and profile plots over time. Hence, in conclusion, imputing missing data does not seriously 
affect the univariate testing of the data.
When the element of time was not considered [section 4.5] and all observations were presented together 
as independent records, the plots of the original data and the imputed data were very similar and 
therefore only the box-plots on the original data are displayed. The method of observing the data 
without considering the element of time, however, is not reliable since results over time for an 
individual are not infact independent. This approach was only useful in gaining a feel for the behaviour 
of the data but, not for making any firm conclusions. Statistical tests were not conducted using this 
approach.
In conclusion, there were no significant treatment differences at any time point or overall data for the 
occurrence of an abnormally ‘high’ heart rate reading. Drug 4 had lower systolic blood pressure than
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any other therapy. The only detection of abnormality differences for diastolic blood pressure were noted 
at time 6 hours where drug 3 had lower readings and drug 1 had highest readings. The following chapter 
introduces the univariate summary measures, as were introduced in chapter 3.3, to make data inferences.
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CHAPTER 5: Univariate Summary Measures Analysis
5.0 Introduction
The previous chapter provided the exploratory data analysis on the data with plots displaying the data 
for each treatment/therapy at each univariate time point. The normality tests conducted showed that 
the data was approximately normally distributed at each univariate time point though this does not 
imply multivariate normality [section 2.1]. It could also be seen that the mean and median plots were 
very similar over time -  confirming this previous point.
Univariate testing at each time point was not of any interest while testing for group differences. The 
only reason for testing at each time point was to compare the information before and after imputing 
missing records. Univariate tests over time were not affected by imputing missing data, so only the 
information for the original data were displayed in the plots in the previous chapter.
The present chapter is concerned with univariate testing of the data after eliminating the association of 
time. This is done by obtaining various univariate summary measures from the data and analysing 
each summary measure independently. Each univariate summary measure independently describes 
the characteristic of the data per individual. This approach is known as a ‘Response Features Analysis’ 
or ‘Summary Measures Approach’. Of all unvariate approaches considered, this is believed to be the 
only univariate testing of some substance. Figures and summaries were obtained on both the original 
data and the data after imputing missing records. Again, as with the plots in the previous chapter, the 
figures on the imputed data were very similar to those from the original data set so they were not 
displayed within this chapter.
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5.1 Continuous Data Analysis: Response Features Analysis
Every patient had a single measurement for each of the summary statistics (mean, median, minimum, 
maximum, lower quartile (Ql), upper quartile (Q3), base and change), mentioned in more detail below, 
for each outcome variable (HR, SBP, DBP and dietary response) of interest. See Listings 3.4.1 and
3.4.2 [section 3.3] for the data structures of summary measures for data sets A and B respectively.
Time was no longer a factor during this analysis.
The 8 summary measures above can be described as follows:
1) MEAN, MEDIAN. Minimum (MIN). Maximum (MAX). Lower and Upper Quartiles (Ol and 03). 
Each of the 6 summary statistics above were calculated over all data for each individual, so that they 
had just one overall reading of each of the summary statistics above for each outcome variable of 
interest. Missing data was not a problem for this method since the summary measurements ignored the 
missing data and calculated measurements on only the available data.
2) Baseline/ Pre-treatment readings (BASE).
The baseline (time=0) or mean run-in reading ‘BASE’ was assumed to be pre-treatment. Each patient 
had one measurement for this variable. Data set A had 2 missing baseline records that were never 
generated and data set B had no missing baseline records.
3) The mean change from baseline.
This was calculated using the difference between the mean response ‘MEAN’ and also the mean 
pre-treatment response ‘BASE’ above.
Univariate normality tests (by treatment / therapy group) and Kruskal-Wallis tests were conducted for 
both the original summary measures data (Tables 5a to 5d -  Appendix A) and the regenerated 
summary measures data (Tables 7a to 7d -  Appendix A) for each respective outcome variable. This 
was done using the same SAS code as in section 4.3. The results from the normal tests and the 
Kruskal-Wallis tests on the data, both before and after data replacement, are also displayed in Tables 
5.1.1-5.1.4 below for HR, SBP, DBP and dietary response respectively. Any significant results are 
highlighted for all tests.
Of the various univariate approaches applied to the data, tests on each of the summary measures was 
considered to be the only univariate testing of any use. In the case of univariate testing of time, any 
missing data lead to imbalance and inconsistency between groups. Univariate testing at each time point 
was not of any interest while testing for group differences. Missing data and imbalance were not an
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issue with the univariate summary measures analysis that was applied to the data. This was because 
the dimension of the summary statistic vector was small compared to the sample size of treatment 
groups, hence, one could arrive at reasonable conclusions via asymptotic tests. While applying these 
there is no loss of generality in assuming the summary statistic vector to be normal even when this is 
not so. A non-parametric Kruskal-Wallis approximation of the Chi-squared test in a 1-way ANOVA 
approach was taken to analyse the data by testing between treatment groups. The tests conducted were 
similar to those conducted at each univariate time point in Tables la-Id  and 2a-2d (Appendix A) and 
also in Tables 4.2.1-4.2.4 [section 4.3], using Proc NPAR1WAY with the WILCOXON option. This 
method was adequate to test for treatment differences in a non-balanced situation and the condition of 
normality, as implied earlier, was not of great importance. The assumption of normality did not need to 
be met in order to use this method.
It was then decided to summarise the summary measures by centre and treatment for data set A. Since 
there were no differences in the results from the original data and the data after imputing missing 
records, this by centre summary was displayed in Table 6a to 6c (Appendix A) for the original HR, 
SBP and DBP data only. Tables 5.1.1-5.1.3 below also show the respective results of all Kruskal- 
Wallis tests per centre for summary measures on the original HR, SBP and DBP data.
Block charts were produced overall and by treatment / therapy group for both the original and imputed 
data sets for each summary measure. It could be seen that there were no vast differences before and 
after imputation so only the charts of the original data (data sets A and B) are displayed for this thesis. 
Block charts were produced for the overall original HR, SBP, DBP and dietary response data and are 
displayed in Figures 5.1.1-5.1.4 below. Here, Figures C and D show the mean and median 
respectively, Figures E and F show the minimum and maximum and Figures G and H show the lower 
quartile and upper quartile. The block charts for baseline data from the original data set only are 
displayed in Figure A and those displayed in Figure B represent the mean change from baseline. 
Similar block charts by treatment groups were produced for the original HR, SBP, DBP and dietary 
response data and are displayed in Figures 5.2.1-5.2.4 below.
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5.1.1: Heart Rate (beats/minute)
The normal tests in Table 4.2.1 [section 4.3.1] above showed that the baseline data for each treatment 
group was normally distributed (p>0.260). From conducting the Kruskal-Wallis test on the data it 
could be seen that there were no significant treatment differences for heart rate at baseline (p>0.918).
Table 5.1.1
Normal Tests Per Treatment and Kruskal-Wallis Tests For Each Summary Measures 
P-Values to Compare Before and After Data Generation: Heart Rates (b/m)
Summary Dataset Treatment K-Wallis
Measure 1 2 3 4
Change Before 0.002* 0.011* 0.475 0.013* 0.161
Centre 1 0.467
Centre 2 0.103
After 0.006* 0.011* 0.506 0.010* 0.173
Mean Before 0.528 0.486 0.204 0.680 0.985
Centre 1 i 0.883
Centre 2 0.630
After 0.583 0.488 0.142 0.639 0.978
Median Before 0.809 0.421 0.222 0.504 0.927
Centre 1 0.832
Centre 2 0.497
After 0.766 0.390 0.178 0.504 0.931
Minimum Before 0.799 0.789 0.963 0.801 0.608
Centre 1 0.767
Centre 2 0.360
After 0.799 0.789 0.797 0.801 0.586
Maximum Before 0.656 0.006* 0.186 0.400 0.739
Centre 1 0.884
Centre 2 0.836
After 0.656 0.006* 0.131 0.400 0.743
Lower Before 0.661 0.912 0.353 0.429 0.904
Quartile Centre 1 0.706
Centre 2 0.843
After 0.573 0.861 0.199 0.429 0.886
Upper Before 0.721 0.428 0.268 0.753 0.987
Quartile Centre 1 0.759
Centre 2 0.481
After 0.736 0.469 0.235 0.729 0.984
Statistical summaries and tests before and after replacement can be seen in Tables 5a and 7a 
respectively (Appendix A). Summary measures on the data, both before and after replacement, were 
tested using normal and Kruskal-Wallis tests (Tables 5.1.1). Normal tests and K-Wallis tests gave 
similar results both before and after replacement for heart rate data. This was also seen with the 
figures, hence only figures on the original data are displayed. There were no treatment differences for 





Summary measures were obtained for the on-treatment data across time. These summary measures were 
displayed in the box-plots above (Figures 5.1.1B to 5.1.1H and 5.2.IB to 5.2.1H). Note that the axes on 
the block charts are not consistent for each summary measure.
From the normal and Kruskal-Wallis tests displayed in Table 5.1.1 above it can be seen there were no 
treatment differences in the mean, median, lower quartile, upper quartile or minimum heart rate (b/m) 
responses. The data was also normally distributed per treatment for all these summary measures.
For the maximum readings (Figures 5.1.IF and 5.2. IF), there was one outlier on drug 2 that ranged from 
162.5 to 187.5 beats/min and another individual on drug 3 had a reading between 37.5 and 62.5 
beats/min. All other readings ranged from 62.5 to 137.5 beats/min. The normal tests in Table 5.1.1 also 
show that the maximum response on drug 2 was not normally distributed. There were no treatment 
differences in the maximum heart rate readings.
Figures 5.1.IB and 5.2.IB describe the summary statistic change in mean from baseline. From Figure 
5.2.1B, it can be seen that 1 individual on drug 4 had an outlier value for change of mean value which 
ranged between 14 to 18. All other changes ranged from -14 to 14. Table 5.1.1 showed that all 
treatments apart from drug 3 had a skewed distribution for the change in mean from baseline. This can 
also be seen in Figure 5.2.1B. There were no treatment differences in the mean change from baseline 
for heart rate data (Table 5.1.1).
The summary measures on the data before replacing missing data were observed for the original data by 
centre (Table 6a-Appendix A). There are some inconsistencies with the normality tests per centre (see 
Table 6a-Appendix A) compared to the results on the original data. This is not however of great 
concern here. Tests for treatment differences by centre are also displayed in Table 5.1.1 above. It can be 
seen that the summary measures did not have any significant treatment differences for either centre 1 or 
2. This agrees with the results on the overall data.
In conclusion, there was only evidence of a non-normal distribution for the maximum data for drug 2 
and the change in mean from baseline for all treatments apart from drug 3. It can be seen that all 
summary measures, on both the overall data and data by centre, showed no significant evidence of 
treatment differences as with the tests at individual time points in the previous chapter. All results on the 
summary measures were consistent both before and after data replacement. This agrees with the 
findings on the univariate time points of data.
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5.1.2: Systolic Blood Pressure (mmHg)
The normal tests in Table 4.2.2 [section 4.3.2] above showed that the data at baseline for only drug 3 
were not normal (p=0.041) and were normally distributed for all other drugs (p>0.066). This can also be 
seen in Figure 5.2.2A. It could be seen, from the Kruskal-Wallis test, that there were no significant 
treatment differences for systolic BP at baseline (p>0.857).
Table 5.1.2
Normal Tests Per Treatment and Kruskal-Wallis Tests For Each Summary Measures 
P-Values to Compare Before and After Data Generation: Systolic BP (mmHg)
Summary Dataset Treatment K-Wallis
Measure 1 2 3 4
Change Before 0.163 0.003* 0.376 0.259 <0.001*
Centre 1 0.002*
Centre 2 0.061
After 0.253 0.003* 0.534 0.273 <0.001*
Mean Before 0.967 0.996 0.531 0.171 0.015*
Centre 1 0.025*
Centre 2 0.576
After 0.983 0.996 0.633 0.146 0.016*
Median Before 0.770 0.975 0.329 0.358 0.015*
Centre 1 0.016*
Centre 2 0.455
After 0.824 0.976 0.324 0.349 0.012*
Minimum Before 0.094 0.766 0.166 0.900 0.022*
Centre 1 0.188
Centre 2 0.135
After 0.094 0.766 0.229 0.900 0.023*
Maximum Before 0.473 0.936 0.727 0.788 0.065
Centre 1 0.042*
Centre 2 0.621
After 0.473 0.936 0.703 0.788 0.063
Lower Before 0.969 0.998 0.697 0.089 0.012*
Quartile Centre 1 0.029*
Centre 2 0.380
After 0.981 0.997 0.889 0.099 0.013*
Upper Before 0.812 0.907 0.458 0.369 0.030*
Quartile Centre 1 0.017*
Centre 2 0.691
After 0.870 0.913 0.394 0.347 0.030*
Statistical summaries and tests before and after replacement can be seen in Tables 5b and 7b 
respectively (Appendix A). Summary measures on the data, both before and after replacement, were 
tested using normal and Kruskal-Wallis tests (Tables 5.1.2). Normal tests and K-Wallis tests gave 
similar results for systolic BP data both before and after replacement. This was also seen with the 
figures, hence only figures on the original data are displayed.
There were significant treatment differences for all systolic BP summary measures described apart 




The mean (Figure 5.1.2C), median (Figure 5.1.2D), minimum (Figure 5.1.2E), maximum (Figure 
5.1.2F), lower quartile (Figure 5.1.2G) and upper quartile (Figure 5.1.2H) response block charts for 
overall data appear to be normally distributed. The normal tests shown in Table 5.1.2 above all agree 
with this statement (p>0.089) for all treatments both before and after imputing missing data.
There was only evidence of a non-normal distribution for the change in mean from baseline for drug 2 
and this was consistent for the data before and after replacing missing records (p=0.003). This can be 
seen clearly in Figure 5.2.2B where drug 2 has one outlying value of mean change from baseline. The 
outlier reading was between 15 and 25 mmHg, whereas all other observations for drug 2 ranged from - 
15 to 5 mmHg. Figure 5.1.2B, shows that the overall mean change data was slightly skewed. From 
observing Figure 5.2.2B it can be seen that drug 4 had the largest change from baseline.
It can be seen that all summary measures in Table 5.1.2 above, apart from the maximum response 
showed significant treatment differences both before and after data replacement. For the mean (p=0.015 
before and p=0.016 after), for the median (p=0.015 before and 0.012 after), for the minimum (p=0.022 
before, p=0.023 after) and for the lower quartile (p=0.012 before and p=0.013 after). For the upper 
quartile (p=0.030 both before and after) and for the change in mean from baseline (p<0.001 both before 
and after).
The summary measures on the data before replacing missing data were observed by centre for the 
original data Table 6b (Appendix A). The Kruskal-Wallis test results on the data by centre are also 
displayed in Table 5.1.2 above. The summary measures did not show significant treatment differences 
for all data in centre 2 and all the data apart from minimum response in centre 1 had a significant 
treatment difference.
5.1.3: Diastolic Blood Pressure (mmHg):
From the block charts below of the overall (Figure 5.1.3A) and by treatment (Figure 5.2.3A) readings at 
baseline, it appears as if the data was normally distributed. The normal tests conducted in Table 4.2.3 
[section 4.3.3] above confirmed this statement (p>0.128 before and after imputing missing data). There 
were also no significant treatment differences at baseline (p=0.900 before and p=0.894 after imputing 
missing data) using the Kruskal-Wallis test for significance in Table 4.2.3.
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Table 5.1.3
Normal Tests Per Treatm ent and Kruskal-Wallis Tests For Each Summary Measures 
P-Values to Compare Before and After Data Generation: Diastolic BP (mmHg)
Summary Dataset Treatment K-Wallis
Measure 1 2 3 4
Change Before 0.801 0.001* 0.036* 0.196 <0.001*
Centre 1 <0.001*
Centre 2 0.034*
After 0.739 0.002* 0.026* 0.174 <0.001*
Mean Before 0.102 0.608 0.552 0.293 0.015*
Centre 1 0.044*
Centre 2 0.589
After 0.135 0.645 0.722 0.299 0.015*
Median Before 0.509 0.802 0.491 0.755 0.029*
Centre 1 0.041*
Centre 2 0.735
After 0.545 0.790 0.591 0.767 0.022*
Minimum Before 0.626 0.701 0.969 0.516 0.006*
Centre 1 0.189
Centre 2 0.059
After 0.626 0.701 0.934 0.516 0.008*
Maximum Before 0.019* 0.462 0.077 0.608 0.002*
Centre 1 0.008*
Centre 2 0.341
After 0.019* 0.462 0.055 0.608 0.002*
Lower Before 0.412 0.806 0.411 0.233 0.086
Quartile Centre 1 0.427
Centre 2 0.357
After 0.402 0.794 0.560 0.270 0.071
Upper Before 0.050 0.699 0.959 0.856 0.026*
Quartile Centre 1 0.017*
Centre 2 0.805
After 0.054 0.715 0.976 0.889 0.022*
Statistical summaries and tests before and after replacement can be seen in Tables 5c and 7c 
respectively (Appendix A). Summary measures on the data, both before and after replacement, were 
tested using normal and Kruskal-Wallis tests (see Tables 5.1.3 above). Normal tests and K-Wallis tests 
gave similar results both before and after replacement for diastolic BP data. This was also seen with 
the figures, hence only figures on the original data are displayed.
There were significant treatment differences for all diastolic BP summary measures described apart 




For the lower quartile for diastolic BP in Table 5.1.3 above it can be seen that the data is normally 
distributed for all four drugs both before (p>0.233) and after (p>0.270) imputing missing records. The 
Kruskal-Wallis tests show no significant treatment differences both before (p=0.086) and after imputing 
missing data (p=0.071). Figures 5.1.3G and 5.2.3G agree with this statement.
For the original data, the change in mean from baseline (Figure 5.2.3B) is slightly skewed for drugs 2 
(p=0.01) and 3 (p=0.036) and the maximum (Figure 5.2.3F) data is skewed for drugs 1 (p=0.019). The 
results after imputing missing data also give similar conclusions. All other summary measures (mean, 
median, minimum and upper quartile) appeared to be normally distributed overall and by treatment 
group. The mean, median, minimum, maximum, change in mean from baseline and upper quartile 
responses on both the original data (p<0.029) and the data after imputing missing records (p< 0.022) all 
showed significant treatment differences.
The summary measures on the data before replacing missing data were observed by centre for the 
original data (Table 6c-Appendix A). The Kruskal-Wallis tests of treatment differences per centre are 
also displayed in Table 5.1.3 above. There was not enough evidence to suggest a treatment difference 
for both the lower quartile (p=0.427) and minimum (p=0.189) response data for individuals in centre 1. 
The only summary measure for which there was a significant treatment difference in centre 2 was the 
change in mean from baseline (p=0.034). The inconsistency in findings between centres is nothing to be 
concerned about.
In conclusion, there were significant treatment differences in the mean, mean change from baseline, 
median, minimum, maximum and upper quartile for diastolic BP.
5.1.4: Dietary Response
A block-chart of the baseline reading is displayed in Figures 5.1.4A and 5.2.4A. Table 4.2.4 [section 
4.3.4] shows the results of the normal test that was conducted on the baseline data (p>0.664). This 
indicates that all data are normally distributed. The Kruskal-Wallis test that was conducted on the data 
showed that there was not significant evidence to suggest a treatment difference at baseline (p=0.539). 
Statistical summaries and tests before and after replacement can be seen in Tables 5d and 7d 
respectively (Appendix A). Summary measures on the data, both before and after replacement, were 
tested using normal and Kruskal-Wallis tests (see Tables 5.1.4 below). Normal tests and K-Wallis tests 
gave similar results both before and after replacement for dietary response data. This was also seen 
with the figures, hence only figures on the original data are displayed below.
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Table 5.1.4
Normal Tests Per Treatment and Kruskal-Wallis Tests For Each Summary Measures 
P-Values to Compare Before and After Data Generation: Dietary Response
Summary Dataset Therapy K-Wallis
Measure 1 2 3
Change Before 0.527 0.589 0.679 <0.001*
After 0.491 0.775 0.855 <0.001*
Mean Before 0.386 0.250 0.498 <0.001*
After 0.444 0.252 0.795 <0.001*
Median Before 0.235 0.241 0.934 <0.001*
After 0.474 0.116 0.996 <0.001*
Minimum Before 0.638 0.217 0.574 <0.001*
After 0.638 0.358 0.546 <0.001*
Maximum Before 0.060 0.402 0.335 <0.001*
After 0.060 0.457 0.562 <0.001*
Lower Before 0.937 0.665 0.676 <0.001*
Quartile After 0.932 0.506 0.884 <0.001*
Upper Before 0.526 0.307 0.726 <0.001*
Quartile After 0.526 0.279 0.717 <0.001*
All results were normal both before and after imputing missing records. There were significant 
treatment differences noted for all summary measures. Both the results before and after imputing 
missing records gave similar findings.
All normal tests that were conducted on the summary measures on the data (Table 5.1.4 above) showed 
that there was not enough evidence to suggest that the data was skewed. It can be seen from all block 
charts that were produced by therapy groups (Figures 5.2.4B-5.2.4H) that there was a treatment 
difference and this was confirmed by the Kruskal-Wallis tests (pcO.OOl in all cases). In all cases, group 
3 had “lower” results than group 2, which had “lower” results than group 1.
These findings agree with the findings at each univariate time point, apart from times 0 and 1, for dietary 
response data as displayed in Table 4.2.4 [section 4.3.4 above]. Figure 5.2.4A below shows the 
distribution of dietary response by treatment at baseline or time 0. There appear to be no treatment 
differences, confirming the findings in Table 4.2.4.
The univariate summary measures on the data were tested both before and after data replacement and the 
results were again consistent. There was a significant treatment difference for each summary measure 
(mean, median, minimum, maximum, lower quartile, upper quartile and change in mean from baseline) 
that was tested both before and after data replacement (Table 5.1.4). Only the baseline measurement 








5.2 Categorical Data Analysis
As previously mentioned, all categorical analyses were conducted on only the variables in data set A and 
all categorical data are obtained from the original data before imputing missing records.
From Listing 3.3 [section 3.2] it can be seen that the data at each time point was categorised as ‘low’, 
‘normal’ or ‘high’. A block chart of the frequency of individuals with vital signs of each level at the 
baseline reading are displayed in Figures 5.3.1A, 5.3.2A and 5.3.3A for overall data and Figures 5.3.IB, 
5.3.2B and 5.3.3B by treatment for heart rate, systolic and diastolic BP respectively.
Following the categorisation above, data set A was set up in the format as described in Listing 3.5 
[section 3.3.2]. There were three summary measures that were looked into. These were ‘NH’,’NL’ and 
‘NN’, which were the number of abnormally ‘HIGH’, ‘LOW’ and ‘NORMAL’ readings over the study 
per individual. Each value per individual could range anything from 0 to 24 but the sum of all three 
readings had to be less than or equal to 24.
The frequencies of occurrence of an event of ‘low’, ‘normal’ or ‘high’ readings respectively were treated 
as continuous data and analysed as such. Tables 13a to 13c (Appendix A) show findings for the Kruskal- 
Wallis tests to test for treatment differences overall and by centre for the frequency of occurrence of 
each of these events for heart rate, SBP and DBP respectively.
The frequencies of ‘low’, ‘normal’ and ‘high’ results per individual by treatment group per centre are 
displayed in Figures 5.4.1 to 5.4.3 below.
It was decided that all further statistical tests were to only be conducted using ‘NH’ and ‘HIGH’.
An approach similar to the response features analysis was applied to the data. Hence, the main measure
considered being of importance for analysis was:
a) Number of Overall Abnormally High Readings On-Treatment.
The summary statistic for the frequency of abnormally ‘high’ on-treatment results per individual, where 
each response value ‘NH’ could range from 0 to 24, was calculated as described above. Scatterplots of 
this variable by centre are shown in Figures 5.4.1 A1 to 5.4.3A2 below. Tables 14a to 14c (Appendix A) 
show the distribution of the number of abnormally ‘high’ readings per treatment group and overall for 
heart rate, systolic and diastolic BP respectively. The frequency of occurrence of abnormally ‘high’ 
results per individual ‘NH’ was treated as a continuous variable. Tables 15a-15c (Appendix A) show the 
contingency tables of the categorised frequency of the number of abnormally ‘high’ readings. A Chi-
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squared test was conducted to test for the relationship between treatment groups. The tests were 
conducted overall and by centre and the p-values are also displayed in these tables,
b) Greater than 50% or greater than 75% of Abnormally High Results over the study.
The number of abnormally ‘high’ results were divided by the number of available results and multiplied 
by 100. The result gave a percentage. If the result was greater than 50% then the variable ‘HALFABN’ 
was “yes” and otherwise was set to “no”. The same approach was taken to calculate the variable 
‘QRTABN’ when the result was greater than 75%. Chi-squared tests were conducted on the frequency of 
individuals that fit each criteria mentioned. This was only applied for systolic and diastolic BP since 
there were few occurrences (less than 50% in all cases) of abnormally high heart rates. See Tables 16b 
and 16c (Appendix A) for these respective frequency tables for systolic and diastolic BP.
5.2.1: Heart Rate (beats/minute)
The data was categorised as being ‘low’, ‘normal’ or ‘high’ at each visit. From the Figure 5.3.1 above, it 
can be seen that there were no individuals with abnormally ‘high’ results at baseline for heart rate (b/m). 
Most individuals (78 out of 84) had ‘normal’ heart rate measurements at baseline. Only 6 of the 84 
individuals with a baseline measurement had a ‘low’ result and 4 of these were on drug 3. None of the 
individuals on drug 4 had a ‘low’ reading at baseline.
Figure 5.3.1
Block Charts of Level of Readings for Baseline Heart Rate (beats/min)
Original Data
A : Overall B : by Treatment
Lew Normal High 
Baseline Heart Rate (beats/min)
Low Normal High 
Baseline Heart Rate (beals/min)
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On observing the scatter-plots above (Figure 5.4.1), it can be seen that the majority of individuals on- 
treatment results were ‘normal’ for heart rate (Figures 5.4.IB 1 and 5.4.1B2).
It was assumed that the frequencies of ‘normal’, ‘high’ or ‘low’ on-treatment results per individual were 
continuous data. Following the Kruskal-Wallis tests on this data (from Table 13a - Appendix A) there 
was significant evidence to suggest a treatment difference overall (p=0.017) for the number of ‘normal’ 
on-treatment results. This was also the case for centre 2 (p=0.031) (see Figure 5.4.1B2). In both cases 
drugs 2 and 3 tended to result in a lower number of ‘normal’ results and drugs 1 and 4 seemed to give 
more ‘normal’ readings per individual.
All other tests in Table 13a (Appendix A) showed no significant treatment differences for the total 
number of ‘low’ or ‘high’ results for any centre or overall (p>0.316).
From the 49 individuals in centre 1, only 4 individuals on drug 4 and 3 individuals on drug 2 had at least 
one ‘low’ result (Figure 5.4.1C1). The maximum number of ‘low’ results for any individual in centre 1 
was 4. Slightly more (16 out of 37) individuals in centre 2 had at least one ‘low’ blood pressure 
measurement (Figure 5.4.1C2). There were 4 individual on drug 3, 2 individuals on drug 2 and 1 
individual on drug 1 with more than 9 ‘low’ readings. Nine individuals had between 1 and 4 ‘low’ 
readings and the remaining 21 out of a total of 37 individuals had no ‘low’ readings at all. From Figure 
5.4.1C2 it can be seen that for patients on drugs 1 and 3 in centre 2 there tended to be greater occurrence 
of abnormally ‘low’ results while on-treatment. However, ‘low’ results are not of much concern.
Only the ‘high’ results were considered worthwhile to report since these mean there is a problem or 
abnormality in the data. From the results in Table 13a (Appendix A), the maximum number of ‘high’ 
heart rate results for an individual was 6 out of a possible 24 on-treatment time measurements. This can 
be seen clearly in Figure 5.4.1A1 and A2 below. Out of 37 individuals in centre 2 (Figure 5.4.1A2) there 
were 11 with at least one ‘high’ reading compared to 31 out of 49 individuals in centre 1 (Figure 
5.4.1A1) with at least one ‘high’ reading. More individuals in centre 1 had at least one abnormally ‘high’ 
reading. The maximum number of ‘high’ results for any individuals in centre 1 was 6. The maximum 
number of ‘high’ responses for individuals in centre 2 was 3.
A frequency table of the total number of abnormally ‘high’ results is shown in Table 14a (Appendix A). 
Of the 86 individuals in the study, 44 had no abnormally ‘high’ readings. From Table 15a (Appendix A), 
it can be seen that there was no relationship between frequency of occurrence per treatment group either 
overall or by centre (p>0.421).
104
It could be seen that none of the patients were classified as having greater than 50% or 75% abnormally 
‘high’ heart rate readings, hence, no further analyses were conducted on these outcomes.
5.2.2: Systolic Blood Pressure (mmHg)
Figure 5.3.2
Block Charts of Level of Readings for Baseline Systolic Blood Pressure(mmHg)
Original Data
A : Overall B : by Treatment
67
Lew Normal High 
Baseline Systolic Blood Pressure(mmHg)
DRUG
Lew Normal High
Baseline Systolic Blood Pressure(mmHg)
Figure 5.3.2 above shows that there were no ‘low’ systolic BP readings at baseline. Only 17 of the 84 
individuals with a baseline measurement had a ‘normal’ baseline result and the remaining 67 had a ‘high’ 
baseline response. There appeared to be an equal distribution of results across treatment groups.
The total numbers of on-treatment responses per individual were calculated for ‘low’ (Figures 5.4.2C1 
and 5.4.2C2), ‘normal’ (Figures 5.4.2B1 and 5.4.2B2) and ‘high’ (Figures 5.4.2A1 and 5.4.2A2) 
responses by centre. From looking at the scatter-plots in Figure 5.4.2 below, it can be seen that most of 
the results for individuals systolic blood pressure measurements were either ‘normal’ or ‘high’. Only 5 
out of 49 individuals in centre 1 and 2 of the 37 individuals in centre 2 had at least one ‘low’ reading. 
The maximum number of ‘low’ readings for any individual was 6 for centre 1 and 3 for centre 2.
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From Table 13b (Appendix A), following the Kruskal-Wallis tests on the data, there was significant 
evidence to suggest a treatment difference overall for the number of ‘normal’ results (p=0.016) and the 
number of ‘high’ results (p=0.019). When the data was explored by centre, it was found that there was 
evidence of a treatment difference for centre 1 only for the number of ‘normal’ results (p=0.023) and the 
number of ‘high’ results (p=0.026).
Only ‘high’ results were of concern for final analysis purposes. Individuals on drugs 1 and 2 had a 
higher frequency of abnormally ‘high’ results than individuals on drugs 3 and 4 overall and for centre 1 
(see Figure 5.4.2A1).
A chi-squared test was conducted to see whether there was any relationship between the overall 
frequency of abnormally ‘high’ readings and treatment group. The findings from Table 14b (Appendix 
A) shows the distribution of ‘high’ results and Table 15b shows the chi-squared test results. It can be 
seen that that there was marginally significant evidence of a treatment difference for the overall data only 
(p=0.069) and no significant evidence by centre (p>0.143).
From Table 14b (Appendix A), it can be seen that there was a good spread for the frequency of ‘high’ 
results. Only 29 individuals had less than or equal to 50% of abnormally ‘high’ readings. The remaining 
57 individuals had more than 50% and 29 of these had greater than 75% of abnormal readings. Chi- 
squared tests were conducted to see of the frequency of occurrence being > 50% or > 75% was related to 
treatment groups. The tests were conducted on the overall data and also by centre (Table 16b -  Appendix 
A). In observing the data overall, it was found that only the occurrence of greater than 75% abnormality 
was significantly different between treatment groups (p=0.025). There was less frequent occurrence for 
drug 4 than for all other drugs. In looking at the data by centre, it was found that there was only a 
significant treatment difference for the occurrence of greater than 50% abnormality overall for centre 1 
(p=0.048). In this case, drug 4 had only 33.3% of individuals with more than 50% abnormality, whereas 
66.7% of the individuals on drug 3, 83.3% of the individuals on drug 1 and 76.9% of the individuals on 
drug 2 had more than 50% abnormality.
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5.2.3: Diastolic Blood Pressure (mmHg)
Figure 5.3.3
Block Charts of Level of Readings for Baseline Diastolic Blood Pressure (mmHg)
Original Data
A : Overall B : by Treatment
Normal High
B aselne Diastolic Blood Pressure(mmHg)
DRUG
HighLow Normal
Baseline Diastolic Blood Preseure(mmHg)
The data was categorised as being ‘low’, ‘normal’ or ‘high’ at each visit. Figure 5.3.3 above shows that 
there were no ‘low’ results at baseline. Only 17 of the 84 individuals with a baseline measurement had a 
‘normal’ result and the remaining 67 had a ‘high’ baseline response. There was an equal distribution of 
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The total number of on-treatment responses were calculated for ‘low’ (Figures 5.4.3C1 and 5.4.3C2), 
‘normal’ (Figures 5.4.3B1 and 5.4.3B2) and ‘high’ (Figures 5.4.3A1 and 5.4.3A2) responses by centre. 
On looking at the scatter-plots, it can be seen that most of the results for individuals diastolic blood 
pressure measurements were either ‘normal’ or ‘high’. Only 7 out of 49 individuals in centre 1 and 4 of 
the 37individuals in centre 2 had at least one ‘low’ reading. The maximum number of ‘low’ readings for 
any individual was 4 in both centres 1 and 2.
From Table 13c, following the Kruskal-Wallis tests (assuming the data was continuous), there was 
significant evidence to suggest a treatment difference overall for the number of ‘low’ results (p=0.025) 
only. This was because all treatments apart from drug 2 had at least 1 low response. When the data was 
explored by centre, it was found that there was only evidence of a treatment difference frequency of 
‘low’ results for centre 1 only (p=0.034). Now there were no ‘low’ results for both drugs 1 and 2.
Only ‘high’ results were considered to be relevant for final analysis purposes. From Table 14c 
(Appendix A), it can be seen that the data for the frequency of ‘high’ results was well distributed. A chi- 
squared test was conducted to see whether there was any relationship between the frequency of 
abnormally ‘high’ readings and treatment groups overall. The findings from Table 15c (Appendix A) 
show that there was no evidence of any relationship between treatment and frequency of abnormality 
either by centre or overall (p>0.179).
From Table 14c (Appendix A), only 29 individuals had less than or equal to 50% of abnormal readings. 
The remaining 57 individuals had more than 50% and 18 of these had greater than 75% of abnormal 
readings. Chi-squared tests were conducted to see of the frequency of occurrence being > 50% or > 75% 
was related to treatment groups. The tests were conducted on the overall data and also by centre (Table 
16c-Appendix A). In observing the data, it was found that only the occurrence of greater than 50% 
abnormality was marginally significant between treatment groups overall (p=0.062). All other tests 
showed no significant relationship between frequency of occurrence and treatment groups (p>0.080).
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5.3 Overview
It is well known that, under some mild conditions, the summary statistics: sample mean, median, upper 
quartile and lower quartile are asymptotically normal (jointly or marginally). However, from the extreme 
value theory, it follows asymptotically that the summary statistics: maximum and minimum (up to their 
linear transformations) are distributed as Weibull, Frechet or Extreme value random variables. (If V is an 
exponentially distributed random variable, then Va,V‘a and log V (where a  > 0) have respectively 
Weibull, Frechet and Extreme value distributions).
Our findings in this chapter seem to support the aforementioned results. To examine whether or not there 
are differences between treatment performances one could appeal to parametric tests such as t (in the case 
of summary statistic vectors, Hotelling T2 or Mahalanobis D2) and likelihood ratio, or non-parametric 
tests such as Wilcoxon Kruskal-Wallis and homogeneity; when the sample sizes within treatment groups 
are sufficiently large, then one could still apply the tests to have reasonably reliable conclusions, without 
insisting that the assumptions of normality be met. The tests that we have applied in the present chapter 
are among these, and hence our results based on these are of substance. However, one of the major 
disadvantages of the approach based on summary statistics, considered in this chapter, is the following: 
The method throws away the information contained in the data on the performances of treatments at 
various time points; in the case of multidimensional summary statistics the information on the treatment­
time interaction is also lost.
As with the univariate data at each time point, it was found that the summary measures data before and 
after imputing missing data gave similar results for the normality tests, the tests of comparing treatment 
groups and also for the block charts overall and by treatment group.
The summary measures described in Listings 3.4.1 and 3.4.2 [section 3.3.1] were analysed in both a 
univariate and multivariate manner. The following chapter 6 will address the details of the analysis in the 
multidimensional case. An explanation is given of the methods of data reduction applied in order to deal 
with the multivariate data for multivariate analysis purposes.
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CHAPTER 6: Data Reduction
6.0 Introduction
The previous chapter dealt with continuous univariate summary measures that were obtained and 
analysed using univariate statistical testing. We will now consider the how to analyse the data in a 
multivariate format. Both Greenhouse and GeisserI27] and Kenward[35] state that while conducting any 
multivariate modelling methods the number of repeated measurements within a study should be less than 
the number of patients within a treatment group. This allows the (asymptotic) normality assumptions 
and hence the model to be approximately valid. The question that we are asking now is what do we do 
when this condition is not met and hence the normality assumption is not valid?
Reducing the data in some manner would lead to asymptotic normality or to relevant tests that are 
approximately valid, and, following the theory mentioned in section 2.1.2, it is believed that this would 
be achieved. Hence the following chapter deals with the various suggested methods of data reduction 
that could be applied to the continuous longitudinal data sets used for this thesis.
Missing data is usually a problem for multivariate approaches since multivariate analysis is only 
conducted on individuals with all data available. Again as in the univariate case, normality is a required 
condition in order for any multivariate statistical testing to be valid. On the other hand, to have the 
relevant test procedures to be robust, the structure of the data set needs to be such that there are 
considerably greater number of individuals than the number of repeated measures on each individual. 
Hence, the various data reduction approaches described below and in section 6.2 were applied to the data 
and (without loss of generality) an assumption of asymptotic normality was then applied to the data. It 
was suggested that one of three data reduction methods could be used to set up the data for analysis and 
allow a more efficient and robust analysis. The three suggested methods of data reduction were:
a) Summary Measures Approach
b) P.C.A.
c) Averaging across time intervals to get segments of time.
The imputation method, used to generate observations for missing records, is described in section 4.2.2. 
Each of the three reduction methods above were applied to both analysis data sets A and B both before 
and after imputing missing data and multivariate analyses on all these reduced data formats are carried 
out in chapter 7. Only the segments of time data (method c above) were analysed using general
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univariate methods and the results were compared with those for the original data [section 4.3]. The 
univariate approach applied to the segments of data is described in chapter 6.
6.1 Multivariate Normality
This is harder to test for than univariate normality. Regression methods could be used to test for 
normality by regressing y on x or in this case ‘RESPONSE’ or ‘VALUE’ on ‘TIME’ and checking the 
distribution of the residual or apply some of the methods that have been referred to in chapter 2. 
However, in the case of our data, we will assume asymptotic normality based on a large sample size [see 
section 2.1.2]. In order for this assumption to hold, it is suggested that the data across time be reduced 
using one of the methods given below. This would validate the assumption of normality or the tests used 
in order for us to proceed with any multivariate analysis methods.
6.2 Reducing the Data Sets
In chapter 2 the reader was introduced to the conditions/assumptions required for conducting most 
methods of analysis. Most of the parametric methods usually require the assumption of normality of the 
data. However, it is not always possible to test for normality and in testing the data it is often found that 
the data are not normally distributed. This is the case especially if the data set were structured such that 
there were a large number of repeated measures per individual unit. As was stated by Diggle, Liang and 
Zeger1171, Greenhouse and Geisser1271 and Kenwardl35], the problem is that this leads to problems in 
calculations for any multivariate methods applied to the data. The problems are associated with the 
calculation of the sums of squares and degrees of freedom (df) for this situation and the condition of 
normality not being met [section 2.3.2].
If one can not test for and conclude multivariate normality, which is something, that is reasonable to 
address, then the multivariate tests would require a justification of robustness. For this and in order to 
satisfy the condition of asymptotic normality [section 2.1.2], to conduct any parametric multivariate 
approaches, it is suggested that one of three data reduction approaches could be applied to the data to 
obtain a smaller number of repeated observations.
Most authors then tend to shy away from repeated measures MANOVA in this situation and look for 
other forms of analysis. For this reason, it has been suggested that rather than shying away from the 
problem, due to the data not being normal when it has the structure mentioned above, an idea could be 
put forward of facing the problem head on. The idea is to ‘Reduce the Data’ using one of three different 
suggested approaches and then analysing the values in each of the reduced data sets. In applying these
reduction methods, the number of individuals would be considerably greater than the number of repeated 
measures on each individual. The following three approaches were used to reduce the number of 
repeated elements in each data set A and B.
Approach 1: Multiple Summary Measures on the Data.
Here a set of 6 summary measures i.e. mean, median, minimum, maximum, lower and upper quartile 
readings could be calculated and all 6 readings could be analysed together for each individual using a 
multivariate procedure.
Approach 2: Principal Components Analysis (P.C.A).
This is an extension of the method conducted by Jones and Rice 1331 that conducted principal component 
analysis to reduce the number of individual response measures for ease of analysis. The proposed 
method here is to use a similar approach, by reducing the repeated measurements instead of reducing the 
individual profiles.
Approach 3: Using an Averaging Method by Grouping Times at Selected Segments.
The proposed method is to select the number of time points and also the number of individuals within a 
group and sum up with a proposed number of grouped times that are considered to be appropriate. The 
method would be to average in-groups of times to come up with a set of grouped time average responses 
that, while summarising the data, also describe the data at various cross sections over the longitudinal 
data set.
6.3 Structure of Reduced Multivariate Data
1) Summary Measures (SM)
The six summary statistics (MEAN, MEDIAN, MIN, MAX, Q1 and Q3) mentioned in the previous 
section were analysed together as one observation. Multivariate vectors of i individuals of 6 readings (or 
summary statistics) were set up for analysis for each response variable in data sets A and B. Listing
3.4.1 shows the layout of the summary measurements of vital sign measurements for only a few 
individuals from data set A. A few individual summary measures from data set B are displayed in 
Listing 3.4.2. These data sets also contain the baseline reading and change of mean from the baseline 
measurement. These two variables are mentioned later.
2) Principal Components Analysis (P.C.A).
Principal component analysis was conducted on the data sets. In each situation, all components with
eigenvalues accounting for approximately 95% of the data were selected for analysis. Multivariate
vectors of i individuals by j readings (principal components) were set up for analysis for both data sets A
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and B. For the multivariate analysis, there were 10 principal components selected from data set A and 
only 5 principal components selected from data set B.
3) Averaging over Segments of Time.
We did not wish to test for multivariate normality and hence the idea of reducing the data by averaging 
across groups of time points was attempted. The assumption of asymptotic normality was met by 
reducing the data by averaging across groups of times. This was since the number of repeated measures 
were proportionately less than the number of individuals on whom the measurements were made. The 
data was split into groups of time points and the mean summary measure was calculated at each of the 
grouped time points. There were two proposed segmentation methods. The initial method was to 
average the data in groups of three time points and the second approach was to average across groups of 
two time points. Data sets A and B were analysed using method 1 and only data set A was analysed 
using method 2 below. The segmentation methods are detailed below:
Method 1: Averaging over three observations.
A grouped data set was created for both data sets A and B. The 24 on-treatment readings for data set A 
were reduced to 8 readings and the 9 on-treatment readings for data set B were reduced to 3 readings. 
Listing 6.1 and Listing 6.2 show the structure of some of the data averaged into groups of 3 times for 
data sets A and B respectively.
Listing 6.1:Data Set A: After Data Generated: Grouped Data (Average 3 Times): HR(beats/min)
DRUG P A T IE N T GTIM E BASE AVERAGE OF 3 T IM E S
1 1 0 0 2 3 1 6 5 . 3 0 8 3 5 9 . 7 5 0
1 1 0 0 2 3 2 6 5 . 3 0 8 3 6 2 . 0 8 3
1 1 0 0 2 3 3 6 5 . 3 0 8 3 6 4 . 5 0 0
1 1 0 0 2 3 4 6 5 . 3 0 8 3 6 1 . 3 3 3
1 1 0 0 2 3 5 6 5 . 3 0 8 3 7 4 . 0 0 0
1 1 0 0 2 3 6 6 5 . 3 0 8 3 7 1 . 1 6 7
1 1 0 0 2 3 7 6 5 . 3 0 8 3 6 2 . 5 0 0
1 1 0 0 2 3 8 6 5 . 3 0 8 3 7 2 . 5 0 0
continued..
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Listing 6.2: Data Set B; After Data Generated:Grouped Data (Average 3): (Dietary Response)
GROUP SU B JE C T GTIM E BASE AVERAGE OF 3 T IM E S
g r o u p 1 1 1 1 . 1 2 5 9 8 0 . 9 2 9 4 0
g r o u p 1 1 2 1 . 1 2 5 9 8 0 . 9 7 2 2 0
g r o u p 1 1 3 1 . 1 2 5 9 8 1 . 0 2 0 8 0
c o n t i n u e d . .
Method 2: Averaging over two observations.
A grouped data set was created for data set A only since data set B had 9 observations, which were not 
divisible by 2. For data set A, the 24 on-treatment readings were reduced to 12 readings. Listing 6.3 
shows data set A for one individual after averaging across pairs of observations.
Listing 6.3: Data Set A; After Data Generated: Grouped Data (Average 2 Times):Vital Signs
DRUG P A T IE N T GTIM E B A SE AVERAGE OF 2  T IM E S
2 1 0 0 5 3 1 7 3 . 6 2 8 5 6 6 . 5 0 0
2 1 0 0 5 3 2 7 3 . 6 2 8 5 6 9 . 2 7 5
2 1 0 0 5 3 3 7 3 . 6 2 8 5 7 0 . 7 9 2
2 1 0 0 5 3 4 7 3 . 6 2 8 5 8 1 . 3 5 0
2 1 0 0 5 3 5 7 3 . 6 2 8 5 7 9 . 1 6 7
2 1 0 0 5 3 1 1 7 3 . 6 2 8 5 6 1 . 7 5 0
2 1 0 0 5 3 1 2 7 3 . 6 2 8 5 7 3 . 3 7 5
c o n t i n u e d . .
6.4 Univariate Methods for Comparison of Reduced Data with Original Data
Of the three approaches that were used to reduce the data, the averaging across time points method was 
the only approach that still retained a time element. In this chapter, any univariate analyses were only 
conducted to compare the univariate analysis findings for the data reduced using approach 3 with the 
univariate analysis findings on the original data. The univariate analyses conducted on the reduced data 
were:
a) Individual profile plots over grouped times.
b)Mean, Median, Minimum and Maximum plots over grouped times.
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c) Univariate Kruskal-Wallis tests to compare treatments per grouped time for the reduced data using 
segmentation.
d) Block chart of the summary measure of mean change from baseline.
e) Univariate Kruskal-Wallis tests to compare treatments for summary measures overall and by centre for 
reduced data using segmentation.
All univariate analysis methods mentioned above were conducted on the reduced data using approach 3 
both before and after generating missing records. However, since there were no vast differences in the 
results before and after generating missing data, only the results on the data after generating missing 
records are displayed in this thesis.
The univariate plots (a) and (b) were produced to show the individual profiles and summary measures 
for the reduced data over each time segment. The block chart (d) showed an overall summary of the data 
per treatment group and overall.
Following the methods of data reduction using method 1, there were only 8 on-treatment measures in 
place of the 24 for vital sign data and 3 observations instead of 9 for the dietary response data. Following 
method 2, there was a set of 12 on-treatment-repeated measurements instead of 24 initial measurements 
for the vital signs data only. This second approach was not applied to the dietary response data set.
6.5 Univariate Analysis for Each Reduced Data Point
The purposes of these analyses were to compare the methods conducted on the reduced data after 
imputing missing data using data reduction approach 3 with those conducted on the original data before 
reduction of the time points and see if the trends in the data were maintained.
6.5.1: Individual Profile Plots.
Plots of the individual response profiles were produced for the reduced data by averaging over grouped 
time points. Only figures on the reduced data after imputing missing readings are displayed below. 
Figures 6.1.1 to 6.1.4 show respective individual profile plots for heart rate, systolic and diastolic BP and 
dietary response for method 1. Figures 6.2.1 to 6.2.3 show the respective individual profile plots for 
method 2 for vital signs data only. Profile plots were produced separately per treatment group. The 
trends in the data could be seen but these plots were not very useful otherwise. There was, as expected, 
far too much variation in individual responses. It was found that reducing the data, by averaging across 
segments of time, gave a similar picture to the original data. Any fluctuations in the data were smoothed
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out after the process of averaging across segments of time points. Individual differences became more 
obvious as more time elements were used in the segmentation process.
6.5.1.1 Heart Rate (beats/min):
Method 1: Averaging Over Three Time Points
FIGURE 6.1.1
Patient Profiles of Heart Rate (b/m) By Treatment After Averaging Over ThreeTime Points
A : Treatment 1 B : Treatment 2
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Using method 1 (Figures 6.1.1A to D) it can be seen that, for all four drugs, the data peaks around 
grouped times 3 or 4 (original time 7 or 12) and dips at grouped time 7 (original times 19 to 21). The 
data finally peaks again at grouped time 8 (original times 22 to 24).
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Method 2: Averaging Over Two Time Points
FIGURE 6.2.1
Patient Profiles of H eart Rate (b/m) By Treatm ent After Averaging Over TwoTime Points. 
A : Treatment 1 B : Treatment 2
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Similar results to method 1 were found using method 2 (Figures 6.2.1 A to D) where it can be seen that 
the data peaks at around grouped times 4 or 6 (7-12 hours), dips around grouped time 10 (19-20 hours) 
and peaks again at grouped time 12 (23-24 hours).
Both reduction methods 1 and 2 above agree with the results obtained for the original data set before 
missing data was replaced (Figures 4.1.1 A to D). Notice, however, that fluctuations in the data are 
smoothed out after the process of averaging across segments of time points. Individual differences 
became more obvious as more time elements were used in the segmentation approach.
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6.5.1.2 Systolic BP (mmHg).
Method 1: Averaging Over Three Time Points
FIGURE 6.1.2
Patient Profiles of Systolic BP (mmHg) By Treatment After Averaging Over Three Time Points.
A : Treatment 1 B : Treatment 2
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The individual profile plots using methods 1 (Figures 6.1.2A to D) seemed to show that almost all 
individuals had a drop in systolic BP at around grouped time 7 (original times 19 to 21). One individual 
on drug 1 and an individual on drug 3 had considerably lower readings than all other individuals 
indicating outlying values.
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Method 2: Averaging Over Two Time Points
FIGURE 6.2.2
Patient Profiles of Systolic BP (mmHg) By Treatment After Averaging Over Two Time Points.
A : Treatment 1 B : Treatment 2
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The individual profile plots Figures 6.2.2 A to D above were produced using method 2. One individual 
on both drug 1 and 3 had considerably lower readings than any other individuals. The data tended to 
drop at about grouped times 10 or 11 (original times 19 to 22).
Both methods 1 and methods 2 above lead to similar findings, as were also observed for the original data 
in Figures 4.1.2 A to D. Notice that fluctuations in the data are smoothed out after the process of 
averaging across segments of time points. Individual differences became more obvious as more time 
elements were used in the segmentation approach.
121
6.5.13 Diastolic BP (mmHg).
Method 1: Averaging Over Three Time Points
FIGURE 6.1.3
Patient Profiles of Diastolic BP (mmHg) By Treatment After Averaging Over Three Time Points.
A : Treatment 1 B : Treatment 2
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The individual profile plots Figures 6.1.3 A to D above were produced using method 1. In all cases, the 
data tended to drop at about grouped times 6 or 7 (original times 16 to 21). These plots are very 
cluttered and difficult to interpret.
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Method 2: Averaging Over TwoTime Points
FIGURE 6.2.3
Patient Profiles of Diastolic BP (mmHg) By Treatment After Averaging Over Two Time Points.
A : Treatment 1 B : Treatment 2
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The individual profile plots Figures 6.2.3 A to D above were produced using method 2. In all cases, the 
average diastolic blood pressure data tended to drop at about grouped times 9 or 10 (original times 17 to 
20).
The individual profile plots using methods 1 (Figures 6.1.3A to D) and a method 2 (Figures 6.2.3A to D) 
were similar in appearance to the original data plots (Figures 4.1.3 A to D). Fluctuations in the data 
became smoother after the averaging process across segments of data. Individual differences became 
more obvious as more time elements were used in the segmentation approach.
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6.5.1.4 Dietary Response.
Method 1: Averaging Over Three Time Points
FIGURE 6.1.4
Patient Profiles of Dietary Response By Therapy After Averaging Over Three Time Points.
After Missing Data Replaced (N=24).
A : Therapy 1 B : Therapy 2
B : Therapy 2A : Therapy 1
TIME GROUP
C : Therapy 3









Figures 6.1.4A to C describe the reduced individual profile data using method 1. Therapy 1 and 2 
appeared to have an increasing linear trend with time and therapy 3 had a decreasing linear trend with 
time. Data reduction on the dietary response data was not conducted using method 2. The findings on 
the reduced data using method 1 agree with those on the original data in Figures 4.1.4A to C.
Note: The fluctuations in the data were reduced following the data reduction approach.
124
6.5.2: Summary Response Profile Plots.
Only figures on the reduced data following the imputing of missing readings are displayed. The 
summary response profiles for the mean, median, minimum and maximum response were produced for 
the reduced data using both method 1 (Figures 6.3.1A-D to 6.3.3A-D) and method 2 (Figures 6.4.1A-D 
to 6.4.3A-D) for the vital signs data. For the dietary response data, summary response profile plots were 
produced using only method 1 (Figures 6.3.4A to D).
6.5.2.1 Heart Rate (beats/min).
Method 1: Averaging Over Three Time Points
FIGURE 6.3.1
Plots of Summary Response Profiles by Treatment Group After Averaging Over Three Times 
For Heart Rate(b/m): After Missing Data Replaced (N=86).
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The mean plot using method 1 (Figure 6.3.1 A) shows a peak at grouped times 4(10-12 hours) and 8 (22-
24 hours) and a drop at grouped time 7 (19-21 hours). The median plots (Figures 6.3.IB) show similar
patterns in the data but there is more variation between treatment groups up to the initial peak of grouped
time 4 (10-12 hours). The data then behaves similarly from that point on. Drug 2 has both the lowest
mean and median heart rate response at grouped time 7 (19-21 hours). The minimum plot (Figures
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6.3.1C) shows much variation between treatment groups especially between drugs 3 and 4. The 
maximum plot (Figure 6.3.ID) indicates that there is an extreme value at grouped time 3 (original time 
9) for drug 2. This is confirmed in the maximum plot for the original data in Figure 4.3. ID.
Method 2: Averaging Over Two Time Points
FIGURE 6.4.1
Plots of Summary Response Profiles by Treatment Group After Averaging Over Two Times For 
Heart Rate(b/m); After Missing Data Replaced (N=86).
A : Mean B : Median
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The mean plot for method 2 (Figure 6.4.1 A) shows a peak at grouped time 6 (11 to 12 hours) and 12 (23 
to 24 hours). The median plots using method 2 (Figures 6.4. IB) show similar patterns to the mean plot 
(Figure 6.3.1 A) but there is more variation between treatment groups for the median plot. Drug 2 has 
both the largest median response at grouped time 6(11-12 hours) and the lowest median response from 
grouped time 8 (15-16 hours) onwards. Again the minimum plot (Figure 6.4.1C) shows much more 
treatment variation.
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Both reduction methods agree with results obtained from the original plots (Figures 4.3.1A-D). All 
mean plots show the data behaves in a similar pattern for all four therapies with the mean data being 
close together. All methods show no vast treatment differences in the mean.
6.5.2.2 Systolic BP (mmHg).
Method 1: Averaging Over Three Time Points
FIGURE 6.3.2
Summary Profiles By Treatment After Averaging Over Three Times For Systolic BP (mmHg)
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Figures 6.3.2A to D show the mean, median, minimum and maximum plots across time by treatment 
groups for data reduction using segmentation method 1. The mean plot for all drugs using data reduction 
method 1 (Figure 6.3.2A) shows a peak at grouped time 4 (10-12 hours). The data stays approximately 
constant before grouped time 4, where it peaks and then immediately drops until grouped time 7 (19-21 
hours) and then suddenly increases at grouped time 8 (22-24 hours). Drug 1 has the largest mean 
responses for most time points following data reduction method 1.
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It can be seen that there is a difference in mean, median and maximum response with drug 4 having 
considerably lower readings than the other treatment groups. The minimum response for drug 3 is 
considerably lower than for the other treatment groups up to grouped time 6 (16 to 18 hours) for method 
1. After this time drug 4 has the lowest readings.
Method 2: Averaging Over Two Time Points
FIGURE 6.4.2
Summary Profiles by Treatment Group After Averaging Over Two Times For Systolic BP
A : Mean B : Median
A : Moan B : Median
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The mean, median, minimum and maximum plots for method 2 (Figures 6.4.2A to D) show a similar 
pattern to the plots for method 1 (Figures 6.3.2A to D) and for the original data (Figures 4.3.2A to D). 
Following data reduction using method 2, drug 4 had the lowest mean (Figure 6.4.2A), median (Figure 
6.4.2B) and maximum (Figure 6.4.2C) systolic BP response over all grouped times. Drug 1 has the 
largest mean responses for all grouped time points following data reduction method 2.
The general patterns in the original data are maintained by data reduction through segmentation.
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All reduction method plots show a similar picture to the plots produced for the original data (Figures 
4.3.2A to D). As the data become further reduced by data segmentation, it can be seen that the 
fluctuations in the data become smoother. Differences in the data become more obvious within the plots 
as more time points are used in the reduction process.
6.5.2.3 Diastolic BP (mmHg).
Method 1: Averaging Over Three Time Points
FIGURE 6.3.3
Summary Profiles By Treatment After Averaging Over Three Times For Diastolic BP (mmHg)
A : Mean B : Median
A : Mean B : Median
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Figures 6.3.3 A to D show the respective mean, median, minimum and maximum diastolic blood 
pressure plots across time by treatment groups for segmentation data reduction method 1.
Drug 4 has lower mean responses than all other treatments at most of the grouped times apart from 
grouped time 5 (13 to 15 hours) using method 1. Drugs 1 and 2 had higher mean and median responses 
over the grouped time points compared with drugs 3 and 4.
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Method 2: Averaging Over Two Time Points
FIGURE 6.4.3
Summary Profiles by Treatment Group After Averaging Over Two Times For Diastolic BP





Figures 6.4.3 A to D show the respective mean, median, minimum and maximum diastolic BP plots 
across time by treatment groups for data reduction method 2. The plots show similar patterns to the 
plots for the data using method 1 (Figures 6.3.3A to D) and the original data plots (Figures 4.3.3A to D). 
Obvious differences in treatment were noticed between drugs 1 and 4, with drug 4 having lower 
responses and drug 1 having higher responses.
The general patterns in the original data were maintained through data reduction. The average diastolic 
blood pressure data varied in a similar pattern to the systolic blood pressure. In other words, times of 
peaks and troughs in the data were consistent for both systolic BP and diastolic BP measurements.
There seem to be larger overall differences in the average responses for treatments at the initial times 
compared to the times later on in the study. Drug 4 had obviously lower mean and median readings after
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grouped time 6 (16-18 hours) for method 1 and grouped time 8 (15-16 hours) for method 2. This agrees 
with the findings on the original data after time 16 hours.
6.5.2.4 Dietary Response.
Method 1: Averaging Over Three Time Points
FIGURE 6.3.4
Summary Profiles By Treatment After Averaging Over Three Times For Dietary Response
A : Mean B : Median
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From Figures 6.3.4A to D, it can be seen that the data are now almost linear in appearance. There are 
obvious treatment differences between all three-therapy groups following data reduction using method 1 
(Figures 6.3.4.A to 6.3.4D). The differences are similar to those seen for the original data before data 
reduction (Figures 4.3.4A to D). Therapy 1 has higher mean, median, minimum and maximum readings 
than therapy 2, which has higher readings than therapy 3. The mean and median differences are 
highlighted further along in time.
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6.5.3: Univariate Testing.
The segmentation methods for data reduction were applied to the data before and after imputing the data. 
The data gave similar results before and after imputing missing information. Hence, only the results for 
the reduced data after replacing missing information are displayed. Univariate normal and Kruskal- 
Wallis tests were conducted to test for the distribution of the data and also test for treatment differences. 
The Kruskal-Wallis Test was conducted on the data at each univariate reduced time point.
For data reduction using segmentation, both methods 1 and 2 were applied to all vital sign data (heart 
rate, systolic blood pressure and diastolic blood pressure). Only method 1 was applied to the dietary 
response data. There is no other purpose to these tests apart from to compare the results obtained on the 
reduced data with those obtained on the original data before imputing missing data.
6.5.3.1 Heart Rate (beats/min).
The univariate Kruskal-Wallis tests for each grouped time using method 1 (p>0.169, Table 3a -  
Appendix A) show no treatment differences, as do the tests using method 2 (p>0.126, Table 4a -  
Appendix A). Both results agree with one another and also with those obtained on the original data 
(Table 4.2.1) for the univariate tests over time.
6.5.3.2 Systolic Blood Pressure (mmHg)
The univariate tests for each grouped time for the data from method 1 (Table 3b -Appendix A) showed 
treatment differences at grouped times 1, 2, 3 ,4 , 6 and 8. The tests on the data from method 2 (Table 4b 
-  Appendix A) showed treatment differences at times 1, 2, 3, 4, 6, 8, 9 and 12. Both results seem to 
agree with the results obtained from the univariate tests on the original data (Table 4.2.2) where 
treatment differences were found at times 1, 3, 5, 6, 7, 8 16,17, 18, 19, 21, 23 and 24 hours.
6.5.3.3 Diastolic Blood Pressure (mmHg)
Univariate tests for the grouped time point for the data using method 1 (Table 3c -  Appendix A) showed 
there to be treatment differences at grouped times 2, 3 ,4  and 6. The tests on the data from method 2 
(Table 4c -  Appendix A) showed treatment differences at grouped times 2, 3,4, 6, and 8. Both results 
agree with the results obtained from the univariate tests on the original data (Table 4.2.3) where 
treatment differences were found at times 3, 5, 6, 7, 8 ,10 ,11 ,16  and 21 hours.
6.5.3.4 Dietary Response.
Significant differences were noted at all reduced time points (p<=0.003) using method 1 (Table 3d -  
Appendix A). This agrees with the findings from the original data (Table 4.2.4), where significant 
treatment differences were found at times 2, 3 ,4 , 5, 6,7, 8 and 9.
6.6 Univariate Summary Measures for Reduced Data
6.6.1: Distribution of the Change in Mean from Baseline.
A block chart of the overall and by treatment change of ‘on-treatment’ mean from baseline response 
across time was produced for the data. Only figures on the reduced data after imputing missing readings 
are displayed. Both normality and univariate Kruskal-Wallis tests on the change in mean from baseline 
were conducted for the reduced imputed data. These results were compared with the corresponding 
findings for the original data before data replacement.
6.6.1.1 Heart Rate (beats/min)
Method 1: Averaging Over Three Time Points
Figure 6.5.1
Block Charts of Change in Heart Rate(beats/min) Values : Average of 3 Time Points
A : Overall B : by Treatment
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Method 2: Averaging Over Two Time Points
Figure 6.6.1
Block Charts of Change in Heart Rate(beats/min) Values : Average of 2 Time Points
A : Overall B : by Treatment
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For the change in the mean from baseline for method 1 (Figures 6.5.1 A and B and Tables 8a -  Appendix 
A) and for method 2 (Figures 6.6.1 A and B and Tables 10a -  Appendix A) the findings agree with the 
results for the original data (Figures 5.1.IB and 5.2.1B and Table 5.1.1). Both figures for methods 1 and 
2 were identical. It can be seen that one individual on drug 4 is an outlier with a reading between 15 to 
21 whereas all other results appear to range from -15 to 15. It can also be seen that all therapy groups 
apart from drug 3 appeared to have a skewed distribution. The normal tests in Tables 8a (Appendix A) 
for method 1 and Table 10a (Appendix A) for method 2 confirm this statement. There are no treatment 
differences for the change in mean from baseline for both methods 1 and 2 (p=0.173 for both).
6.6.1.2 Systolic BP (mmHg).
Method 1: Averaging Over Three Time Points
Figure 6.5.2
Block Charts of Change in Systolic BP (mm/Hg) Values : Average of 3 Time Points
A : Overall B : by Treatment
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Method 2: Averaging Over Two Time Points
Figure 6.6.2
Block Charts of Change in Systolic BP (mrrVHg) Values : Average of 2 Time Points
A : Overall B : by Treatment
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The findings for the change in the mean from baseline for method 1 (Figures 6.5.2A and B and Tables 
8b-Appendix A) and for method 2 (Figures 6.6.2A and B and Tables lOb-Appendix A) agree with the 
results for the original data (Figures 5.1.2B and 5.2.2B and Table 5.1.2). Both figures for methods 1 and 
2 were identical. Individuals on drugs 3 and 4 have larger changes than those individuals on drugs 1 and 
2 (p<0.001 for both methods). Only drug 2 appears to be obviously skewed and the normal tests in 
Tables 8b (Appendix A) for method 1 and Table 10b (Appendix A) for method 2 confirm this statement. 
It is believed that the individual on drug 2 with a change of between 15-25 mmHg is probably an outlier. 
6.6.X.3 Diastolic BP (mmHg).
Method 1: Averaging Over Three Time Points
Figure 6.5.3
Block Charts of Change in Diastolic BP (mm/Hg) Values : Average of 3 Time Points
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Method 2: Averaging Over Two Time Points
Figure 6.6.3
Block Charts of Change in Diastolic BP (mm/Hg) Values : Average of 2 Time Points
A : Overall B : by Treatment
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The findings for the change in the mean from baseline for method 1 (Figures 6.5.3A and B and Table 8c- 
Appendix A) and for method 2 (Figures 6.6.3A and B and Table lOc-Appendix A) agreed with those 
from the original data (Figures 5.1.3B and 5.2.3B and Table 5.1.3). Both figures for methods 1 and 2 
were identical. The normal tests in Tables 8c and 10c (Appendix A) showed drugs 2 and 3 were not 
normally distributed. Figures 6.5.3B and 6.6.3B confirm this statement. For both methods 1 and 2, there 
was a treatment difference for the change in mean from baseline (p<0.001 for both methods). For both 
methods, there is a much larger average change in baseline for diastolic BP on drugs 3 and 4 (mean=-6.2 
and -7.6 respectively) compared to drugs 1 and 2 (mean=-3.1 and -2 .0  respectively).
6.6.1.4 Dietary Response
Method 1: Averaging Over Three Time Points
Figure 6.5.4
Block Charts of Change in Dietary Response Values : Average of 3 Time Point s
A : Overall B : by Therapy
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It can be seen that all change in mean from baseline data are normally distributed per therapy group 
using Tables 8d (Appendix A) and 5.1.4 for the data reduced using method 1 and for the original data 
respectively. This can also be seen in Figure 6.5.4B above for the reduced data using method 1 and also 
in Figures 5.2.4B for the original data. In both cases, the block-chart of the change in mean from 
baseline shows that there are obvious treatment differences (pcO.OOl). Group 1 has largest readings, 
group 2 has mid range readings and group 3 has the lowest readings.
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6.6.2: Univariate Testing.
Six summary measures (mean, median, minimum, maximum, lower and upper quartiles) were calculated 
per treatment for each reduced data set both overall and by centre. Univariate normality and Kruskal- 
Wallis tests were conducted on the summary measures for the reduced data sets. Only results on the 
summary measures for the reduced data after data replacement are displayed since the findings on the 
reduced data both before and after data replacement gave similar conclusions. The findings for the 
summary measures on the reduced data after data replacement were compared with the findings for the 
summary measures on the original data before data replacement. Since the findings for the summary 
measures for the original data both before and after data replacement gave similar results [section 5.1], 
only findings for the original data before data replacement were used for comparison purposes.
6.6.2.1 Heart Rate (beats/min).
The summary measures were obtained for the data from both methods 1 (Table 8a -  Appendix A) and 2 
(Table 10a -  Appendix A) respectively. The normal tests for all summary variables (mean, median, 
minimum, lower and upper quartile) apart from the maximum response agree for methods 1 and 2. The 
normal test for the maximum response for the original data before replacement shows that drug 2 is not 
normal, the maximum data from method 1 are all normally distributed per treatment group. Using 
method 2, the variable of maximum response for drug 4 is not normally distributed and all other drugs 
are normally distributed. This suggests that the data reduction may be reducing the effects of outliers in 
certain situations (namely with method 1) and increases the effects in other situations (method 2) and 
this in turn is influencing the results of the normal tests.
The Kruskal-Wallis tests for both method 1 (Table 8a -Appendix A) and method 2 (Table 10a -  
Appendix A) agree with one another. The results show no significant treatment differences per 
summary measure for both methods 1 (p>0.667) and 2 (p>0.664). These results also agreed with the 
findings for the original data before data replacement (p>0.608, Tables 5.1.1).
The summary measures from method 1 (Table 9a -  Appendix A) and from method 2 (Table 1 1 a- 
Appendix A) both after replacing missing data were tabulated by centre. Kruskal-Wallis tests were 
conducted on this data. It can be seen that all summary measures for both centres 1 and 2 showed no 
significant treatment differences as was the case with all prior analyses that were conducted on heart rate 
data.
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6.6.2.2 Systolic Blood Pressure (mmHg)
The summary measures were obtained for the data from both methods 1 (Table 8b -Appendix A) and 2 
(Table 10b -Appendix A) respectively. The normal test results for both methods 1 (Table 8b-Appendix 
A) and 2 (Table 10b -  Appendix A) agreed with those findings for the original data before data 
replacement (Tables 5.1.2). All summary measures per treatment group are normally distributed.
The Kruskal-Wallis tests on the overall reduced segmentation data using methods 1 and 2 lead to similar 
conclusions as each other for all summary measures (mean, median, maximum, lower and upper 
quartile) apart from the minimum response. The minimum response for method 1 agrees with the results 
for the original data. Using method 1 there was significant evidence to suggest a treatment difference in 
the minimum response (p=0.020, Table 8b -  Appendix A). For the original data before imputing 
missing records, there was significant evidence to suggest a treatment difference in the minimum 
response (p=0.022, Table 5.1.2). There was not significant evidence to suggest a treatment difference 
between the minimum response for reduced data using method 2 (p=0.052, Table 10b-Appendix A).
Since the test result for method 2 was marginally significant, we will not worry about this any further.
Of all other Kruskal-Wallis tests conducted there was significant evidence to suggest a treatment 
difference for the mean, median, lower and upper quartile summary measures. There were no treatment
differences detected for the maximum response for both methods 1 (p=0.079, Table 8b -  Appendix A)
\
and 2 (p=0.096, Table 10b -  Appendix A). These findings agreed with those conclusions obtained for 
the original data (p=0.065, Table 5.1.2).
The summary measures from method 1 (Table 9b -Appendix A) and from method 2 (Table 1 lb  — 
Appendix A) both after replacing missing data were tabulated by centre. Kruskal-Wallis tests were 
conducted on this data. It can be seen that all Kruskal-Wallis tests by centre conducted on the summary 
measures gave similar results for both methods 1 and 2. It was found that there were no significant 
treatment differences between any of the summary measures for centre 2 (p>0.065). For centre 1, 
treatment differences were detected for the mean (p=0.023 both methods 1 and 2), median (p=0.023 both 
methods 1 and 2), upper quartile (p=0.047 for method 1 and p=0.034 for method 2) and lower quartile 
(p=0.007 for method 1 and 0.012 for method 2). This by centre difference in results was also detected for 
the original data before replacement (Table 5.1.2). However, a difference in the maximum response for 
centre 1 was not detected for both reduction methods 1 (p=0.101) and 2 (p=0.064) but was detected for 
the original data (p=0.042).
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6.6.23 Diastolic Blood Pressure (mmHg)
The summary measures on the reduced data using method 1 are displayed in Table 8c (Appendix A) and 
the results for method 2 are in Table 10c (Appendix A). Following normal tests on the summary 
measures it was found that all summary measures using method 2 (Table 10c -  Appendix A) were 
normally distributed per treatment group. The results using method 1 (Table 8c -Appendix A) showed a 
skewed distribution for both the maximum and upper quartile on drug 1. The results on the original data 
(Table 5.1.3) showed that the maximum response on drug 1 was also non-normal. All other results were 
normal per treatment group and agreed for reduction using methods 1 and 2 and for the original data.
The Kruskal-Wallis test results from method 1 (Table 8c-Appendix A) agree with those obtained for the 
original data before data replacement (Tables 5.1.3). There was significant evidence of a treatment 
difference for all variables (p<0.022) apart from the lower quartile (p=0.069) response. For method 2 
(Table 10c -Appendix A), all summary measures apart from the minimum (p=0.118) response were 
significantly different between treatment groups (p<0.037).
The summary measures from method 1 (Table 9c -Appendix A) and from method 2 (Table 1 1 c- 
Appendix A) both after replacing missing data were tabulated by centre. Kruskal-Wallis tests were 
conducted on this data. All Kruskal-Wallis tests conducted on the summary measures per centre gave 
similar results for data reduction methods 1 (Table 9c -Appendix A) and 2 (Table 11c -Appendix A) 
and both methods in turn agreed with the by centre results for the original data (Table 5.3.3). For centre 
1, treatment differences were detected for the mean (p=0.038 both methods 1 and 2) and median 
(p=0.017 for method 1 and p=0.026 for method 2) responses. Other response treatment differences were 
observed for maximum (p=0.009 for method 1 and p=0.004 for method 2) and the upper quartile 
(p=0.014 for method 1 and p=0.010 for method 2). There were no treatment differences detected for any 
summary measures in centre 2.
6.6.2.4 Dietary Response.
Summary measures were obtained for dietary response data after data replacement reduced using method 
1 only (Table 8d -  Appendix A). The normal tests conducted on the data show that all summary 
measures per treatment group were normally distributed. These findings agree with the original data 
results (Table 5.1.4). The Kruskal-Wallis tests on the data reduced using method 1 (Table 8d-Appendix 
A) show treatment differences for all summary measures (p<0.001 in all cases). This again agrees with 
the findings for the original data (Table 5.1.4).
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6.7 Overview
Only the multivariate principal components analysis (P.C.A.) approach of data reduction stated in the 
chapter above was affected by the missing nature of the data. SAS was used to analyse the data set. It 
was decided to analyse the data using both univariate and multivariate parametric techniques. The 
univariate methods conducted in the chapter above were applied to only the data retaining an element of 
time. It was found that the univariate results both before and after data replacement gave similar 
findings. Comparisons were made between the univariate results on the reduced data after data 
replacement and the original data before data replacement. It was found that in all cases, the results using 
data reduction method 1 were consistent with those on the original data for the overall data. There were 
slight discrepancies in the findings for method 2 compared with the original data for systolic and 
diastolic blood pressure but they were not of concern.
Multivariate tests were applied to the data following all methods of data reduction described in the 
chapter above and on the original data both before and after imputing missing data. All results were then 
compared. An optimal approach of reducing the data was then suggested based on all multivariate test 
results. All multivariate tests and corresponding results are described in chapter 7 below.
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CHAPTER 7: Multivariate Testing
7.0 Introduction
Multivariate methods were applied to the data following all methods of data reduction described in 
chapter 6 and on the original data both before and after imputing missing data. All results were then 
compared. Any multivariate testing performed on the data and results obtained are explained in the 
following chapter. The multivariate test used to test between treatment groups was based on the 
Mahalanobis D2 statistic.
An optimal approach of reducing the data was suggested based on the multivariate test results. The 
optimal approach was one where normality tests would not be required and the assumption of asymptotic 




Following the three methods of data reduction (summary measures, P.C.A. and segmentation of the data) 
mentioned in chapter 6, we were left with four reduced data sets for data sets A and three reduced data 
sets for data set B both before and after imputing missing records. The Mahallanobis Distances, from a 
discriminant analysis viewpoint, were used to test for paired group difference in distance for each of the 
data sets that were available. The data sets were as follows:
a) Data sets A and B both before and after imputing missing data.
b) Principal Components Analysis (P.C.A.) vector, on data sets A and B, both before and after imputing 
missing records. A principal component analysis was conducted on the data and the first 10 principal 
components were selected to represent the data both before and after data replacement for the vital signs 
data and the first 5 principal components were selected to represent the dietary response data.
c) Grouped mean vector of average of observations at 3 successive time points (method 1) for data sets 
A and B, both before and after imputing missing records. Grouped mean vector of average of 2 times 
(method 2) for data set A only, both before and after imputing missing records.
d) Summary Measures (S.M.) vector, for data sets A and B, both before and after imputing missing 
records. Six summary measures (mean, median, minimum maximum, lower and upper quartile) were 
each calculated both before and after data replacement. They were calculated for the original data and 
also for the data using methods 1 and 2 for data reduction. All six summary measures were analysed 
together in a multivariate manner.
Any similarities or differences between the results from the various approaches were noted and 
discussed whenever appropriate.
The original data of 24 or 9 readings, the 8 or 3 readings using method 1, the 12 readings using method 
2, the 10 or 5 readings using the P.C.A and each of the S.M. vector of 6 readings were each analysed as a 
multivariate vector. This was the case both before and after replacement of missing data. All results are 
displayed in Table 7.1.1 to 7.1.4 below.
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7.2 Results
7.2.1: Heart Rate (beats/min)
Table 7.1.1
Mahalanobis Distances and p-values for Each Multivariate Vector: Heart Rate (b/m).
D ata Form at
T reatm ent D istances
l - > 2 1 ^ 3 l - > 4 2 -> 3 2 - > 4 3 ^ 4
Original Data (N=73) 
Before Data Replaced
Distance2 4.73 3.92 2.21 3.74 5.11 2.33
P-value 0.319 0.574 0.950 0.501 0.171 0.911
S. Measures (N=86) 
Before Data Replaced
Distance2 0.475 0.299 0.297 0.760 0.916 0.261
P-value 0.574 0.804 0.816 0.264 0.177 0.851
Original Data (N=84) 
After Data Replaced
Distance2 3.51 2.21 1.95 3.32 4.73 2.07
P-value 0.355 0.856 0.909 0.445 0.104 0.892
S. Measures (N=84) 
After Data Replaced
Distance2 0.485 0.373 0.271 0.767 0.923 0.235
P-value 0.563 0.731 0.847 0.289 0.174 0.892
Prin. Comps. (N=73) 
Before Data Replaced
Distance2 0.016 0.014 0.041 0.018 0.046 0.056
P-value 1.000 1.000 1.000 1.000 1.000 1.000
Prin. Comps. (N=84) 
After Data Replaced
Distance2 0.019 0.036 0.016 0.024 0.016 0.056
P-value 1.000 1.000 1.000 1.000 1.000 1.000
3HR Av. Grp (N=74) 
Before Data Replaced
Distance2 0.863 1.060 0.685 1.264 1.544 1.039
P-value 0.402 0.290 0.588 0.168 0.074 0.303
S.Measure. (N=86) 
3HR Av. Grp Before
Distance2 0.724 0.365 0.327 0.761 0.667 0.151
P-value 0.307 0.719 0.778 0.263 0.358 0.956
3HR Av. Grp (N=84) 
After Data Replaced
Distance2 0.864 1.039 0.657 1.269 1.522 0.953
P-value 0.402 0.303 0.616 0.167 0.079 0.364
S.Measure. (N=84) 
3HR Av. Grp After
Distance2 0.721 0.252 0.353 0.657 0.720 0.198
P-value 0.310 0.875 0.746 0.384 0.311 0.926
2HR A v. Grp (N=83) 
Before Data Replaced
Distance2 1.056 1.454 0.748 1.751 1.634 1.074
P-value 0.635 0.424 0.864 0.250 0.263 0.680
S.Measure. (N=86) 
2HR Av. Grp Before
Distance2 0.336 0.639 0.199 0.450 0.270 0.368
P-value 0.757 0.385 0.921 0.592 0.840 0.715
2HR Av. Grp (N=84) 
After Data Replaced
Distance2 1.078 1.408 0 .730 1.779 1.677 1.082
P-value 0.617 0.427 0.873 0.217 0.242 0.652
S.Measure. (N=84) 
2HR Av. Grp After
Distance2 0.330 0.666 0.208 0.400 0.298 0.348
P-value 0.766 0.391 0.913 0.686 0.806 0.763
* Significant results
All results are displayed in Table 7.1.1 and it can be seen that in all cases there are no significant 
treatment differences for heart rate data. These results all agree with all methods conducted thus far.
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7.2.2: Systolic Blood Pressure (mmHg)
Table 7.1.2
Mahalanobis Distances and p-values for Each Multivariate Vector: SBP (mmHg)
D ata Form at
Treatm ent D istances
l - > 2 l - > 3 l - » 4 2->3 2 - » 4 3 -» 4
Original Data (N =84) 
Before Data Replaced
Distance2 3.95 5.19 6.34 4.46 3.47 3.29
P-value 0.514 0.275 0.107 0.313 0.556 0.666
S. Measures (N =86) 
Before Data Replaced
Distance2 0.576 0.254 1.266 0.633 0.767 0.976
P-value 0.453 0.858 0.065 0.376 0.272 0.147
Original Data (N =73) 
After Data Replaced
Distance2 2.69 2.99 4.21 3.82 1.86 2.71
P-value 0.652 0.591 0.200 0.291 0.920 0.692
S. Measures (N =84) 
After Data Replaced
Distance2 0.555 0.321 1.353 0.541 0.767 0.930
P-value 0.478 0.796 0.050* 0.510 0.273 0.194
Prin. Comps. (N =73) 
Before Data Replaced
Distance2 0.029 0.104 1.208 0.035 0.939 0.649
P-value 1.000 1.000 0.528 1.000 0.633 0.869
Prin. Comps. (N =84) 
After Data Replaced
Distance2 0.088 0.124 1.144 0.009 0.623 0.539
P-value 1.000 1.000 0.399 1.000 0.813 0.891
3HR Av. Grp (N =74) 
Before Data Replaced
Distance2 0.762 1.100 1.795 0.755 0.845 0.867
P-value 0.495 0.265 0.042* 0.520 0.418 0.434
S.M. 3HR Av. Grp 
Before (N=86)
Distance2 0.803 0.411 1.519 0.355 0.878 0.927
P-value 0.246 0.657 0.029* 0.720 0.197 0.171
3HR Av. Grp (N=84) 
After Data Replaced
Distance2 0.745 1.127 1.791 0.776 0.838 0.885
P-value 0.511 0.249 0.042* 0.500 0.424 0.419
S.M. 3HR Av.Grp 
After (N=84)
Distance2 0.768 0.372 1.534 0.260 0.861 0.793
P-value 0.273 0.733 0.028* 0.860 0.209 0.282
2HR Av. Grp (N =83) 
Before Data Replaced
Distance2 1.347 1.722 2.239 1.699 1.375 1.056
P-value 0.424 0.280 0.089 0.274 0.407 0.693
S.M. 2HR Av.Grp 
Before (N=86)
Distance2 0.767 0.583 2.040 0.106 0.721 0.778
P-value 0.272 0.445 0.006* 0.981 0.309 0.264
2HR Av. Grp (N=84) 
After Data Replaced
Distance2 1.314 1.703 2.229 1.692 1.367 0.980
P-value 0.445 0.266 0.090 0.254 0.411 0.726
S.M. 2HR Av.Grp 
After (N=84)
Distance2 0.806 0.740 1.961 0.204 0.706 0.857
P-value 0.245 0.324 0.007* 0.917 0.323 0.237
* Significant results
It can be seen that significant differences were detected between drug 1 and 4 only. Differences were
detected using method 1 both before and after data replacement (p=0.042 in both cases) and for the
corresponding matrix of summary measures (p=0.029 before replaced and p=0.028 after replaced).
The actual data using the grouped average method 2 did not show up any significant treatment
differences. However, the summary measures on the data using method 2 both before (p=0.006) and
after (p=0.007) data replacement showed a significant treatment difference between drugs 1 and 4. None
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of the other methods showed any significant treatment differences. After looking more closely at the 
table it can be seen that the summary measures on the data both before (p=0.065) and after data 
replacement (p=0.05) are marginally significant. This is also the case with the original data from method 
2 both before (p=0.089) and after (p=0.09) data replacement. There were no differences detected using 
the principal component analysis or for the original data both before and after data replacement 
(p>0.107).
7.2.3: Diastolic Blood Pressure (mmHg)
Table 7.1.3
Mahalanobis Distances and p-values for Each Multivariate Vector: DBP (mmHg)
D ata F orm at
T reatm ent D istances
l-> 2 l - » 3 l - > 4 2 -> 3 2 - > 4 3 -» 4
Original Data (N=73) 
Before Data Replaced
Distance2 2.44 6.95 4.73 6.97 3.89 4.23
P-value 0.909 0.076 0.342 0.038* 0.429 0.395
S. Measures Before Data 
Replaced (N=86)
Distance2 0.78 1.28 1.15 1.45 2.01 1.33
P-value 0.260 0.056 0.092 0.029* 0.005* 0.049*
Original Data (N=84) 
After Data Replaced
Distance2 1.55 5.47 3.87 5.90 3.38 3.50
P-value 0.970 0.059 0.276 0.031* 0.396 0.410
S. Measures After Data 
Replaced (N=84)
Distance2 0.64 1.08 1.28 1.46 1.97 1.41
P-value 0.382 0.125 0.063 0.037* 0.006* 0.047*
Prin. Comps. (N=73) 
Before Data Replaced
Distance2 0.003 0.283 0.789 0.268 0.765 0.139
P-value 1.000 0.995 0.811 0.993 0.767 1.000
Principal Components 
After Data Replaced
Distance2 0.010 0.397 0.759 0 .382 0.734 0.063
P-value 1.000 0.959 0.715 0.962 0.722 1.000
3HR Grp A v Before Data 
Replaced (N=73)
Distance2 0.352 1.556 1.377 1.162 1.049 0.820
P-value 0.898 0.087 0.126 0.2162 0.264 0.475
S.M . 3 Hr Grp Av 
Before (N=86)
Distance2 0.622 0.870 1.242 1.829 1.697 1.497
P-value 0.403 0.202 0.070 0.008* 0.015* 0.028*
3HR Grp A v After Data 
Replaced (N=84)
Distance2 0.352 1.561 1.364 1.164 1.034 0.852
P-value 0.898 0.086 0.130 0.215 0.274 0.447
S.M . 3 Hr Grp Av 
After (N=84)
Distance2 0.580 0.506 1.278 1.403 1.673 1.260
P-value 0.449 0.566 0.063 0.043* 0.016* 0.074
2HR Grp A v Before Data 
Replaced (N=83)
Distance2 0.656 2.363 1.414 2.611 1.827 1.249
P-value 0.904 0.088 0.403 0.048* 0.184 0.557
S.M . 2 Hr Grp Av  
Before (N = 8 6 )
Distance2 0.565 0.383 0.864 0.933 1.190 0.363
P-value 0.465 0.694 0.218 0.157 0.076 0.721
2HR Grp Av After Data 
Replaced (N=84)
Distance2 0.653 2.540 1.406 2.833 1.842 1.317
P-value 0.905 0.054 0.406 0.025* 0.177 0.486
S.M. 2 Hr Grp Av  
After (N=84)
Distance2 0.534 0.434 0.865 0.988 1.223 0.448
P-value 0.502 0.655 0.218 0.154 0.069 0.638
* Significant results
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It can be seen that significant differences were detected between drug 2, 3 and 4 only. Differences were 
detected mainly between drugs 2 and 3 both before and after data replacement for the original data 
(p=0.038 and 0.031 respectively) and on the corresponding summary measures (p=0.029 and 0.037) 
respectively. Also for the data both before and after data replacement for summary measures on the 
reduced data using method 1 (p=0.008 and 0.043 respectively) and on the actual reduced data using 
method 2 (p=0.048 and 0.025). The differences between drugs 2 and 4 were only detected both before 
and after data replacement for the summary measures on the original data (p=0.005 and 0.006 
respectively) and on the grouped data using method 1 (p=0.015 and 0.016). A treatment difference was 
found between drugs 3 and 4 for both the data before and after replacement using the summary measures 
on the original data (p=0.049 and 0.047 respectively) and only for the data before replacement for the 
reduced data using method 1 (p=0.028). The summary measures approach tended to allow detection of 
treatment differences. There were no differences detected using the principal component analysis.
7.2.4: Dietary Response
Table 7.1.4:
Mahalanobis Distances and p-yalues for Each Multivariate Vector: Dietary Data
V ector
T reatm ent D istances
l-> 2 l ->  3 2 -> 3
Original Data (N=20) 
Before Data Replaced
Distance2 21.1 171.9 82.0
P-value 0.020* <0.001* <0.001*
S. Measures Before Data 
Replaced (N=24)
Distance2 8.5 31.7 16.7
P-value 0.009* <0.001* <0.001*
Original Data (N=22) 
After Data Replaced
Distance2 16.8 165.4 85.3
P-value 0.017* <0.001* <0.001*
S. M easures After Data 
Replaced (N=22)
Distance2 7.4 31.8 14.3
P-value 0.029* <0.001* 0.003*
Prin. Comps. (N=22) 
Before Data Replaced
Distance2 9.919 38.37 9.285
P-value 0.007* <0.001* 0.012*
Prin. Comps. After Data 
Replaced (N=22)
Distance2 8.0 33.1 8.6
P-value 0.009* <0.001* 0.009*
3HR A v Grp (N -2 4 )  
Before Data Replaced
Distance2 8.4 94 .6 53.3
P-value <0.001* <0.001* <0.001*
S.Measure. (N=24) 
3HR A v Grp Before
Distance2 7.4 22.8 9.4
P-value 0.016* <0.001* 0.006*
3HR A v Grp (N=22) 
After Data Replaced
Distance2 9.8 100.7 53.2
P-value <0.001* <0.001* <0.001*
S.Measure. (N=22) 
3HR A v Grp After
Distance2 8.4 27.5 7.9
P-value 0.018* <0.001* 0.028*
* Significant results
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Table 7.1.4 showed a significant difference in every pair of therapy groups that were tested. These 
results were consistent with all other methods conducted thus far.
7.3 Overview
The findings for tests before and after data reduction are similar in nature. However, in the latter case, 
the tests turn out to be more robust and hence the corresponding results tend to be more reliable. In the 
case of non-normal data, the test findings relative to the original data can not be viewed as very reliable. 
This is especially so because the sample size of 24 for a treatment group can not be considered to be 
large enough in the case when there are p=24 time points. The results given in the present chapter are 
based on Mahalanobis D2. This test statistic assumes that all treatment groups have the same variance- 
covariance matrix. One could relax the assumptions concerning the variance-covariance matrices using 
a likelihood ratio test; essentially Wilks theorem asserts that when p time points is moderate and the 
sample sizes are large, the test is equivalent to a %2 test. Although this latter test could also be considered 
to be robust in the case of reduced data, it is not dealt with in this thesis.
Among various methods of data reduction that are addressed in this chapter, only the approach of 
averaging the observations at three successive time points (method 1) seems to retain the information on 
the performances of treatments at various time points. This is especially so, if it is assumed that there is 
not much variation between observations at two successive time points (method 2).
All modelling methods applied to the continuous and categorical data and corresponding results are 
described in the following chapter 8.
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CHAPTER 8: Parametric and Non-Parametric Modelling
8.0 Introduction
Both the continuous and categorical data were modelled using various modelling approaches.
Categorical data set A following classification by vital sign status (Listing 3.3) and the summary 
measures of these categorical data (Listing 3.5) were modelled using the following methods:
A time to event (where the event was the first abnormally ‘high’ reading) survival analysis approach 
[section 8.1.1] was conducted. Also, the number of individuals with either at least 50% or 75% of 
abnormally ‘high’ readings over the course of the study was modelled using a logistic regression 
approach [section 8.1.2]. This second approach was not applied to the heart rate data since there were no 
individuals with more than 50% of abnormally ‘high’ heart rate readings.
The reduction in continuous data from 24 time points to either 8 or 12 time points for data set A (vital 
signs) and from 9 to 3 on-treatment time points for data set B (dietary response) was required for the 
assumption of asymptotic normality or robustness of tests to hold. The assumption in question was one 
of the most important conditions required to conduct any multivariate analysis methods on the data.
Once it was determined how the data was behaving following the plotting and multivariate testing (using 
Mahalanobis D2) of the data, the original data was described using a multivariate model [8.2] on the 
reduced data. A mixed modelling approach [8.2.1] was used to model the continuous data sets (Listings
3.1.1 and 3.2.1 for the original data sets A and B, Listings 6.1 and 6.3 for reduced data set A using 
methods 1 and 2 and Listing 6.2 for reduced data set B using method 1).
The original data before data replacement and the reduced time data after data replacement (using both 
methods 1 and 2 for vital signs data and method 1 only for dietary response data) were all finally 
modelled using a generalised mixed effects model. In all cases, the final model had random subject 
effects and adjustments for baseline readings. All other effects in the model were fixed. The final model 
based mean and 95% Cl was plotted for each data structure that was analysed.
Finally, an optimal method of multivariate analysis of the data was devised.
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8.1 Categorical Data Analysis
8.1.1: Survival Analysis on the Time to an Abnormal Result.
In this case, the variable ‘HIGH’ was used. Any missing data was set to ‘0’ (having ‘no’ ‘high’ result) 
and the data set was viewed in a univariate format. The occurrence of a ‘high’ result was considered to 
be an event= “yes”. The time to the event was the time of the first ‘high’ reading. If an individual never 
had a ‘high’ reading, then they were censored with and event= “no” and time to event of 24 hours. A 
Kaplan-Meier survival analysis approach [section 2.2.5] was conducted for the time to the first 
abnormally ‘high’ reading and the corresponding results are displayed in Tables 19a to 19c (Appendix
A). Wilcoxon and Log-rank tests are also displayed in these tables. The survival rates are displayed 
visually in Figures 8.1.1-8.1.4 below. In conclusion, there were no treatment differences for the time to 
an abnormal result for any of the vital sign measurements.
8.1.1.1 Heart Rate (beats/min)
Figure 8.1.1:
Kaplan-Meier Cumulative Survival Plot For Time to First Abnormal Heart Rate Over 24 hours.
Heart Rate (beats/min)
Time To First Abnormal Reading
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Figure 8.1.1 above shows the cumulative survival plot over time. Table 19a (Appendix A) shows the 
cumulative survival rates for the time to incidence data. From this table, it can be seen that most 
individuals on drugs 2 and 3 had an event by time 24 since 54.6% failed in both cases. Only 38.1% 
individuals on drug 4 failed by time 24 hours. Those individuals on drug 2 did not have an event until 
time 7 hours and individuals on drug 4 did not have the first event until time 5 hours. The other two
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drugs 1 and 3 initially failed at time 3 hours. Following the Log-rank test (p=0.590) it can be seen that 
there were no treatment differences in time to occurrence of the first abnormal event.
8.1.1.2: Systolic Blood Pressure
Figure 8.1.2:
Kaplan Meier Cumulative Survival Plot For Time to First Abnormal Systolic BP Over 24 Hrs.
Systolic BP (mmHg)
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Figure 8.1.2 shows the cumulative survival plot over time. Table 19b (Appendix A) shows the 
cumulative survival rates for the time to incidence data. From this table, it can be seen that most 
individuals on drug 2 had an event by time 3 (95.5 % failed). For drug 1, there were 95.3% of 
individuals that failed at time 5 hours. For drug 3, 95.5% of individuals failed at time 11 hours and for 
drug 4, 81% of individuals failed at time 11 hours. At time 24 all individuals remaining without an 
event were censored. There was greater than 95% failure for drugs 1 to 3 overall. Individuals on drug 4 
had a 90.5% failure rate at this final time point. Following the Log-rank test, it can be seen that there 
were no treatment differences in time to occurrence of the first abnormal event (p=0.263).
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8.1.1.3: Diastolic Blood Pressure
Figure 8.1.3:
Kaplan Meier Cumulative Survival Plot For Time to First Abnormal Diastolic BP Over 24 Hrs.
Diastolic BP (mmHg)
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Figure 8.1.3 shows the cumulative survival plot over time. Table 19c (Appendix A) shows the 
cumulative survival rates for the time to incidence data. From this table, it can be seen that all 
individuals on drug 2 had a high result by time 8 hours (100 % failed). For drug 4, 100% failed by time 
13 hours and for drug 3 100% failed or had at least one abnormal result by time 24 hours. Only drug 1 
had one individual that survived past the end of the study without having even one high reading.
The Log-rank test (p=0.412) shows that there were no treatment differences in time to occurrence of the 
first abnormal event for diastolic blood pressure.
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8.1.2: Logistic Regression on having greater than 50% or greater than 75% of 
Abnormally “High” Results.
There was only a maximum of 6 abnormally high heart rate readings for any patient, so this type of 
testing for heart rate data was considered to be of no use. The following tests were conducted for 
systolic and diastolic blood pressure readings only. A logistic regression analysis [section 2.2.7] was 
conducted on frequency of having greater than 50% abnormality or greater than 75% abnormality for 
both variables mentioned. A dummy variable was created for each drug (1 to 3) vs. drug 4. The three 
dummy variables for drug together with interactions between each main effect and a centre dummy 
variable were modelled. The initial test was conducted by modelling the interaction between centre and 
drug and if a significant interaction effect was not found, then only the main effects were tested in a 
reduced model. Tables 17b and 18b (Appendix A) show respective estimates and results obtained for 
having greater than 50% and 75% abnormality for systolic blood pressure. Tables 17c and 18c 
(Appendix A) show the respective estimates and the results obtained for having greater than 50% and 
75% abnormality for diastolic blood pressure.
8.1.2.1 Systolic Blood Pressure
A] Greater than 50% Abnormality.
The outcome of having a frequency of 50% or more abnormality was modelled after adjusting for centre 
(Table 17b-Appendix A).
Full Model:
For the full model, none of the interactions in the model were significant (p<0.187). Hence all 
interactions were removed and only the reduced model was fitted.
Final: Reduced Model:
In this case there was significant evidence of an effect for drug 1 compared with drug 4 (p=0.032). All 
other treatment effects (for drugs 2 and 3 compared to drug 4) were marginally significant (p=0.051 in 
both cases). In all cases, there was an odds ratio of greater than 3.5 in favour of the other drug over drug 
4. This treatment difference was not picked up with the Chi-squared test (p=0.075) in Table 16b 
(Appendix A).
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B) Greater than 75% Abnormality.
The outcome of the frequency of 75% or more abnormality was modelled after adjusting for centre 
(Table 18b -Appendix A).
Full Model:
For the full model, none of the interactions in the model were significant (p<0.613). Hence all 
interactions were removed and only the reduced model was fitted.
Final: Reduced Model:
In this case there was significant evidence of an effect for drug 1 compared with drug 4 (p=0.007) and 
drug 2 compared to drug 4 (p=0.029). The effect of drug 3 compared to drug 4 was insignificant 
(p=0.088) in the model. The odds ratio was 10.5 times in favour of drug 1 over drug 4 and 6 .6  times in 
favour of drug 2 over drug 4. The treatment differences were also picked up with the Chi-squared test 
result (p=0.025) in Table 16b (Appendix A).
C) Overall Conclusion:
For systolic blood pressure, the final logistic regression models for the proportion of individuals with 
greater than or equal to 50% abnormality and 75% abnormality gave similar findings, showing that there 
was a significant effect for drug 1 compared to drug 4 (p<0.032). For the proportion of individuals with 
greater than or equal to 75% abnormality, there was also a significant treatment difference between 
drugs 2 and 4 (p=0.029). This finding was also marginally obvious using the proportion of individuals 
with greater than or equal to 50% abnormality (p=0.051). The Chi-squared tests conducted in Table 16b 
(Appendix A) confirm the findings for the models on the proportion of individuals with greater than or 
equal to 75% abnormality only, suggesting that there is indeed a treatment difference between drugs 2 
and 4 and also 1 and 4.
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8.1.2.2 Diastolic Blood Pressure
A)  Greater than 50% Abnormality.
The outcome of the frequency of 50% or more abnormality was modelled after adjusting for centre 
(Table 17c-Appendix A).
Full Model:
For the full model, none of the interactions in the model were significant (p<0.112). Hence all 
interactions were removed and only the reduced model was fitted.
Final: Reduced Model:
In this case there was significant evidence of an effect for drug 1 compared with drug 4 (p=0.047). All 
other treatment effects (for drugs 2 and 3 compared with drug 4) were not significantly different. The 
odds ratio of greater than 4.6 in favour of the other drug over drug 4. This treatment difference was not 
detected with the Chi-squared test result (p=0.062) in Table 16c (Appendix A).
B) Greater than 75% Abnormality.
The outcome of the frequency of 75% or more abnormality was modelled after adjusting for centre 
(Table 18c -Appendix A).
Full Model:
For the full model, none of the interactions in the model were significant (p<0.346). Hence all 
interactions were removed and only the reduced model was fitted.
Final: Reduced Model:
In this case there was no evidence of any significant treatment effect (p>0.524). This result agrees with 
the Chi-squared tests that were conducted in Table 16c (Appendix A).
C) Overall Conclusion:
For diastolic blood pressure, proportion of individuals with greater than 50% abnormality, there was 
significant evidence of a treatment effect for drug 1 compared with drug 4 (p=0.047). This difference 
was not detected, however, for the proportion of individuals with greater than 75% abnormality. The 
Chi-squared tests conducted in Table 16c (Appendix A) confirm the findings for the models on the 
proportion of individuals with greater than or equal to 75% abnormality only, suggesting no treatment 
differences.
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8.2 Continuous Data Analysis
It was believed that data reduction methods are the best way to get valid multivariate test results and the 
aim here is to see whether the methods do indeed give valid comparable results for the final models 
selected to describe the data.
Modelling the original data (assuming normality) gave an idea of the pattern for the actual observed 
mean response over time. The reduced data (where normality did not need to be tested) was modelled 
since the assumption of multivariate normality was based on an asymptotic theory requiring the number 
of individuals to be large and the number of observations for an individual to be small. Some researchers 
have claimed that multivariate analysis of variance can not be applied if this scenario is not met since 
there can be convergence problems. This is especially true when using Proc GLM in SAS.
The model on the original data was studied in conjunction with the models for the reduced data using 
methods 1 and 2 respectively. The original data was only modelled for comparison purposes.
The data could have been modelled using Proc GLM. The problem was that Proc GLM could not handle 
either missing data or unbalanced data structures when it came to multivariate analysis. Hence, it was 
decided to use Proc MIXED with the ‘REPEATED’ statement since it catered for most of the 
shortcomings of Proc GLM. Using this approach, there was no issue with missing or unbalanced data 
and the original data could also be modelled without any convergence problems since the variance- 
covariance matrix could be selected before running the model. SAS iterated the covariance parameter 
estimated using the REML approach.
A modified version of the mixed effects model [section 2.4.3 -  (e), page 39] with additional components 
for time and centre (when available) was selected to model the data [section 8 .2 .1].
For the original data, only the mixed effects model with a compound symmetry variance-covariance 
structure would converge, due to the large number of repeated measurements. The preferred 




Proc MIXED was used to model the mean response data using a multivariate generalised mixed 
modelling approach. Following essentially the modelling methods of Crowder and Hand1141 the original 
model (combining both the random effect and error terms) for data set A can be expressed follows:
[6]
y  ijkl =  P  +  CCj +  Pk +  +  Yik +  £ ijkl
Here p would be the grand mean adjusting for baseline measurement, 0Cj would represent fixed group 
effects, pk would represent the fixed time effects, 81 would represent the fixed centre effects, yik would 
be the group by time interaction effects and are random. We assume in the model the vectors
(8jjn 8jjPi) to be mutually independent and identically distributed with zero mean vector, for distinct
ijl.
The original model selected for data set B and the final model for both data sets A and B is as follows:
[7]
y  ijk =  p  +  oti +  Pk +  Yik +  e yk
Here p  would be the grand mean adjusting for baseline measurement, oij would represent fixed group 
effects, pk would represent the fixed time effects, Yik would be the group by time interaction effects and
8ijkare random. We assume in the model the vectors (e^i 8jjP) to be mutually independent and
identically distributed with zero mean vector, for distinct ij.
Note that the models [6 ] and [7] above can also be interpreted as means models.
For each of the vital sign variables, the original data both before and after imputing missing records and 
the reduced imputed data by averaging across either two or three time points were modelled. For the 
dietary data, the original data both before and after imputing missing records and the imputed data 
averaged across three time points were modelled.
Initially, the original data were modelled both before and after imputing missing records. The results for 
both approaches were similar and therefore only the results on the original data before imputing missing 
data were considered for comparison purposes.
Only the reduced data following the regeneration of data was modelled for reasons of consistency with 
any previous analyses conducted for this study. The data sets using the average of two or three times for 
data set A and the average of three times for data set B were modelled independently.
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A mixed modelling approach was taken to analyse the mean response profile for both the original and 
reduced data sets. The data was modelled as a combination of both fixed and random effects.
Individuals were treated as (contributing to) random effects and all other effects were fixed. Interactions 
between time and dmg were modelled with adjustments being made for ‘time’ and ‘baseline readings’ 
for both data sets A and B and an addition adjustment was made for ‘centre’ for data set A. This was 
considered to be the full model.
Note: [6] shows the full model structure for data set A and [7] shows the full model structure for data set 
B. The models for the original data sets were fitted using a compound symmetry (CS) variance- 
covariance matrix and for the reduced data sets were fitted using an unstructured (UN) variance- 
covariance matrix.
Various models after removing insignificant effects and interactions were also looked at. All p-values 
from the various mixed models that were applied to model the vital signs and dietary response data over 
the course of study are displayed in Tables 8.1.1 to 8.1.4 for heart rate, systolic blood pressure, diastolic 
blood pressure and dietary response respectively.
For all vital sign measurements, the ‘centre’ effect and ‘interaction’ term were both insignificant effects 
in the model. After comparing results it was found that the results before and after adjusting for ‘centre’ 
for data set A were very similar. Hence, it was decided to remove the insignificant ‘centre’ term (since 
this gave no additional information) but to keep the insignificant ‘interaction’ term in all the final models 
to best describe the data over time for all vital sign measurements.
Note: [7] shows the final model for both data sets A and B.
The SAS output for the final models of both the original and reduced data are displayed in Tables 20a to 
20d (Appendix A).
A least squares approach was used to estimate the means and 95% Cl for the final model after adjusting
for ‘baseline reading’ and ‘time’ effects only. The models were conducted for the original vital signs
data before replacing missing records together with the reduced vital signs data using methods 1 and 2.
The estimated mean and 95% Cl results are displayed in Figures 8.2.1 to 8.2.3 for heart rate, systolic and
diastolic blood pressure respectively. Figure 8.2.4 shows the estimated dietary response mean and 95%
Cl for the original data before imputing missing records and for data reduced using method 1 only.
Tables la-d (Appendix A) show actual observed means for the original data and Tables 3a-d and 4a-c
(Appendix A) show observed means for the reduced data using methods 1 and 2 respectively. See
Figures 4.4.1-4.4.4 for plots of the actual mean and 95% Cl plots for the original data. These plots
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correspond to Figures 8.2.1 A-8.2.4A, which show the model based mean and 95% Cl for heart rate, 
systolic BP, diastolic BP and dietary response respectively. Comparisons of these plots show that the 
final model for the original data was a valid one. In each case, the plot of the estimated final mean model 
response for the original data (Figures 8.2.1 A-8.2.4A) appears similar to the plots of the actual means on 
the original data (Figures 4.4.1-4.4.4). All final models appropriately describe the data since any 




Comparison of Models Fixed Effects for Mean Grouped Heart Rate (b/m)
Heart Rate Centre Drug Base Time Time*Drug
Original Before 0.338 0.283 <0.001* <0.001* 0.488
Replaced 0.272 <0.001* <0.001* 0.487
Original After 0.378 0.327 <0.001* <0.001* 0.428
Replaced 0.319 <0.001* <0.001* 0.428
Average 2 Hours 0.545 0.899 <0.001* 0.252
0.467 0.346 <0.001* <0.001* 0.360
0.544 0.794 <0.001*




0.333 <0.001* <0.001* 0.359
Average 3 Hours 0.195 0.898 <0.001* 0.107
0.719 0.347 <0.001* <0.001* 0.159
0.195 0.644 <0.001*




0.338 <0.001* <0.001* 0.159
Note: Each row represents one of the various mixed models that were applied to the data. Each cell 
contains the p-values for the effects of covariates in the model.
Original Data:
The results both before and after imputing missing records gave similar findings, hence, only the results 
on the original data before imputing missing data will be considered. ‘Centre’ (p=0.338) was an 
insignificant effect in the model and can be removed. It can then be seen that there are no significant 
treatment differences (p=0.272).
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Method 1: Averaging over 3 Time Points:
The ‘interaction’ (p>0.106) and the ‘centre’ term (p>0.195) are both insignificant effects in the model.
If both these terms are removed from the models, then there is no change in the ‘time’ and ‘baseline’ 
effects (p<0.001 for both). The ‘drug’ effect also becomes more significant in the model (p=0.097). 
Finally, ‘drug’, ‘base’ and ‘time’ and the ‘time’ by ‘treatment’ interaction are all kept in the model. This 
is because the results for ‘base’ and ‘time’ do not change and ‘drug’ has the lowest significance. See 
Figure 8.2.1C for the final model based mean and 95% Cl plot. There are no significant treatment 
differences (p=0.338).
Method 2: Averaging over 2 Time Points:
The ‘interaction’ (p>0.252) and the ‘centre’ term (p>0.467) are both insignificant effects in the model.
If both these terms are removed from the models, then there is no change in the ‘time’ and ‘baseline’ 
effects (pcO.OOl for both). The ‘drug’ effect also becomes more significant in the model (p=0.116). 
Finally, ‘drug’, ‘base’ and ‘time’ and the ‘time’ by ‘treatment’ interaction are all kept in the final model 
(see Figure 8.2.IB). This is because the results for ‘base’ and ‘time’ do not change and ‘drug’ has the 
lowest significance. There are no significant treatment differences (p=0.333).
NOTE: Both the reduced data structures (Figures 8.2.IB and C) have similar models and they appear 
similar to the original data model (Figure 8.2.1 A). The original patterns in the data are maintained 
through the reduced models. No treatment differences were detected for any of the final models, 
agreeing with all test results and plots in the previous chapters. From the contrast comparisons in Table 




8.2.1.2 Systolic Blood Pressure
Table 8.1.2
Comparison of Models Fixed Effects for Mean Grouped Systolic Blood Pressure
Systolic BP Centre Drug Base Time Time*Drug
Original Before 
Replaced
0.693 <0.001* <0.001* <0.001* 0.748
<0.001* <0.001* <0.001* 0.748
Original After 
Replaced




Average 2 Hours 0.534 <0.001* 0.397
0.659 <0.001* <0.001* <0.001* 0.320
0.534 0.006* <0.001*




<0.001* <0.001* <0.001* 0.320
Average 3 Hours 0.540 0.014* <0.001* 0.569
0.672 <0.001* <0.001* <0.001* 0.490
0.540 0.008* <0.001*




<0.001* <0.001* <0.001* 0.489
Note: Each row represents one of the various mixed models that were applied to the data. Each
cell contains the p-values for the effects of covariates in the model.
Original Data:
The results both before and after imputing missing records gave similar findings, hence, only the results 
on the original data before imputing missing data will be considered. ‘Centre’ (p=0.693) was an 
insignificant effect in the model and can be removed. It can then be seen that there were significant 
treatment differences (pcO.OOl).
Method 1: Averaging over 3 Time Points:
The ‘interaction’ (p>0.489) and the ‘centre’ term (p>0.540) are both insignificant effects in the model.
If both these terms are removed from the models, then there is no change in the ‘time’ and ‘baseline’ 
effects (pcO.OOl for both). The ‘drug’ effect is also most significant in this model (pcO.OOl) after 
removing just ‘interaction’, just ‘centre’ or ‘both’ terms. Finally, ‘drug’, ‘base’ and ‘time’ and the ‘time’ 
by ‘drug’ interaction are all kept for the final model. This is because the results for ‘base’ and ‘time’ do 
not change, ‘drug’ has no change in significance and all other effects are still highly insignificant. It can 
then be seen that there were significant treatment differences (pcO.OOl).
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Method 2: Averaging over 2 Time Points:
The ‘interaction’ (p>0.320) and the ‘centre’ term (p>0.534) are both insignificant effects in the model.
If both these terms are removed from the models, then there is no change in the ‘time’ and ‘baseline’ 
effects (pcO.OOl for both). The ‘drug’ effect is also most significant in this model (pcO.OOl) after 
removing just interaction, just ‘centre’ or ‘both’ terms. ‘Drug’, ‘base’ and ‘time’ and the ‘time’ by ‘drug’ 
interaction are all kept for the final model. This is because the results for ‘base’, ‘time’ and ‘drug’ do 
not change and all other effects are highly insignificant. It can then be seen that there were significant 
treatment differences (pcO.OOl).
NOTE: Both the reduced data structures have similar models and agree with the findings for the original 
data. In all cases a ‘drug’ effect can be seen (Figures 8.2.2A-C). It appears as if drug 4 has the lowest 
mean systolic blood pressure response over time. From the contrast comparisons in Table 20b 
(Appendix A) it can be seen that there were differences in mean systolic blood pressure for drug 4 
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8.2.1.3 Diastolic Blood Pressure
Table 8.1.3
Comparison of Models Fixed Effects for Mean Grouped Diastolic Blood Pressure
Diastolic BP Centre Drug Base Time Time*Drag
Original Before 0.487 cO.001* cO.OOl* cO.OOl* 0.175
Replaced cO.OOl* cO.OOl* cO.OOl* 0.175
Original After 0.450 cO.OOl* cO.OOl* cO.OOl* 0.271
Replaced cO.001* cO.OOl* cO.OOl* 0.271
Average 2 Hours 0.437 0.020* cO.OOl* 0.129
0.934 cO.001* cO.OOl* cO.OOl* 0.126
0.438 0.018* cO.OOl*




cO.001* cO.OOl* cO.OOl* 0.125
Average 3 Hours 0.309 0.020* cO.OOl* 0.358
0.501 cO.001* cO.OOl* cO.OOl* 0.313
0.309 0.026* cO.OOl*




cO.001* cO.OOl* cO.OOl* 0.312
Note: Each row represents one of the various mixed models that were applied to the data. Each
cell contains the p-values for the effects of covariates in the model.
Original Data:
The results both before and after imputing missing records gave similar findings, hence, only the results 
on the original data before imputing missing data will be considered. ‘Centre’ (p=0.487) was an 
insignificant effect in the model and can be removed. It can then be seen that there were significant 
treatment differences (p<0.001).
Method 1: Averaging over 3 Time Points:
The ‘interaction’ (p>0.312) and the ‘centre’ term (p>0.309) are both insignificant effects in the model. 
If both these terms are removed from the models, then there is no change in the ‘time’ and ‘baseline’ 
effects (pcO.OOl for both). The ‘drug’ effect is also most significant in this model (pcO.OOl) after 
removing just interaction, just centre or both terms. ‘Drug’, ‘base’ and ‘time’ effects and the ‘time’ by 
‘treatment’ interaction are all kept in the final model. This is because the results for ‘base’, ‘time’ and 
‘drug’ do not change and all other effects are highly insignificant. It can then be seen that there were 
significant treatment differences (pcO.OOl).
164
Method 2: Averaging over 2 Time Points:
The ‘interaction’ (p>0.125) and the ‘centre’ term (p>0.437) are both insignificant effects in the model.
If both these terms are removed from the models, then there is no change in the ‘time’ and ‘baseline’ 
effects (p<0.001 for both). The ‘drug’ effect is also most significant in this model (p<0.001) after 
removing just ‘interaction’, just ‘centre’ or ‘both’ terms. The ‘drug’, ‘base’, ‘time’ and the ‘time’ by 
‘treatment’ interaction are all kept in the final model. This is because the results for ‘base’, ‘time’ and 
‘drug’ do not change and all other effects are not significant. It can then be seen that there were 
significant treatment differences (pcO.OOl).
NOTE: Both the reduced data structures have similar models. There is a significant treatment effect in 
the final model for all three data stuctures (Figures 8.2.3A-C). From the reduced data set plots (Figures 
8.2.3B and C) it can be seen that drug 4 has the lowest mean diastolic blood pressure readings and drug 2 
has the highest mean responses over the course of the study. These differences are not picked up as 
easily for the original data (Figure 8.2.3A). Comparisons of contrasts are displayed in Table 20c 
(Appendix A). It can be seen that there were differences in mean diastolic blood pressure for drug 1 
compared to drug 4 (p=0.004 for all three data structures) and drug 2 compared with drug 4 (pcO.OOl for 
all three data structures). Differences were also observed for drug 2 compared to drug 3 (pc0.003 for all 
three data structures). There was a difference between drug 1 and 3 for the original data (p=0.045) but 
this was not detected for the reduced data structures (p>0.05). It is believed that the results for the 
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8.2.1.4 Dietary Response
Table 8.1.4
Comparison of Models Fixed Effects for Mean Grouped Dietary Response Data
Dietary Response Group Base Time Time*Group
Original Before Replaced <0.001* 0.121 <0.001* <0.001*








<0.001* 0.056 0.101 <0.001*
<0.001* 0.196
<0.001* 0.056 0.197
Note: Each row represents one of the various mixed models that were applied to the data. Each
cell contains the p-values for the effects of covariates in the model.
Original Data:
The results both before and after imputing missing records gave similar findings, hence, only the results 
on the original data before imputing missing data will be considered. It can then be seen that there were 
significant treatment differences (pcO.OOl).
Method 1: Averaging over 3 Time Points:
The interaction term (pcO.OOl) is an extremely significant effects in the model and therefore will not be 
dropped. ‘Time’ is insignificant (p=0.101) and ‘baseline’ measurement is borderline significant 
(p=0.056) for the full model. ‘Group’, ‘base’ and ‘time’ and ‘time’ by ‘group’ interaction were all kept 
in the final model. This is because the all terms were somehow describing the data. There were 
significant treatment differences (p<0.001).
NOTE: The reduced data structure has a similar model to the original data. There was a significant 
treatment effect in the final model for both data stuctures (Figures 8.2.4A-B). From the reduced data set 
plot (Figures 8.2.4B) it can be seen that therapy 3 has the lowest mean dietary response and therapy 1 
had the highest mean response over the course of the study. These differences are not picked up as 
easily for the original data plot (Figure 8.2.4A). From the contrast comparisons in Table 20d (Appendix 
A) it can be seen that there were significant differences in mean dietary response for each therapy 




































Looking at the Kaplan-Meier time to event analysis plot for the first abnormal heart rate reading, drugs 4 
and 3 seem to have the best and worst performances respectively. The drugs behave in a similar manner 
for systolic blood pressure also. However, for diastolic blood pressure, drug 1 and possibly drug 3 seem 
to have the best performances and drug 2 has the worst performance. Both the Log-rank and Wilcoxon 
tests do not reveal any significant differences between the treatment performances for the times to the 
first abnormally ‘high’ reading for any of the vital sign measurements.
Logistic regression analyses (with dichotomised categories of having either less than 50% or greater than 
or equal to 50% of abnormally high results and similarly of having less than 75% or greater than or equal 
to 75% of abnormally high results) were conducted. These analyses both indicate that the time-drug 
‘interaction’ as well as the ‘centre’ term has no significant effect in the models. These terms are 
therefore considered to be non-influential in the models. The logistic models on the proportion of 
individuals with greater than or equal to 50% and 75% abnormality disagree with one another for 
diastolic blood pressure findings but do agree for systolic blood pressure results. The logistic analyses 
for greater than or equal to 75% abnormality gave comparable findings to the Chi-squared test results in 
Tables 16b and 16c (Appendix A) for both categorical systolic and diastolic blood pressure readings.
The logistic analysis showed that there was a treatment difference between drugs 1 and 4 and also drugs 
2 and 4 for systolic blood pressure, corresponding to the mixed modelling findings. However, no 
treatment difference was detected for proportion of individuals with greater than or equal to 75% 
abnormality for diastolic blood pressure, as with the survival analysis findings above. This finding does, 
however, contradict the results from the mixed model approach where differences in diastolic BP were 
noticed. Differences were detected between drugs 1 and 4 for the proportion of individuals with greater 
than or equal to 50% diastolic blood pressure abnormality and these differences were actually seen with 
the mixed modelling approach.
The mixed modelling approach (for reduced data using the approach of averaging either 2 or 3 
successive observations respectively) was conducted on the data and these analyses indicated that the 
time-drug ‘interaction’ as well as the ‘centre’ term has no significant effect in the models. There are 
treatment differences for systolic and diastolic blood pressure as well as dietary response. Treatment 
differences were not detected for any heart rate data.
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The mixed modelling approach was more sensitive to picking up data differences than the categorical 
data analyses approaches of time to event and logistic regression analyses that were conducted together 
with the Chi-squared tests for categorical data.
One should remember that the multivariate analysis assumes normality or robustness of tests; which may 
be OK in the case of averaging 3 successive observations (method 1), but may be questionable in the 
case of the averaging approach for 2 successive observations (method 2). Hence, it is believed that 
method 1 is more appropriate over method 2 to describe the data following data reduction.
It should also be mentioned that the present chapter does not consider in its study, the reduced data sets 
based on principal components and summary measures, since for these the information about the 
performances of various characteristics at different time points is lost.
It can be seen that for diastolic blood pressure, differences between drug 1 and 3 were not found for the 
reduced data but were seen for the original data only. The original data is studied here, but since the 
number of repeated measures is too large compared to the sample sizes there are serious doubts about the 
validity of any associated results, especially in the case of diastolic blood pressure, where differences in 
conclusion were noticed.
Hence, It was decided that data reduced using method 1 was the best format for the data to take in order 
for any multivariate testing to be conducted. This would allow the assumption of asymptotic normality 
without any further testing of the data and would lead to more robust test results than results on the 
original data. The multivariate mixed models approach of modelling the data was the optimal analysis 
methodology since it was more sensitive at picking up treatment differences than any other approach of 
those conducted. All the methods used for the categorical data analysis were not sensitive at picking up 
treatment differences when they actually existed.
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CHAPTER 9: OVERVIEW
9.1 Discussion and Conclusions
Since the data were non-normal at some points and normal at others, it was decided to use robust[32] 
non-parametric or parametric statistical approaches as opposed to transforming the data. The result was 
to use the non-parametric Kruskal-Wallis approach, as well as parametric tests with a reduced number of 
repeated measurements p. The idea of using the Kruskal-Wallis tests was not to analyse the data at each 
repeated measurement, but was only used to compare the results both before and after imputing missing 
results. In all cases, tests on both data sets gave similar conclusions. This suggested that missing data 
generation was appropriate and would not distort the results that drastically for univariate testing. All 
univariate tests on the summary measures were conducted to compare treatments. The results both 
before and after imputing missing records gave similar conclusions; again suggesting that missing data 
generation was not distorting the results and also that data generation was not crucial in analysing the 
data in a univariate manner.
Mahalanobis distances were used to test for treatment differences between pairs of distances and also to 
compare results before and after data replacement for both the original and the reduced data sets. The 
findings before and after imputing missing records were similar for all data structures that were 
analysed. It was decided that the reduced average data and, possibly, the summary measures methods 
were the most appropriate data structures to describe the actual data. The principal component analysis 
(in all cases with significant initial results) was not a very useful approach for reducing the larger 
repeated measures data sets. The P.C.A. approach was only tested using the Mahalanobis distances and 
not using the multivariate modelling approaches.
The reduced data only after replacing missing records were analysed for all multivariate modelling to 
keep things consistent for both methods 1 and 2. This was since the same numbers of observations were 
available for each reduced data set following replacement of missing records.
In all cases, the best multivariate generalised mixed effects model for continuous data was after adjusting 
for ‘baseline’ readings and ‘times’.
From the original data actual mean plots (Figures 4.4.1 to 4.4.3), it can be seen that the data peaks at two 
times, namely at 11 and 23 hours, for all vital sign measurements (heart rate, systolic and diastolic BP 
respectively). From observing this, it is suggested that the reasoning behind this could be that the
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individuals are hungry or that some activity may be occurring at the particular time of drug 
administration.
All survival tests for time to the first abnormality showed insignificant treatment differences. This 
approach is not sensitive at picking up treatment differences and is subjective to what is considered to be 
an ‘abnormality’ in results.
The Chi-squared tests on the proportion of individuals having greater than or equal to 75% abnormality 
gave similar findings to the corresponding logistic regression models. These results agreed with the 
mixed model results for systolic blood pressure only, showing a treatment difference between drugs 4 
and 1 and also drugs 4 and 2. However, the logistic regression results for greater than or equal to 75% 
abnormality did not agree with the mixed model findings for diastolic blood pressure showing no 
treatment differences as with the time to event analysis. The results for greater than or equal to 50% 
abnormality did agree with the mixed model findings for diastolic blood pressure showing a treatment 
difference between drugs 1 and 4. It is believed that the Chi-squared tests on categorical data are again 
dependent on the definition of ‘abnormality’ and hence the approach is unreliable to describe the data 
because of a lack of sensitivity. The logistic regression approach is also dependent on the definition of 
‘abnormality’ but is more reliable than the Chi-squared approach, which in turn is more reliable than the 
time to event analysis. Of all multivariate analysis approaches, the mixed modelling approach was the 
most reliable and data sensitive method of analysing the data. The non-parametric testing approach of 
Mahalanobis distances was not as sensitive as the mixed modelling procedure. This was because not all 
treatment differences were detected when differences existed and some differences were detected when 
they may not be valid results due to the data being non-normal in nature.
The data reduction method 1 was the most reliable data reduction approach that still retained the element 
of time. The multivariate results obtained for this data set was more reliable than the results on the 
original data since asymptotic normality was met for the reduced data set.
There were no treatment differences for any of the summary measures for heart rate (beats/min). 
Treatment differences occurred for systolic blood pressure, diastolic blood pressures and also dietary 
response. For the vital signs analyses, the mean systolic and diastolic blood pressures responses for 
individuals on drug 4 were considerably lower than for any other treatments. For the dietary response 
data, there were significantly different mean responses between all three-therapy groups.
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9.2 Further Work
• Time series approach could be applied.
• Covariance structure modelling could be attempted.
• There are other modelling procedures but only the generalised mixed effects model was selected for 
the primary analysis.
• The reasons for trends in the data could be due to external factors that aren’t readily controllable such 
as whether an individual is taking other medications, whether the individual has eaten or not and when 
was drug administered. These are all things that influence the results of vital signs measurements in 
particular and could be used in the models if the information were available.
• Other variables could have been important in modelling the data. These are variables such as age. 
This was not available and therefore was not considered, however, it is definitely known to be a factor 
that would influence the heart rates for individuals.
• Multivariate normality could be tested using a regression approach (or other approaches that were 
suggested but not addressed).
• Zeger and Liang’s GEE could be applied for multivariate analysis of repeated categorical data.
• The approaches in this thesis could be applied to other larger and smaller longitudinal data sets to see 
if the same conclusions could be obtained.
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Summary Statistics and Tests for Time and Drug
Original Data Set: Heart Rate
DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W
1 71.2 73 .7 8.1 59.8 89.9 67.5 79.6 20 0.288 0.9182 75.7 73.7 10.4 48.7 97.3 65.5 79.6 21 0.3543 73.7 72.8 12.5 46.2 92.9 65.8 83.4 22 0.5314 72.8 72.0 6.2 63.1 86.3 68.1 75.2 21 0.348
1 68.0 69.7 9.0 49.8 86.3 63.0 74.5 19 0.731 0.9062 67.8 68.5 9.6 47.8 83.5 62.0 75.6 22 0.7623 70.5 67.8 10.6 46.2 85.0 65.4 73.8 21 0.3574 71.3 69.8 6.8 53.5 80.5 67.4 74.3 21 0.179
1 72.8 72.4 7.2 56.5 83.3 68.5 79.0 21 0.632 0.5542 69.0 70.1 12.7 50.8 97.3 60.8 79.5 22 0.4223 70.5 71.3 13.0 48.8 94.0 66.3 77.3 21 0.5314 76.0 73.5 10.1 54.5 87.5 68.3 81.2 21 0.088
1 79.5 78.1 9.6 59.5 100.0 71.5 81.8 21 0.402 0.5282 74.7 74.0 11.6 51.8 94.7 67.3 83.8 21 0.8293 81.3 78.5 16.2 49.3 106.0 70.5 88.5 21 0.6614 78.7 78.3 10.1 56.7 92.3 74.0 86.8 21 0.144
1 74.0 75.0 9.2 58.0 90.5 71.8 79.8 21 0.578 0.5542 71.6 71.8 11.2 50.3 93.0 65.0 79.3 22 0.9363 76.1 74.3 14.2 43.8 95.0 65.3 86.8 22 0.1974 76.3 76.3 8.5 57.3 90.5 71.3 83.8 21 0.863
1 75.5 76.7 12.1 59.0 102.3 69.3 85.0 21 0.632 0.4862 75.6 74.8 11.2 50.0 94.0 66.3 81.8 22 0.8453 79.8 78.7 15.1 46.0 106.3 67.5 88.0 22 0.9734 79.8 79.9 8.8 63.3 100.0 75.0 84.5 21 0.977
1 75.8 75.8 9.9 62.0 93.5 66.7 83.7 21 0.238 0.6312 75.8 75.7 11.2 51.5 97.0 67.0 84.8 22 0.9593 76.1 77.2 15.2 45.8 100.3 65.3 90.3 22 0.5064 79.8 79.4 8.3 65.8 97.5 74.3 85.8 21 0.897
1 76.0 78.5 9.5 61.8 93.3 72.8 88.0 21 0.245 0.9132 78.3 80.5 14.1 52.8 120.3 71.5 89.0 22 0.1773 83.7 79.3 16.7 47.5 102.3 68.0 91.3 22 0.1234 78.8 79.9 11.4 67.7 121.3 73.5 82.0 21 0.000*
1 74.0 77.6 12.9 60.5 109.8 68.5 80.8 21 0.089 0.6932 79.8 80.6 15.1 45.8 109.3 71.0 91.5 22 0.7343 83.0 79.3 17.4 44.3 107.3 67.7 90.0 22 0.5354 75.8 77.9 9.6 66.0 101.5 71.5 80.8 21 0.029*
1 75.8 80.3 16.5 58.5 123.0 67.5 91.5 21 0.082 0.8942 76.8 80.3 20.1 44.3 145.0 68.0 90.0 22 0.014*3 81.0 78.2 15.7 42.5 105.5 69.0 88.8 22 0.5054 72.0 76.2 9.3 64.8 93.8 69.5 83.3 21 0.025*
1 75.8 75.7 10.2 54.8 104.5 71.0 79.0 21 0.143 0.7212 77.5 77.1 12.4 50.3 99.5 68.3 89.0 22 0.7043 82.6 78.0 13.4 51.0 96.5 67.4 87.8 22 0.0984 77.0 76.2 8.4 55.8 92.0 71.3 80.8 21 0.608
1 82.3 84.7 13.0 63.8 113.0 76.5 93.0 21 0.637 0.8462 87.2 88.4 13.2 65.3 118.7 78.0 94.8 22 0.8843 83.9 83.8 17.0 49.7 107.8 76.3 99.5 22 0.1524 85.3 86.0 9.6 73.0 105.7 80.5 91.3 21 0.266
























Table la  cont.
Summary Statistics and Tests for Time and Drug 
Original Data Set: Heart Rate
MEDIAN MEAN STD MIN MAX Q 1 Q 3 N NORMAL K.W77.8 76.2 12.0 55.0 96.3 67.0 86.3 20 0.648 0.97777.0 77.9 15.5 47.0 109.0 69.0 85.0 21 0.91777.8 77.8 16.5 45.0 109.5 67.5 88.5 22 0.95877.0 78.9 12.3 66.0 113.0 73.5 82.0 21 0.000*
73.0 72.8 9.2 54.0 90.5 65.5 78.0 21 0.815 0.72477.0 76.2 12.6 47.0 107.0 70.0 84.0 22 0.82373.0 74.7 15.9 43.0 113.0 65.5 84.0 21 0.82774.5 75.7 8.4 64.0 93.5 69.0 79.0 21 0.182
70.0 72.1 11.9 51.5 100.5 66.0 75.0 21 0.038* 0.86667.8 73.1 14.4 48.5 102.5 64.0 82.0 22 0.12568.3 70.3 11.3 51.3 92.0 62.5 76.5 22 0.53171.0 73.1 11.2 54.5 106.5 67.0 75.5 21 0.016*
70.0 69.4 8.4 54.0 89.5 63.0 75.0 21 0.901 0.84367.3 69.6 14.1 46.0 104.0 60.5 82.5 22 0.49066.0 66.8 11.3 44.5 87.0 60.5 73.5 22 0.74766.0 68.2 9.4 50.0 88.0 62.0 71.0 21 0.108
69.5 69.3 7.4 55.5 83.0 63.0 75.0 21 0.946 0.86868.0 69.4 12.5 45.0 94.0 61.0 76.5 22 0.90367.3 66.7 11.0 42.5 86.0 61.0 73.0 22 0.69067.0 68.5 8.5 53.0 86.5 62.5 73.5 21 0.655
67.5 68.6 8.3 54.0 82.0 62.3 77.3 20 0.475 0.43162.5 64.6 10.3 47.5 85.5 57.0 73.0 22 0.70466.3 65.8 10.9 40.0 82.0 61.5 73.5 20 0.34166.5 68.5 6.7 56.5 82.5 64.0 73.0 21 0.862
66.3 66.7 7.3 49.5 78.0 62.5 72.0 20 0.639 0.85565.5 64.3 9.6 44.0 79.0 57.5 72.5 22 0.65668.3 66.4 11.0 45.5 84.5 60.3 73.3 20 0.76865.5 67.3 7.4 53.0 82.0 63.0 70.0 21 0.724
64.5 66.0 8.6 54.0 85.0 61.0 71.0 21 0.390 0.78263.3 65.0 11.8 45.0 95.0 56.0 70.5 22 0.25764.3 64.3 10.4 41.5 80.0 57.5 73.5 20 0.52565.5 66.4 4.8 57.5 75.0 63.5 70.0 21 0.671
66.0 68.6 8.9 55.5 94.0 62.0 75.0 21 0.082 0.24560.5 62.6 9.7 45.0 83.0 55.5 69.0 22 0.38469.5 66.1 11.6 40.5 84.0 61.0 76.0 21 0.52865.0 67.3 10.3 57.0 106.5 64.5 67.5 21 0.000*
75.0 72.9 11.7 52.5 100.0 62.5 80.0 21 0.568 0.66469.8 72.3 15.6 43.5 103.5 60.0 82.5 22 0.57371.5 71.5 15.6 45.0 111.0 60.0 85.0 21 0.52573.8 75.8 11.9 61.0 102.5 67.0 85.5 20 0.112
91.6 91.1 15.6 59.5 118.0 78.6 103.3 20 0.939 0.25081.8 89.5 25.7 50.3 173.0 74.3 101.3 22 0.006*78.8 81.1 14.8 51.0 105.0 75.7 89.0 21 0.43884.3 87.7 12.0 72.5 122.7 79.0 95.0 19 0.024*
77.0 78.4 10.2 61.8 102.0 71.5 83.0 21 0.626 0.14172.7 74.1 10.0 54.5 94.0 69.0 77.8 22 0.29974.0 73.4 12.6 47 .0 104.7 68.0 81.7 22 0.71478.5 80.5 12.5 60.5 105.7 76.8 88.3 21 0.167
3
Table lb
Summary Statistics and Tests for Time and Drug
Original Data Set: Systolic Blood Pressure
TIME DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W
0 1 149.7 151.3 12.1 128.4 174.4 143.1 158.8 20 0.968 0.8572 146.8 148.7 11.1 128.5 177.6 143.2 154.1 21 0.385
3 147.2 152.3 14.1 129.9 179.6 144.5 166.5 22 0.041*4 149.0 149.1 13.6 128.5 167.3 139.8 162.6 21 0.066
1 1 153.5 153.1 14.3 127.3 178.0 143.3 162.5 19 0.794 0.038*2 150.8 151.4 12.7 122.0 170.0 144.8 163.8 22 0.2783 154.8 154.2 18.9 99.4 184.0 145.4 166.2 21 0.1504 143.0 143.3 11.6 125.0 168.5 137.8 149.3 21 0.808
2 1 153.5 153.9 13.9 127.0 177.8 146.0 164.8 21 0.864 0.1102 149.1 152.5 12.2 129.5 172.3 143.8 162.6 22 0.4163 146.5 149.8 16.3 107.5 183.3 141.8 161.5 21 0.4254 145.5 142.9 14.0 111.3 166.2 132.5 152.0 21 0.727
3 1 162.3 158.2 16.6 122.5 185.5 142.3 170.8 21 0.374 0.015*2 150.3 152.2 14.4 127.3 188.0 145.7 157.5 21 0.3273 152.3 150.7 14.2 115.0 176.7 144.3 157.0 21 0.6244 146.5 142.9 11.1 122.0 158.5 131.3 150.3 21 0.025*
4 1 155.3 154.6 16.9 125.0 196.8 140.3 159.5 21 0.633 0.1862 149.1 151.3 15.1 130.3 178.8 137.8 160.3 22 0.0893 148.8 147.9 16.9 96.3 177.0 140.8 155.5 22 0.0574 142.0 142.1 15.2 112.5 166.8 138.0 151.5 21 0.426
5 1 157.0 157.0 14.6 125.8 184.0 150.5 165.5 21 0.947 0.033*2 152.0 153.9 13.7 124.5 179.5 145.3 165.7 22 0.9903 152.6 152.1 15.7 109.3 193.8 144.3 157.3 22 0.0714 147.3 144.8 12.5 117.8 169.8 139.0 152.7 21 0.922
6 1 154.0 156.0 17.3 119.5 198.5 144.8 163.3 21 0.149 0.005*2 150.7 150.9 12.3 124.5 174.0 140.8 157.3 22 0.8563 147.4 147.5 19.2 108.0 186.3 137.5 156.5 22 0.9014 138.5 139.3 13.3 116.0 169.0 132.0 146.5 21 0.752
7 1 158.0 156.6 19.2 116.0 192.0 143.0 166.5 21 0.690 0.023*2 151.4 153.5 11.9 129.3 178.5 144.0 161.8 22 0.9853 149.9 150.4 14.5 109.7 176.5 143.7 158.3 22 0.3354 144.3 141.8 12.7 120.8 166.0 133.0 150.0 21 0.465
8 1 149.0 153.3 16.6 118.8 184.3 142.0 164.0 21 0.483 0.039*2 147.7 154.1 16.7 118.8 187.0 143.3 168.3 22 0.2143 146.8 146.8 16.5 100.3 173.3 138.0 158.3 22 0.1934 139.8 142.0 15.4 118.0 178.0 131.5 152.3 21 0.502
9 1 159.8 156.7 16.8 120.8 185.5 146.0 163.7 21 0.786 0.1502 148.4 150.2 15.4 123.3 182.0 137.8 163.7 22 0.9023 154.1 152.4 17.4 112.8 186.8 138.3 162.8 22 0.9634 144.8 144.7 14.9 116.0 169.5 135.0 154.7 21 0.815
10 1 159.5 159.4 14.5 124.8 189.5 148.8 170.5 21 0.839 0.0542 150.3 151.7 13.6 127.8 178.0 140.7 160.8 22 0.4493 154.8 154.7 20.3 100.3 193.0 142.8 167.0 22 0.5064 148.3 146.5 13.1 125.8 173.5 134.3 155.3 21 0.317
11 1 163.8 161.7 17.7 125.3 192.0 154.0 170.0 21 0.748 0.0592 150.8 153.9 18.7 115.3 184.0 145.3 169.8 22 0.3433 153.3 154.4 17.0 116.3 191.8 144.5 162.8 22 0.9864 148.5 146.5 15.1 121.7 168.8 133.3 158.0 21 0.219









































Summary Statistics and Tests for Time and Drug
Original Data Set: Systolic Blood Pressure
MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W
149.5 151.2 17.1 115.5 177.5 141.0 164.5 20 0.649 0.120150.0 152.2 17.5 116.0 196.5 145.5 161.0 21 0.473148.3 146.7 18.3 105.0 186.0 133.5 157.5 22 0.996144.0 141.4 14.4 114.5 175.5 135.5 148.0 21 0.536
151.5 152.1 12.4 129.0 180.0 146.0 159.0 21 0.890 0.082150.0 148.8 15.4 118.5 174.0 139.0 163.0 22 0.539145.0 147.5 20.2 95.0 186.5 137.0 160.0 21 0.421141.5 140.9 14.2 114.0 166.0 133.0 148.5 21 0.786
145.0 145.8 18.5 108.5 181.0 136.0 156.5 21 0.935 0.154146.3 147.0 15.6 117.0 172.0 141.0 159.5 22 0.234135.8 140.9 19.7 96.0 187.0 131.0 154.0 22 0.782140.5 136.9 13.4 114.0 160.0 124.0 148.5 21 0.139
136.5 138.1 17.6 115.0 192.0 127.0 144.0 21 0.006* 0.002'138.5 136.9 15.2 99.0 160.0 131.0 146.0 22 0.221129.0 133.0 16.2 112.5 183.5 122.5 138.0 22 0.002*122.5 123.5 11.2 102.5 148.5 115.5 132.5 21 0.662
139.5 136.1 17.8 98.5 175.0 124.0 145.5 21 0.921 0.037'133.8 133.8 14.3 106.0 166.0 126.0 139.0 22 0.179129.8 131.6 14.4 105.0 162.0 121.5 142.0 22 0.690125.0 122.8 14.7 103.0 160.5 109.5 133.5 21 0.189
132.0 135.0 18.1 108.0 179.0 121.8 143.8 20 0.359 0.049'132.8 131.1 13.8 107.0 154.0 119.5 140.0 22 0.492129.8 134.4 21.7 102.0 193.5 118.3 147.3 20 0.205115.5 120.2 15.6 91.0 144.5 110.0 136.5 21 0.167
125.8 129.7 21.0 91.5 187.5 117.8 137.0 20 0.056 0.023131.8 130.3 10.8 113.0 148.0 120.0 138.0 22 0.087131.8 132.6 19.4 90.5 169.5 121.3 139.8 20 0.733118.3 117.9 14.5 84.5 141.0 110.0 128.0 21 0.838
128.5 130.7 19.9 97.0 176.0 115.0 139.0 21 0.282 0.199132.5 131.9 15.2 104.0 180.5 121.0 140.5 22 0.016*134.0 134.1 17.4 103.0 166.0 120.8 144.8 20 0.909123.5 122.9 14.7 83.0 147.0 114.0 133.0 21 0.379
134.5 134.5 18.1 111.0 175.0 121.5 141.0 21 0.175 0.016130.0 130.6 13.1 106.0 165.5 122.0 134.0 22 0.034*133.0 134.5 18.4 99.0 166.5 124.0 148.0 21 0.514118.5 119.9 14.6 96.0 146.5 111.0 129.0 21 0.464
135.0 143.6 21.6 117.5 196.5 129.5 152.5 21 0.018* 0.398144.0 142.3 16.2 117.5 179.5 133.0 152.0 22 0.343141.5 141.3 20.2 98.5 176.0 132.5 156.5 21 0.811134.8 133.2 16.8 101.5 166.0 120.3 146.5 20 0.922
157.5 158.6 20.4 129.0 203.0 147.9 171.0 20 0.430 0.003*
153.8 150.1 14.3 120.0 177.0 143.3 158.5 22 0.242151.0 150.4 21.5 91.0 183.3 140.0 163.0 21 0.308138.5 137.8 11.7 112.7 154.0 128.5 148.5 19 0.455















Summary Statistics and Tests for Time and Drug
Original Data Set: Diastolic Blood Pressure
DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W
1 97.5 96.9 6.8 82.1 111.3 92.4 100.2 20 0.995 0.9002 96.4 95.0 5.9 82.2 103.9 92.8 99.4 21 0.128
3 94.8 96.3 7.8 83.9 112.0 91.3 102.7 22 0.5284 95.1 95.6 8.7 81.8 113.0 89.5 99.0 21 0.425
1 97.8 98.1 9.1 81.3 115.8 93.8 104.3 19 0.799 0.1732 99.4 99.2 9.0 81.3 115.4 94.0 105.6 22 0.9643 100.8 98.1 10.6 67.6 114.0 93.7 105.5 21 0.0784 95.0 94.2 6.8 82.0 105.3 91.0 99.3 21 0.540
1 100.5 98.2 10.0 82.0 115.3 90.0 106.8 21 0.536 0.1452 98.5 99.6 10.5 81.8 123.8 93.0 106.0 22 0.8593 92.8 94.2 9.6 76.3 111.0 88.3 103.0 21 0.6894 93.5 93.1 8.6 77.0 109.0 87.8 98.0 21 0.981
1 104.5 103.0 10.6 80.8 115.3 96.8 112.8 21 0.061 0.019'2 101.8 100.3 11.3 74.7 121.3 90.8 106.2 21 0.6993 94.0 95.0 10.8 77.8 113.0 87.0 104.0 21 0.3784 90.5 94.0 9.8 80.0 115.0 87.0 99.3 21 0.305
1 100.5 100.3 10.7 80.3 116.5 94.8 106.0 21 0.475 0.0622 101.3 99.4 11.2 75.8 123.0 91.8 107.8 22 0.9923 93.6 92.3 10.7 68.3 108.3 86.3 101.5 22 0.4614 97.6 93.2 10.9 69.3 110.5 86.5 100.0 21 0.200
1 105.3 103.2 9.9 81.8 118.0 99.0 110.5 21 0.094 0.0352 99.5 101.8 10.7 87.5 132.5 93.8 109.8 22 0.0683 96.5 96.8 11.0 69.0 114.5 91.0 106.0 22 0.4274 94.3 95.8 7.2 83.0 109.3 91.5 101.0 21 0.594
1 93.0 94.8 9.7 74.0 112.8 90.8 103.3 21 0.497 0.0172 93.5 94.6 10.0 80.0 119.0 86.0 101.0 22 0.0913 85.9 87.7 9.2 67.0 103.3 82.3 95.0 22 0.4504 88.3 87.8 8.2 71.3 106.8 82.0 91.7 21 0.695
1 99.5 98.3 11.8 73.0 121.3 94.7 106.8 21 0.621 0.0192 98.3 99.0 7.8 86.3 119.5 93.0 103.0 22 0.4083 93.5 94.1 9.3 74.7 113.5 89.0 99.5 22 0.7214 94.0 91.7 7.7 76.0 102.0 85.5 98.5 21 0.244
1 100.5 100.2 9.4 77.8 113.5 95.0 106.0 21 0.513 0.0042 102.5 102.6 11.8 82.3 133.7 98.0 108.0 22 0.2273 93.6 94.1 10.2 75.0 113.7 85.8 98.3 22 0.8334 91.0 92.8 7.8 81.5 109.8 88.3 97.3 21 0.099
1 99.7 99.4 10.2 81.5 116.8 91.3 108.8 21 0.664 0.6732 97.5 97.5 9.6 79.3 114.8 91.3 105.3 22 0.8213 95.4 96.4 10.9 75.3 114.3 89.5 103.5 22 0.6104 95.3 96.2 11.6 79.0 125.5 90.0 101.0 21 0.446
1 102.8 102.2 10.2 80.0 122.0 97.8 108.8 21 0.503 0.0192 97.2 97.8 6.6 88.0 111.8 93.3 102.5 22 0.3383 95.4 95.1 11.6 63.0 117.5 90.0 99.0 22 0.0614 93.8 94.1 9.3 77.5 110.7 87.3 97.8 21 0.545
1 108.0 104.6 13.0 76.3 124.0 99.0 114.0 21 0.496 0.0332 102.1 103.5 13.4 86.5 140.0 93.3 109.0 22 0.045*3 94.9 96.4 10.9 78.5 113.0 89.3 104.3 22 0.2474 93.5 94.9 10.9 75.0 117.3 88.3 100.6 21 0.743

















































Summary Statistics and Tests for Time and Drug
Original Data Set: Diastolic Blood Pressure
MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W
98.0 96.0 12.1 66.0 120.5 88.0 100.8 20 0.415 0.27698.0 96.7 10.2 72.5 113.0 91.0 103.0 21 0.81092.3 91.6 11.7 70.0 110.5 85.0 99.0 22 0.36694.0 91.5 11.3 69.0 108.5 83.0 97.0 21 0.415
94.8 95.2 9.8 77.0 110.5 88.5 104.0 21 0.538 0.52192.8 93.6 14.0 66.0 114.0 86.5 103.0 22 0.16693.5 90.5 14.0 56.5 113.0 84.0 99.5 21 0.16689.0 91.7 11.8 77.5 122.5 83.0 96.0 21 0.017*
90.5 89.8 16.1 56.5 112.5 84.0 100.0 21 0.248 0.09595.8 95.6 15.1 69.0 121.5 79.5 107.0 22 0.60286.5 84.3 12.8 51.0 106.0 81.5 91.5 22 0.06085.0 86.9 12.1 64.5 112.5 80.0 91.5 21 0.810
81.5 84.2 12.0 70.0 119.0 78.0 89.5 21 0.011* 0.006*82.5 85.4 12.0 63.0 107.5 78.0 98.0 22 0.69175.8 77.3 10.0 58.0 97.5 70.5 84.5 22 0.80974.0 75.3 9.4 57.0 95.5 70.5 79.0 21 0.626
80.0 81.8 10.4 55.5 100.5 78.5 91.0 21 0.143 0.07080.8 81.4 10.0 66.0 104.5 74.0 89.5 22 0.75282.3 81.2 12.0 58.5 101.0 72.5 90.5 22 0.83171.5 72.8 13.3 49.5 99.0 66.0 81.5 21 0.928
80.5 82.3 13.0 61.5 107.5 76.0 89.3 20 0.400 0.15181.0 81.8 10.3 62.5 100.0 74.5 89.5 22 0.52180.3 79.4 12.4 62.0 101.5 68.8 90.5 20 0.32070.0 74.1 13.5 54.5 97.5 65.5 86.0 21 0.060
79.5 79.8 13.8 49.0 113.0 73.0 86.3 20 0.330 0.21680.8 81.1 9.5 66.0 97.5 74.0 88.0 22 0.21378.5 79.0 12.7 51.0 107.0 69.0 87.0 20 0.96273.0 73.5 11.7 48.5 95.5 68.0 82.0 21 0.998
78.5 81.0 12.8 57.0 108.5 74.5 86.5 21 0.340 0.32782.0 81.8 7.2 70.5 103.5 77.5 84.0 22 0.025*82.8 83.3 12.3 64.0 113.0 74.3 89.8 20 0.74874.5 77.1 13.7 42.0 106.5 71.5 84.0 21 0.244
82.5 82.8 9.1 70.0 108.0 78.0 87.0 21 0.111 0.018*82.3 82.0 7.8 69.0 102.5 78.0 86.0 22 0.48083.0 82.8 12.5 58.5 110.0 73.0 88.0 21 0.89772.5 74.2 11.5 56.0 99.0 67.5 76.5 21 0.071
87.5 89.0 11.9 69.5 111.0 83.0 97.5 21 0.294 0.88289.5 90.8 10.7 72.5 108.5 83.0 96.5 22 0.53990.5 89.1 14.8 62.5 119.0 77.5 101.0 21 0.94688.5 87.6 13.3 65.0 110.0 76.5 98.0 20 0.656
98.8 98.6 13.0 76.0 124.5 90.5 105.6 20 0.660 0.430100.3 98.2 10.4 66.0 115.3 92.0 104.3 22 0.032*96.5 96.1 12.2 58.0 112.3 87.7 106.0 21 0.015*93.0 93.7 9.8 74.0 109.0 87.0 100.0 19 0.789
96.8 97.0 10.6 77.5 115.7 92.3 104.5 21 0.499 0.15696.4 97.2 7.1 86.7 113.3 92.3 101.5 22 0.47295.3 96.6 8.6 81.5 117.0 92.0 102.0 22 0.78692.0 92.3 8.7 79.0 113.8 85.0 96.0 21 0.151
7
Table Id
Summary Statistics and Tests bv Time and Therapy
Original Data Set: Dietary Response






















Summary Statistics and Tests for Time and Drug
After Data Replaced: Heart Rate
MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K
71.2 73.7 8.1 59.8 89.9 67.5 79.6 20 0.288 075.7 73.7 10.4 48.7 97.3 65.5 79.6 21 0.35473.7 72.2 12.2 46.2 89.9 66.0 82.5 20 0.28072.8 72.0 6.2 63.1 86.3 68.1 75.2 21 0.348
69.3 70.5 8.9 49.8 86.3 64.5 74.7 21 0.749 067.8 68.5 9.6 47.8 83.5 62.0 75.6 22 0.76270.5 67.8 10.9 46.2 85.0 61.0 74.2 20 0.35671.3 69.8 6.8 53.5 80.5 67.4 74.3 21 0.179
72.8 72.4 7.2 56.5 83.3 68.5 79.0 21 0.632 069.0 70.1 12.7 50.8 97.3 60.8 79.5 22 0.42270.1 71.1 13.3 48.8 94.0 64.9 80.7 20 0.47376.0 73.5 10.1 54.5 87.5 68.3 81.2 21 0.088
79.5 78.1 9.6 59.5 100.0 71.5 81.8 21 0.402 075.2 74.7 11.8 51.8 94.7 67.3 84.0 22 0.73681.3 78.8 16.5 49.3 106.0 67.5 89.9 20 0.49778.7 78.3 10.1 56.7 92.3 74.0 86.8 21 0.144
74.0 75.0 9.2 58.0 90.5 71.8 79.8 21 0.578 071.6 71.8 11.2 50.3 93.0 65.0 79.3 22 0.93676.1 74.4 14.6 43.8 95.0 65.3 86.9 20 0.20076.3 76.3 8.5 57.3 90.5 71.3 83.8 21 0.863
75.5 76.7 12.1 59.0 102.3 69.3 85.0 21 0.632 075.6 74.8 11.2 50.0 94.0 66.3 81.8 22 0.84579.8 78.0 14.6 46.0 106.3 70.0 87.5 20 0.89279.8 79.9 8.8 63.3 100.0 75.0 84.5 21 0.977
75.8 75.8 9.9 62.0 93.5 66.7 83.7 21 0.238 075.8 75.7 11.2 51.5 97.0 67.0 84.8 22 0.95976.1 76.7 15.3 45.8 100.3 65.1 89.0 20 0.62879.8 79.4 8.3 65.8 97.5 74.3 85.8 21 0.897
76.0 78.5 9.5 61.8 93.3 72.8 88.0 21 0.245 078.3 80.5 14.1 52.8 120.3 71.5 89.0 22 0.17783.7 78.9 17.0 47.5 102.3 66.8 90.9 20 0.11378.8 79.9 11.4 67.7 121.3 73.5 82.0 21 0.000*
74.0 77.6 12.9 60.5 109.8 68.5 80.8 21 0.089 079.8 80.6 15.1 45.8 109.3 71.0 91.5 22 0.73483.0 79.3 18.0 44.3 107.3 65.6 91.3 20 0.46175.8 77.9 9.6 66.0 101.5 71.5 80.8 21 0.029*
75.8 80.3 16.5 58.5 123.0 67.5 91.5 21 0.082 076.8 80.3 20.1 44.3 145.0 68.0 90.0 22 0.014*81.0 78.0 16.4 42.5 105.5 68.7 90.0 20 0.55472.0 76.2 9.3 64.8 93.8 69.5 83.3 21 0.025*
75.8 75.7 10.2 54.8 104.5 71.0 79.0 21 0.143 077.5 77.1 12.4 50.3 99.5 68.3 89.0 22 0.70482.6 78.0 13.6 51.0 96.5 70.0 87.1 20 0.09777.0 76.2 8.4 55.8 92.0 71.3 80.8 21 0.608





























Summary Statistics and Tests for Time and Drug
After Data Replaced: Heart Rate
DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W
1 76.0 81.1 16.2 58.3 115.0 68.0 92.0 21 0.098 0.6432 85.9 85.2 14.8 56.7 108.8 72.8 94.0 22 0.5703 82.4 82.0 17.8 51.7 118.5 73.5 91.4 20 0.6364 81.5 82.3 8.4 63.5 94.0 77.7 89.0 21 0.224
1 78.0 77.2 12.5 55.0 97.0 68.5 86.5 21 0.516 0.9952 78.5 78.3 15.3 47.0 109.0 69.0 85.8 22 0.9373 77.5 77.2 17.2 45.0 109.5 67.5 86.3 20 0.9204 77.0 78.9 12.3 66.0 113.0 73.5 82.0 21 0.000*
1 73.0 72.8 9.2 54.0 90.5 65.5 78.0 21 0.815 0.6422 77.0 76.2 12.6 47.0 107.0 70.0 84.0 22 0.8233 71.8 72.8 13.6 43.0 101.5 64.3 82.5 20 0.9844 74.5 75.7 8.4 64.0 93.5 69.0 79.0 21 0.182
1 70.0 72.1 11.9 51.5 100.5 66.0 75.0 21 0.038* 0.8252 67.8 73.1 14.4 48.5 102.5 64.0 82.0 22 0.1253 68.3 69.6 10.7 51.3 89.0 62.3 75.5 20 0.6914 71.0 73.1 11.2 54.5 106.5 67.0 75.5 21 0.016*
1 70.0 69.4 8.4 54.0 89.5 63.0 75.0 21 0.901 0.8272 67.3 69.6 14.1 46.0 104.0 60.5 82.5 22 0.4903 66.0 66.5 10.8 44.5 87.0 61.0 72.0 20 0.7774 66.0 68.2 9.4 50.0 88.0 62.0 71.0 21 0.108
1 69.5 69.3 7.4 55.5 83.0 63.0 75.0 21 0.946 0.8482 68.0 69.4 12.5 45.0 94.0 61.0 76.5 22 0.9033 67.3 66.3 10.4 42.5 85.5 61.3 72.5 20 0.5404 67.0 68.5 8.5 53.0 86.5 62.5 73.5 21 0.655
1 68.0 68.5 8.1 54.0 82.0 62.5 77.0 21 0.506 0.4272 62.5 64.6 10.3 47.5 85.5 57.0 73.0 22 0.7043 66.3 65.7 10.8 40.0 82.0 61.5 72.8 20 0.3304 66.5 68.5 6.7 56.5 82.5 64.0 73.0 21 0.862
1 67.0 66.8 7.1 49.5 78.0 63.5 72.0 21 0.645 0.8502 65.5 64.3 9.6 44.0 79.0 57.5 72.5 22 0.6563 68.3 66.1 10.5 45.5 84.0 60.3 73.3 20 0.7754 65.5 67.3 7.4 53.0 82.0 63.0 70.0 21 0.724
1 64.5 66.0 8.6 54.0 85.0 61.0 71.0 21 0.390 0.7842 63.3 65.0 11.8 45.0 95.0 56.0 70.5 22 0.2573 64.3 64.7 11.0 41.5 84.0 57.5 73.5 20 0.9124 65.5 66.4 4.8 57.5 75.0 63.5 70.0 21 0.671
1 66.0 68.6 8.9 55.5 94.0 62.0 75.0 21 0.082 0.2692 60.5 62.6 9.7 45.0 83.0 55.5 69.0 22 0.3843 67.8 65.6 11.6 40.5 84.0 58.3 74.3 20 0.6974 65.0 67.3 10.3 57.0 106.5 64.5 67.5 21 0.000*
1 75.0 72.9 11.7 52.5 100.0 62.5 80.0 21 0.568 0.5242 69.8 72.3 15.6 43.5 103.5 60.0 82.5 22 0.5733 70.8 69.6 13.1 45.0 88.0 59.3 81.3 20 0.3014 74.0 75.7 11.6 61.0 102.5 67.0 83.0 21 0.101
1 90.8 90.5 15.5 59.5 118.0 78.1 102.5 21 0.947 0.1842 81.8 89.5 25.7 50.3 173.0 74.3 101.3 22 0.006*3 78.6 79.9 14.4 51.0 105.0 72.6 88.1 20 0.6364 84.3 88.0 12.4 72.5 122.7 79.0 95.0 21 0.036*















Summary Statistics and Tests for Time and Drug
After Data Replaced: Systolic Blood Pressure
DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W
1 149.7 151.3 12.1 128.4 174.4 143.1 158.8 20 0.968 0.8662 146.8 148.7 11.1 128.5 177.6 143.2 154.1 21 0.385
3 147.2 152.2 13.7 129.9 179.6 144.8 160.3 20 0.029*4 149.0 149.1 13.6 128.5 167.3 139.8 162.6 21 0.066
1 153.5 153.6 13.9 127.3 178.0 143.8 162.5 21 0.910 0.022*2 150.8 151.4 12.7 122.0 170.0 144.8 163.8 22 0.2783 155.5 155.0 19.0 99.4 184.0 147.3 166.3 20 0.1104 143.0 143.3 11.6 125.0 168.5 137.8 149.3 21 0.808
1 153.5 153.9 13.9 127.0 177.8 146.0 164.8 21 0.864 0.1112 149.1 152.5 12.2 129.5 172.3 143.8 162.6 22 0.4163 147.3 150.1 16.6 107.5 183.3 140.8 163.0 20 0.6074 145.5 142.9 14.0 111.3 166.2 132.5 152.0 21 0.727
1 162.3 158.2 16.6 122.5 185.5 142.3 170.8 21 0.374 0.012*2 152.8 152.4 14.1 127.3 188.0 145.7 158.3 22 0.2983 152.5 151.8 13.6 115.0 176.7 144.9 157.8 20 0.3694 146.5 142.9 11.1 122.0 158.5 131.3 150.3 21 0.025*
1 155.3 154.6 16.9 125.0 196.8 140.3 159.5 21 0.633 0.1862 149.1 151.3 15.1 130.3 178.8 137.8 160.3 22 0.0893 148.8 148.0 17.5 96.3 177.0 141.4 155.1 20 0.0584 142.0 142.1 15.2 112.5 166.8 138.0 151.5 21 0.426
1 157.0 157.0 14.6 125.8 184.0 150.5 165.5 21 0.947 0.035*2 152.0 153.9 13.7 124.5 179.5 145.3 165.7 22 0.9903 152.6 152.3 16.3 109.3 193.8 144.6 159.1 20 0.1414 147.3 144.8 12.5 117.8 169.8 139.0 152.7 21 0.922
1 154.0 156.0 17.3 119.5 198.5 144.8 163.3 21 0.149 0.006*2 150.7 150.9 12.3 124.5 174.0 140.8 157.3 22 0.8563 147.4 147.8 20.0 108.0 186.3 134.6 157.6 20 0.9034 138.5 139.3 13.3 116.0 169.0 132.0 146.5 21 0.752
1 158.0 156.6 19.2 116.0 192.0 143.0 166.5 21 0.690 0.024*2 151.4 153.5 11.9 129.3 178.5 144.0 161.8 22 0.9853 149.9 150.5 15.0 109.7 176.5 145.2 158.5 20 0.3784 144.3 141.8 12.7 120.8 166.0 133.0 150.0 21 0.465
1 149.0 153.3 16.6 118.8 184.3 142.0 164.0 21 0.483 0.042*2 147.7 154.1 16.7 118.8 187.0 143.3 168.3 22 0.2143 146.8 147.1 17.1 100.3 173.3 139.9 158.9 20 0.2014 139.8 142.0 15.4 118.0 178.0 131.5 152.3 21 0.502
1 159.8 156.7 16.8 120.8 185.5 146.0 163.7 21 0.786 0.1512 148.4 150.2 15.4 123.3 182.0 137.8 163.7 22 0.9023 154.1 152.4 17.6 112.8 186.8 139.5 162.6 20 0.9724 144.8 144.7 14.9 116.0 169.5 135.0 154.7 21 0.815
1 159.5 159.4 14.5 124.8 189.5 148.8 170.5 21 0.839 0.0502 150.3 151.7 13.6 127.8 178.0 140.7 160.8 22 0.4493 154.8 155.5 20.8 100.3 193.0 145.3 168.1 20 0.4984 148.3 146.5 13.1 125.8 173.5 134.3 155.3 21 0.317
1 163.8 161.7 17.7 125.3 192.0 154.0 170.0 21 0.748 0.0582 150.8 153.9 18.7 115.3 184.0 145.3 169.8 22 0.3433 153.3 154.1 17.2 116.3 191.8 145.1 162.2 20 0.9594 148.5 146.5 15.1 121.7 168.8 133.3 158.0 21 0.219















Summary Statistics and Tests for Time and Drug
After Data Replaced: Systolic Blood Pressure
*UG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W
1 150.5 151.3 16.6 115.5 177.5 142.5 163.5 21 0.715 0.1172 149.5 151.5 17.4 116.0 196.5 142.0 161.0 22 0.5483 149.5 148.5 18.1 105.0 186.0 138.5 158.8 20 0.8814 144.0 141.4 14.4 114.5 175.5 135.5 148.0 21 0.536
1 151.5 152.1 12.4 129.0 180.0 146.0 159.0 21 0.890 0.0842 150.0 148.8 15.4 118.5 174.0 139.0 163.0 22 0.5393 147.0 148.1 20.6 95.0 186.5 137.3 163.3 20 0.5344 141.5 140.9 14.2 114.0 166.0 133.0 148.5 21 0.786
1 145.0 145.8 18.5 108.5 181.0 136.0 156.5 21 0.935 0.1632 146.3 147.0 15.6 117.0 172.0 141.0 159.5 22 0.2343 135.8 141.1 20.6 96.0 187.0 130.5 155.3 20 0.8844 140.5 136.9 13.4 114.0 160.0 124.0 148.5 21 0.139
1 136.5 138.1 17.6 115.0 192.0 127.0 144.0 21 0.006* 0.002*2 138.5 136.9 15.2 99.0 160.0 131.0 146.0 22 0.2213 127.5 132.8 16.9 112.5 183.5 122.0 137.3 20 0.002*4 122.5 123.5 11.2 102.5 148.5 115.5 132.5 21 0.662
1 139.5 136.1 17.8 98.5 175.0 124.0 145.5 21 0.921 0.036*2 133.8 133.8 14.3 106.0 166.0 126.0 139.0 22 0.1793 129.8 131.6 14.2 105.0 162.0 122.5 139.0 20 0.6434 125.0 122.8 14.7 103.0 160.5 109.5 133.5 21 0.189
1 133.5 136.0 18.3 108.0 179.0 122.0 146.5 21 0.574 0.039*2 132.8 131.1 13.8 107.0 154.0 119.5 140.0 22 0.4923 128.8 132.4 20.8 102.0 193.5 118.3 142.8 20 0.0634 115.5 120.2 15.6 91.0 144.5 110.0 136.5 21 0.167
1 127.5 130.8 21.0 91.5 187.5 118.0 137.0 21 0.118 0.033*2 131.8 130.3 10.8 113.0 148.0 120.0 138.0 22 0.0873 129.8 130.0 17.6 90.5 167.5 118.1 138.3 20 0.9164 118.3 117.9 14.5 84.5 141.0 110.0 128.0 21 0.838
1 128.5 130.7 19.9 97.0 176.0 115.0 139.0 21 0.282 0.3352 132.5 131.9 15.2 104.0 180.5 121.0 140.5 22 0.016*3 131.0 131.6 17.3 103.0 166.0 116.3 144.0 20 0.8404 123.5 122.9 14.7 83.0 147.0 114.0 133.0 21 0.379
1 134.5 134.5 18.1 111.0 175.0 121.5 141.0 21 0.175 0.020*2 130.0 130.6 13.1 106.0 165.5 122.0 134.0 22 0.034*3 133.0 133.1 17.6 99.0 166.5 122.8 142.3 20 0.6514 118.5 119.9 14.6 96.0 146.5 111.0 129.0 21 0.464
1 135.0 143.6 21.6 117.5 196.5 129.5 152.5 21 0.018* 0.4912 144.0 142.3 16.2 117.5 179.5 133.0 152.0 22 0.3433 139.8 139.6 19.1 98.5 167.0 132.0 154.8 20 0.4524 136.0 133.7 16.5 101.5 166.0 120.5 145.0 21 0.852
1 157.4 158.6 19.9 129.0 203.0 148.5 167.5 21 0.388 0.007*2 153.8 150.1 14.3 120.0 177.0 143.3 158.5 22 0.2423 151.0 152.5 22.9 91.0 183.3 142.0 172.7 20 0.2354 139.7 140.1 13.8 112.7 174.0 129.8 150.0 21 0.719
































































Summary Statistics and Tests for Time and Drug
After Data Replaced: Diastolic Blood Pressure
MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W
97.5 96.9 6.8 82.1 111.3 92.4 100.2 20 0.995 0.89496.4 95.0 5.9 82.2 103.9 92.8 99.4 21 0.12894.8 96.1 6.9 83.9 109.8 91.6 101.2 20 0.66395.1 95.6 8.7 81.8 113.0 89.5 99.0 21 0.425
98.0 98.5 8.7 81.3 115.8 95.3 102.8 21 0.728 0.11899.4 99.2 9.0 81.3 115.4 94.0 105.6 22 0.964100.8 98.7 10.6 67.6 114.0 94.2 105.5 20 0.045*95.0 94.2 6.8 82.0 105.3 91.0 99.3 21 0.540
100.5 98.2 10.0 82.0 115.3 90.0 106.8 21 0.536 0.16498.5 99.6 10.5 81.8 123.8 93.0 106.0 22 0.85993.5 94.5 9.8 76.3 111.0 87.5 103.6 20 0.70993.5 93.1 8.6 77.0 109.0 87.8 98.0 21 0.981
104.5 103.0 10.6 80.8 115.3 96.8 112.8 21 0.061 0.0201102.0 100.8 11.3 74.7 121.3 90.8 110.2 22 0.65894.3 95.9 10.3 79.0 113.0 87.4 105.0 20 0.32390.5 94.0 9.8 80.0 115.0 87.0 99.3 21 0.305
100.5 100.3 10.7 80.3 116.5 94.8 106.0 21 0.475 0.065101.3 99.4 11.2 75.8 123.0 91.8 107.8 22 0.99293.6 92.2 10.8 68.3 108.3 86.4 101.1 20 0.52597.6 93.2 10.9 69.3 110.5 86.5 100.0 21 0.200
105.3 103.2 9.9 81.8 118.0 99.0 110.5 21 0.094 0.030'99.5 101.8 10.7 87.5 132.5 93.8 109.8 22 0.06896.5 96.6 10.8 69.0 114.5 91.0 104.8 20 0.40294.3 95.8 7.2 83.0 109.3 91.5 101.0 21 0.594
93.0 94.8 9.7 74.0 112.8 90.8 103.3 21 0.497 0.016'93.5 94.6 10.0 80.0 119.0 86.0 101.0 22 0.09185.9 87.4 9.0 67.0 103.3 82.6 94.8 20 0.64188.3 87.8 8.2 71.3 106.8 82.0 91.7 21 0.695
99.5 98.3 11.8 73.0 121.3 94.7 106.8 21 0.621 0.01598.3 99.0 7.8 86.3 119.5 93.0 103.0 22 0.40893.5 93.7 9.2 74.7 113.5 89.0 98.6 20 0.66694.0 91.7 7.7 76.0 102.0 85.5 98.5 21 0.244
100.5 100.2 9.4 77.8 113.5 95.0 106.0 21 0.513 0.003102.5 102.6 11.8 82.3 133.7 98.0 108.0 22 0.22793.6 93.7 9.4 75.0 112.8 86.7 98.1 20 0.96991.0 92.8 7.8 81.5 109.8 88.3 97.3 21 0.099
99.7 99.4 10.2 81.5 116.8 91.3 108.8 21 0.664 0.63397.5 97.5 9.6 79.3 114.8 91.3 105.3 22 0.82195.4 95.9 11.1 75.3 114.3 88.9 101.5 20 0.58795.3 96.2 11.6 79.0 125.5 90.0 101.0 21 0.446
102.8 102.2 10.2 80.0 122.0 97.8 108.8 21 0.503 0.01997.2 97.8 6.6 88.0 111.8 93.3 102.5 22 0.33895.4 95.0 12.1 63.0 117.5 90.5 98.7 20 0.07693.8 94.1 9.3 77.5 110.7 87.3 97.8 21 0.545
108.0 104.6 13.0 76.3 124.0 99.0 114.0 21 0.496 0.031102.1 103.5 13.4 86.5 140.0 93.3 109.0 22 0.045*94.0 95.8 11.1 78.5 113.0 88.8 104.1 20 0.27793.5 94.9 10.9 75.0 117.3 88.3 100.6 21 0.743















Summary Statistics and Tests for Time and Drug
After Data Replaced: Diastolic Blood Pressure
DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W1 98.0 96.2 11.9 66.0 120.5 88.0 101.0 21 0.267 0.2792 98.5 96.8 10.0 72.5 113.0 91.0 103.0 22 0.7613 92.8 92.7 11.2 70.0 110.5 86.5 99.0 20 0.6214 94.0 91.5 11.3 69.0 108.5 83.0 97.0 21 0.415
1 94.8 95.2 9.8 77.0 110.5 88.5 104.0 21 0.538 0.4742 92.8 93.6 14.0 66.0 114.0 86.5 103.0 22 0.1663 92.0 89.9 14.0 56.5 113.0 83.8 99.3 20 0.2224 89.0 91.7 11.8 77.5 122.5 83.0 96.0 21 0.017*
1 90.5 89.8 16.1 56.5 112.5 84.0 100.0 21 0.248 0.0902 95.8 95.6 15.1 69.0 121.5 79.5 107.0 22 0.6023 85.5 83.8 13.3 51.0 106.0 78.5 92.0 20 0.1974 85.0 86.9 12.1 64.5 112.5 80.0 91.5 21 0.810
1 81.5 84.2 12.0 70.0 119.0 78.0 89.5 21 0.011* 0.008*2 82.5 85.4 12.0 63.0 107.5 78.0 98.0 22 0.6913 75.0 77.3 10.5 58.0 97.5 70.3 85.0 20 0.6954 74.0 75.3 9.4 57.0 95.5 70.5 79.0 21 0.626
1 80.0 81.8 10.4 55.5 100.5 78.5 91.0 21 0.143 0.0732 80.8 81.4 10.0 66.0 104.5 74.0 89.5 22 0.7523 82.3 80.8 11.5 58.5 98.0 72.8 89.0 20 0.6804 71.5 72.8 13.3 49.5 99.0 66.0 81.5 21 0.928
1 80.0 82.2 12.7 61.5 107.5 78.0 86.5 21 0.295 0.1472 81.0 81.8 10.3 62.5 100.0 74.5 89.5 22 0.5213 80.3 78.9 12.1 62.0 101.5 68.8 87.3 20 0.4054 70.0 74.1 13.5 54.5 97.5 65.5 86.0 21 0.060
1 78.5 79.5 13.6 49.0 113.0 73.0 86.0 21 0.225 0.2142 80.8 81.1 9.5 66.0 97.5 74.0 88.0 22 0.2133 77.0 77.4 10.9 51.0 94.5 69.0 85.3 20 0.6594 73.0 73.5 11.7 48.5 95.5 68.0 82.0 21 0.998
1 78.5 81.0 12.8 57.0 108.5 74.5 86.5 21 0.340 0.4592 82.0 81.8 7.2 70.5 103.5 77.5 84.0 22 0.025*3 81.8 81.2 10.4 64.0 99.5 73.8 89.5 20 0.7014 74.5 77.1 13.7 42.0 106.5 71.5 84.0 21 0.244
1 82.5 82.8 9.1 70.0 108.0 78.0 87.0 21 0.111 0.020*2 82.3 82.0 7.8 69.0 102.5 78.0 86.0 22 0.4803 82.5 81.4 11.1 58.5 99.0 72.3 87.8 20 0.6124 72.5 74.2 11.5 56.0 99.0 67.5 76.5 21 0.071
1 87.5 89.0 11.9 69.5 111.0 83.0 97.5 21 0.294 0.8102 89.5 90.8 10.7 72.5 108.5 83.0 96.5 22 0.5393 90.0 87.6 13.4 62.5 107.0 76.8 100.0 20 0.4614 88.0 87.1 13.2 65.0 110.0 77.0 98.0 21 0.653
1 97.7 98.3 12.7 76.0 124.5 92.8 105.3 21 0.666 0.5302 100.3 98.2 10.4 66.0 115.3 92.0 104.3 22 0.032*3 96.3 95.7 12.1 58.0 112.3 89.5 104.3 20 0.022*4 93.0 94.4 10.2 74.0 111.9 89.0 100.0 21 0.878
1 96.8 97.0 10.6 77.5 115.7 92.3 104.5 21 0.499 0.1282 96.4 97.2 7.1 86.7 113.3 92.3 101.5 22 0.4723 96.4 97.3 8.5 81.5 117.0 92.3 102.8 20 0.9024 92.0 92.3 8.7 79.0 113.8 85.0 96.0 21 0.151
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Table 2d
Summary Statistics and Tests hv Time and Therapy
After Data Replaced: Dietary Response
TIME GROUP MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W0 Groupl 0.9 1.0 0.1 0.8 1.1 0.9 1.0 8 0.835 0.495Group2 1.0 1.0 0.1 0.8 1.1 1.0 1.1 7 0.359Group3 1.0 1.0 0.1 0.9 1.1 1.0 1.1 7 0.7491 Groupl 0.9 0.9 0.1 0.7 1.1 0.8 1.0 8 0.952 0.090Group2 0.8 0.8 0.1 0.6 0.9 0.7 0.9 7 0.975Group3 0.8 0.8 0.1 0.6 0.9 0.7 0.8 7 0.5622 Groupl 0.8 0.8 0.1 0.6 1.0 0.8 1.0 8 0.350 0.013*Group2 0.7 0.7 0.1 0.6 0.7 0.6 0.7 7 0.412Group3 0.7 0.7 0.1 0.5 0.8 0.6 0.7 7 0.8353 Groupl 0.8 0.8 0.1 0.7 0.9 0.7 0.8 8 0.795 0.004*Group2 0.7 0.6 0.1 0.5 0.7 0.5 0.7 7 0.109Group3 0.6 0.6 0.1 0.5 0.6 0.5 0.6 7 0.028*4 Groupl 0.8 0.8 0.1 0.7 0.9 0.8 0.9 8 0.231 0.011*Group2 0.6 0.7 0.2 0.5 0.9 0.5 0.8 7 0.665Group3 0.6 0.6 0.1 0.5 0.8 0.5 0.6 7 0.5575 Groupl 0.9 0.9 0.1 0.7 1.1 0.9 1.0 8 0.866 <0.001*Group2 0.8 0.8 0.1 0.7 0.9 0.8 0.9 7 0.856Group3 0.5 0.5 0.1 0.4 0.7 0.4 0.6 7 0.7826 Groupl 1.0 1.0 0.1 0.8 1.1 0.8 1.1 8 0.170 <0.001*Group2 0.7 0.7 0.1 0.6 0.9 0.6 0.8 7 0.912Group3 0.5 0.5 0.0 0.4 0.5 0.5 0.5 7 0.023*7 Groupl 1.0 1.0 0.1 0.9 1.1 0.9 1.1 8 0.277 <0.001*Group2 0.9 0.8 0.1 0.7 0.9 0.7 0.9 7 0.261Group3 0.5 0.5 0.0 0.5 0.5 0.5 0.5 7 0.1278 Groupl 1.0 1.0 0.1 0.8 1.2 0.9 1.1 8 0.844 <0.001*Group2 0.8 0.8 0.1 0.7 1.0 0.8 0.9 7 0.961Group3 0.5 0.5 0.1 0.4 0.6 0.5 0.6 7 0.7779 Groupl 1.0 1.0 0.1 0.8 1.1 0.9 1.0 8 0.074 <0.001*Group2 0.8 0.8 0.1 0.7 0.9 0.7 0.9 7 0.334Group3 0.5 0.5 0.0 0.5 0.5 0.5 0.5 7 0.755
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Table 3a
Summary Statistics and Tests for Time and Drug
After Data Replaced: Average 3 Hrs Heart Rate









Summary Statistics and Tests for Time and Drug 
After Data Replaced: Average 3 Hrs Systolic Blood Pressure
TIME DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W1 1 156.3 155.2 13.9 125.6 180.4 147.5 163.7 21 0.841 0.024*2 15T.6 152.1 11.9 126.3 175.1 144.3 162.3 22 0.9333 151.9 152.3 15.7 107.3 179.6 145.8 162.9 20 0.1604 146.2 143.1 11.4 120.8 161.2 133.9 151.9 21 0.3652 1 155.5 155.9 15.5 123.4 191.9 147.4 161.9 21 0.753 0.021*2 150.9 152.0 12.5 126.4 175.4 142.4 160.9 22 0.7583 149.0 149.4 17.3 104.5 185.7 141.4 156.5 20 0.5694 142.4 142.1 12.3 120.5 168.5 135.1 149.5 21 0.7163 1 156.2 155.5 16.7 118.5 184.9 144.3 163.8 21 0.651 0.044*2 151.5 152.6 12.0 126.3 178.6 144.4 159.8 22 0.8323 148.8 150.0 15.9 107.6 178.3 144.0 157.3 20 0.3204 143.9 142.8 13.1 118.3 168.8 133.4 150.4 21 0.8464 1 160.8 159.2 16.1 122.7 187.7 146.9 167.5 21 0.916 0.027*2 149.8 152.8 13.9 130.3 177.1 142.7 162.5 22 0.2383 153.4 153.1 17.4 109.2 188.1 143.4 163.2 20 0.8254 148.9 145.2 11.2 127.0 162.0 136.2 151.9 21 0.2985 1 153.2 149.7 13.8 119.3 177.2 143.7 155.7 21 0.300 0.0612 151.7 149.1 14.9 117.3 176.7 141.5 154.0 22 0.4193 147.8 145.9 18.3 98.7 186.5 134.2 154.3 20 0.5544 138.2 139.7 12.2 120.3 163.8 130.3 146.2 21 0.7356 1 136.2 136.7 16.6 108.2 176.2 128.5 141.0 21 0.187 0.008*2 133.8 133.9 12.6 108.5 156.3 126.8 144.2 22 0.9043 129.3 132.3 16.1 111.8 179.7 122.3 137.5 20 0.018*4 120.9 122.1 12.2 103.3 150.5 112.8 131.7 21 0.2627 1 128.8 132.0 18.7 99.8 178.3 120.2 137.5 21 0.094 0.0682 132.8 130.9 11.4 110.0 162.2 121.0 136.3 22 0.2053 132.3 131.6 15.7 109.2 166.7 116.9 140.8 20 0.5294 118.5 120.3 13.7 87.8 142.7 112.8 129.7 21 0.7168 1 152.8 151.5 16.3 126.2 186.8 141.8 157.4 21 0.289 0.028*2 148.0 147.1 11.8 120.6 170.8 141.8 155.3 22 0.9703 146.8 148.9 19.0 105.5 182.5 137.3 158.8 20 0.8404 140.3 138.6 12.7 117.6 174.0 129.4 145.6 21 0.128
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Table 3c
Summary Statistics and Tests for Time and Drug
After Data Replaced; Average 3 Hrs Diastolic Blood Pressure
TIME DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K1 1 101.4 99.9 8.7 81.7 115.2 95.1 105.7 21 0.682 02 97.9 99.8 9.4 81.4 117.8 94.1 107.6 22 0.8123 96.8 96.4 9.3 74.3 109.3 90.3 103.8 20 0.5704 96.1 93.8 7.3 81.4 108.1 87.8 99.5 21 0.1572 1 99.7 99.4 9.3 78.7 115.0 97.3 104.3 21 0.233 02 98.0 98.6 10.0 81.1 124.8 91.3 105.4 22 0.5873 90.5 92.1 9.3 68.1 108.0 88.9 99.7 20 0.3414 93.4 92.2 7.7 75.6 107.0 88.8 97.5 21 0.8623 1 100.4 99.3 9.3 78.1 116.8 93.7 104.7 21 0.575 02 101.0 99.7 6.7 85.3 109.1 97.7 105.1 22 0.0533 95.5 94.4 8.6 75.7 108.2 88.1 100.5 20 0.8474 92.5 93.6 8.3 78.8 111.0 88.6 99.6 21 0.8704 1 105.3 101.4 10.9 72.2 114.3 97.7 108.8 21 0.011* 02 97.6 99.2 8.2 85.9 122.9 93.6 105.0 22 0.0913 94.9 94.7 9.5 74.4 111.8 89.1 101.6 20 0.9774 92.8 94.2 8.1 82.1 111.0 88.8 98.0 21 0.3295 1 94.3 93.8 9.5 75.7 107.2 92.0 101.2 21 0.076 02 97.7 95.3 11.2 69.2 114.7 88.3 102.3 22 0.6953 88.3 88.8 11.5 59.2 109.8 84.0 96.3 20 0.5444 88.7 90.0 10.3 76.0 112.0 84.5 92.7 21 0.0596 1 82.5 82.7 10.1 62.5 108.0 76.8 86.2 21 0.094 02 81.8 82.9 8.8 68.5 99.3 77.7 90.5 22 0.4073 79.8 79.0 9.7 64.2 96.2 71.3 86.2 20 0.4864 73.2 74.1 10.4 58.0 94.8 68.7 82.5 21 0.7397 1 79.5 81.1 10.9 58.7 109.8 74.7 83.5 21 0.025* 02 81.0 81.6 6.8 71.8 96.5 76.3 85.3 22 0.1913 80.9 80.0 8.5 66.5 94.7 71.3 85.7 20 0.4314 74.3 75.0 11.5 48.8 97.5 70.2 77.7 21 0.1958 1 95.5 94.8 8.7 75.8 108.3 89.2 99.8 21 0.738 02 97.0 95.4 7.1 75.7 108.9 90.1 98.5 22 0.0773 92.6 93.5 9.7 67.3 110.1 89.1 101.9 20 0.3524 90.8 91.3 8.7 75.2 111.9 85.8 97.5 21 0.931
,w.084








Summary Statistics and Tests by Time and Therapy 
After Data Replaced: Average 3 Hrs Dietary Response
TIME GROUP MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W
1 groupl 0.8 0.8 0.1 0.7 1.0 0.8 0.9 8 0.174 0.003*group2 0.7 0.7 0.1 0.6 0.8 0.7 0.8 7 0.420group3 0.7 0.7 0.1 0.6 0.8 0.6 0.7 7 0.707
2 groupl 0.9 0.9 0.1 0.7 1.0 0.9 1.0 8 0.070 <0.001*group2 0.7 0.7 0.1 0.6 0.9 0.7 0.8 7 0.902group3 0.5 0.5 0.1 0.5 0.6 0.5 0.6 7 0.685














Summary Statistics and Tests for Time and Drug
After Data Replaced; Average 2 Hrs Heart Rate
DRUG MEDIAN MEAN STD MIN MAX Q 1 Q 3 N NORMAL K.W1 73.1 71.5 7.6 57.3 84.8 67.5 76.0 21 0.806 0.7222 69.3 69.3 10.9 49.9 90.1 62.4 77.1 22 0.7933 70.4 69.4 11.7 48.1 89.5 63.9 79.2 20 0.6484 72.8 71.7 8.2 54.0 81.7 65.7 77.8 21 0.038*
1 77.1 76.6 8.6 58.8 92.6 71.6 81.4 21 0.937 0.4912 73.1 73.3 11.0 51.0 91.4 67.5 81.5 22 0.7493 81.3 76.6 14.8 46.7 94.5 67.4 88.3 20 0.033*4 78.1 77.3 8.8 57.0 89.5 71.4 84.5 21 0.461
1 75.6 76.3 10.4 60.5 93.0 68.3 85.7 21 0.214 0.5262 75.1 75.2 10.7 50.8 95.5 68.8 84.6 22 0.9583 77.7 77.3 14.3 49.0 101.1 70.6 89.1 20 0.2804 80.1 79.6 8.0 65.4 93.6 74.2 86.5 21 0.850
1 76.3 78.1 10.7 61.1 101.5 70.3 84.4 21 0.577 0.7292 79.0 80.6 13.7 49.3 113.5 73.0 86.5 22 0.3093 83.3 79.1 16.1 45.9 103.5 68.0 90.1 20 0.1174 77.0 78.9 9.8 68.3 108.7 72.1 81.6 21 0.003*
1 75.8 78.0 11.7 59.4 103.1 69.6 86.8 21 0.462 0.8102 77.6 78.7 15.0 47.3 117.7 67.9 88.1 22 0.3663 81.9 78.0 14.4 46.8 101.0 69.7 87.4 20 0.2194 74.5 76.2 8.0 63.9 92.2 70.0 82.3 21 0.464
1 79.4 82.9 13.8 61.0 110.0 72.4 91.6 21 0.344 0.5772 88.0 86.8 12.9 61.0 106.0 74.7 97.3 22 0.4963 81.9 82.7 17.0 52.3 110.6 76.5 92.1 20 0.2574 83.4 84.1 7.0 68.9 97.5 80.8 86.2 21 0.311
1 75.8 75.0 10.5 54.5 92.0 66.3 79.8 21 0.704 0.9262 78.6 77.2 13.7 47.0 107.3 68.8 83.8 22 0.9753 73.5 75.0 15.0 46.3 105.5 66.0 86.8 20 0.9404 75.0 77.3 9.0 65.8 103.3 71.5 80.5 21 0.018*
1 68.8 70.7 9.4 52.8 95.0 66.0 73.5 21 0.170 0.8962 67.0 71.4 13.8 47.3 103.3 62.8 81.8 22 0.4223 67.3 68.0 10.0 48.5 88.0 63.4 74.9 20 0.8304 69.0 70.6 9.5 52.3 97.3 64.8 74.5 21 0.072
1 68.0 68.9 7.3 54.8 82.5 64.5 75.3 21 0.916 0.7762 65.0 67.0 11.0 46.3 89.8 60.0 75.5 22 0.6633 66.6 66.0 10.4 41.3 83.0 60.8 73.3 20 0.4264 67.5 68.5 7.3 54.8 83.3 63.3 74.0 21 0.901
1 65.8 66.4 7.6 52.3 81.5 61.3 71.5 21 0.992 0.8242 63.3 64.6 10.1 44.5 85.0 56.8 71.5 22 0.9313 66.1 65.4 10.1 44.8 82.0 59.1 72.9 20 0.6634 65.8 66.9 5.6 57.8 76.0 63.5 69.3 21 0.096
1 70.0 70.7 9.0 58.3 88.5 62.5 77.5 21 0.219 0.5972 65.8 67.5 11.8 44.3 88.0 58.8 75.8 22 0.4803 71.3 67.6 11.4 45.5 83.0 59.4 76.4 20 0.1704 70.0 71.5 9.5 59.8 104.5 64.3 75.0 21 0.000*














Summary Statistics and Tests for Time and Drug
After Data Replaced: Average 2 Hrs Systolic Blood Pressure
DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL
1 155.9 153.8 13.4 127.1 177.9 144.6 160.1 21 0.9532 151.3 151.9 11.7 125.8 171.1 144.1 162.9 22 0.6473 153.2 152.5 17.3 103.5 183.6 143.0 165.2 20 0.2474 146.4 143.1 12.2 118.4 164.9 135.1 151.3 21 0.746
1 159.9 156.4 16.1 123.8 191.1 146.0 164.4 21 0.8732 148.3 151.8 13.8 128.8 182.4 141.8 158.9 22 0.6323 149.9 149.9 15.2 105.6 174.3 145.9 157.4 20 0.0614 145.5 142.5 12.4 117.3 162.6 136.0 152.2 21 0.044*
1 156.0 156.5 15.2 122.6 189.5 147.8 163.1 21 0.7432 150.6 152.4 12.3 124.5 174.8 144.3 161.6 22 0.7143 150.2 150.1 17.8 108.6 190.0 138.3 158.0 20 0.8434 143.5 142.1 12.1 120.9 169.4 131.1 148.1 21 0.688
1 153.3 155.0 17.4 117.4 186.1 143.0 163.8 21 0.5932 153.0 153.8 12.4 124.0 177.0 145.1 162.9 22 0.9153 147.4 148.8 15.6 105.0 174.0 143.1 156.8 20 0.1224 143.2 141.9 13.1 119.4 172.0 132.5 147.1 21 0.371
1 154.5 158.0 14.9 122.8 187.0 148.5 166.3 21 0.8502 150.0 150.9 13.9 131.7 180.0 140.3 162.9 22 0.3723 153.5 153.9 18.8 106.5 188.1 142.4 164.9 20 0.5364 147.8 145.6 13.2 123.8 164.4 132.7 158.1 21 0.217
1 161.1 159.2 17.4 121.6 186.8 147.0 166.0 21 0.5842 154.8 153.4 15.7 130.3 181.5 140.6 164.5 22 0.3693 151.4 151.9 16.3 113.7 185.6 142.0 161.6 20 0.9854 145.8 144.5 12.1 124.7 164.2 134.3 154.3 21 0.379
1 153.8 151.7 13.7 122.8 177.5 143.3 159.8 21 0.9882 150.6 150.1 15.5 117.3 185.3 141.8 160.5 22 0.8703 150.0 148.3 18.3 100.0 186.3 136.5 158.4 20 0.4914 139.5 141.1 13.4 118.3 170.8 133.3 148.3 21 0.882
1 141.3 141.9 14.6 111.8 173.5 137.3 148.3 21 0.5702 143.1 141.9 14.8 109.5 164.0 138.3 154.0 22 0.0753 134.4 137.0 17.4 110.8 185.3 126.9 145.4 20 0.1494 133.0 130.2 11.2 112.9 154.3 120.3 137.8 21 0.403
1 135.0 136.0 17.1 104.8 172.8 124.5 144.0 21 0.7902 131.5 132.5 13.4 107.8 160.0 124.8 139.3 22 0.4213 129.6 132.0 16.5 108.5 177.8 120.5 140.8 20 0.1734 122.0 121.5 14.1 98.5 151.5 110.5 134.0 21 0.222
1 127.0 130.7 19.7 94.3 180.0 120.5 136.8 21 0.1002 132.4 131.1 11.7 112.0 164.3 120.5 138.3 22 0.0963 133.0 130.8 16.5 105.5 166.8 116.5 140.4 20 0.4534 118.5 120.4 14.1 83.8 142.5 113.3 130.3 21 0.355
1 134.5 139.0 18.0 116.8 173.0 125.0 150.3 21 0.048*2 136.5 136.4 12.8 115.3 168.8 126.8 143.3 22 0.6803 134.1 136.3 17.3 98.8 165.0 126.6 149.8 20 0.7814 123.3 126.8 14.1 104.8 149.0 117.5 136.3 21 0.205



























Summary Statistics and Tests for Time and Drug
After Data Replaced: Average 2 Hrs Diastolic Blood Pressure
DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W
1 98.9 98.4 8.9 82.1 115.3 94.0 104.6 21 0.777 0.2062 97.6 99.4 9.3 82.3 119.6 94.1 104.8 22 0.9513 97.2 96.6 9.7 71.9 112.5 89.4 104.8 20 0.5824 95.8 93.6 7.1 80.5 106.2 89.1 98.4 21 0.250
1 102.3 101.6 9.9 80.5 115.3 97.3 109.6 21 0.114 0.021*2 101.7 100.1 10.6 75.2 118.7 90.8 106.4 22 0.8683 92.1 94.1 9.8 73.6 110.6 89.0 102.4 20 0.8424 94.0 93.6 9.0 76.3 105.1 86.6 101.0 21 0.172
1 99.8 99.0 9.2 77.9 114.8 95.8 103.9 21 0.241 0.011*2 95.6 98.2 10.0 83.8 125.8 90.5 103.8 22 0.0923 90.5 92.0 9.5 68.0 107.9 87.2 99.1 20 0.3584 92.7 91.8 7.0 78.8 108.0 85.4 96.0 21 0.798
1 100.8 99.3 10.0 76.4 117.4 95.0 104.3 21 0.423 0.003*2 101.7 100.8 8.4 86.0 118.2 95.4 104.8 22 0.4773 93.3 93.7 8.7 74.8 112.2 88.8 98.6 20 0.9814 91.1 92.2 7.2 78.8 104.1 87.3 96.4 21 0.587
1 99.8 100.8 9.5 81.9 119.4 96.3 107.7 21 0.933 0.1882 97.3 97.6 7.1 86.5 110.4 92.8 104.4 22 0.5173 97.5 95.5 10.6 70.3 115.5 89.6 101.2 20 0.4724 92.0 95.1 9.8 80.3 116.1 88.1 101.7 21 0.660
1 106.2 101.0 12.4 68.3 115.5 95.7 109.6 21 0.020* 0.044*2 98.9 99.8 10.6 83.6 128.5 92.0 104.0 22 0.1933 92.1 94.5 9.4 79.8 110.3 88.3 102.1 20 0.4214 93.8 94.3 8.9 82.3 111.3 87.0 97.1 21 0.174
1 97.0 95.7 9.0 72.8 113.8 93.8 100.3 21 0.403 0.2782 97.6 95.2 10.8 69.3 113.5 87.0 100.5 22 0.7003 90.8 91.3 11.7 63.3 111.8 87.1 99.3 20 0.7524 89.3 91.6 10.5 75.3 111.8 84.8 94.8 21 0.224
1 87.5 87.0 11.6 63.5 104.8 82.5 96.0 21 0.283 0.014*2 88.8 90.5 12.6 66.0 113.5 82.0 99.8 22 0.9523 81.0 80.5 10.2 62.8 96.0 75.0 88.5 20 0.4394 82.0 81.1 9.1 65.0 100.5 74.8 85.0 21 0.334
1 80.5 82.0 10.5 58.5 102.8 79.3 86.0 21 0.326 0.0772 81.1 81.6 9.2 64.5 102.3 74.0 85.3 22 0.6253 80.5 79.9 10.8 61.3 95.5 71.9 89.9 20 0.3214 71.8 73.5 12.0 54.8 97.0 67.0 81.5 21 0.477
1 77.8 80.2 12.6 53.0 110.8 75.0 85.0 21 0.090 0.2292 79.8 81.5 7.4 68.3 98.5 77.5 84.5 22 0.3713 78.9 79.3 9.0 65.3 92.5 70.9 88.3 20 0.1554 75.3 75.3 12.4 45.3 101.0 69.8 81.5 21 0.798
1 86.5 85.9 8.6 73.8 103.0 . 79.0 91.0 21 0.471 0.2172 85.6 86.4 7.1 76.0 104.5 80.5 91.0 22 0.2253 84.8 84.5 10.7 63.0 103.0 77.3 93.4 20 0.6744 80.0 80.6 10.8 64.8 100.3 71.6 88.8 21 0.217
1 97.2 97.7 10.8 78.4 120.1 92.3 103.3 21 0.785 0.2052 99.0 97.7 7.9 77.0 111.1 93.1 101.7 22 0.5643 94.4 96.5 9.3 69.8 114.6 91.8 102.1 20 0.0724 92.0 93.4 8.6 78.0 112.8 91.0 97.0 21 0.277
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Table 5a
Summary Statistics and Tests for Summary Measures and Drug;
Original Data Set: Heart Rate
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 0.6 1.4 3.9 -2.9 12.1 -1.0 2.7 20 0.002* 0.161
2 2.3 1.2 4.8 -12.0 9.5 -0.6 3.7 21 0.011*3 1.3 1.2 4.5 -10.2 11.2 -0.2 2.9 22 0.4754 3.7 3.5 4.6 -2.9 17.8 1.3 5.8 21 0.013*MEAN 1 72.7 75.0 8.0 59.2 90.2 70.2 82.1 21 0.528 0.9852 74.1 74.4 10.1 49.2 91.4 67.6 83.2 22 0.4863 77.8 74.0 11.9 48.4 91.9 67.5 81.4 22 0.2044 75.4 75.6 5.8 64.8 88.1 71.8 78.9 21 0.680MEDIAN 1 72.5 73.8 8.2 58.8 90.0 67.3 81.1 21 0.809 0.9272 72.3 72.9 9.7 48.1 88.4 66.4 78.3 22 0.4213 75.8 73.2 12.2 48.3 90.1 65.6 83.0 22 0.2224 75.3 75.0 6.1 64.4 89.0 70.8 77.4 21 0.504MIN 1 61.0 61.6 7.2 49.5 76.0 57.0 67.5 21 0.799 0.6082 58.3 59.2 8.7 43.5 79.0 52.0 66.0 22 0.7893 61.0 59.9 9.3 40.0 77.3 54.0 65.5 22 0.8634 62.0 61.7 5.2 50.0 71.5 58.0 64.0 21 0.801MAX 1 98.3 97.8 14.3 71.0 123.0 86.0 106.7 21 0.656 0.7392 100.6 101.9 21.3 65.3 173.0 88.3 109.3 22 0.006*3 100.4 94.4 16.0 54.5 118.5 85.6 105.0 22 0.1864 94.8 97.5 12.1 78.5 122.7 89.8 105.7 21 0.400
Q1 1 68.0 68.4 6.9 55.3 82.6 63.3 74.0 21 0.661 0.9042 66.7 66.8 9.6 45.4 84.4 59.8 74.6 22 0.9123 69.4 67.2 10.6 44.4 84.5 58.5 73.5 22 0.3534 66.8 68.4 6.2 55.5 80.1 64.5 72.8 21 0.429Q3 1 78.3 80.3 10.0 61.9 101.7 74.7 87.5 21 0.721 0.9872 80.9 80.9 12.2 51.6 99.3 72.2 91.5 22 0.4283 82.0 79.7 14.0 50.6 99.8 69.8 88.9 22 0.2684 80.9 81.0 6.3 68.6 94.0 76.6 84.5 21 0.753
Table 5b
Summary Statistics and Tests for Summary Measures and Drug 
Original Data Set: Systolic Blood Pressure
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 -1.9 -3.3 5.1 -14.8 2.9 -6.8 0.7 20 0.163 <o.oor2 -3.6 -2.7 6.8 -11.4 19.9 -6.9 -0.4 21 0.003*3 -6.0 -6.9 6.9 -21.8 10.0 -11.8 -3.6 22 0.3764 -9.1 -12.4 9.1 -32.2 2.7 -17.4 -6.5 21 0.259MEAN 1 150.9 149.5 14.5 121.7 179.8 138.2 156.2 21 0.967 0.015:2 146.5 146.3 10.8 122.3 170.8 139.7 154.0 22 0.9963 143.6 145.4 14.3 108.2 175.9 137.1 153.7 22 0.5314 138.0 136.7 10.5 119.5 151.4 131.3 143.8 21 0.171MEDIAN 1 150.5 151.8 14.3 121.6 177.9 141.1 159.4 21 0.770 0.015'2 146.4 147.2 11.7 121.5 173.9 140.9 152.5 22 0.9753 147.6 147.6 14.5 108.6 175.3 139.9 154.5 22 0.3294 139.6 138.3 10.6 119.5 157.1 131.3 146.8 21 0.358MIN 1 120.5 122.3 14.9 91.5 166.5 115.0 129.0 21 0.094 0.0222 121.8 121.8 11.1 99.0 148.0 114.0 129.5 22 0.7663 122.0 121.1 15.3 90.5 162.0 112.5 128.7 22 0.1664 110.5 111.1 12.2 83.0 132.0 105.0 120.5 21 0.900MAX 1 170.8 172.0 18.4 130.0 203.0 165.5 183.0 21 0.473 0.0652 171.5 170.0 13.8 139.0 196.5 160.3 178.5 22 0.9363 166.7 166.5 17.4 133.0 201.5 154.8 176.0 22 0.7274 161.5 159.2 13.5 135.0 182.0 148.8 168.8 21 0.788
Q1 1 141.8 140.2 14.8 113.0 174.9 132.0 148.0 21 0.969 0.0122 138.3 137.7 10.6 116.8 161.3 129.5 143.8 22 0.9983 136.1 136.5 14.3 99.8 167.5 127.5 148.5 22 0.6974 125.8 127.5 10.4 111.1 141.8 119.0 137.3 21 0.089Q3 1 158.6 158.6 15.3 125.6 185.0 146.8 164.3 21 0.812 0.0302 155.7 155.3 11.3 129.4 178.1 148.1 160.9 22 0.9073 156.0 154.0 15.5 114.0 183.6 147.5 162.5 22 0.4584 146.0 145.9 11.1 124.9 166.0 143.2 151.9 21 0.369
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Table 5c
Summary Statistics and Tests for Summary Measures and Drug
Original Data Set; Diastolic Blood Pressure
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W
CHANGE 1 -3.3 -3.4 4.7 -11.3 5.1 -7.1 0.5 20 0.801 <0.001*2 -2.0 -1.5 4.7 -7.2 14.7 -4.4 -0.2 21 0.001*3 -7.4 -6.1 5.3 -13.0 9.8 -10.1 -2.7 22 0.036*4 -6.9 -7.6 5.0 -21.0 1.4 -9.6 -5.1 21 0.196MEAN 1 94.6 94.1 8.1 77.7 109.8 92.6 97.4 21 0.102 0.015*2 93.8 94.0 6.3 83.2 105.4 89.8 98.1 22 0.6083 90.7 90.2 7.9 70.8 102.5 84.5 97.0 22 0.5524 89.2 88.0 7.4 77.4 102.7 81.2 91.9 21 0.293MEDIAN 1 96.1 96.1 8.2 78.8 113.3 92.6 99.3 21 0.509 0.029*2 95.8 94.9 7.2 79.2 107.8 88.6 99.1 22 0.8023 90.6 91.6 8.2 69.5 104.8 86.7 96.8 22 0.4914 91.4 89.7 6.8 77.9 102.0 84.1 94.3 21 0.755MIN 1 73.0 72.2 10.3 49.0 98.0 66.0 79.5 21 0.626 0.006*2 73.0 73.8 7.2 62.5 89.0 68.0 78.5 22 0.7013 70.0 69.7 9.1 51.0 87.0 63.5 75.0 22 0.9694 65.0 64.0 11.1 42.0 90.5 57.0 69.0 21 0.516MAX 1 113.7 112.0 10.2 86.5 124.5 108.8 120.5 21 0.019* 0.002*2 115.1 115.6 11.0 99.7 140.0 107.8 121.5 22 0.4623 106.6 106.4 8.2 93.8 119.0 98.0 113.5 22 0.0774 105.3 105.6 8.5 93.0 125.5 98.7 110.7 21 0.608
Q1 1 84.3 85.6 8.6 70.3 106.6 81.0 88.8 21 0.412 0.0862 86.5 86.4 7.3 69.8 98.3 81.3 90.6 22 0.8063 84.5 83.9 9.0 62.8 ■97.5 79.3 90.8 22 0.4114 77.4 80.4 8.0 67.3 95.5 75.1 84.9 21 0.233
Q3 1 104.3 102.0 8.9 82.0 115.7 98.5 108.3 21 0.050 0.026*2 101.7 101.1 7.1 88.4 113.8 94.6 105.5 22 0.6993 97.3 97.5 8.5 77.9 112.6 92.3 103.0 22 0.9594 95.8 95.6 7.5 82.8 109.0 90.8 100.3 21 0.856
Table 5d
Summary Statistics and Tests for Summary Measures and Therapy 
Original Data Set; Dietary Response
SM GROUP MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W
CHANGE groupl -0.1 -0.1 0.1 -0.2 0.1 -0.1 0.0 8 0.527 <0.001*group2 -0.3 -0.2 0.1 -0.5 -0.1 -0.3 -0.1 8 0.589group3 -0.4 -0.4 0.1 -0.5 -0.3 -0.5 -0.4 8 0.679
MEAN groupl 0.9 0.9 0.1 0.8 1.0 0.8 1.0 8 0.386 <0.001*group2 0.8 0.8 0.1 0.7 0.8 0.7 0.8 8 0.250group3 0.6 0.6 0.0 0.5 0.6 0.6 0.6 8 0.498
MEDIAN groupl 0.9 0.9 0.1 0.8 1.0 0.8 1.0 8 0.235 <0.001*group2 0.7 0.8 0.1 0.7 0.9 0.7 0.8 8 0.241group3 0.5 0.5 0.0 0.5 0.6 0.5 0.6 8 0.934
MIN groupl 0.7 0.8 0.1 0.6 0.9 0.7 0.8 8 0.638 <0.001*group2 0.6 0.6 0.1 0.5 0.7 0.5 0.7 8 0.217group3 0.4 0.4 0.0 0.4 0.5 0.4 0.5 8 0.574
MAX groupl 1.1 1.1 0.1 0.9 1.2 1.0 1.1 8 0.060 <0.001*group2 0.9 0.9 0.1 0.8 1.0 0.9 1.0 8 0.402group3 0.8 0.8 0.1 0.6 0.9 0.8 0.8 8 0.335
Q1 groupl 0.8 0.8 0.1 0.7 1.0 0.8 0.9 8 0.937 <0.001*group2 0.7 0.7 0.1 0.6 0.7 0.6 0.7 8 0.665
group3 0.5 0.5 0.0 0.4 0.5 0.5 0.5 8 0.676
Q3 groupl 1.0 1.0 0.1 0.9 1.0 0.9 1.0 8 0.526 <0.001*group2 0.8 0.8 0.1 0.8 1.0 0.8 0.9 8 0.307group3 0.6 0.7 0.1 0.5 0.8 0.6 0.7 8 0.726
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Table 6a
Summary Statistics and Tests for Summary Measures and Drug
Original Data Set: Heart Rate: Centre 1
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W
CHANGE 1 0.5 2.0 4.8 -2.9 12.1 -1.0 3.4 12 0.025* 0.4672 2.3 2.5 3.3 -3.1 9.5 0.3 4.6 12 0.9063 1.1 0.5 3.6 -5.8 6.6 -2.3 2.5 12 0.8674 2.8 2.2 3.3 -2.9 7.4 -0.3 3.9 12 0.453MEAN 1 79.5 78.1 7.9 66.0 90.2 70.6 83.9 12 0.395 0.8832 78.6 76.7 8.7 64.4 91.4 70.2 83.2 13 0.6163 78.0 78.2 9.1 65.8 91.9 69.1 85.4 12 0.3274 76.4 75.9 6.3 64.8 88.1 71.9 80.0 12 0.998MEDIAN 1 78.1 76.7 8.6 64.5 90.0 69.0 83.5 12 0.448 0.8322 75.8 74.3 8.1 60.3 88.0 68.6 78.3 13 0.8193 77.6 77.0 9.6 62.8 90.1 67.2 85.3 12 0.3774 74.1 74.6 6.9 64.4 89.0 69.8 78.3 12 0.783MIN 1 64.0 62.7 8.4 49.5 76.0 56.8 68.3 12 0.538 0.7672 60.8 60.3 9.0 50.0 79.0 52.0 64.5 13 0.2973 63.3 63.5 8.6 51.5 77.3 56.0 70.1 12 0.6894 61.0 61.3 6.0 50.0 70.0 57.9 65.8 12 0.887MAX 1 105.0 103.2 13.3 81.0 123.0 94.1 114.0 12 0.297 0.8842 107.5 107.7 22.6 83.3 173.0 93.5 110.7 13 0.004*3 102.8 101.1 11.3 85.5 118.5 89.5 110.0 12 0.3514 99.1 101.4 11.4 89.0 122.7 92.6 107.6 12 0.090Q1 1 70.0 70.0 7.4 61.0 82.6 63.0 76.1 12 0.208 0.7062 68.0 67.7 8.9 56.3 84.4 59.8 72.6 13 0.2953 72.5 71.2 8.8 58.3 84.5 64.3 76.8 12 0.6524 67.8 68.6 7.6 55.5 80.1 64.0 74.4 12 0.888Q3 1 85.4 84.8 9.8 69.0 101.7 76.8 91.9 12 0.930 0.7592 83.8 84.6 11.1 66.3 99.3 76.8 94.0 13 0.5473 83.8 83.9 11.2 67.8 99.8 75.1 93.7 12 0.4084 81.3 81.0 6.5 68.6 94.0 76.8 84.9 12 0.970
Table 6a cont.
Original Data Set: Heart Rate: Centre 2
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W
CHANGE 1 0.6 0.5 2.2 -2.7 4.4 -1.2 1.6 8 0.919 0.1032 2.3 -0.6 6.1 -12.0 4.8 -1.6 3.6 9 0.021*3 2.4 2.0 5.5 -10.2 11.2 0.4 4.5 10 0.2224 4.5 5.2 5.7 -2.9 17.8 3.7 6.9 9 0.183MEAN 1 72.0 70.8 6.4 59.2 81.8 66.9 72.7 9 0.919 0.6302 68.7 71.1 11.6 49.2 85.8 67.6 80.7 9 0.4803 72.0 69.0 13.4 48.4 85.0 60.8 80.7 10 0.2544 73.3 75.1 5.3 69.9 86.7 71.1 77.2 9 0.104MEDIAN 1 70.5 69.9 6.3 58.8 78.5 67.1 72.5 9 0.866 0.4972 68.0 70.9 11.9 48.1 88.4 66.4 78.5 9 0.5653 71.5 68.6 13.9 48.3 85.8 56.5 81.0 10 0.3504 75.3 75.5 5.2 68.5 86.4 71.4 77.4 9 0.436MIN 1 61.0 60.0 5.3 51.5 68.5 57.5 63.5 9 0.966 0.3602 56.5 57.7 8.6 43.5 69.0 52.0 66.0 9 0.7983 57.8 55.6 8.6 40.0 64.5 52.3 62.5 10 0.1344 62.0 62.3 4.3 57.0 71.5 61.0 62.0 9 0.137MAX 1 90.8 90.5 13.0 71.0 118.0 84.0 93.0 9 0.489 0.8362 89.5 93.5 17.1 65.3 118.5 86.0 108.0 9 0.8983 87.6 86.4 17.5 54.5 104.7 76.0 104.0 10 0.2644 89.8 92.3 11.5 78.5 113.0 82.8 95.5 9 0.495
Q1 1 68.0 66.3 5.9 55.3 74.0 63.3 68.5 9 0.697 0.8432 65.4 65.4 10.9 45.4 79.8 60.9 75.5 9 0.8223 67.2 62.3 10.8 44.4 73.5 54.8 71.0 10 0.0794 65.8 68.1 4.1 64.5 76.5 65.5 69.0 9 0.025*
Q3 1 75.1 74.2 6.7 61.9 86.0 70.8 76.6 9 0.925 0.4812 73.3 75.4 12.2 51.6 93.8 71.1 83.4 9 0.5173 77.8 74.6 15.8 50.6 93.9 61.6 88.1 10 0.2814 79.5 80.9 6.3 72.6 93.5 76.6 84.3 9 0.651
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Table 6b
Summary Statistics and Tests for Summary Measures and Drug
Original Data Set: Systolic Blood Pressure: Centre 1SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 -0.2 -0.8 3.9 -10.9 2.9 -1.5 2.3 12 0.015* 0.0022 -3.8 -2.1 7.8 -11.4 19.9 -6.8 -0.2 12 0.003*3 -5.6 -8.3 6.8 -21.8 -0.5 -14.4 -3.6 12 0.1574 -13.3 -13.3 11.2 -32.2 2.7 -19.9 -5.5 12 0.717MEAN 1 148.3 151.0 12.2 137.6 173.1 140.7 158.7 12 0.209 0.0252 146.9 146.8 10.3 132.9 170.8 139.7 151.7 13 0.4283 141.5 144.1 16.7 108.2 175.9 136.3 154.1 12 0.6124 137.9 135.4 9.7 119.8 150.1 128.4 141.9 12 0.471MEDIAN 1 151.9 153.4 12.8 137.6 177.0 143.6 159.9 12 0.396 0.0162 148.5 148.1 11.3 130.5 173.9 140.9 152.2 13 0.6903 143.5 144.7 16.2 108.6 175.3 139.1 155.0 12 0.4584 138.4 136.5 9.3 119.5 148.5 129.4 142.9 12 0.336MIN 1 121.3 123.5 8.5 112.5 139.0 116.8 130.0 12 0.537 0.1882 120.5 120.7 12.7 99.0 148.0 114.0 128.0 13 0.7753 123.3 123.6 19.3 90.5 162.0 115.0 129.8 12 0.6924 108.0 111.1 14.2 83.0 132.0 103.3 121.8 12 0.656MAX 1 170.2 173.0 14.6 153.8 196.5 165.5 182.5 12 0.072 0.0422 171.0 171.7 11.2 158.0 196.5 162.0 176.8 13 0.2813 160.3 163.6 17.2 133.0 201.5 153.8 174.4 12 0.6134 159.4 159.1 12.0 138.5 182.0 151.3 166.8 12 0.881Q1 1 142.2 142.4 11.2 127.5 163.0 133.1 150.3 12 0.763 0.0292 137.8 137.8 10.9 121.5 161.3 129.5 142.4 13 0.7973 136.1 137.2 17.4 99.8 167.5 125.8 148.9 12 0.7714 125.6 126.9 10.3 112.1 141.8 118.5 136.1 12 0.402Q3 1 158.9 160.0 13.5 143.1 185.0 149.3 168.2 12 0.573 0.0172 157.5 156.3 9.7 142.0 178.1 149.3 160.4 13 0.6453 148.2 151.4 16.8 114.0 183.5 145.9 160.8 12 0.3944 145.9 143.7 9.3 124.9 156.0 137.8 150.1 12 0.117
Table 6b cont.
Original Data Set: Systolic Blood Pressure: Centre 2SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 -6.8 -7.2 4.2 -14.8 -2.1 -9.6 -3.9 8 0.660 0.0612 -3.6 -3.4 5.4 -11.2 4.5 -7.4 -0.7 9 0.6293 -6.5 -5.2 6.9 -15.7 10.0 -7.9 -1.5 10 0.3584 -8.5 -11.2 5.7 -21.4 -6.5 -15.4 -7.0 9 0.024*MEAN 1 151.4 147.4 17.7 121.7 179.8 134.7 156.2 9 0.891 0.5762 143.2 145.6 12.1 122.3 162.6 140.9 154.0 9 0.7923 146.3 147.0 11.4 131.0 168.7 140.0 151.0 10 0.8524 143.6 138.5 11.8 119.5 151.4 131.3 148.0 9 0.327MEDIAN 1 150.5 149.7 16.8 121.6 177.9 138.6 159.4 9 0.998 0.4552 143.5 145.8 12.7 121.5 165.5 142.0 152.5 9 0.5363 149.3 151.0 12.2 133.3 174.8 147.5 154.5 10 0.4734 146.4 140.8 12.4 121.4 157.1 131.3 149.4 9 0.367MIN 1 116.0 120.6 21.2 91.5 166.5 108.5 124.0 9 0.290 0.1352 122.5 123.6 8.6 107.0 134.0 119.5 130.5 9 0.4913 121.0 118.1 8.5 103.0 129.5 109.0 124.0 10 0.4224 111.5 111.1 9.6 94.0 127.0 106.5 118.0 9 0.978MAX 1 174.3 170.7 23.4 130.0 203.0 157.5 183.0 9 0.906 0.6212 172.7 167.5 17.3 139.0 187.5 156.5 184.0 9 0.4833 171.8 170.0 18.0 143.0 201.0 160.5 176.3 10 0.7234 165.0 159.3 16.0 135.0 178.0 148.8 173.5 9 0.359
Q1 1 135.0 137.3 19.0 113.0 174.9 122.5 146.5 9 0.591 0.3802 138.8 137.5 10.7 116.8 152.0 132.5 144.3 9 0.9033 134.8 135.8 10.1 118.3 151.3 130.5 142.3 10 0.8284 125.8 128.2 11.1 111.1 141.3 121.8 138.0 9 0.439Q3 1 158.6 156.7 18.2 125.6 185.0 144.3 164.3 9 0.992 0.6912 152.5 153.8 13.9 129.4 175.6 147.0 162.8 9 0.9933 156.8 157.2 14.0 136.0 183.6 151.0 162.5 10 0.6244 151.9 148.9 13.2 127.9 166.0 143.2 155.1 9 0.658
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Table 6c
Summary Statistics and Tests for Summary Measures and Drug
Original Data Set: Diastolic Blood Pressure: Centre 1
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K
CHANGE 1 -0.5 -1.3 4.5 -9.0 5.1 -4.7 2.4 12 0.521 <02 -2.4 -0.9 5.8 -6.4 14.7 -4.5 0.4 12 0.005*3 -9.1 -8.0 4.2 -13.0 0.4 -11.5 -5.4 12 0.3414 -6.3 -7.8 6.2 -21.0 1.4 -11.8 -4.8 12 0.678MEAN 1 96.4 95.4 7.5 77.7 109.8 93.4 97.5 12 0.104 02 93.9 95.2 6.1 83.2 105.4 92.3 97.2 13 0.3383 91.6 90.4 8.4 70.8 100.6 86.6 97.2 12 0.2314 87.3 88.0 8.4 77.4 102.7 80.4 93.0 12 0.403MEDIAN 1 97.6 97.2 8.5 78.8 113.3 92.6 100.0 12 0.377 02 96.0 96.0 7.1 79.2 107.8 93.5 99.1 13 0.4603 92.3 91.2 9.2 69.5 104.0 87.4 97.3 12 0.3704 89.0 89.1 7.2 77.9 102.0 83.9 93.5 12 0.903MIN 1 74.5 72.7 7.6 60.3 84.0 66.8 79.5 12 0.632 02 72.0 74.1 7.3 63.0 86.5 69.0 79.0 13 0.7733 73.5 71.0 10.6 51.0 87.0 64.3 76.0 12 0.4284 65.0 64.4 14.4 42.0 90.5 52.0 71.8 12 0.863MAX 1 114.5 114.3 8.7 91.0 124.5 112.8 120.8 12 0.017* 02 119.5 120.1 10.8 106.5 140.0 109.8 126.5 13 0.4353 112.6 108.4 8! 1 96.0 119.0 99.8 113.9 12 0.0934 105.8 106.7 9.3 94.5 125.5 99.3 112.8 12 0.581
Q1 1 85.8 86.2 8.4 73.8 106.6 81.0 89.6 12 0.250 02 86.7 86.4 7.0 69.8 97.6 83.0 89.5 13 0.4203 84.6 84.2 9.0 62.8 94.5 80.3 91.3 12 0.1414 79.6 80.8 9.1 67.3 95.5 74.2 87.8 12 0.644
Q3 1 105.3 103.9 8.3 83.3 115.7 101.8 108.8 12 0.103 02 103.0 103.1 6.4 94.1 113.8 98.0 105.5 13 0.4743 97.5 97.3 8.4 77.9 109.3 93.6 102.6 12 0.5244 94.5 95.2 7.6 82.8 109.0 90.3 98.9 12 0.900
Table 6c cont.
Original Data Set: Diastolic Blood Pressure: Centre 2
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL
CHANGE 1 -5.4 -6.5 3.3 -11.3 -3.0 -9.6 -3.8 8 0.2162 -2.0 -2.2 3.1 -7.2 1.8 -3.4 -0.2 9 0.7093 -6.2 -3.9 5.9 -9.4 9.8 -7.7 -1.3 10 0.039*4 -6.9 -7.3 3.1 -13.6 -3.8 -9.2 -5.4 9 0.370MEAN 1 93.6 92.3 9.1 79.1 106.6 88.5 94.8 9 0.4692 93.4 92.3 6.6 84.0 100.8 87.4 98.1 9 0.2853 86.9 89.9 7.8 81.9 102.5 83.7 94.5 10 0.0854 89.2 88.1 6.4 78.4 99.1 84.9 91.7 9 0.660MEDIAN 1 94.8 94.5 8.2 80.8 106.5 93.0 97.3 9 0.6342 93.8 93.3 7.5 84.4 103.5 86.4 99.0 9 0.2643 89.1 92.0 7.4 82.8 104.8 86.7 96.8 10 0.2364 92.3 90.6 6.6 79.7 100.0 87.0 94.6 9 0.786MIN 1 68.0 71.4 13.6 49.0 98.0 65.5 78.0 9 0.6722 74.0 73.3 7.6 62.5 89.0 68.0 76.0 9 0.5503 67.3 68.2 7.1 58.5 81.0 63.5 71.5 10 0.7764 63.5 63.4 4.9 56.5 70.0 60.5 66.5 9 0.649MAX 1 112.0 108.8 11.8 86.5 123.0 100.8 116.5 9 0.5432 109.5 109.3 8.0 99.7 122.5 100.7 115.0 9 0.4413 103.3 104.0 8.1 93.8 117.5 98.0 109.5 10 0.6884 104.0 104.1 7.5 93.0 113.3 97.3 110.7 9 0.547
Q1 1 84.0 84.7 9.4 70.3 102.5 81.0 88.8 9 0.9532 84.8 86.3 8.3 75.3 98.3 80.9 93.5 9 0.5453 83.4 83.6 9.4 66.8 97.5 79.3 90.3 10 0.8864 77.4 79.8 6.7 71.8 93.5 76.5 83.3 9 0.233Q3 1 101.5 99.4 9.6 82.0 110.8 95.8 107.0 9 0.5532 101.3 98.1 7.5 88.4 108.1 91.1 101.5 9 0.2063 95.8 97.7 9.0 85.7 112.6 90.0 104.2 10 0.6414 96.4 96.2 7.8 84.9 108.0 91.7 100.8 9 0.882
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Summary Statistics and Tests for Summary Measures and Drug
After Data Replaced: Heart Rate
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 0.6 1.4 4.0 -3.5 12.1 -0.9 2.8 20 0.006* 0.1732 2.3 1.2 4.8 -12.0 9.5 -0.6 3.7 21 0.011*3 1.3 1.3 4.7 -10.2 11.2 0.1 3.7 20 0.5064 3.7 3.5 4.6 -2.9 18.1 1.3 5.8 21 0.010*
MEAN 1 72.7 75.0 8.0 59.2 90.2 70.3 81.8 21 0.583 0.9782 74.1 74.4 10.1 49.2 91.4 67.6 83.2 22 0.4883 77.8 73.5 11.8 48.4 91.9 66.6 81.1 20 0.1424 75.4 75.6 5.8 64.8 88.1 71.8 78.9 21 0.639MEDIAN 1 72.5 73.8 8.3 58.8 90.0 67.3 81.1 21 0.766 0.9312 72.3 72.9 9.8 48.1 88.4 66.4 78.3 22 0.3903 75.8 72.6 12.2 48.3 90.1 64.7 82.0 20 0.1784 75.3 75.0 6.1 64.4 89.0 70.8 77.4 21 0.504
MIN 1 61.0 61.6 7.2 49.5 76.0 57.0 67.5 21 0.799 0.5862 58.3 59.2 8.7 43.5 79.0 52.0 66.0 22 0.7893 61.0 59.4 9.1 40.0 77.3 53.3 65.0 20 0.7974 62.0 61.7 5.2 50.0 71.5 58.0 64.0 21 0.801MAX 1 98.3 97.8 14.3 71.0 123.0 86.0 106.7 21 0.656 0.7432 100.6 101.9 21.3 65.3 173.0 88.3 109.3 22 0.006*3 100.4 94.3 15.8 54.5 118.5 85.9 104.8 20 0.1314 94.8 97.5 12.1 78.5 122.7 89.8 105.7 21 0.400
Q1 1 68.0 68.5 6.9 55.3 82.6 63.3 74.8 21 0.573 0.8862 66.7 66.8 9.8 45.4 84.4 59.8 74.6 22 0.8613 69.4 66.4 10.3 44.4 83.7 58.4 73.4 20 0.1994 66.8 68.4 6.1 55.5 80.1 65.3 72.8 21 0.429
Q3 1 78.3 80.1 9.7 61.9 99.8 74.7 87.5 21 0.736 0.9842 80.9 80.8 12.1 51.6 99.3 72.2 91.5 22 0.4693 82.2 79.0 14.0 50.6 99.8 68.9 88.5 20 0.2354 80.9 81.0 6.3 68.6 94.0 76.6 84.5 21 0.729
Table 7b
Summary Statistics and Tests for Summary Measures and Drug 
After Data Replaced: Systolic Blood Pressure
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL KCHANGE 1 -2.5 -3.3 5.0 -14.8 2.9 -6.8 0.7 20 0.253 <02 -3.6 -2.6 6.8 -11.4 19.9 -6.9 -0.4 21 0.003*3 -6.0 -6.8 6.8 -21.8 10.0 -10.2 -3.5 20 0.5344 -9.1 -12.4 9.1 -32.2 2.7 -17.4 -6.5 21 0.273MEAN 1 150.9 149.5 14.4 121.7 179.8 138.4 156.2 21 0.983 02 146.8 146.3 10.8 122.3 170.8 139.7 154.0 22 0.9963 143.6 145.4 14.8 108.2 176.2 138.5 152.3 20 0.6334 138.0 136.7 10.5 119.5 151.1 131.3 143.8 21 0.146MEDIAN 1 150.5 151.8 14.3 121.6 177.9 141.1 159.4 21 0.824 02 146.4 147.3 11.7 121.5 173.9 140.9 152.5 22 0.9763 147.6 147.6 15.0 108.6 175.6 139.9 153.7 20 0.3244 139.6 138.3 10.7 119.5 157.1 131.3 146.8 21 0.349MIN 1 120.5 122.3 14.9 91.5 166.5 115.0 129.0 21 0.094 02 121.8 121.8 11.1 99.0 148.0 114.0 129.5 22 0.7663 122.0 120.9 15.9 90.5 162.0 110.8 126.8 20 0.2294 110.5 111.1 12.2 83.0 132.0 105.0 120.5 21 0.900MAX 1 170.8 172.0 18.4 130.0 203.0 165.5 183.0 21 0.473 02 171.5 170.0 13.8 139.0 196.5 160.3 178.5 22 0.9363 166.7 167.2 17.4 133.0 201.5 155.6 175.6 20 0.7034 161.5 159.2 13.5 135.0 182.0 148.8 168.8 21 0.788
Q1 1 141.8 140.6 14.7 113.0 174.9 132.3 148.0 21 0.981 02 138.3 137.7 10.6 116.8 161.3 129.5 143.8 22 0.9973 136.1 136.1 14.9 99.8 168.1 125.8 146.0 20 0.8894 125.8 127.5 10.5 111.1 142.0 119.0 137.3 21 0.099Q3 1 158.6 158.5 15.2 125.6 185.0 146.8 165.3 21 0.870 02 155.7 155.3 11.3 129.4 178.1 148.1 160.9 22 0.9133 156.0 154.3 15.7 114.0 183.6 147.5 161.0 20 0.3944 146.0 145.9 11.1 124.9 164.5 143.2 151.9 21 0.347
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Table 7c
Summary Statistics and Tests for Summary Measures and Drug
After Data Replaced: Diastolic Blood Pressure
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W
CHANGE 1 -3.1 -3.4 4.8 -11.3 5.3 -7.7 0.5 20 0.739 •<0.001*2 -2.0 -1.4 4.8 -7.2 14.7 -4.4 -0.2 21 0.002*3 -7.4 -6.2 5.2 -13.0 9.8 -9.8 -4.1 20 0.026*4 -6.9 -7.6 5.0 -21.0 1.4 -9.6 -5.1 21 0.174MEAN 1 94.7 94.1 8.2 77.7 109.8 91.2 97.5 21 0.135 0.015*2 93.8 94.1 6.3 83.2 105.4 89.8 98.1 22 0.6453 90.6 89.9 7.9 70.8 102.5 84.1 95.8 20 0.7224 89.2 88.0 7.5 77.4 103.1 81.2 91.9 21 0.299MEDIAN 1 96.1 96.2 8.3 78.8 113.3 92.6 99.4 21 0.545 0.022*2 95.8 94.9 7.2 79.2 107.8 88.6 99.1 22 0.7903 90.6 91.2 8.1 69.5 104.8 86.9 96.7 20 0.5914 91.4 89.7 6.8 77.9 102.1 84.1 94.3 21 0.767MIN 1 73.0 72.2 10.3 49.0 98.0 66.0 79.5 21 0.626 0.008*2 73.0 73.8 7.2 62.5 89.0 68.0 78.5 22 0.7013 70.8 69.7 9.5 51.0 87.0 62.3 76.0 20 0.9344 65.0 64.0 11.1 42.0 90.5 57.0 69.0 21 0.516MAX 1 113.7 112.0 10.2 86.5 124.5 108.8 120.5 21 0.019* 0.002*2 115.1 115.6 11.0 99.7 140.0 107.8 121.5 22 0.4623 106.6 106.4 7.6 95.0 117.5 98.0 113.1 20 0.0554 105.3 105.6 8.5 93.0 125.5 98.7 110.7 21 0.608
Q1 1 85.3 86.0 8.5 70.3 106.6 81.3 88.8 21 0.402 0.0712 86.9 86.5 7.3 69.8 98.3 81.3 90.6 22 0.7943 84.6 83.4 9.2 62.8 97.5 77.6 90.5 20 0.5604 77.4 80.4 8.1 67.3 96.6 75.1 84.9 21 0.270Q3 1 104.3 101.9 8.9 82.0 115.7 98.5 108.3 21 0.054 0.022*2 101.6 101.1 7.1 88.4 113.8 94.6 105.5 22 0.7153 97.3 97.2 8.3 77.9 112.6 92.6 102.6 20 0.9764 95.8 95.7 7.5 82.8 109.5 90.8 100.3 21 0.889
Table 7d
Summary Statistics and Tests for Summary Measures and Therapy 
After Data Replaced: Dietary Response
SM GROUP MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE groupl -0.1 0.0 0.1 -0.2 0.1 -0.1 0.0 8 0.491 <0.001*group2 -0.3 -0.3 0.1 -0.5 -0.1 -0.3 -0.2 7 0.775group3 -0.4 -0.4 0.1 -0.5 -0.3 -0.5 -0.4 7 0.855
MEAN groupl 0.9 0.9 0.1 0.8 1.0 0.9 1.0 8 0.444 <0.001*group2 0.7 0.7 0.1 0.7 0.8 0.7 0.8 7 0.252group3 0.6 0.6 0.0 0.5 0.6 0.6 0.6 7 0.795
MEDIAN groupl 0.9 0.9 0.1 0.8 1.0 0.8 1.0 8 0.474 <0.001*group2 0.7 0.8 0.1 0.7 0.9 0.7 0.8 7 0.116group3 0.5 0.5 0.0 0.5 0.6 0.5 0.6 7 0.996
MIN groupl 0.7 0.8 0.1 0.6 0.9 0.7 0.8 8 0.638 <0.001*group2 0.6 0.6 0.1 0.5 0.7 0.5 0.7 7 0.358group3 0.4 0.4 0.1 0.4 0.5 0.4 0.5 7 0.546
MAX groupl 1.1 1.1 0.1 0.9 1.2 1.0 1.1 8 0.060 <0.001*group2 0.9 0.9 0.1 0.8 1.0 0.9 0.9 7 0.457group3 0.8 0.8 0.1 0.6 0.9 0.7 0.8 7 0.562
Q1 groupl 0.8 0.8 0.1 0.7 1.0 0.8 0.9 8 0.932 <0.001*group2 0.7 0.7 0.1 0.6 0.7 0.6 0.7 7 0.506group3 0.5 0.5 0.0 0.5 0.5 0.5 0.5 7 0.884
Q3 groupl 1.0 1.0 0.1 0.9 1.0 0.9 1.0 8 0.526 <0.001*group2 0.8 0.8 0.1 0.8 0.9 0.8 0.9 7 0.279group3 0.6 0.6 0.1 0.5 0.8 0.6 0.7 7 0.717
Table 8a
Summary Statistics and Tests for Summary Measures and Drug
After Data Replaced: Average 3 Hrs Heart Rate
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 0.6 1.4 4.0 -3.5 12.1 -0.9 2.8 20 0.006* 0.1732 2.3 1.2 4.8 -12.0 9.5 -0.6 3.7 21 0.011*3 1.3 1.3 4.7 -10.2 11.2 0.1 3.7 20 0.5064 3.7 3.5 4.6 -2.9 18.1 1.3 5.8 21 0.010*MEAN 1 72.7 75.0 8.0 59.2 90.2 70.3 81.8 21 0.583 0.9782 74.1 74.4 10.1 49.2 91.4 67.6 83.2 22 0.4883 77.8 73.5 11.8 48.4 91.9 66.6 81.1 20 0.1424 75.4 75.6 5.8 64.8 88.1 71.8 78.9 21 0.639MEDIAN 1 72.4 74.8 8.5 60.0 92.2 68.7 82.4 21 0.720 0.9172 73.6 73.7 9.7 48.5 89.4 67.3 79.9 22 0.5673 77.2 73.9 12.3 47.8 92.8 65.1 84.1 20 0.3134 75.7 76.0 6.7 63.1 91.5 71.5 79.0 21 0.420MIN 1 64.7 65.6 6.5 53.5 77.0 60.5 70.7 21 0.709 0.6672 62.1 62.7 9.1 44.7 80.8 56.5 70.2 22 0.9273 65.3 63.2 9.7 42.3 81.0 56.0 69.3 20 0.7684 64.3 64.8 5.7 53.2 76.0 61.3 67.7 21 0.703MAX 1 82.8 86.0 10.3 67.3 108.2 79.8 91.9 21 0.739 0.9022 86.3 88.6 14.6 57.4 124.0 79.1 97.7 22 0.8993 87.6 84.4 13.8 53.1 105.8 76.1 93.5 20 0.3244 85.8 86.1 7.2 76.7 102.6 80.6 89.1 21 0.226
Q1 1 69.1 69.2 7.2 55.2 84.8 63.8 75.2 21 0.630 0.8062 66.3 67.6 9.8 46.8 85.3 61.5 74.4 22 0.8403 70.5 67.4 10.5 44.1 84.0 60.8 74.4 20 0.1944 69.0 70.1 6.4 56.7 81.9 65.4 74.7 21 0.524
Q3 1 76.4 79.9 9.5 61.3 97.8 74.5 86.4 21 0.590 0.9842 80.5 80.8 12.0 50.5 101.6 72.2 90.7 22 0.4353 82.4 78.8 13.7 48.9 99.5 70.0 87.5 20 0.2744 79.7 80.7 6.2 71.8 94.6 75.7 83.5 21 0.175
Table 8b
Summary Statistics and Tests for Summary Measures and Drug 
After Data Replaced; Average 3 Hrs Systolic Blood Pressure
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 -2.5 -3.3 5.0 -14.8 2.9 -6.8 0.7 20 0.253 <0.0012 -3.6 -2.6 6.8 -11.4 19.9 -6.9 -0.4 21 0.003*3 -6.0 -6.8 6.8 -21.8 10.0 -10.2 -3.5 20 0.5344 -9.1 -12.4 9.1 -32.2 2.7 -17.4 -6.5 21 0.273
MEAN 1 150.9 149.5 14.4 121.7 179.8 138.4 156.2 21 0.983 0.016*2 146.8 146.3 10.8 122.3 170.8 139.7 154.0 22 0.9963 143.6 145.4 14.8 108.2 176.2 138.5 152.3 20 0.6334 138.0 136.7 10.5 119.5 151.1 131.3 143.8 21 0.146
MEDIAN 1 154.7 152.7 14.5 122.8 178.8 141.6 159.8 21 0.470 0.008*2 147.1 147.9 11.0 123.4 174.6 142.5 153.6 22 0.8093 147.0 148.1 15.2 107.4 176.3 140.3 156.5 20 0.3924 140.3 138.9 10.3 119.5 157.6 132.7 147.4 21 0.600
MIN 1 128.5 129.3 15.2 99.8 171.0 120.2 135.0 21 0.343 0.020*2 131.7 129.8 11.3 108.5 156.3 119.8 136.0 22 0.4943 128.2 127.8 16.1 98.7 166.7 114.0 134.6 20 0.5964 116.2 118.1 12.4 87.8 139.0 111.5 127.7 21 0.684
MAX 1 161.8 162.3 16.0 126.2 191.9 150.7 172.6 21 0.954 0.0792 159.9 159.8 11.7 137.3 178.6 152.3 165.7 22 0.5893 159.5 158.7 16.3 116.7 188.1 150.0 165.5 20 0.3554 151.9 151.0 12.6 127.8 174.0 145.6 159.2 21 0.580
Q1 1 142.3 141.5 14.1 115.1 173.5 135.2 150.4 21 0.950 0.018*2 138.1 138.5 11.9 116.5 166.5 131.7 146.2 22 0.8193 137.2 137.3 15.1 105.0 172.3 126.4 146.2 20 0.9414 129.5 128.8 10.2 112.0 142.6 122.6 138.9 21 0.116
Q3 1 157.4 157.8 15.3 124.5 185.3 147.9 165.9 21 0.971 0.018*2 154.4 154.2 11.6 126.4 175.8 147.3 160.4 22 0.9303 152.7 153.1 16.2 112.6 183.1 145.4 160.6 20 0.4784 145.3 144.7 11.0 124.9 162.7 139.8 150.2 21 0.473
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Table 8c
Summary Statistics and Tests for Summary Measures and Drug
After Data Replaced: Average 3 Hrs Diastolic Blood PressureSM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 -3.1 -3.4 4.8 -11.3 5.3 -7.7 0.5 20 0.739 <0.001*2 -2.0 -1.4 4.8 -7.2 14.7 -4.4 -0.2 21 0.002*3 -7.4 -6.2 5.2 -13.0 9.8 -9.8 -4.1 20 0.026*4 -6.9 -7.6 5.0 -21.0 1.4 -9.6 -5.1 21 0.174MEAN 1 94.7 94.1 8.2 77.7 109.8 91.2 97.5 21 0.135 0.015*2 93.8 94.1 6.3 83.2 105.4 89.8 98.1 22 0.6453 90.6 89.9 7.9 70.8 102.5 84.1 95.8 20 0.7224 89.2 88.0 7.5 77.4 103.1 81.2 91.9 21 0.299MEDIAN 1 97.5 96.6 8.4 76.8 111.2 94.3 100.5 21 0.082 0.022*2 96.8 95.5 6.7 83.1 106.9 92.4 98.5 22 0.5213 91.6 92.7 8.4 71.2 107.5 88.3 97.8 20 0.5354 92.2 90.4 6.6 80.1 102.6 84.3 94.2 21 0.473MIN 1 78.7 79.1 8.6 58.7 101.2 74.0 82.7 21 0.156 0.014*2 79.5 80.0 7.4 68.5 95.2 76.3 82.5 22 0.4013 76.8 75.8 9.3 59.2 93.5 68.1 81.7 20 0.8784 70.8 71.3 10.6 48.8 94.8 64.5 77.3 21 0.997MAX 1 107.3 104.4 9.3 83.5 116.8 100.4 111.1 21 0.018* 0.008*2 105.7 106.5 8.1 93.2 124.8 100.8 111.8 22 0.4873 100.8 98.9 8.6 79.5 111.8 92.8 105.0 20 0.6274 98.7 98.8 8.2 86.3 112.0 92.0 106.3 21 0.318
Q1 1 86.8 87.3 9.0 69.1 108.0 82.9 90.8 21 0.483 0.0692 86.4 87.1 7.3 70.5 98.3 82.8 93.0 22 0.7473 83.3 83.7 8.2 67.7 97.0 78.9 89.3 20 0.6904 81.3 81.5 7.8 68.9 97.0 75.5 85.8 21 0.534Q3 1 102.0 100.6 8.6 80.8 115.1 98.6 104.8 21 0.037* 0.019*2 101.2 100.4 6.6 90.6 112.1 95.5 104.7 22 0.3503 96.4 95.6 8.4 75.1 110.0 90.7 101.5 20 0.8964 94.6 95.1 7.6 83.3 109.5 89.2 99.8 21 0.471
Table 8d
After Data Replaced: Average 3 Hrs Dietary Response
SM GROUP MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WBASE groupl 0.9 1.0 0.1 0.8 1.1 0.9 1.0 8 0.835 <0.001*group2 1.0 1.0 0.1 0.8 1.1 1.0 1.1 7 0.359group3 1.0 1.0 0.1 0.9 1.1 1.0 1.1 7 0.749CHANGE groupl -0.1 0.0 0.1 -0.2 0.1 -0.1 0.0 8 0.491 <0.001*group2 -0.3 -0.3 0.1 -0.5 -0.1 -0.3 -0.2 7 0.775group3 -0.4 -0.4 0.1 -0.5 -0.3 -0.5 -0.4 7 0.855MEAN groupl 0.9 0.9 0.1 0.8 1.0 0.9 1.0 8 0.444 <0.001*group2 0.7 0.7 0.1 0.7 0.8 0.7 0.8 7 0.252group3 0.6 0.6 0.0 0.5 0.6 0.6 0.6 7 0.795MEDIAN groupl 0.9 0.9 0.1 0.7 1.0 0.9 1.0 8 0.167 <0.001*group2 0.7 0.7 0.1 0.7 0.9 0.7 0.8 7 0.527group3 0.5 0.5 0.0 0.5 0.6 0.5 0.6 7 0.720MIN groupl 0.8 0.8 0.1 0.7 0.9 0.8 0.9 8 0.211 <0.001*group2 0.7 0.7 0.1 0.6 0.8 0.6 0.8 7 0.886group3 0.5 0.5 0.0 0.5 0.6 0.5 ‘ 0.5 7 0.615MAX groupl 1.0 1.0 0.1 0.9 1.1 0.9 1.0 8 0.464 <0.001*group2 0.8 0.8 0.1 0.7 0.9 0.8 0.9 7 0.463group3 0.7 0.7 0.1 0.6 0.8 0.6 0.7 7 0.707Q1 groupl 0.8 0.8 0.1 0.7 0.9 0.8 0.9 8 0.211 <0.001*group2 0.7 0.7 0.1 0.6 0.8 0.6 0.8 7 0.886group3 0.5 0.5 0.0 0.5 0.6 0.5 0.5 7 0.615Q3 groupl 1.0 1.0 0.1 0.9 1.1 0.9 1.0 8 0.464 <0.001*group2 0.8 0.8 0.1 0.7 0.9 0.8 0.9 7 0.463group3 0.7 0.7 0.1 0.6 0.8 0.6 0.7 7 0.707
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Table 9a
Summary Statistics and Tests for Summary Measures and Drug
After Data Replaced: Average 3 Hrs Heart Rate: Centre 1
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 0.5 2.0 4.9 -3.5 12.1 -0.9 3.6 12 0.054 0.5502 2.3 2.5 3.3 -3.1 9.5 0.3 4.6 12 0.9083 1.1 0.7 3.7 -5.8 6.6 -3.3 2.9 11 0.6584 2.9 2.2 3.3 -2.9 7.4 -0.3 3.9 12 0.431MEAN 1 79.1 78.0 7.9 66.0 90.2 70.6 83.9 12 0.474 0.9022 78.6 76.7 8.7 64.4 91.4 70.2 83.2 13 0.6143 77.8 77.0 8.4 65.8 91.9 68.4 84.9 11 0.4514 76.4 75.9 6.3 64.8 88.1 72.0 80.0 12 0.998MEDIAN 1 81.3 78.0 9.1 63.5 92.2 69.6 84.1 12 0.454 0.8932 76.3 75.4 8.3 59.1 89.4 70.4 79.5 13 0.9433 77.8 76.7 9.0 63.9 92.8 69.1 85.2 11 0.8554 75.1 76.0 7.1 63.1 91.5 72.0 79.5 12 0.808MIN 1 66.8 67.1 6.8 58.0 77.0 60.9 73.3 12 0.262 0.5942 65.6 63.5 8.8 52.1 80.8 57.0 67.8 13 0.5053 67.7 66.4 8.5 55.0 81.0 57.3 73.4 11 0.7604 63.6 64.6 6.9 53.2 76.0 60.5 69.9 12 0.933MAX 1 91.2 90.0 9.1 74.0 108.2 83.2 95.2 12 0.911 0.7322 90.0 92.4 13.9 71.5 124.0 83.1 97.7 13 0.6673 87.7 88.4 9.8 74.9 105.8 80.1 96.5 11 0.7554 86.3 87.4 8.0 76.7 102.6 81.0 91.8 12 0.630
Q1 1 73.2 71.1 7.5 61.7 84.8 64.2 76.2 12 0.199 0.7322 68.9 68.8 9.1 57.5 85.3 61.8 74.1 13 0.1923 73.0 71.3 7.4 60.5 84.0 65.0 76.2 11 0.8034 69.7 70.5 7.6 56.7 81.9 65.1 75.7 12 0.915Q3 1 84.2 84.5 8.9 71.8 97.8 75.8 91.5 12 0.498 0.8332 83.8 84.8 10.4 70.8 101.6 78.2 92.5 13 0.5633 82.5 82.6 10.2 67.8 99.5 72.7 89.2 11 0.7064 80.9 81.1 5.9 72.3 93.7 77.3 83.7 12 0.806
Table 9a cont
After Data Replaced; Average 3 Hrs Heart Rate: Centre 2
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 0.6 0.5 2.2 -2.6 4.4 -1.2 1.6 8 0.906 0.1092 2.3 -0.6 6.1 -12.0 4.8 -1.6 3.6 9 0.021*3 2.2 2.0 5.8 -10.2 11.2 0.4 4.5 9 0.3914 4.5 5.3 5.8 -2.9 18.1 3.7 6.9 9 0.164MEAN 1 72.0 70.8 6.4 59.2 81.8 66.9 72.7 9 0.920 0.6912 68.7 71.1 11.6 49.2 85.8 67.6 80.7 9 0.4793 75.8 69.1 14.2 48.4 85.0 60.8 80.7 9 0.1404 73.3 75.1 5.4 69.9 86.9 71.1 77.2 9 0.094MEDIAN 1 71.5 70.6 5.8 60.0 79.3 67.3 73.9 9 0.980 0.5572 69.0 71.3 11.5 48.5 85.8 66.9 79.9 9 0.3193 76.6 70.5 15.3 47.8 87.3 60.0 83.3 9 0.2034 75.7 76.1 6.4 68.8 89.6 70.8 77.8 9 0.325MIN 1 64.2 63.7 5.8 53.5 71.8 60.5 66.2 9 0.918 0.7632 59.8 61.5 9.9 44.7 74.0 56.5 70.3 9 0.7543 63.7 59.2 10.1 42.3 69.7 54.3 67.5 9 0.1374 64.3 65.1 3.9 60.2 73.8 63.5 65.7 9 0.147MAX 1 80.8 80.7 9.8 67.3 103.3 77.3 81.1 9 0.038* 0.7492 81.2 83.0 14.4 57.4 102.3 76.7 93.8 9 0.5843 82.2 79.4 16.7 53.1 100.4 73.3 93.3 9 0.4234 84.3 84.3 5.8 77.3 95.2 79.6 87.3 9 0.622Q1 1 67.1 66.8 6.3 55.2 75.8 63.1 69.3 9 0.948 0.8342 65.3 66.0 11.0 46.8 80.7 61.5 76.9 9 0.7553 69.2 62.6 12.1 44.1 76.3 55.1 70.7 9 0.2044 68.7 69.6 4.7 64.7 79.0 66.9 69.5 9 0.109Q3 1 74.5 73.8 6.7 61.3 84.9 70.2 76.4 9 0.922 0.5872 73.8 75.1 12.4 50.5 92.8 71.0 83.7 9 0.5403 80.0 74.1 16.6 48.9 92.5 64.3 87.3 9 0.1574 79.3 80.1 6.8 71.8 94.6 74.8 83.5 9 0.387
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Table 9b
Summary Statistics and Tests for Summary Measures and Drug
After Data Replaced: Average 3 Hrs Systolic Blood Pressure: Centre 1SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 -0.2 -0.8 3.8 -10.3 2.9 -2.3 2.3 12 0.057 0.0032 -3.8 -2.0 7.8 -11.4 19.9 -6.8 0.0 12 0.004*3 -5.6 -7.6 6.7 -21.8 -0.5 -12.9 -3.4 11 0.1004 -13.0 -13.3 11.1 -32.2 2.7 -19.9 -5.5 12 0.743MEAN 1 148.4 151.0 11.9 137.6 171.5 140.9 158.7 12 0.201 0.0232 147.3 146.8 10.3 132.9 170.8 139.7 151.7 13 0.4263 141.3 143.2 17.2 108.2 176.2 135.6 153.7 11 0.5624 137.9 135.5 9.8 119.8 151.1 128.4 141.9 12 0.538MEDIAN 1 152.7 154.3 13.2 138.4 178.2 143.9 162.0 12 0.238 0.0062 150.6 149.2 10.2 132.6 174.6 142.5 153.6 13 0.1993 143.5 143.9 16.6 107.4 174.7 138.8 153.7 11 0.3674 139.2 137.0 9.3 119.5 149.7 130.4 143.1 12 0.580MIN 1 129.3 131.4 10.4 117.5 152.0 123.8 137.6 12 0.367 0.0732 130.5 129.8 12.9 110.0 156.3 119.2 136.0 13 0.7533 133.4 132.0 19.9 98.7 166.7 115.8 148.3 11 0.9944 115.4 117.9 13.9 87.8 139.0 111.7 128.4 12 0.602MAX 1 161.5 163.2 13.3 144.3 186.8 152.4 171.8 12 0.389 0.1012 162.3 159.9 9.2 143.3 176.7 153.1 164.6 13 0.9253 153.0 154.9 17.3 116.7 186.5 148.2 166.5 11 0.2294 151.8 150.3 11.9 130.5 174.0 143.8 156.1 12 0.372
Q1 1 141.7 143 .1 10.8 127.2 162.8 136.1 151.1 12 0.945 0.0472 136.9 138.4 12.8 120.4 166.5 131.7 144.1 13 0.5543 134.9 136.9 18.4 105.0 172.3 125.9 149.1 11 0.9914 129.6 128.3 10.0 112.0 142.6 120.1 137.2 12 0.674Q3 1 156.3 159.2 13.3 140.2 183.2 149.6 169.0 12 0.512 0.0072 155.3 155.0 9.5 140.6 175.8 149.0 159.6 13 0.7363 146.5 148.5 17.0 112.6 181.1 142.6 156.3 11 0.4054 145.3 142.4 9.4 124.9 155.4 135.6 148.9 12 0.172
Table 9b cont
After Data Replaced: Average 3 Hrs Systolic Blood Pressure: Centre 2SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 -6.8 -7.1 4.3 -14.8 -2.1 -9.6 -3.6 8 0.609 0.0652 -3.6 -3.4 5.4 -11.2 4.5 -7.4 -0.7 9 0.6303 -6.6 -5.8 7.3 -15.7 10.0 -8.5 -5.2 9 0.2524 -8.5 -11.2 5.6 -21.4 -6.5 -15.4 -7.0 9 0.026*MEAN 1 151.4 147.5 17.7 121.7 179.8 134.7 156.2 9 0.885 0.5382 143.2 145.6 12.1 122.3 162.6 140.9 154.0 9 0.7933 147.2 148.2 11.6 129.2 168.7 140.9 151.0 9 0.9354 143.6 138.4 11.8 119.5 151.1 131.3 148.0 9 0.298MEDIAN 1 156.0 150.7 16.6 122.8 178.8 140.0 159.8 9 0.798 0.2932 144.6 146.0 12.5 123.4 164.7 140.9 152.2 9 0.7263 150.8 153.1 12.4 131.8 176.3 146.3 157.8 9 0.8464 145.9 141.4 11.7 123.6 157.6 133.9 149.5 9 0.496MIN 1 120.2 126.5 20.3 99.8 171.0 115.2 134.3 9 0.282 0.1142 132.8 129.9 9.2 108.5 138.5 129.5 134.7 9 0.038*3 127.0 122.7 8.4 111.4 131.3 112.2 129.2 9 0.018*4 118.5 118.4 10.9 100.8 133.0 111.5 124.8 9 0.816MAX 1 161.8 161.2 19.9 126.2 191.9 149.6 172.6 9 0.996 0.5042 155.5 159.8 15.2 137.3 178.6 148.8 175.9 9 0.4243 163.0 163.3 14.4 136.2 188.1 157.4 164.4 9 0.3774 159.2 152.0 14.2 127.8 168.8 145.6 161.2 9 0.287Q1 1 142.3 139.4 18.1 115.1 173.5 125.4 147.9 9 0.740 0.4282 139.3 138.6 11.2 116.5 154.3 135.2 146.2 9 0.7903 138.4 137.7 10.8 123.0 155.8 127.4 142.3 9 0.8274 129.4 129.5 11.1 112.9 142.5 122.9 139.7 9 0.308Q3 1 159.3 156.0 18.3 124.5 185.3 142.7 165.9 9 0.964 0.5202 153.4 153.0 14.7 126.4 173.0 146.3 160.8 9 0.9153 155.5 158.8 14.0 134.3 183.1 153.0 160.8 9 0.4564 150.1 147.6 12.7 127.0 162.7 139.8 155.5 9 0.581
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Table 9c
Summary Statistics and Tests for Summary Measures and Drug
After Data Replaced: Average 3 Hrs Diastolic Blood Pressure: Centre 1
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 -0.5 -1.4 4.7 -9.0 5.3 -5.1 2.4 12 0.388 0.002*2 -2.4 -0.9 5.8 -6.4 14.7 -4.5 0.8 12 0.006*3 -8.0 -7.7 4.3 -13.0 0.4 -11.5 -5.3 11 0.5964 -6.3 -7.8 6.2 -21.0 1.4 -11.6 -4.8 12 0.651MEAN 1 96.4 95.3 7.5 77.7 109.8 92.8 97.6 12 0.145 0.038*2 93.9 95.3 6.1 83.2 105.4 92.3 97.2 13 0.3933 91.4 89.4 8.1 70.8 98.9 84.7 97.0 11 0.1854 87.3 88.0 8.5 77.4 103.1 80.4 93.0 12 0.411MEDIAN 1 98.3 98.2 8.3 76.8 111.2 96.9 101.4 12 0.033* 0.017*2 97.2 96.8 5.9 83.5 106.9 93.8 98.3 13 0.6013 91.1 91.2 8.3 71.2 101.4 86.4 98.2 11 0.1544 90.7 90.2 6.9 80.1 102.6 83.8 94.5 12 0.795MIN 1 79.2 79.8 5.5 72.2 93.0 76.6 82.6 12 0.191 0.2302 78.8 80.3 7.4 68.7 95.2 76.3 82.5 13 0.8913 79.2 78.0 10.8 59.2 93.5 66.5 87.3 11 0.5724 72.2 71.6 13.2 48.8 94.8 60.2 79.3 12 0.972MAX 1 107.6 106.1 8.3 84.1 116.8 104.1 110.5 12 0.034* 0.009*2 107.4 109.5 7.9 100.0 124.8 103.8 112.5 13 0.2003 101.6 98.9 9.1 79.5 108.8 90.6 105.5 11 0.1954 96.3 98.1 8.5 86.3 112.0 91.4 103.9 12 0.504
Q1 1 87.2 87.8 8.7 74.1 108.0 82.8 92.1 12 0.366 0.2332 87.1 87.4 7.3 70.5 98.3 85.5 92.6 13 0.3993 83.4 83.5 7.7 67.7 94.3 81.4 89.6 11 0.5394 80.5 81.7 9.0 68.9 97.0 74.9 88.2 12 0.687
Q3 1 103.3 102.4 7.8 82.0 115.1 100.7 105.0 12 0.020* 0.014*2 102.8 102.1 6.1 92.0 112.1 96.3 104.7 13 0.6133 97.1 94.7 8.4 75.1 105.0 90.1 101.4 11 0.1894 93.7 95.2 8.4 83.3 109.5 89.0 99.5 12 0.418
Table 9c cont.
After Data Replaced; Average 3 H rs Diastolic Blood Pressure: Centre 2
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 -5.4 -6.4 3.3 -11.3 -3.0 -9.6 -3.7 8 0.213 0.036*2 -2.0 -2.2 3.1 -7.2 1.8 -3.4 -0.2 9 0.7073 -7.3 -4.5 6.0 -9.4 9.8 -7.7 -3.1 9 0.009*4 -6.9 -7.3 3.1 -13.6 -3.8 -9.2 -5.4 9 0.365MEAN 1 93.6 92.3 9.1 79.1 106.6 88.5 94.7 9 0.467 0.5952 93.4 92.3 6.6 84.0 100.8 87.4 98.1 9 0.2833 88.3 90.4 8.2 81.2 102.5 83.7 94.5 9 0.1854 89.2 88.1 6.4 78.4 99.1 84.8 91.7 9 0.663MEDIAN 1 94.8 94.4 8.5 78.6 105.4 92.4 97.9 9 0.590 0.7122 93.8 93.6 7.6 83.1 103.7 87.9 98.5 9 0.5723 92.0 94.5 8.5 82.7 107.5 88.9 97.3 9 0.4054 92.2 90.7 6.4 81.5 99.8 86.0 94.2 9 0.530MIN 1 74.7 78.1 11.9 58.7 101.2 73.2 86.2 9 0.381 0.0982 80.0 79.7 7.9 68.5 94.7 77.5 81.7 9 0.5343 72.2 73.1 6.7 64.3 83.8 69.7 76.2 9 0.7464 69.8 70.8 6.4 61.2 82.5 68.0 75.0 9 0.972MAX 1 106.3 102.2 10.6 83.5 113.6 97.7 111.4 9 0.301 0.7122 100.8 102.3 6.7 93.2 111.8 97.9 107.4 9 0.5993 97.4 99.0 8.4 86.0 111.8 95.7 102.8 9 0.8744 100.2 99.6 8.2 87.0 111.0 95.5 107.0 9 0.699
Q1 1 86.8 86.7 9.8 69.1 103.9 82.9 89.0 9 0.838 0.4302 85.3 86.6 7.6 76.4 96.7 81.2 94.5 9 0.4353 81.6 84.1 9.4 68.8 97.0 78.8 89.0 9 0.5844 81.3 81.3 6.5 72.4 94.3 78.7 82.9 9 0.691Q3 1 101.5 98.1 9.5 80.8 109.8 93.6 103.9 9 0.688 0.7642 99.1 97.9 6.8 90.6 108.5 91.5 101.5 9 0.2023 95.5 96.8 8.8 84.2 110.0 91.3 102.3 9 0.8044 95.3 95.0 7.0 84.0 105.4 91.0 99.8 9 0.908
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Table 10a
Summary Statistics and Tests for Summary Measures and Drug
After Data Replaced: Average 2 Hrs Heart Rate
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 0.6 1.4 4.0 -3.5 12.1 -0.9 2.8 20 0.006* 0.1732 2.3 1.2 4.8 -12.0 9.5 -0.6 3.7 21 0.011*3 1.3 1.3 4.7 -10.2 11.2 0.1 3.7 20 0.5064 3.7 3.5 4.6 -2.9 18.1 1.3 5.8 21 0.010*MEAN 1 72.7 75.0 8.0 59.2 90.2 70.3 81.8 21 0.583 0.9782 74.1 74.4 10.1 49.2 91.4 67.6 83.2 22 0.4883 77.8 73.5 11.8 48.4 91.9 66.6 81.1 20 0.1424 75.4 75.6 5.8 64.8 88.1 71.8 78.9 21 0.639MEDIAN 1 73.2 74.5 8.9 59.1 91.8 67.1 83.0 0.573 0.9892 74.1 73.8 9.9 48.3 90.6 68.3 79.4 22 0.4953 76.4 73.0 12.1 48.0 88.6 65.1 82.4 20 0.1154 75.2 75.1 5.8 66.5 88.7 70.9 77.5 21 0.331MIN 1 63.8 63.7 6.6 52.3 77.0 58.8 68.0 21 0.967 0.6642 61.5 61.6 8.8 44.3 79.3 56.0 68.5 22 0.9923 64.1 61.4 9.2 41.3 79.7 54.5 66.9 20 0.4554 63.5 64.1 5.8 52.3 76.0 61.3 67.3 21 0.833MAX 1 90.0 90.8 12.0 70.5 110.0 81.9 100.0 21 0.357 0.8482 95.8 91.8 14.1 61.0 124.4 81.8 101.0 22 0.7893 88.5 87.1 15.0 52.3 110.6 79.3 96.1 20 0.5254 88.5 90.8 9.9 78.4 112.5 83.4 94.4 21 0.041*
Q1 1 68.7 69.2 7.3 55.4 85.5 63.5 75.1 21 0.569 0.7962 65.9 67.3 10.1 46.6 84.3 60.2 74.2 22 0.4883 70.4 67.1 10.3 45.8 83.0 60.0 73.8 20 0.1434 67.6 69.0 5.9 55.9 79.9 65.5 73.7 21 0.134Q3 1 77.1 79.3 9.3 61.1 97.1 74.8 86.7 21 0.741 0.9062 80.3 80.5 12.6 50.9 109.8 72.4 88.6 22 0.8093 82.0 79.5 13.9 49.2 100.6 70.4 88.3 20 0.2344 81.0 80.9 6.2 71.6 95.4 77.3 83.9 21 0.103
Table 10b
Summary Statistics and Tests for Summary Measures and Drug 
After Data Replaced; Average 2 Hrs Systolic Blood Pressure
SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.W
CHANGE 1 -2.5 -3.3 5.0 -14.8 2.9 -6.8 0.7 20 0.253 <0.001*2 -3.6 -2.6 6.8 -11.4 19.9 -6.9 -0.4 21 0.003*3 -6.0 -6.8 6.8 -21.8 10.0 -10.2 -3.5 20 0.5344 -9.1 -12.4 9.1 -32.2 2.7 -17.4 -6.5 21 0.273MEAN 1 150.9 149.5 14.4 121.7 179.8 138.4 156.2 21 0.983 0.016*2 146.8 146.3 10.8 122.3 170.8 139.7 154.0 22 0.9963 143.6 145.4 14.8 108.2 176.2 138.5 152.3 20 0.6334 138.0 136.7 10.5 119.5 151.1 131.3 143.8 21 0.146MEDIAN 1 153.6 152.6 14.0 122.2 177.7 140.6 159.6 21 0.879 0.006*2 147.8 148.1 11.3 123.1 171.0 142.4 155.4 22 0.9623 148.4 148.0 15.1 107.0 175.3 140.8 154.3 20 0.2654 139.2 138.7 10.0 118.9 152.8 133.5 147.1 21 0.303MIN 1 125.0 127.0 16.4 94.3 172.0 117.0 133.0 21 0.180 0.0522 128.9 127.1 11.4 107.8 156.8 118.0 134.3 22 0.1163 127.8 125.9 16.2 98.8 165.0 115.0 131.9 20 0.3764 114.0 116.8 13.1 83.8 141.5 110.5 126.5 21 0.663MAX 1 162.9 165.1 16.6 127.1 191.3 155.1 179.9 21 0.474 0.0962 164.5 163.4 12.4 136.5 185.3 156.8 168.4 22 0.8203 164.1 161.6 17.5 119.0 192.1 151.7 168.3 20 0.3684 154.3 153.7 14.2 126.4 178.0 147.8 163.5 21 0.395Q1 1 138.4 141.7 14.1 119.1 173.3 134.5 147.3 21 0.711 0.013*2 139.8 138.3 11.2 116.1 165.4 131.0 143.1 22 0.7183 136.2 136.5 14.8 105.3 171.6 126.9 145.6 20 0.9834 127.8 128.4 10.8 112.8 144.3 119.2 137.8 21 0.116Q3 1 . 160.3 158.1 15.4 123.3 186.9 149.4 165.6 21 0.947 0.016*2 154.0 153.9 11.8 127.3 176.1 146.0 161.1 22 0.9613 154.6 153.6 16.4 111.5 185.2 145.8 161.5 20 0.5134 144.8 144.8 10.7 125.8 164.5 138.8 150.9 21 0.571
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Table 10c
Summary Statistics and Tests for Summary Measures and Drug
After Data Replaced: Average 2 Hrs Diastolic Blood PressureSM DRUG MEDIAN MEANCHANGE 1 -3.1 -3.42 -2.0 -1.43 -7.4 -6.24 -6.9 -7.6MEAN 1 94.7 94.12 93.8 94.1
3 90.6 89.94 89.2 88.0MEDIAN 1 97.3 96.22 95.4 95.03 91.3 91.94 91.8 90.2MIN 1 77.3 76.82 76.9 77.43 76.0 74.44 69.3 70.3MAX 1 109.6 106.92 109.8 109.43 104.9 101.84 99.4 100.8
Q1 1 88.1 87.22 86.6 87.3
3 84.6 83.54 79.4 81.2
Q3 1 102.1 101.02 100.7 100.53 96.7 96.24 94.0 94.6
STD MIN MAX Q14.8 -11.3 5.3 -7.74.8 -7.2 14.7 -4.45.2 -13.0 9.8 -9.85.0 -21.0 1.4 -9.68.2 77.7 109.8 91.26.3 83.2 105.4 89.87.9 70.8 102.5 84.17.5 77.4 103.1 81.28.1 79.3 113.3 93.56.8 82.2 107.7 90.88.3 70.3 106.1 87.46.6 78.8 101.6 84.710.2 53.0 100.3 70.36.8 64.5 91.0 73.88.8 61.3 91.8 67.012.1 45.3 96.0 63.310.1 83.8 120.1 102.38.8 94.3 128.5 104.08.6 80.3 115.5 95.87.9 86.5 116.1 95.78.8 70.0 103.4 83.07.3 70.4 98.4 82.18.2 66.4 95.8 79.07.5 72.2 98.4 75.08.4 81.9 115.3 99.87.2 89.9 114.9 94.78.5 74.2 112.1 90.67.8 81.4 107.6 87.4
Q3 N NORMAL K.W0.5 20 0.739 <0.001-0.2 21 0.002*-4.1 20 0.026*-5.1 21 0.17497.5 21 0.135 0.015*98.1 22 0.64595.8 20 0.72291.9 21 0.29999.3 21 0.201 0.037*100.3 22 0.89097.6 20 0.55195.3 21 0.63881.3 21 0.616 0.11880.8 22 0.50980.0 20 0.46280.5 21 0.969112.6 21 0.052 0.006*114.5 22 0.744107.1 20 0.410104.6 21 0.73691.9 21 0.861 0.033*93.2 22 0.641
88.8 20 0.29484.1 21 0.099106.2 21 0.094 0.021*105.8 22 0.332102.6 20 0.768100.0 21 0.619
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Table 11a
Summary Statistics and Tests for Summary Measures and Drug
After Data Replaced: Average 2 Hrs Heart Rate: Centre 1SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 0.5 2.0 4.9 -3.5 12.1 -0.9 3.6 12 0.054 0.5502 2.3 2.5 3.3 -3.1 9.5 0.3 4.6 12 0.9083 1.1 0.7 3.7 -5.8 6.6 -3.3 2.9 11 0.6584 2.9 2.2 3.3 -2.9 7.4 -0.3 3.9 12 0.431MEAN 1 79.1 78.0 7.9 66.0 90.2 70.6 83.9 12 0.474 0.9022 78.6 76.7 8.7 64.4 91.4 70.2 83.2 13 0.6143 77.8 77.0 8.4 65.8 91.9 68.4 84.9 11 0.4514 76.4 75.9 6.3 64.8 88.1 72.0 80.0 12 0.998MEDIAN 1 80.3 77.6 9.4 63.8 91.8 68.2 83.7 12 0.336 0.8622 77.0 75.4 8.7 59.9 90.6 70.7 78.3 13 0.6263 77.5 75.7 8.7 63.4 88.6 65.9 82.5 11 0.5844 74.1 74.9 6.6 66.5 88.7 70.5 78.4 12 0.623MIN 1 64.9 64.6 7.5 52.3 77.0 58.0 70.1 12 0.816 0.7862 61.8 62.3 8.6 51.5 79 .3 56.7 66.0 13 0.4133 65.5 64.0 8.1 52.7 79.7 55.5 70.1 11 0.7784 62.9 63.6 6.8 52.3 76.0 59.8 67.9 12 0.968MAX 1 96.5 95.3 10.9 75.8 110.0 88.4 104.9 12 0.518 0.5432 97.3 96.6 12.6 75.0 124.4 87.1 104.4 13 0.6993 89.3 91.2 10.8 77.4 110.6 81.6 94.0 11 0.1174 89.8 92.3 9.9 79.5 112.5 87.0 95.7 12 0.197
Q1 1 71.2 70.9 7.6 62.0 85.5 63.8 76.8 12 0.157 0.6382 68.0 68.0 9.1 57.0 84.3 60.2 72.9 13 0.1293 72.9 70.5 7.7 59.8 83.0 63.9 74.4 11 0.5634 67.8 69.6 7.2 55.9 79.9 65.5 75.1 12 0.593Q3 1 86.2 84.2 8.4 70.6 97.1 76.3 90.7 12 0.685 0.8472 82.0 84.8 11.8 67.8 109.8 76.1 92.2 13 0.8313 82.5 83.6 10.2 69.6 100.6 73.9 90.5 11 0.8074 81.1 81.2 5.7 71.6 94.7 77.4 84.1 12 0.365Table 11a cont 
After Data Replaced: Average 2 Hrs Heart Rate: Centre 2SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 0.6 0.5 2.2 -2.6 4.4 -1.2 1.6 8 0.906 0.1092 2.3 -0.6 6.1 -12.0 4.8 -1.6 3.6 9 0.021*3 2.2 2.0 5.8 -10.2 11.2 0.4 4.5 9 0.3914 4.5 5.3 5.8 -2.9 18.1 3.7 6.9 9 0.164MEAN 1 72.0 70.8 6.4 59.2 81.8 66.9 72.7 9 0.920 0.6912 68.7 71.1 11.6 49.2 85.8 67.6 80.7 9 0.4793 75.8 69.1 14.2 48.4 85.0 60.8 80.7 9 0.1404 73.3 75.1 5.4 69.9 86.9 71.1 77.2 9 0.094MEDIAN 1 70.3 70.2 6.3 59.1 79.6 67.1 74.3 9 0.971 0.5342 68.3 71.4 11.5 48.3 85.6 68.3 79.6 9 0.1933 75.3 69.7 15.3 48.0 87.9 58.8 82.3 9 0.2024 75.8 75.3 5.0 69.0 86.0 71.7 77.5 9 0.363MIN 1 63.8 62.6 5.2 52.8 70.3 60.8 66.0 9 0.873 0.7442 61.3 60.7 9.4 44.3 73.0 56.0 68.5 9 0.8843 63.5 58.2 9.8 41.3 67.8 54.3 66.0 9 0.0954 63.5 64.7 4.5 57.8 74.0 62.8 67.3 9 0.388MAX 1 82.4 84.8 11.0 70.5 110.0 81.5 86.0 9 0.089 0.8112 82.5 84.9 13.9 61.0 101.8 77.0 100.2 9 0.4113 83.3 82.1 18.4 52.3 102.8 74.6 98.1 9 0.4294 87.5 88.7 10.0 78.4 105.7 81.3 88.6 9 0.054Q1 1 67.4 66.9 6.5 55.4 75.5 63.1 69.6 9 0.836 0.9582 63.8 66.3 11.8 46.6 82.1 62.3 75.6 9 0.7263 69.8 62.9 11.9 45.8 75.6 55.1 71.9 9 0.0894 67.3 68.4 3.8 65.1 74.8 65.1 68.8 9 0.017*Q3 1 74.8 72.9 6.1 61.1 81.4 69.3 75.9 9 0.824 0.3502 73.3 74.4 11.7 50.9 89.7 69.7 81.8 9 0.3873 81.0 74.4 16.6 49.2 92.3 64.8 87.6 9 0.1314 79.0 80.6 7.1 72.0 95.4 75.5 83.9 9 0.478
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Table lib
Summary Statistics and Tests for Summary Measures and Drug
After Data Replaced: Average 2 Hrs Systolic Blood Pressure: Centre 1SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 -0.2 -0.8 3.8 -10.3 2.9 -2.3 2.3 12 0.057 0.0032 -3.8 -2.0 7.8 -11.4 19.9 -6.8 0.0 12 0.004*3 -5.6 -7.6 6.7 -21.8 -0.5 -12.9 -3.4 11 0.1004 -13.0 -13.3 11.1 -32.2 2.7 -19.9 -5.5 12 0.743MEAN 1 148.4 151.0 11.9 137.6 171.5 140.9 158.7 12 0.201 0.0232 147.3 146.8 10.3 132.9 170.8 139.7 151.7 13 0.4263 141.3 143.2 17.2 108.2 176.2 135.6 153.7 11 0.5624 137.9 135.5 9.8 119.8 151.1 128.4 141.9 12 0.538MEDIAN 1 151.8 153.8 12.3 138.6 177.2 144.2 162.8 12 0.562 0.0082 150.0 148.7 10.4 130.5 171.0 142.4 154.8 13 0.8363 143.6 144.1 16.6 107.0 174.2 138.6 153.7 11 0.3534 138.3 136.6 9.3 118.9 150.1 130.5 143.0 12 0.828MIN 1 126.0 129.1 10.8 116.8 154.8 121.4 134.9 12 0.106 0.1652 128.5 126.7 13.3 108.0 156.8 117.0 134.3 13 0.3023 131.3 129.1 20.1 98.8 165.0 117.5 140.8 11 0.7764 114.5 116.6 15.2 83.8 141.5 108.8 128.3 12 0.766MAX 1 163.0 165.7 12.3 151.1 186.6 157.5 173.6 12 0.116 0.0642 164.5 164.3 9.3 150.5 185.3 157.6 168.0 13 0.4923 153.9 157.1 18.4 119.0 192.0 148.6 169.8 11 0.5834 154.1 152.9 13.1 133.5 178.0 142.9 159.9 12 0.207Q1 1 142.1 143.8 11.7 128.1 161.9 135.3 152.8 12 0.246 0.0342 140.0 138.7 12.1 120.3 165.4 129.7 143.1 13 0.4193 135.5 137.0 18.1 105.3 171.6 123.1 148.4 11 0.9784 128.9 128.1 10.2 112.8 144.3 118.4 136.2 12 0.728Q3 1 157.8 159.2 12.9 140.8 182.4 150.7 166.0 12 0.627 0.0122 155.8 154.8 10.0 139.2 176.1 149.5 159.9 13 0.8373 147.7 148.5 17.2 111.5 181.5 142.4 158.7 11 0.3964 144.4 143.0 8.7 126.0 154.6 137.8 149.0 12 0.141
Table l ib  cont 
After Data Replaced: Average 2 Hrs Systolic Blood Pressure: Centre 2SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL K.WCHANGE 1 -6.8 -7.1 4.3 -14.8 -2.1 -9.6 -3.6 8 0.609 0.0652 -3.6 -3.4 5.4 -11.2 4.5 -7.4 -0.7 9 0.6303 -6.6 -5.8 7.3 -15.7 10.0 -8.5 -5.2 9 0.2524 -8.5 -11.2 5.6 -21.4 -6.5 -15.4 -7.0 9 0.026*MEAN 1 151.4 147.5 17.7 121.7 179.8 134.7 156.2 9 0.885 0.5382 143.2 145.6 12.1 122.3 162.6 140.9 154.0 9 0.7933 147.2 148.2 11.6 129.2 168.7 140.9 151.0 9 0.9354 143.6 138.4 11.8 119.5 151.1 131.3 148.0 9 0.298MEDIAN 1 153.6 150.9 16.6 122.2 177.7 140.0 159.5 9 0.977 0.3302 145.1 147.3 13.1 123.1 166.2 142.6 155.4 9 0.6593 151.2 152.8 12.1 131.6 175.3 148.3 154.6 9 0.5494 146.5 141.6 10.7 124.8 152.8 135.6 149.1 9 0.140MIN 1 117.0 124.1 22.2 94.3 172.0 110.8 132.5 9 0.342 0.2582 129.3 127.8 8.8 107.8 137.8 126.8 133.0 9 0.1123 126.5 122.0 9.6 105.5 131.8 112.5 128.0 9 0.0594 113.5 117.0 10.7 100.5 133.0 111.3 122.0 9 0.781MAX 1 162.9 164.3 21.8 127.1 191.3 152.0 180.0 9 0.799 0.5702 161.8 162.2 16.5 136.5 181.5 150.4 180.0 9 0.4673 165.5 167.1 15.6 139.2 192.1 163.9 166.9 9 0.1844 163.5 154.7 16.2 126.4 172.0 147.8 164.4 9 0.221Q1 1 138.4 139.0 17.0 119.1 173.3 124.3 145.1 9 0.346 0.4912 136.8 137.7 10.5 116.1 152.5 134.8 142.4 9 0.6213 139.1 135.9 10.5 117.1 150.4 132.3 140.0 9 0.8014 127.8 128.9 12.1 113.5 143.1 120.3 141.1 9 0.170Q3 1 161.8 156.5 18.9 123.3 186.9 145.3 165.6 9 0.943 0.3012 151.0 152.6 14.5 127.3 175.5 146.0 162.3 9 0.9743 156.5 159.8 13.9 135.5 185.2 155.9 163.0 9 0.6514 150.3 147.1 13.1 125.8 164.5 138.8 155.3 9 0.845
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Table 11c
Summary Statistics and Tests for Summary Measures and Drug
After Data Replaced: Average 2 Hrs Diastolic Blood Pressure: Centre 1SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMALCHANGE 1 -0.5 -1.4 4.7 -9.0 5.3 -5.1 2.4 12 0.3882 -2.4 -0.9 5.8 -6.4 14.7 -4.5 0.8 12 0.006*3 -8.0 -7.7 4.3 -13.0 0.4 -11.5 -5.3 11 0.5964 -6.3 -7.8 6.2 -21.0 1.4 -11.6 -4.8 12 0.651MEAN 1 96.4 95.3 7.5 77.7 109.8 92.8 97.6 12 0.1452 93.9 95.3 6.1 83.2 105.4 92.3 97.2 13 0.3933 91.4 89.4 8.1 70.8 98.9 84.7 97.0 11 0.1854 87.3 88.0 8.5 77.4 103.1 80.4 93.0 12 0.411MEDIAN 1 98.4 97.4 7.9 79.3 113.3 94.3 99.5 12 0.1382 95.8 96.0 6.3 82.2 107.7 92.9 100.3 13 0.7953 91.3 90.6 8.3 70.3 101.1 86.1 96.8 11 0.1074 90.2 89.9 7.1 78.8 101.6 84.0 94.5 12 0.914MIN 1 78.5 77.9 7.5 66.5 94.8 72.9 81.0 12 0.3462 78.0 77.8 6.6 66.0 91.0 73.8 80.8 13 0.5953 76.5 76.1 9.4 62.8 91.8 66.8 81.0 11 0.6224 71.1 70.9 15.1 45.3 96.0 57.0 81.4 12 0.847MAX 1 109.7 108.7 8.6 87.5 120.1 106.4 113.4 12 0.1342 112.6 112.6 8.3 100.4 128.5 106.4 115.8 13 0.5873 105.3 101.3 9.3 80.3 112.2 93.1 106.3 11 0.0774 97.7 100.9 8.2 91.5 116.1 94.6 106.7 12 0.188
Q1 1 87.5 87.9 8.3 71.4 103.4 83.9 93.1 12 0.9812 87.1 88.1 7.3 70.4 98.4 86.1 91.8 13 0.2583 84.6 83.7 8.1 66.4 93.5 79.6 91.5 11 0.2294 81.5 81.9 8.5 72.2 98.4 74.4 86.6 12 0.259Q3 1 103.0 102.8 7.5 83.7 115.3 100.3 106.5 12 0.0562 102.9 102.3 6.9 90.5 114.9 98.4 105.8 13 0.8363 97.5 94.9 8.6 74.2 103.8 89.1 102.5 11 0.0854 92.9 94.1 8.5 81.4 107.6 87.4 99.7 12 0.713
Table 11c cont.
After Data Reolaced: Average 2 Hrs Diastolic Blood Pressure: Centre 2SM DRUG MEDIAN MEAN STD MIN MAX Q1 Q3 N NORMAL ]CHANGE 1 -5.4 -6.4 3.3 -11.3 -3.0 -9.6 -3.7 8 0.213 12 -2.0 -2.2 3.1 -7.2 1.8 -3.4 -0.2 9 0.7073 -7.3 -4.5 6.0 -9.4 9.8 -7.7 -3.1 9 0.009*4 -6.9 -7.3 3.1 -13.6 -3.8 -9.2 -5.4 9 0.365MEAN 1 93.6 92.3 9.1 79.1 106.6 88.5 94.7 9 0.467 12 93.4 92.3 6.6 84.0 100.8 87.4 98.1 9 0.2833 88.3 90.4 8.2 81.2 102.5 83.7 94.5 9 0.1854 89.2 88.1 6.4 78.4 99.1 84.8 91.7 9 0.663MEDIAN 1 95.5 94.5 8.4 79.3 106.2 91.9 97.7 9 0.739 12 94.9 93.6 7.8 84.3 104.0 87.4 98.9 9 0.3253 91.4 93.4 8.6 80.7 106.1 88.1 98.9 9 0.6744 91.9 90.7 6.2 80.9 99.4 86.4 95.3 9 0.721MIN 1 74.3 75.3 13.4 53.0 100.3 67.8 83.3 9 0.883 12 75.8 77.0 7.5 64.5 91.0 75.2 80.0 9 0.8703 70.0 72.2 8.1 61.3 84.8 67.3 78.0 9 0.7714 67.5 69.4 6.9 63.0 85.5 64.8 70.8 9 0.047*MAX 1 108.3 104.5 11.9 83.8 117.8 97.6 112.6 9 0.411 I2 104.5 104.9 7.8 94.3 114.5 97.1 110.3 9 0.3493 101.3 102.4 8.2 90.3 115.5 97.6 107.3 9 0.9084 103.1 100.7 8.0 86.5 111.3 96.4 104.6 9 0.836Q1 1 88.1 86.2 9.8 70.0 102.9 81.0 90.4 9 0.987 12 83.3 86.0 7.6 77.7 96.0 80.9 95.1 9 0.0593 84.6 83.1 8.7 68.3 95.8 78.4 85.7 9 0.8684 78.4 80.3 6.4 72.6 92.6 76.5 83.4 9 0.652Q3 1 100.3 98.6 9.4 81.9 111.0 96.1 104.8 9 0.789 12 100.7 98.0 7.1 89.9 107.7 91.5 102.7 9 0.1173 95.9 97.8 8.6 86.3 112.1 91.8 102.6 9 0.8564 96.6 95.4 7.4 84.0 105.3 91.7 100.9 9 0.788
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Frequencies and Chi Squared Tests for Abnormally ‘High’ Results at Each Time Point; Heart












% (Ratio) % (Ratio)
0
(0/21)







1 H r 0 0 0 0
(0/19) (0/22) (0/21) (0/21)
2  H rs 0 0 0 0
(0/21) (0/22) (0/21) (0/21)
3 H rs 4.8 0 9.5 0 0.611
(1/21) (0/21) (2/21) (0/21)
4 H rs 0 0 0 0
(0/21) (0/22) (0/22) (0/21)
5 H rs 4.8 0 9.1 4.8 0.698
(1/21) (0/22) (2/22) (1/21)
6 H rs 0 0 4.5 0 1.000
(0/21) (0/22) (1/22) (0/21)
7 H rs 0 4.5 4.5 4.8 1.000
(0/21) (1/22) (1/22) (1/21)
8 H rs 4.8 13.6 9.1 4.8 0.829
(1/21) (3/22) (2/22) (1/21)
9 H rs 14.3 9.1 9.1 0 0.448
(3/21) (2/22) (2/22) (0/21)
10 H rs 4.8 0 0 0 0.488
(1/21) (0/22) (0/22) (0/21)
11 H rs 14.3 18.2 18.2 14.3 1.000
(3/21) (4/22) (4/22) (3/21)
12 H rs 19 22.7 13.6 0 0.119
(4/21) (5/22) (3/22) (0/21)
13 H rs 0 9.5 13.6 9.5 0.503
(0/20) (2/21) (3/22) (2/21)
14 H rs 0 4.5 9.5 0 0.464
(0/21) (1/22) (2/21) (0/21)
15 H rs 4.8 9.1 0 4.8 0.698
(1/21) (2/22) (0/22) (1/21)
16 H rs 0 4.5 0 0 1.000
(0/21) (1/22) (0/22) (0/21)
17 H rs 0 0 0 0
(0/21) (0/22) (0/22) (0/21)
18 H rs 0 0 0 0
(0/20) (0/22) (0/20) (0/21)
19 H rs 0 0 0 0
(0/20) (0/22) (0/20) (0/21)
20 H rs 0 0 0 0
(0/21) (0/22) (0/20) (0/21)
21 H rs 0 0 0 4.8 0.741
(0/21) (0/22) (0/21) (1/21)
22 H rs 4.8 9.1 4.8 5 1.000
(1/21) (2/22) (1/21) (1/20)
23 H rs 35 27.3 19 15.8 0.517
(7/20) (6/22) (4/21) (3/19)
24 H rs 4.8 0 4.5 14.3 0.231
(1/21) (0/22) (1/22) (3/21)
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Table 12b
Frequencies and Chi Squared Tests for Abnormally ‘High* Results at Each Time Point
























1 H r 78.9 81.8 81.0 52.4 0.091
(15/19) (18/22) (17/21) (11/21)
2  H rs 81.0 86.4 76.2 61.9 0.310
(17/21) (19/22) (16/21) (13/21)
3  H rs 85.7 85.7 85.7 71.4 0.624
(18/21) (18/21) (18/21) (15/21)
4  H rs 81.0 68.2 77.3 61.9 0.500
(17/21) (15/22) (17/22) (13/21)
5  H rs 85.7 86.4 90.9 71.4 0.426
(18/21) (19/22) (20/22) (15/21)
6 H rs 95.2 81.8 68.2 47.6 0.004*
(20/21) (18/22) (15/22) (10/21)
7 H rs 85.7 90.9 81.8 61.9 0.120
(18/21) (20/22) (18/22) (13/21)
8 H rs 90.5 86.4 72.7 42.9 0.002*
(19/21) (19/22) (16/22) (9/21)
9 H rs 85.7 72.7 72.7 61.9 0.384
(18/21) (16/22) (16/22) (13/21)
10 H rs 95.2 81.8 77.3 61.9 0.060
(20/21) (18/22) (17/22) (13/21)
11 H rs 85.7 77.3 86.4 66.7 0.393
(18/21) (17/22) (19/22) (14/21)
12 H rs 81.0 81.8 77.3 61.9 0.399
(17/21) (18/22) (17/22) (13/21)
13 H rs 75.0 85.7 68.2 57.1 0.218
(15/20) (18/21) (15/22) (12/21)
14 H rs 85.7 72.7 66.7 52.4 0.128
(18/21) (16/22) (14/21) (11/21)
15 H rs 61.9 77.3 45.5 52.4 0.160
(13/21) (17/22) (10/22) (11/21)
16 H rs 33.3 50.0 18.2 4.8 0.006*
(7/21) (11/22) (4/22) (1/21)
17 H rs 42.9 22.7 27.3 9.5 0.099
(9/21) (5/22) (6/22) (2/21)
18 H rs 35.0 31.8 30.0 9.5 0.231
(7/20) (7/22) (6/20) (2/21)
19 H rs 20.0 13.6 25.0 4.8 0.304
(4/20) (3/22) (5/20) (1/21)
20 H rs 23.8 31.8 40.0 9.5 0.144
(5/21) (7/22) (8/20) (2/21)
21 H rs 28.6 13.6 28.6 14.3 0.442
(6/21) (3/22) (6/21) (3/21)
22 H rs 47.6 54.5 52.4 40.0 0.794
(10/21) (12/22) (11/21) (8/20)
23  H rs 80.0 81.8 76.2 42.1 0.019*
(16/20) (18/22) (16/21) (8/19)
24 H rs 81.0 81.8 72.7 52.4 0.116
(17/21) (18/22) (16/22) (11/21)
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Table 12c
Frequencies and Chi Squared Tests for Abnormally ‘High’ Results at F.nrh Time Point






















1 H r 84.2 81.8 81.0 81.0 1.000
(16/19) (18/22) (17/21) (17/21)
2  H rs 81.0 86.4 57.1 66.7 0.124
(17/21) (19/22) (12/21) (14/21)
3 H rs 81.0 81.0 66.7 57.1 0.241
(17/21) (17/21) (14/21) (12/21)
4 H rs 81.0 81.8 59.1 71.4 0.290
(17/21) (18/22) (13/22) (15/21)
5 H rs 85.7 90.9 81.8 81.0 0.811
(18/21) (20/22) (18/22) (17/21)
6 H rs 81.0 63.6 31.8 38.1 0.004*
(17/21) (14/22) (7/22) (8/21)
7 H rs 81.0 90.9 68.2 61.9 0.116
(17/21) (20/22) (15/22) (13/21)
8 H rs 85.7 86.4 63.6 61.9 0.106
(18/21) (19/22) (14/22) (13/21)
9 H rs 85.7 77.3 72.7 76.2 0.798
(18/21) (17/22) (16/22) (16/21)
10 H rs 85.7 90.9 77.3 71.4 0.359
(18/21) (20/22) (17/22) (15/21)
11 H rs 85.7 86.4 72.7 66.7 0.344
(18/21) (19/22) (16/22) (14/21)
12 H rs 76.2 77.3 59.1 81.0 0.367
(16/21) (17/22) (13/22) (17/21)
13 H rs 70.0 76.2 54.5 61.9 0.470
(14/20) (16/21) (12/22) (13/21)
14 H rs 71.4 72.7 57.1 47.6 0.269
(15/21) (16/22) (12/21) (10/21)
15 H rs 52.4 63.6 31.8 38.1 0.145
(11/21) (14/22) (7/22) (8/21)
16 H rs 23.8 31.8 9.1 9.5 0.166
(5/21) (7/22) (2/22) (2/21)
17 H rs 28.6 22.7 27.3 9.5 0.423
(6/21) (5/22) (6/22) (2/21)
18 H rs 25.0 22.7 25.0 23.8 1.000
(5/20) (5/22) (5/20) (5/21)
19 H rs 10.0 22.7 20.0 9.5 0.555
(2/20) (5/22) (4/20) (2/21)
20 H rs 19.0 9.1 25.0 9.5 0.479
(4/21) (2/22) (5/20) (2/21)
21 H rs 14.3 18.2 23.8 14.3 0.877
(3/21) (4/22) (5/21) (3/21)
22  H rs 33.3 45.5 52.4 40.0 0.641
(7/21) (10/22) (11/21) (8/20)
23 H rs 75.0 86.4 71.4 68.4 0.533
(15/20) (19/22) (15/21) (13/19)
24  H rs 81.0 81.8 81.8 57.1 0.163
(17/21) (18/22) (18/22) (12/21)
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Table 13a
Summary Statistics and Kruskal-Wallis Tests on Frequency of Occurrence
Heart Rate (beats/min) 
Overall
Frequency DRUG Mean+/-SD RANGE N
Low Drug 1 Drug 2 Drug 3 Drug 4
1.6+/-3.2 3.8+/-5 . 6 4.0+/-7.2 1.1+/-2.5
0-14
0-230-240-10
(N=21) (N=22) (N=22) (N=21)
Normal Drug 1 Drug 2 
Drug 3 Drug 4
21+/-3.2 18.8+/-5.2 




High Drug 1 Drug 2 Drug 3 Drug 4
1.1+/-1.7 0-6 1.3+/-1.8 0-6 1.3+/-1.8 0-6 0.8+/-1.2 0-4
Centre 1
(N=21) (N=22) (N=22) (N=21)
Frequency DRUG Mean+/-SD RANGE N
Low Drug 1 Drug 2 Drug 3 Drug 4




Normal Drug 1 
Drug 2 Drug 3 Drug 4
20.8+/-2.1 




High Drug 1 Drug 2 Drug 3 Drug 4




Frequency DRUG Mean+/-SD RANGE N
Low Drug 1 Drug 2 Drug 3 Drug 4
2.2+/-4.5 4.8+/-7 . 6 7.2+/-9.7 0.6+/-1.3
0-140-230-240-4
(N=9) (N=9) (N=10) (N=9)




(N=9) (N=9) (N=10) (N=9)
High Drug 1 Drug 2 Drug 3 Drug 4
0.3+/-10.8+/-1.10.7+/-1.10.6+/-1.1
0-30-30-30-3















Summary Statistics and Kruskal-Wallis Tests on Frequency of Occurrence
Systolic BP (mmHg)
Overall
Frequency DRUG Mean+/-SD RANGE N K.W.PROB
Low Drug 1 0.1+/-0.7 0-3 (N=21) 0.619Drug 2 0+/-0.2 0-1 (N=22)Drug 3 0.4+/-1.3 0-6 (N=22)Drug 4 0.3+/-1 0-4 (N=21)
Normal Drug 1 7.3+/-5.6 0-24 (N=21) 0.016*Drug 2 8.0+/-5.7 0-24 (N=22)Drug 3 8.4+/-5.6 0-19 (N=22)Drug 4 12.9+/-6.5 3-24 (N=21)
High Drug 1 16.3+/-5.8 0-24 (N=21) 0.019*Drug 2 15.9+/-5.8 0-24 (N=22)Drug 3 14.7+/-6.7 0-24 (N=22)Drug 4 10.7+/-6.8 0-20 (N=21)
Centre 1
Frequency DRUG Mean+/-SD RANGE N K.W.PROB
Low Drug 1 0+/-0 0-0 (N=12) 0.455Drug 2 0.1+/-0.3 0-1 (N=13)Drug 3 0.7+/-1.8 0-6 (N=12)Drug 4 0.4+/-1.2 0-4 (N=12)
Normal Drug 1 6.1+/-4.1 1-13 (N=12) 0.023*Drug 2 7.3+/-5.1 0-17 (N=13)Drug 3 8.1+/-6.5 0-18 (N=12)Drug 4 13.5+/-6.2 3-24 (N=12)
High Drug 1 17.6+/-4.1 11-23 (N=12) 0.026*Drug 2 16.5+/-5.1 7-24 (N=13)Drug 3 14.9+/-7.3 0-24 (N=12)Drug 4 10+/-6.5 0-20 (N=12)
Centre 2
Frequency DRUG Mean+/-SD RANGE N K.W.PROE
Low Drug 1 0.3+/-1 0-3 (N=9) 0.537Drug 2 0+/-0 0-0 (N=9)Drug 3 0+/-0 0-0 (N=10)Drug 4 0.2+/-0.7 0-2 (N=9)
Normal Drug 1 8.9+/-7.2 0-24 (N=9) 0.695Drug 2 8.9+/-6.8 2-24 (N=9)Drug 3 8.7+/-4.5 5-19 (N=10)Drug 4 12+/-7.2 4-23 (N=9)
High Drug 1 14.6+/-7.4 0-24 (N=9) 0.688Drug 2 15+/-6.8 0-22 (N=9)Drug 3 14.4+/-6.2 2-19 (N=10)Drug 4 11.6+/-7.4 0-20 (N=9)
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Table 13c
Summary Statistics and Kruskal-Wallis Tests on Frequency of Occurrence
Diastolic BP (mmHg)
Overalluv n
Frequency DRUG Mean+/-SD RANGE N K.W.PROB
Low Drug 1 Drug 2 Drug 3 Drug 4
0 .2+/-0.9 0+/-0 0 . 3 + /-0.9 0 . 6+/-1.2
0-40-00-40-4
(N=21) (N=22) (N=22) (N=21)
0.025*






(N=21) (N=22) (N=22) (N=21)
0.117
High Drug 1 Drug 2 Drug 3 Drug 4




(N=21) (N=22) (N=22) (N=21)
0.096









Normal Drug 1 Drug 2 Drug 3 Drug 4















Frequency DRUG Mean+/-SD RANGE N K.W.PROB
Low Drug 1 Drug 2 Drug 3 Drug 4
0.4+/-1.3 0+/-0 0.1+/-0.3 0.3+/-0.7
0-40-00-10-2
(N=9) (N=9) (N=10) (N=9)
0.531




(N=9) (N=9) (N=10) (N=9)
0.769










Number of Abnormally High Results over the Course of the Study by Treatment:
Heart Rate (N=86).




Total1 2 3 4
0 11 10 10 13 44
1 4 6 6 3 19
2 3 2 2 2 9
3 1 1 1 2 5
4 - - 1 1 2
5 1 2 1 - 4
6 1 1 1 - 3
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Table 14b
Number of Abnormally High Results over the Course of the Study by Treatment: SBP (N=86).
Number of Abnormally 
High Readings
Treatment
Total1 2 3 4
0 1 1 1 2 5
1 - - - 3 3
2 - - 1 - 1
4 - - 1 - 1
6 - - 1 - 1
7 1 1 - 1 3
9 - 1 - 1 2
10 - - - 3 3
11 2 1 1 1 5
12 1 2 1 1 5
13 1 1 2 1 5
14 1 1 - - 2
15 - 1 1 - 2
16 2 1 3 3 9
17 1 1 2 3 7
18 - 2 1 - 3
19 5 2 3 - 10
20 1 2 1 2 6
21 3 2 - - 5
22 - 2 - - 2
23 1 - 2 - 3
24 1 1 1 - 3
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Table 14c





Total1 2 3 4
0 1 - - - 1
1 1 - 2 - 3
2 1 - - 2 3
3 - - - 1 1
4 - - 1 1 2
5 - 1 - 1
6 - - 1 1 2
7 - - 1 1 2
8 - 2 1 1 4
9 - 1 - 1
10 - - 2 1 3
11 - 1 - 1 2
12 - 1 3 4
13 - - 1 1 2
14 1 - 1 1 3
15 5 1 - 6 12
16 4 6 1 - 11
17 2 2 2 - 6
18 2 1 2 - 5
19 1 2 3 2 8
20 1 1 - 1 3
21 - 2 1 - 3
22 1 - - - 1
23 - 1 - 1 2
24 1 - - - 1
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Table 15a







P-Value1 2 3 4
1 0 3 5 4 6
0.8510-3 7 5 5 5
4-6 2 3 3 1
2 0 8 5 6 7
0.4210-3 1 4 4 2
Overall 0 11 10 10 13
0.9300-3 8 9 9 7
4-6 2 3 3 1
Table 15b
Chi-squared Tests on Frequency of Occurrence of Abnormal Results bv Treatment
Systolic BP (mmHg)
Centre Number of Abnormal 
Readings
Treatment
p-value1 2 3 4
1 0-12 2 3 4 8
0.14313-18 3 5 4 3
19-24 7 5 4 1
2 0-12 3 3 2 4
0.62213-18 2 2 5 4
19-24 4 4 3 1
Overall 0-12 5 6 6 12 0.069
13-18 5 7 9 7
19-24 11 9 7 2
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Table 15c







P-value1 2 3 4
1 0-12 1 2 5 6
0.17913-18 9 8 5 3
19-24 2 3 2 3
2 0-12 2 4 6 3
0.50213-18 5 2 2 5
19-24 2 3 2 1
Overall 0-12 3 6 11 9
0.19513-18 14 10 7 8
19-24 4 6 4 4
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Table 16b















% (Ratio) % (Ratio) % (R atio) % (Ratio)









>75%  H igh 58.3 38.5 33.3 8.3 0.081
(7/12) (5/13) (4/12) (1/12)
2 >50%  H igh 66.7 66.7 80 55.6 0.728
(6/9) (6/9) (8/10) (5/9)
>75%  H igh 44.4 44.4 30 11.1 0.380
(4/9) (4/9) (3/10) (1/9)
O verall >50%  H igh 76.2 72.7 72.7 42.9 0.075
(16/21) (16/22) (16/22) (9/21)
>75%  H igh 52.4 40.9 31.8 9.5 0.025*
(11/21) (9/22) (7/22) (2/21)
Table 16c




























>75%  H igh 16.7 23.1 16.7 25 1.000
(2/12) (3/13) (2/12) (3/12)
2 >50%  H igh 77.8 55.6 40 66.7 0 .424
(7/9) (5/9) (4/10) (6/9)
>75%  H igh 22.2 33.3 20 11.1 0.827
(2/9) (3/9) (2/10) (1/9)
O verall >50%  H igh 85.7 72.7 50 57.1 0 .062
(18/21) (16/22) (11/22) (12/21)
>75%  H igh 19 27.3 18.2 19 0.908
(4/21) (6/22) (4/22) (4/21)
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Table 17b
Logistic Regression Analysis on For more than 50% Abnormality after Adjusting for Centre.
Systolic BP (mrnHg)
Analysis of Maximum Likelihood Estimates 
Logistic Regression Analysis on the Full Model.
Parameter Standard Wald Pr > Standardized OddsVariable DF Estimate Error Chi-Square Chi'-Square Estimate Ratio
INTERCPT 1 0.2231 0.6708 0.1107 0.7394ICENTRE 1 -0.9163 0.9083 1.0177 0.3131 -0.251585 0.400IA 1 0.4700 0.9747 0.2325 0.6297 0.111975 1.600IB 1 0.4700 0.9747 0.2325 0.6297 0.113725 1.600IC 1 1.1632 1.0368 1.2585 0.2619 0.281442 3.200INTA 1 1.8326 1.3874 1.7446 0.1866 0.352145 6.250INTB 1 1.4271 1.3260 1.1583 0.2818 0.283494 4.167INTC 1 0.2231 1.3509 0.0273 0.8688 0.042879 1.250
Logistic Regression Analysis on the Reduced Model adjusting for Centre.
Parameter Standard Wald Pr > S tandardi z ed OddsVariable DF Estimate Error Chi-Square Chi--Square Estimate Ratio
INTERCPT 1 -0.2260 0.5191 0.1896 0.6633ICENTRE 1 -0.1083 0.4819 0.0505 0.8222 -0.029729 0.897IA 1 1.4518 0.6762 4.6091 0.0318 0.345877 4.271IB 1 1.2715 0.6513 3.8114 0.0509 0.307651 3.566IC 1 1.2666 0.6511 3.7843 0.0517 0.306464 3.549
Conditional Odds Ratios and 95% Confidence IntervalsWaldConfidence LimitsOddsVariable Unit Ratio Lower Upper
ICENTRE 1.0000 0.897 0.349 2.308IA 1.0000 4.271 1.135 16.074IB 1.0000 3.566 0.995 12.781IC 1.0000 3.549 0.991 12.713
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Table 17c
Logistic Regression Analysis For more than 50% Abnormality after Adiuting for Centre.
Diastolic BP (mmHg)
Analysis of Maximum Likelihood Estimates
Logistic Regression Analysis on the Full Model.
Parameter Standard Wald Pr > Standardized OddsVariable DF Estimate Error Chi-Square Chi-Square Estimate Ratio
INTERCPT 1 0.6931 0.7071 0.9609 0.3270ICENTRE 1 -0.6931 0.9129 0.5765 0.4477 -0.190316 0.500IA 1 0.5596 1.0690 0.2740 0.6006 0.133324 1.750IB 1 -0.4700 0.9747 0.2325 0.6297 -0.113725 0.625IC 1 -1.0986 0.9574 1.3167 0.2512 -0.265826 0.333INTA 1 1.8383 1.6022 1.3164 0.2512 0.353240 6.286INTB 1 2.1748 1.3690 2.5234 0.1122 0.432011 8.800INTC 1 1.4351 1.2621 1.2929 0.2555 0.275763 4.200
Logistic Regression Analysis on the Reduced Model adjusting for Centre.
Parameter Standard Wald Pr > Standardized OddsVariable DF Estimate Error Chi-Square Chi-Square Estimate Ratio
INTERCPT 1 -0.0253 0.5194 0.0024 0.9611ICENTRE 1 0.5564 0.4829 1.3280 0.2492 0.152779 1.744IA 1 1.5264 0.7696 3.9337 0.0473 0.363643 4.601IB 1 0.6941 0.6565 1.1180 0.2903 0.167957 2.002IC 1 -0.2785 0.6192 0.2023 0.6529 -0.067393 0.757
Conditional Odds Ratios and 95% Confidence IntervalsWaldConfidence LimitsOddsVariable Unit Ratio Lower Upper
ICENTRE 1.0000 1.744 0.677 4.494IA 1.0000 4.601 1.018 20.795IB 1.0000 2.002 0.553 7.248IC 1.0000 0.757 0.225 2.548
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Table 18b
Logistic Regression Analysis For more than 75% Abnormality after Adjusting for Centre.
Systolic BP (mmHg)
Analysis of Maximum Likelihood Estimates 
Logistic Regression Analysis on the Full Model.
Parameter Standard Wald Pr > Standardized OddsVariable DF Estimate Error Chi-Square Chi-Square Estimate Ratio
INTERCPT 1 -2.0794 1.0607 3.8436 0.0499ICENTRE 1 -0.3185 1.4886 0.0458 0.8306 -0.087437 0.727IA 1 1.8563 1.2550 2.1878 0.1391 0.442248 6.400IB 1 1.8563 1.2550 2.1878 0.1391 0.449160 6.400IC 1 1.2321 1.2654 0.9482 0.3302 0.298136 3.429INTA 1 0.8781 1.7346 0.2563 0.6127 0.168728 2.406INTB 1 0.0716 1.7294 0.0017 0.9670 0.014222 1.074INTC 1 0.4726 1.7513 0.0728 0.7873 0.090815 1.604
Logistic Regression Analysis on the Reduced Model adjusting for Centre.
Parameter Standard Wald Pr > Standardized OddsVariable DF Estimate Error Chi-Square Chi-Square Estimate Ratio
INTERCPT 1 -2.3117 0.7979 8.3946 0.0038ICENTRE 1 0.1039 0.4892 0.0451 0.8318 0.028529 1.109IA 1 2.3477 0.8625 7.4094 0.0065 0.559328 10.462IB 1 1.8824 0.8608 4.7824 0.0288 0.455468 6.569IC 1 1.4924 0.8733 2.9202 0.0875 0.361116 4.448
Conditional Odds Ratios and 95% Confidence Intervals
WaldConfidence Limits
Variable Unit OddsRatio Lower Upper
ICENTRE 1.0000 1.109 0.425 2.894IA 1.0000 10.462 1.930 56.724IB 1.0000 6.569 1.216 35.496IC 1.0000 4.448 0.803 ' 24.635
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Table 18c
Logistic Regression Analysis For more than 75% Abnormality after Adjusting for Centre.
Diastolic BP (mmHg)
Analysis of Maximum Likelihood Estimates 
Logistic Regression Analysis on the Full Model.
Parameter Standard Wald Pr > Standardized OddsVariable DF Estimate Error Chi-Square Chi-Square Estimate Ratio
INTERCPT 1 -2.0794 1.0606 3.8437 0.0499ICENTRE 1 0.9808 1.2528 0.6130 0.4337 0.269305 2.667IA 1 0.8267 1.3296 0.3866 0.5341 0.196950 2.286IB 1 1.3863 1.2747 1.1827 0.2768 0.335435• 4.000IC 1 0.6931 1.3229 0.2745 0.6003 0.167718 2.000INTA 1 -1.3375 1.6770 0.6361 0.4251 -0.257012 0.263INTB 1 -1.4917 1.5820 0.8890 0.3457 -0.296315 0.225INTC 1 -1.2040 1.6717 0.5187 0.4714 -0.231353 0.300
Logistic Regression Analysis on the Reduced Model adjusting for Centre.
Parameter Standard Wald Pr > S tandardi z edVariable DF Estimate Error Chi-Square Chi-Square Estimate




Conditional Odds Ratios and 95% Confidence Intervals WaldConfidence LimitsOddsVariable Unit Ratio Lower Upper
ICENTRE 1.0000 0.917 0.320 2.626IA 1.0000 1.000 0.214 4.667IB 1.0000 1.597 0.379 6.726IC 1.0000 0.942 0.203 4.381
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Table 19a: Cumulative Survival estimates using Kaplan Meier Estimates for Time to an Abnormally High Result.: Heart Rate (beats/minute)
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Table 20a
Final Selected Mixed Models for
Heart Rate Data (b/m)
Original Data: Adjust for Time and Base
REML Estimation Iteration History 
Iteration Evaluations Objective Criterion
0 1 10569.422527
1 2 10321.156006 0.00000000
Convergence criteria met.
Covariance Parameter Estimates (REML)
Cov Parm Subject Estimate
CS PATIENT 15.93802351
Residual 67.20719991
Model Fitting Information for VALUE
Description Value
Observations 1992.000
Res Log Likelihood -6901.97
Akaike's Information Criterion -6903.97
Schwarz's Bayesian Criterion -6909.51
-2 Res Log Likelihood 13803.93
Null Model LRT Chi-Square 248.2665
Null Model LRT DF 1.0000
Null Model LRT P-Value 0.0000
Tests of Fixed Effects
Source NDF DDF Type III F Pr > FBASE 1 79 294.80 0.0001TIME 23 1816 46.92 0.0001
DRUG 3 79 1.32 0.2723
TIME*DRUG 69 1816 1.00 0.4866
CONTRAST Statement Results
Source NDF DDF F Pr > F
G 1 vs G2 1 79 0.02 0.8886G 1 vs G3 1 79 0.11 0.7430G 1 vs G4 1 79 2.03 0.1582G 2 vs G3 1 79 0.04 0.8501
G 2 vs G4 1 79 2.51 0.1170
G 3 vs G4 1 79 3.22 0.0767
57
Method 1: Adjust for Time, Base 
REML Estimation Iteration History 
Iteration Evaluations Objective Criterion
0 1 3201.8344723
1 2 2946.1671936 0.00000046
2 1 2946.1665083 0.00000000
Convergence criteria met.
Model Fitting Information for VALUE 
Description Value
Observations 656.0000
Res Log Likelihood -2045 .58
Akaike's Information Criterion -2081 .58
Schwarz's Bayesian Criterion -2161 .40
-2 Res Log Likelihood 4091. 164
Null Model LRT Chi-Square 255.6680
Null Model LRT DF 35.0000
Null Model LRT P-Value 0.0000
Tests of :Fixed Effects
Source NDF DDF Type III F Pr > F
BASE 1 77 274.34 0.0001TIME 7 77 50.33 0.0001
DRUG 3 77 1.14 0.3379
TIME*DRUG 21 77 1.37 0.1588
CONTRAST Statement Results
Source NDF DDF F Pr > F
G 1 vs G2 1 77 0.02 0.8936
G 1 vs G3 1 77 0.08 0.7801G 1 vs G4 1 77 1.80 0.1840G 2 vs G3 1 77 0.02 0.8816G 2 vs G4 1 77 2.23 0.1396G 3 vs G4 1 77 2.65 0.1078
58
Method 2: Adjust for Time, and Base 
REML Estimation Iteration History 
Iteration Evaluations Objective Criterion
0 1 4961.8472792
1 2 4505.8940051 0.00000023
2 1 4505.8934880 0.00000000
Convergence criteria met.
Model Fitting Information for VALUE 
Description Value
Observations 984.0000
Res Log Likelihood -3112.15
Akaike's Information Criterion -3190.15
Schwarz's Bayesian Criterion -3378.94
-2 Res Log Likelihood 6224.309
Null Model LRT Chi-Square 455.9538
Null Model LRT DF 77.0000
Null Model LRT P-Value 0.0000
Tests of Fixed Effects
Source NDF DDF Type III F Pr1 > F
BASE 1 77 304.35 0.0001
TIME 11 77 34.95 0.0001
DRUG 3 77 1.15 0.3332
TIME*DRUG 33 77 1.10 0.3592
CONTRAST Statement Results
Source NDF DDF F Pr > F
G 1 vs G2 1 77 0.02 0.8932
G 1 vs G3 1 77 0.07 0.7858
G 1 vs G4 1 77 1.83 0.1804
G 2 vs G3 1 77 0.02 0.8879
G 2 vs G4 1 77 2.26 0.1365
G 3 vs G4 1 77 2.66 0.1071
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Table 20b
Final Selected Mixed Models for
Systolic BP (mmHg)
Original Data: Adjust for Time and Base 
REML Estimation Iteration History 
Iteration Evaluations Objective Criterion
0 1 11594.616898
1 2 11143.166845 0.00000000
Convergence criteria met.
Covariance Parameter Estimates (REML)
Cov Parm Subject Estimate
CS PATIENT 40.87530639
Residual 101.69061144
Model Fitting Information for VALUE
Description Value
Observations 1992.000
Res Log Likelihood -7312.97
Akaike's Information Criterion -7314.97
Schwarz' s Bayesian Criterion -7320.52
-2 Res Log Likelihood 14625.94
Null Model LRT Chi-Square 451.4501
Null Model LRT DF 1.0000
Null Model LRT P-Value 0.0000
Tests of Fixed Effects
Source NDF DDF Type III F Pr > F
BASE 1 79 192.45 0.0001
TIME 23 1816 66.42 0.0001
DRUG 3 79 9.41 0.0001
TIME*DRUG 69 1816 0.88 0.7475
CONTRAST Statement Results
Source NDF DDF F Pr > F
G 1 vs G2 1 79 0.02 0.9015G 1 vs G3 1 79 2.82 0.0968
G 1 vs G4 1 79 20.13 0.0001
G 2 vs G3 1 79 3.32 0.0724G 2 vs G4 1 79 21.89 0.0001
G 3 vs G4 1 79 8.34 0.0050
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Method 1: Adjust for Time, Base
REML Estimation Iteration History
Iteration Evaluations Objective Criterion
0 1 3578.9605278
1 2 3233.5174799 0.00000000
Convergence criteria met.
Model Fitting Information for VALUE
Description Value
Observations 656.0000
Res Log Likelihood -2189.26
Akaike's Information Criterion -2225.26
Schwarz's Bayesian Criterion -2305.08
-2 Res Log Likelihood 4378.515
Null Model LRT Chi-Square 345.4430
Null Model LRT DF 35.0000
Null Model LRT P-Value 0.0000
Tests of Fixed Effects
Source NDF DDF Type III F Pr > F
BASE 1 77 209.57 0.0001
TIME 7 77 49.29 0.0001
DRUG 3 77 9.18 0.0001
TIME*DRUG 21 77 0.99 0.4894
CONTRAST Statement Results
Source NDF DDF F Pr > F
G 1 vs G2 1 77 0.02 0.8889
G 1 vs G3 1 77 2.36 0.1288
G 1 vs G4 1 77 19.58 0.0001
G 2 vs G3 1 77 2.85 0.0956
G 2 vs G4 1 77 21.44 0.0001
G 3 vs G4 1 77 8.23 0.0053
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Method. 2: Adjust for Time, and Base
REML Estimation Iteration History 
Iteration Evaluations Objective Criterion
0 1 5488.0354094
1 2 4934.9030469 0.00000000
Convergence criteria met.
Model Fitting Information for VALUE
Description Value
Observations 984.0000
Res Log Likelihood -3326.66
Akaike's Information Criterion -3404.66
Schwarz's Bayesian Criterion -3593.44
-2 Res Log Likelihood 6653.318
Null Model LRT Chi-Square 553.1324
Null Model LRT DF 77.0000
Null Model LRT P-Value 0.0000
Tests of Fixed Effects
Source NDF DDF Type III F Pr > F
BASE 1 77 211.49 0.0001
TIME 11 77 33 .08 0.0001
DRUG 3 77 9.21 0.0001
TIME*DRUG 33 77 1.13 0.3199
CONTRAST Statement Results
Source NDF DDF F Pr > F
G 1 vs G2 1 77 0.01 0.9031
G 1 vs G3 1 77 2.34 0.1301
G 1 vs G4 1 77 19.75 0.0001
G 2 vs G3 1 77 2 .77 0.1001
G 2 vs G4 1 77 21.45 0.0001G 3 vs G4 1 77 8.37 0.0050
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Table 20c
Final Selected Mixed Models for
Diastolic BP (mmHg)
Original Data: Adjust for Time and Base 
REML Estimation Iteration History 
Iteration Evaluations Objective Criterion
0 1 10621.690802
1 2 10303.057354 0.00000000
Convergence criteria met.
Covariance Parameter Estimates (REML)
Cov Parm Subject Estimate
CS PATIENT 19.20695240
Residual 66.10349926
Model Fitting Information for VALUE
Description Value
Observations 1992.000
Res Log Likelihood -6892.92
Akaike's Information Criterion -6894.92
Schwarz's Bayesian Criterion -6900.46
-2 Res Log Likelihood 13785.83
Null Model LRT Chi-Square 318.6334
Null Model LRT DF 1.0000
Null Model LRT P-Value 0.0000
Tests of Fixed Effects
Source NDF DDF Type III F Pr > F
BASE 1 79 121.51 0.0001
TIME 23 1816 72 .16 0.0001
DRUG 3 79 7.13 0.0003
TIME*DRUG 69 1816 1.16 0.1748
CONTRAST Statement Results
Source NDF DDF F Pr > F
G 1 vs G2 1 79 1.17 0.2831
G 1 vs G3 1 79 4.14 0.0452
G 1 vs G4 1 79 9.05 0.0035
G 2 vs G3 1 79 10.03 0.0022
G 2 vs G4 1 79 17.22 0.0001
G 3 vs G4 1 79 1.05 0.3096
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Method 1; Adjust for Time, Base
REML Estimation Iteration History
Iteration Evaluations Objective Criterion
0 1 3186.3017083
1 2 2929.7106451 0.00000005
2 1 2929.7105753 0.00000000
Convergence criteria met.
Model Fitting Information for VALUE
Description Value
Observations 656.0000
Res Log Likelihood -2037.35
Akaike's Information Criterion -2073.35
Schwarz's Bayesian Criterion -2153.18
-2 Res Log Likelihood 4074.708
Null Model LRT Chi-Square 256.5911
Null Model LRT DF 35.0000
Null Model LRT P-Value 0.0000
Tests of Fixed. Effects
Source NDF DDF Type III F Pr > F
BASE 1 77 141.32 0.0001
TIME 7 77 78. 64 0.0001
DRUG 3 77 6.98 0.0003
TIME*DRUG 21 77 1.16 0.3122
CONTRAST Statement Results
Source NDF DDF F Pr > F
G 1 vs G2 1 77 1.31 0.2562
G 1 vs G3 1 77 3.82 0.0543
G 1 vs G4 1 77 8.59 0.0044
G 2 vs G3 1 77 9.75 0.0025
G 2 vs G4 1 77 17 .08 0.0001
G 3 vs G4 1 77 0.92 0.3417
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Method 2: Adjust for Time, and Base 














0 . 0 0 0 0 0 0 0 1
0 . 0 0 0 0 0 0 0 0
Convergence criteria met.
Model Fitting Information for VALUE
Description Value
Observations 984.0000
Res Log Likelihood -3140.57
Akaike's Information Criterion -3218.57
Schwarz's Bayesian Criterion -3407.35
-2 Res Log Likelihood 6281.136
Null Model LRT Chi-Square 3 84.4668
Null Model LRT DF 77.0000
Null Model LRT P-Value 0.0000
Tests of Fixed Effects
Source NDF DDF Type III F Pr > F
BASE 1 77 140.26 0.0001
TIME 11 77 53 .58 0.0001
DRUG 3 77 6.99 0.0003
TIME*DRUG 33 77 1.38 0.1249
CONTRAST Statement Results
Source NDF DDF F Pr > F
G 1 vs G2 1 77 1.26 0.2646
G 1 vs G3 1 77 3.87 0.0529
G 1 vs G4 1 77 8.71 0.0042
G 2 vs G3 1 77 9.71 0.0026
G 2 vs G4 1 77 17 .08 0.0001
G 3 vs G4 1 77 0.93 0.3378
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Table 20d
Final Selected Mixed Models for
Dietary Response Data
Original Data Adjust for Time and Base
REML Estimation Iteration History 
Iteration Evaluations Objective Criterion
0 1 -605.7076663
1 2 -632.7527163 0.00000006
2 1 -632.7527339 0.00000000
Convergence criteria met.
Covariance Parameter Estimates (REML)
Cov Parm Subject Estimate
CS SUBJECT 0.00269038
Residual 0.00728640
Model Fitting Information for RESPONSE 
Description Value
Observations 211.0000
Res Log Likelihood 148.2106
Akaike's Information Criterion 146.2106
Schwarz's Bayesian Criterion 143.0011
-2 Res Log Likelihood -296.421
Null Model LRT Chi-Square 27.0451
Null Model LRT DF 1.0000
Null Model LRT P-Value 0.0000
Tests of Fixed. Effects
Source NDF DDF Type III F Pr > F
BASE 1 20 2.62 0.1214TIME 8 163 7.00 0.0001GROUP 2 20 63.92 0.0001
TIME*GROUP 16 163 7.94 0.0001
CONTRAST Statement Results
Source NDF DDF F Pr > F
G 1 vs G2 1 20 29.52 0.0001
G 1 vs G3 1 20 127. 68 0.0001
G 2 vs G3 1 20 36.28 0.0001
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Method 1: Adjust for Base and Time 
REML Estimation Iteration History 
Iteration Evaluations Objective Criterion
0 1 -224.4049275
1 2 -250.8973360 0.00000039
2 1 -250.8973855 0.00000000
Convergence criteria met.
Model Fitting Information for VALUE
Description Value
Observations 66.0000
Res Log Likelihood 73.9881
Akaike's Information Criterion 67.9881
Schwarz's Bayesian Criterion 61.9121
-2 Res Log Likelihood -147.976
Null Model LRT Chi-Square 26.4925
Null Model LRT DF 5.0000
Null Model LRT P-Value 0.0001
Tests iof Fixed Effects
Source NDF DDF Type III F Pr > F
TIME 2 18 2.61 0.1010
BASE 1 18 4.18 0.0559
GROUP 2 18 58.78 0.0001
TIME*GROUP 4 18 41.39 0.0001CONTRAST Statement Results
Source NDF DDF F Pr > F
G 1 vs G2 1 18 29. 81 0.0001
G 1 vs G3 1 18 117. 49 0.0001




/ * • * • • * * * * • • * * • * * * • • • • * * • * * * • » * * • * • • • • * * • * * * * * * * • • * * * * * • « * • • • • • * * * • * * * * * * * • * * * * * • • * * * * • • * * * * *
Program Name: ORXGDATA.SAS Date: Jan-15-96Programmer: Sharayu Shanbhag
Description: Selects out reguired data for original ambulatory and diet data sets, input: ABP.ABPMDIF (For Data set A)DIET.DIET (for Data set B) output: ABP.OUNI_l (contains CENTRE (1-2), TIME (0-24),PATIENT, MEASURE (SBP,HR,DBP),VALUE, DRUG (1-4),BASE).ABP.OMULT_l (contains CENTRE, PATIENT, MEASURE, DRUG, BASE, _1 to _24) .DIET.OUNI_l (contains TIME (0-9),SUBJECT, RESPONSE, GROUP (1-3),BASE).DIET.OMULT_l (contains SUBJECT, RESPONSE, GROUP, BASE, _1 to _9). *«**•••**•***•*•••*•****•***•**•••*«••***•***•********•***••**•*. ****!**********************/




** DATA SET IN UNIVARIATE FORM **;
** CONTAINED SOME MISSING RECORDS *; 
** Set Base for data set B and **;




%if &1=1 %then %do; 
data base;












%if &1=2 %then %do; 
data base(keep=subject base); 
set origuni; 
base=&v;
if time=0 then output;
run;
proc sort data=base nodupkey; 
by subject;
r\in;









proc sort data=origuni; 
by &sort &t;
run;
proc transpose data=orig\ini out=origmult(keep=&sort &multt &b) ; 




proc sort data=origmult; 
by &sort;
run;















** DATA SET-IN UNIVARIATE FORM **; 







%data(l,abpmdif,abp,centre time patient measure drug value base,measure centre drug base 
patient,time,value,_0,_l-_24.
Vital Signs,centre time patient measure drug value base);




PROGRAM: MXSSDATA.SAS PROGRAMMER: SHARAYU SHANBHAG DATE: 10-FEB-96Description: Lists the time points when missing data records occur *****************************************************.***********************************„/
libname abp '/home/sshanbha/Project/abp/SSDfiles'; 
libname diet '/home/sshanbha/Project/diet/SSDfiles'; 
options pageno=l ps=55 ls=65 nodate;









if _1=- or _2=. or _3=. or _4=. or _5=. or _6=. or _7=. or _8=. or _9=. or _10=. 
or _11=. or _12=. or _13=. or _14=. or _15=. or _16=. or _17=. or _18=. or _19=. 






proc print data=&d; 
id drug centre; 
by drug centre; 
var patient base fcvars; 
titlel “Listing 2a"; 


































var group subject base &vars;
titlel “Listing 2a";















Programmer: Sharayu Shanbhag Name: MISSGENA.SAS Date: 01 June 1996Description: Generated missing data if possible.Uses Permanent data set OMULT to create NOMISSM and NOMOLTU For Ambulatory Data Set.The method used to generate a data set with no missing data was as follows:(a) If a patient had greater than or equal to 20%,(b) If the last observation was missing (Early Termination),(c) If there was more than one missing record at the start.All the synario above were deleted from the data set.The program MISSDATA.SAS generates a listing of patients with missing data.This data was generated as follows:(1) For 1st visit missing: 2nd visit bought back.(2) If any one value was missing then the mean of the 2 surrounding values was used.(3) If two values were missing then the adjacent value on the left was carried forward and the adjacent value on the right was carried backwards.(4) If an even number of missing data >2 then divide number of missing values by 2 and carry that number back from the right and the same number forward from the left.(5) If an odd number of missing data >1 then remove 1 from the number of missing data and divide the remaining number by two. Then carry that number back from the right and the same number forward from the left There should be one missing value and it can be generated as in (1).
This was an adhoc method which was decided by Sharayu Shanbhag.Better methods can be found in the literature but since there were small numbers of missing data this method was used to save time.
libname abp '/home/sshanbha/Project/abp/SSDfiles'; 
libname diet '/home/sshanbha/Project/diet/SSDfiles'; 
options ps=55 ls=65 nodate pageno=l;
data nomissm(keep=drug centre base measure patient _0-_24 per); 
set abp.omult_l;
if _1 gt . then vl=l
if _2 gt . then v2=l
if _3 gt . then v3=l
if _4 gt . then v4=l
if _5 gt . then v5=l
if _6 gt . then v6=l
if _7 gt . then v7=l
if _8 gt . then v8=l
if _9 gt . then v9=l
if _10 gt . then vl0==1
if _ H gt . then vll==1if _12 gt . then vl2==1
if _13 gt . then vl3==1
if _14 gt . then vl4==1
if _15 gt . then vl5==1
if _16 gt . then vl6==1
if _17 gt . then vl7 =1
if _18 gt . then vl8==1
if _19 gt . then vl9==1
if _20 gt . then v20==1
if _21 gt . then v21==1
if _22 gt . then v22==1
if _23 gt . then v23 ==1
if _24 gt . then v24==1
sum=sum (vl, v2, v3, v4, v5, v6, v7, v8, v9, vl 0, vll, vl2, vl3, vl4, vl5, 
vl6,vl7,vl8,vl9,v20,v21,v22,v23,v24); 
per=100-((sum/24)*100);
** ONLY KEEP RECORDS WITH LESS THAN 20% MISSING DATA*; 
** EARLY TERMINATION (Shouldn't Analyse)***;
if per>=20 then delete; 
if _24=. then delete; 
if _1=. then do;
if _2 ne . then _1=_2; 
else if _2=. then delete; 
end;
RECORDS DON'T BEGIN UNTIL AFTER VISIT 2 
Shouldn't Analyse **;
if _3=. and _2 ne . and _4 ne . then _3=mean(_2,_4);
if _13=. and _12 ne . and _14 ne . then _13=mean(_12,_14)
if _14=. and _13 ne . and _15 ne . then _14=mean(_13,_15)
if _23=. and _22 ne . and _24 ne . then _23=mean(_22,_24)
if _17 ne . and _18=. then do; 
if _19=. then do;




if _20=. and _21 ne . then do;
_18=_17;
_ 2 0 = _ 2 1 ;
_19=mean(_18,_20); 
end;

















if per > 0 then output;
run;
proc sort data=ERRORl;
by measure drug centre;
run;
*** Lists Regenerated Data **;
%macro measure(m,title);
%macro sprint(vars,d); 
proc print data=&d; 
id drug centre; 
by drug centre; 
var patient base &vars; 
titlel "Listing 2b"; 











%measure(DBP,Diastolic Blood Pressure); 
proc sort data=nomissm(drop=per);
by measure drug centre patient base;
run;
proc transpose data=nomissm(keep=drug measure centre base patient _0-_24) out=datas; 
by measure drug centre patient base; 
var _0-_24;
run;
data nomissu(keep=drug measure centre base patient time value);
set datas; *** IN UNIVARIATE FORM ***;
time= (substr (_NAME_, 2,2))*1; 
value=COLl;
run;







data nomissm(keep=group base subject _0-_9 per); 
set diet.omult_l; 
if _1 gt . then vl=l;
if _2 gt . then v2=l;
if _3 gt . then v3=l;
if _4 gt . then v4=l;
if _5 gt . then v5=l;
if _6 gt . then v6=l;
if _7 gt . then v7=l;
if _8 gt . then v8=l;
if _9 gt . then v9=l;
sum=sum(vl,v2,v3,v4,v5,v6,v7,v8,v9); 
per=100-((sum/9)*100);
if per>=20 then delete; ** ONLY KEEP RECORDS WITH LESS THAN 20% MISSING DATA*; 
if _9=. then delete; ** EARLY TERMINATION (Shouldn't Analyse)***;
if _1=. then do;
if _2 ne . then _1=_2;
else if _2=. then delete; ** RECORDS DON'T BEGIN UNTIL AFTER VISIT 2 **; 
end; ** Shouldn't Analyse **;
if _6=. and _5 ne . and _7 ne . then _6=mean( 5, 7);








b y  g ro u p ;
run;
%macro sprint(vars,d); 
proc print data=&d; 
by group; 
id group;
var subject base fcvars;
titlel "Listing 2b";





proc sort data=nomissm(drop=per); 
by group subject base;
run;
proc transpose data=nomissm(keep=group subject base  0 — 9) out=datas;
by group subject base; 
var _0-_9;
run;
data nomissu(keep=group base subject time response);













Program: REDUCSUM.SAS Programmer: Sharayu Shanbhag Bate: Dec 1995Bescription: Provides the reduced data sets of summary statistics.INPUT BATA SETS: OUNX and NOMISSU.Produces a data set of summary statistics by drug individual (required for PCA).SUMP1«= summaries for original data.SUMP2=summaries for non missing data.Produces a data set of summary statistics by drug time (required for PLOTS).SUMTl=summaries for original data.SUMT2=summaries for non missing data. ******************************************************************************************,
libname abp '/home/sshanbha/Project/abp/SSDfiles'; 
libname diet '/home/sshanbha/Project/diet/SSDfiles'; 
options pageno=l;
%macro both (id,id2,perm, sort,v,sort2,sub,vars);
** IN THE MACRO BELOW THE DATA SETS ARE SUMPAT1 SUMPAT2 SUMTIME1 SUMTIME2 ** 
** FOR ORIGINAL DATA (1) AND DATA AFTER MISSINGS GENERATED (2) **;
%macro suml(data,a,l,g);
*********** TESTING FOR NORMALITY AT EACH TIME POINT BY TREATMENT * * * * * * * * * * * * * * * * * * * * * *  
* * * *  TEST STATISTIC FOR NORMALITY. IF THE SAMPLE SIZE IS LESS THAN OR EQUAL TO 2000 IS * 
**** SHAPIRO-WILK STATISTICOTHERWISE IS KOLMOGROV STATISTIC *
**** creates SUMM for summaries per patient * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
proc sort data=&perm. .&data out=data; 
by &sort;
where &g ne 0; * * * On Treatment Readings Only * *;
run;
proc univariate data=data normal noprint; 
by &sort; 
var &v;
output n=n nmiss=miss normal=norm probn=probn min=min max=max 
mean=mean std=std median=median sum=sum 
ql=ql q3=q3 
out=SUMM
(keep=&sort median mean miss std ql q3 min max miss probn n) ;
run;
*********** Data SUMPAT used to carry out PCA and Discriminant Analysis * * * * * * * * * * * * * * *  
* * *  contains summaries and drug for variables by patient ***************
data Sperm..sump&l._&a; 
set summ;
change=mean-base; *** Change in mean from baseline **;
run;
proc sort data=&perm..sump&l._&a out=data(keep=&sub Svars median mean base change min max ql q3); 
by &sub Svars;
run;
proc transpose data=data out=tpose(keep=&sub Svars _NAME_ COL1); 
by Ssub Svars;
run;








proc univariate data=data normal noprint; 
by Svars variable; 
var value;
output n=n probn=probn min=min max=max




data Sperm..msum&l._&a; *** Sum Stats of Sum Stats **;
set smmean;
run;
For missing data: All data summaries above will be missing if there is no data for a 
patient.
In all other cases all patients have calculations for the summaries that miss out the 
missing time data. The variable nmiss tells us how many missing observations there are 
per patient.
proc sort data=&perm..&data out=data; 
by &sort2;
run;
proc univariate data=data normal noprint;
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var &v;
output n=n nmiss=miss normal=norm probn=probn 
mean=mean std=std median=median sum=sum 
ql=ql q3=q3 min=min max=max 
out=STATS
(keep=&sort2 median mean miss std ql q3 min max miss probn n);
run;
*********** Data SUMTIME used to produce PLOTS. ****** 
*** Contains summaries and drug for variables by time




%if &id=l %then %do;
%suml(ouni_l,l,o,time);
%suml (o\oni_2,2, o, time) ;
%end;
%if &id=2 %then %do;








%both(l, ,abp,measure drug centre base patient,value,measure drug time,patient centre, measure 
drug);
%both(l, ,diet,group base subject,response,group time,subject,group);
%both(2,1,abp,measure drug centre base patient,value.measure drug time,patient centre, measure 
drug);
%both(2,2,diet,group base subject,value,group time,subject,group);
Program: SUMCENT.SAS Programmer: sharayu Shanbhag Date:Description: Same as REDUCSUM. SAS but by centre for data set A only. 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . * * * * * * * * * * * * * * /
libname perm '/home/sshanbha/Project/abp/SSDfiles'; 
libname abp '/home/sshanbha/Project/abp/SSDcentre' ; 
options pageno=l;
%macro both(id,id2,perm,sort,v,sort2,sub,vars);
** IN THE MACRO BELOW THE DATA SETS ARE SUMPAT1 SUMPAT2 SUMTIME1 SUMTIME2 ** 
** FOR ORIGINAL DATA (1) AND DATA AFTER MISSINGS GENERATED (2) **;
%macro suml(data,a,l,g);
*********** TESTING FOR NORMALITY AT EACH TIME POINT BY TREATMENT * * * * * * * * * * * * * * * * * * * * * *  
**** TEST STATISTIC FOR NORMALITY. IF THE SAMPLE SIZE IS LESS THAN OR EQUAL TO 2000 IS * 
**** SHAPIRO-WILK STATISTICOTHERWISE IS KOLMOGROV STATISTIC *
**** creates SUMM for summaries per patient * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
proc sort data=perm.Adata out=data; 
by Asort;
where Ag ne 0; *** On Treatment Readings Only **;
run;
proc univariate data=data normal noprint; 
by Asort; 
var &v;
output n=n nmiss=miss normal=norm probn=probn min=min max=max 
mean=mean std=std median=median sum=sum 
ql=ql q3=q3 
OUt=SUMM
(keep=Asort median mean miss std ql q3 min max miss probn n);
run;
*********** Data SUMPAT used to carry out PCA and Discriminant Analysis 
*** Contains summaries and drug for variables by patient
data Aperm. .sumpAl ._Aa; 
set summ;
change=mean-base; *** Change in mean from baseline **;
run;
proc sort data=Aperm..sumpAl._Aa out=data(keep=Asub Avars median mean base change min max ql q3) 
by A sub Avars;
run;
proc transpose data=data out=tpose(keep=Asub Avars _NAME_ COLl); 
by Asub Avars;
run;








proc univariate data=data normal noprint; 
by Avars variable; 
var value;
output n=n probn=probn min=min max=max




data Aperm. .msumAl._Aa; *** Sim Stats of Sum Stats **;
set smmean;
run;
For missing data: All data summaries above will be missing if there is no data for a 
patient.
In all other cases all patients have calculations for the summaries that miss out the 
missing time data. The variable nmiss tells us how many missing observations there are 
per patient.
proc sort data=perm.Adata out=data; 
by Asort2;
run;
proc univariate data=data normal noprint; 
by Asort2; 
var Av;
output n=n nmiss=miss normal=norm probn=probn 
mean=mean std=std median=median sum=sum 
ql=ql q3=q3 min=min max=max
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OUt=STATS
(keep=&sort2 median mean miss std ql q3 min max miss probn n) ;
run;
* * * * * * * * * * *  Data SUMTIME used to produce PLOTS. ***** 





%if Sid=l %then %do;
%suml (ouni_l, 1, o, time) ;
%suml(ouni_2,2,o, time);
%end;
%if Sid=2 %then %do;








%both(l, ,abp,measure drug centre base patient,value,measure drug centre time,patient, measure 
centre drug);




Program: REDUCGRP.SAS Programmer: Sharayu Shanbhag Date: Jan 1996 Description:This program looks into reducing the data set o£ non-missing data to get a data set containing less than 20 observations (minimum number o£ patients in a group).An ad-hoc data reduction method which was proposed by me was to get means of groups o£ data over the study to use as summaries to then analyse.Since there are 24 times of data, it is suggested that data could be grouped into 2's or 3'sand these groups could be averaged. The average would then be used as the data to beanalysed.Grouping into 2's would yield 12 group (Av2) observations instead o£ 24 time points. (MGRP2,UGRP2)Grouping into 3's would yield 8 group (Av3) observations instead o£ 24 time points. (MGRP3,DGRP3)Summary Statistics were found by measure drug group (Av2) = SUMGRP2Summary Statistics were found by measure drug group (Av3) = SUMGRP3Note: This method could also be applied to data sets with single missing data pointssince the average would be calculated of the remaining data (excluding the missing data).
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * • * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ,
libname abp '/home/sshanbha/Project/abp/SSDfiles'; 
libname diet '/home/sshanbha/Project/diet/SSDfiles' ; 
options pageno=l;
****** THE FOLLOWING MACRO CREATES MGRP,UGRP & SUMGRP FOR NON MISSING DATA
%macro group(data,v,v2);
data abp.MGRP2_&v(keep=measure drug centre patient base GRP1-GRP12); 
set abp.&data; ** IN MULTIVARIATE FORM ***;















proc sort data=abp.mgrp2_&v out=mgrp;
by measure drug centre patient base;
run;
proc transpose data=mgrp(keep=measure drug centre patient base GRP1-GRP12) 
out=grp(rename=(COLl=value));
by measure drug centre patient base; 
var GRP1-GRP12;
run;
data abp.UGRP2_&v(keep=measure patient centre drug base time t value av2); *** SAME AS GRPMEAN ***; 
set grp; *** in UNIVARIATE FORM





*********** Data SUMGRPT (2) used to produce plots***********************; 
*********** Data SUMGRPP (2) used to produce SUMMARY LISTING ALSO TESTED *;
*** Contains summaries and drug for variables by grouped (Av2)times ***********;
data abp.MGRP3_&v(keep=measure drug centre patient base GRP1-GRP8); 
set abp.&data; ** IN MULTIVARIATE FORM ***;











data diet.MGRP3_&v(keep=group subject base GRP1-GRP3);
set diet.&data; ** IN MULTIVARIATE FORM ***;








proc sort data=&perm..mgrp3_&v out=mgrp; 
by &vals base;
run;
proc transpose data=mgrp(keep=&vals base GRPl-&uval) out=grp(rename=(C0L1=value)); 
by &vals base; 
var GRPl-&uval;
run;
data Sperm. .UGRP3_&v(keep=&vals base t value time av3); *** SAME AS GRPMEAN ***;






%grp3(abp,GRP8,measure drug centre patient,measure drug);
%grp3(diet,GRP3,group subject,group);
%mend group;
%group (omult_l, 1) ;
% group (omult_2,2) ;
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/
PROGRAM: REDUCPCA. SAS PROGRAMMER: SHARAYU SHAMBHAG DATE: 10-AUG-96Description:A PCA was conducted to reduce the components in TPOSED from 24 to something lower. Here the option COV was used since all data was in the same units, option NOXNT stopped the data from removing the mean.
libname abp '/home/sshanbha/Project/abp/SSDfiles'; 
libname diet '/home/sshanbha/Project/diet/SSDfiles'; 
options pageno=l ps=63 ls=78 nodate;
***.**********1NPUTTING THE ORIGINAL DATA : DATA *************************;
* * * * * * * *  CONDUCTING PCA ON DATA SETS * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
%macro anal(pea,pca2,data,v,title,n,n2); 
proc sort data=abp.&data out=new; 
by measure &pca;
run;
proc princomp data=new cov noint noprint out=pca outstat=corr; 
by measure &pca; 
var _l-_24;























var test &vars; 
titlel "APPENDIX &app”; 
title2 "Listing &a.&n";























*%sprint2(8,_l-_6,STD); **** ONLY COMPUTE FOR THE OPTION TYPE=CORR **;















proc sort data=corr; 
by &pca;
run;
proc print data=pca; 
var patient fcvars; 
by &pca; 
id &pca;
titlel "APPENDIX &app"; 
title2 "Listing &n2";






















proc sort data=diet.&data out=new; 
by &pca2;
run;
proc princomp data=new cov noint noprint out=pca outstat=corr; 
by &pca2; 
var _l-_9;





















var test &vars; 
titlel "APPENDIX D"; 
title2 "Listing &a.&n";














*%sprint2(8,_l-_4,STD); **** ONLY COMPUTE FOR THE OPTION TYPE=CORR **;
*%sprint2(8,_4-_9,STD); **** NA **;
%sprint2(8,_1-_4,UC0V,Unstructured Covariance Matrix);
82
%sprint2(8,_5-_9,UCOV,Unstructured Covariance Matrix); 
* /
%MACRO SPRINT(vars);
proc sort data=diet.pca_&v out=pca;
by &pca2; 
run;
proc print data=pca; 
var subject &vars; 
by &pca2; 
id &pca2;
titlel "APPENDIX D"; 
title2 "Listing &n2";















/ * • * * * • * * * * • * * * * • * * • * • » * • » * • * • * • * • * • • * * * * * • * • * * * • • • * * • * * * • * • * * • * * • » * • * • • * * • • * * * * * * * • • * * * * * •
PROGRAM: ANALDATA.SAS PROGRAMMER: SHARAYU SHANBHAG DATE: 10-AUG-97Creates permanent data set MANAL_1 and MANAL_2 for each data set 1 and 2.These are the final multivariate data sets used for analysis purposes. 
* * * • • * * • • * • * * • • * * * • * • • » * • * * • * • * * • • * • • * * * • • * • * • • * • * * * « * • * * * • • • * * * * * * * * * » • » * . * * • * » * * » • • * * * * * /




options pageno=l ps=55 ls=80;
%macro type(i,title2);
%macro data(id,perm,vars,times,time2,time3); 
data orig(keep=&vars &times); 
set &perm..omult_&i;
run;




set &perm..sumpo_&i(keep=&vars base mean median min max ql q3 change);
run;






















proc sort data=grp3; 
by &vars;
run;
data sum3(keep=&vars mean3 med3 min3 max3 ql_3 q3_3 change3);
























%if &id=l %then %do;
data grp2(keep=&vars &time3); 
set &perm..mgrp2_&i;
run;
proc sort data=grp2; 
by &vars;
run;
data sum2(keep=&vars mean2 med2 min2 max2 ql_2 q3_2 change2);




































PROGRAM: CATDATA.SAS PROGRAMMER: SHARAYU SHANBHAG DATE: 10-ADG-97ONLY CONDUCTED ON VITAL SIGNS DATACATEGORISES THE NUMBER OF OCCURRENCES OF NORMAL, ABNORMAL (HIGH AND LOW) READINGS The input data sets is: DB.OUNI and NOMISSUThe output data sets were : DB.CAT1 and CAT2 and DB.ABN1 and ABN2.Creates multivariate data sets for categorical data analysis
libname abp '/home/sshanbha/Project/abp/SSDfiles';
%include '/home/sshanbha/Project/macros/formats.sas';
%include '/home/sshanbha/Project/macros/anal.sas' ; 
options pageno=l ps=55 ls=80;
****************** INPUTTING THE DATA **********************»*************; 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * .
title ' ';
%macro data(data,outcat,outabn,outbase,v);





proc sort data=base nodupkey;
by measure patient centre drug; 
run;




if value > 0 then do; ** CATEGORY:missing, 1-7 for each variable category **;
if measure='HR' then do; ** ABNORMAL:missing -1, 0 or 1 **;
if value < 60 then do; 
abnormal=-l;
if value >=40 then category=l; 
end;
else if value < 100 then do; 
abnormal=0;
if value < 80 then category=2; 
else category=3; 
end;
else if value >= 100 then do; 
abnormal=l;
if value < 120 then category=4; 
else if value < 140 then category=5; 





else if measure='SBP' then do; 
if value < 100 then do; 
abnormal=-l;
if value >= 80 then category=l; 
end;
else if value <140 then do; 
abnormal=0;
if value < 130 then category=2; 
else category=3; 
end;
else if value >= 140 then do; 
abnormal=l;
if value < 160 then category=4; 
else if value < 180 then category=5; 





else if measure='DBP' then do; 
if value < 60 then do; 
abnormal=-l;
if value >= 40 then category=l; 
end;
else if value < 90 then do; 
abnormal=0;
if value < 85 then category=2; 
else category=3; 
end;
else if value >= 90 then do; 
abnormal=1;
if value It 100 then category=4; 
else if value It 110 then category=5;
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outbase; ** low,normal and high ,**;
set cat; ** values missing,0 or 1 **;
if abnormal=. then low=.;
else if abnormal=-l then low=l;
else low=0;
if abnormal=. then high=.; 
else if abnormal=l then high=l; 
else high=0;
if abnormal=. then normal=.; 
else if abnormal=0 then normal=l; 
else normal=0;
format category BP. abnormal abn. low high normal yesn.; 
if time=0 then output outbase; 
output outcat;
run;
proc sort data=outcat out=sort;
by measure drug centre patient; 
where time ne 0;
run;
proc univariate data=sort(drop=time) noprint; 
by measure drug centre patient; 
var low normal high;





if measure in ('SBP','DBP') then do; 
if 0 <= nh <= 12 then freq=l; 
else if 12 < nh <= 18 then freq=2; 
else if 18 < nh <= 24 then freq=3; 
if freq in(2,3) then halfabn=l; 
else halfabn=0; 
if freq in(3) then qrtabn=l; 
else qrtabn=0; 
format freq frqa.; 
output; 
end;
if measure in ('HR') then do; 
if nh=0 then freq2=l; 
else if 0 < nh <= 3 then freq2=2; 
else if 3 < nh <= 6 then freq2=3; 




proc sort data=outcat out=abp.u&outcat;
by measure drug centre patient time;
run;
proc transpose data=abp.u&outcat out=mult; 




proc sort data=outabn out=abp.u&outabn; 
by measure drug centre patient;
run;
proc sort data=outbase out=abp.u&outbase; 
by measure drug centre patient;
run;
data abp.mhigh&v;
merge mult(keep=measure drug centre patient _0 _l-_24)
abp.u&outabn(keep=measure drug centre patient n halfabn qrtabn freq freq2 nh nl nn) 
abp.u&outbase(keep=measure drug centre patient high); 







PROGRAM: DISCRIM.SAS PROGRAMMER: SHARAYU SHANBHAG DATE: 10-AUG-96A Discriminant Analysis was conducted on the data sets for PCA's (PCAa for drug & PCAh for centre drug)SUMPAT's (Summaries across patients)GRP's (MGRP2 and MGRP3);
• * • * * • * * * • * • • * * • • • • * • • * * * • * • • • • * * * * * * * * • • * • * * • * * * * • • * • * » * * * • * • • * * * * * * * * * * * • * • * * • * * * * * * * • * • /
libname abp '/home/sshanbha/Project/abp/SSDfiles'; 
libname diet '/home/sshanbha/Project/diet/SSDfiles'; 
options pageno=l ps=66 ls=80 nodate;
%macro candisc (anal,c,var,tit);
%macro meas(m,mtit); 




proc candisc data=disc(keep=patient drug &var) outstat=cdiscl distance; 
class drug; 
var &var;





%meas(SBP,Systolic Blood Pressure (rranHg));
%meas(DBP,Diastolic Blood Pressure (mmHg));
%mend candisc;
%candisc(omult_l,od_l,_l-_24,Original Data Before Missing Data Replaced);
%candisc(omult_2,od_2,_l-_24,Original Data After Missing Data Replaced);
%candisc(sumpo_l,os_l,mean median max min ql q3, Summaries of Original Data Before Missing Data 
Replaced); ** 13 obs dropped **;
%candisc(sumpo_2,os_2,mean median max min ql q3. Summaries of Original Data After Missing Data 
Replaced);
%candisc(pca_l,op_l,prinl prin2 prin3 prin4 prin5 prin6 prin7 prin8 prin9 prinlO,PCA on Original 
Data Before Missing Data Replaced);
%candisc(pca_2,op_2,prinl prin2 prin3 prin4 prin5 prin6 prin7 prin8 prin9 prinlO,PCA on Original 
Data After Missing Data Replaced);
%candisc(mgrp3_l,og3_l,GRPl-GRP8,Average Grouped In Threes for Data Before Missing Data Replaced); 
%candisc(mgrp3_2,og3_2,GRPl-GRP8,Average Grouped In Threes for Data After Missing Data Replaced); 
%candisc(sumpg3_l,g3s_l,mean median max min ql q3, Summaries of Average of 3 Data Before Missing 
Data Replaced); ** 13 obs dropped **;
%candisc(sumpg3_2,g3s_2,mean median max min ql q3, Summaries of Average of 3 After Missing Data 
Replaced);
%candisc(mgrp2_l,og2_l,GRPl-GRP12,Average Grouped In Pairs for Data Before Missing Data Replaced); 
%candisc(mgrp2_2,og2_2,GRPl-GRP12,Average Grouped In Pairs for Data After Missing Data Replaced); 
%candisc(sumpg2_l,g2s_l,mean median max min ql q3, Summaries of Average of 2 Before Missing Data 
Replaced); **13 obs dropped **;
%candisc(sumpg2_2,g2s_2,mean median max min ql q3. Summaries of Average of 2 After Missing Data 
Replaced);
%macro candisc (anal,c,var,tit); 
proc sort data=diet.&anal out=disc; 
by group;
run;
proc candisc data=disc(keep=subject group &var) outstat=cdiscl distance; 
class group; 
var &var;
titlel "Discriminant Analysis: &tit"; 




%candisc(omult_l,od_l,_l-_9,Original Data Before Missing Data Replaced);
%candisc(omult_2,od_2,_l-_9,Original Data After Missing Data Replaced);
%candisc(sumpo_l,os_l,mean median max min ql q3, Summaries of Original Data Before Missing Data 
Replaced); ** 13 obs dropped **;
%candisc(sumpo_2,os_2,mean median max min ql q3. Summaries of Original Data After Missing Data 
Replaced);
%candisc(pca_l,op_l,prinl prin2 prin3 prin4 prin5,PCA on Original Data Before Missing Data 
Replaced);
%candisc(pca_2,op_2,prinl prin2 prin3 prin4 prin5,PCA on Original Data After Missing Data Replaced); 
%candisc(mgrp3_l,og3_l,GRPl-GRP3,Average Grouped In Threes for Data Before Missing Data Replaced); 
%candisc(mgrp3_2,og3_2.GRP1-GRP3.Average Grouped In Threes for Data After Missing Data Replaced); 
%candisc(sumpg3_l,g3s_l,mean median max min ql q3, Summaries of Average of 3 Data Before Missing 
Data Replaced); ** 13 obs dropped **;




PROGRAM: LOGISTIC.SAS PROGRAMMER: SHARAYU SHANBHAG DATE: 10-AUG-97
Conducts Logistic Regression on the Data. ******************************•***********************************************************/
libname db ’/home/sshanbha/Project/abp/SSDfiles'; 





proc sort data=db.mhigh_l out=base; 
by measure centre drug ; 
where measure="&m" ;
run;
proc freq data=base noprint; 













proc logistic descending; 
freq count;
model &var = icentre ia ib ic inta intb intc; 
title "Full Model: Atitle &title2";
run;
proc logistic descending; 
freq count;
model &var = icentre ia ib ic / scale=none 
aggregate risklimits; 











PROGRAM: ORIGMOD.SAS Models on the original complete dataset.
f t * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * /
libname abp '-/Project/abp/SSDfiles'; 
libname diet '-/Project/diet/SSDfiles'; 









if time ne 0;
run;







if time ne 0;
run;
/ *
title2 "Sctitle : Original Data"; 
proc mixed data=unil noclprint;
class patient centre time drug;
model value=centre base time drug drug*time;
repeated/sub=patient type=CS;




title2 "&title : Original Data :No centre"; 
proc mixed data=unil noclprint; 
class patient time drug; 
model value=base time drug drug*time; 
repeated/sub=patient type=CS; 
contrast 'G 1 vs G2' drug 1 -1 0 0; 
contrast 'G 1 vs G3' drug 1 0 - 1  0; 
contrast 'G 1 vs G4' drug 1 0 0 -1;
contrast 'G 2 vs G3' drug 0 1-1 0;
contrast 'G 2 vs G4' drug 0 10-1;
contrast 'G 3 vs G4' drug 0 0 1-1;
lsmeans time drug drug*time / alpha=0.05 cl; 
make 'lsmeans' out=abp.ml_&t;
run;
* random int /subject=idno type=UN;
/ *
title2 "&title : After Missing Replaced"; 
proc mixed data=uni2 noclprint;
class patient centre time drug;
model value=centre base time drug drug*time;
repeated/sub=patient type=CS;
lsmeans centre time drug drug*time / alpha=0.05 cl; 
make 'lsmeans' out=&out;
run;
title2 "Sctitle : After Missing Replaced: No Center"; 
proc mixed data=uni2 noclprint; 
class patient time drug; 
model value=base time drug drug*time; 
repeated/sub=patient type=CS; 













if time ne 0;
90
run;






if time ne 0;
run;
title2 "&title : Original Data";
proc mixed data=unil noclprint; 
class subject time group; 
model response=base time group group*time; 
repeated/sub=subject type=CS; 
contrast 'G 1 vs G2' group 1 -1 0;
contrast 'G 1 vs G3' group 1 0 -1;
contrast 'G 2 vs G3' group 0 1 -1;




title2 "&title : After Missing Replaced";
proc mixed data=uni2 noclprint; 
class subject time group; 
model response=base time group group*time; 
repeated/sub=subject type=CS; 





PROGRAM: AVMODEL.SAS Models the Average Reduced Data.This program models data set A after adjusting for centre time and baseline reading also, models data set B after adjusting for time and baseline reading also.Then removes centre and then baseline. ******************************************************************************************,
libname abp '-/Project/abp/SSDfiles'; 
libname diet '-/Project/diet/SSDfiles'; 














titlel 'Model: Adjust for Time and centre for Group 2';
title2 "fctitle";
proc mixed data=unil noclprint;
class patient centre time drug; 
model value=centre time drug drug*time; 
repeated/sub=patient type=UN;
lsmeans centre time drug drug*time / alpha=0.05 cl; 
make 'lsmeans' out=&out;
run;
titlel 'Model: Adjust for Time, Centre and Base for Group 2';
title2 “&title";
proc mixed data=unil noclprint;
class patient centre time drug;
model value=centre base time drug drug*time;
repeated/sub=patient type=UN;




titlel 'Model: Adjust for Time, and Base for Group 2'; 
title2 "&title"; 
proc mixed data=unil noclprint; 
class patient time drug; 
model value=base time drug drug*time; 
repeated/sub=patient type=UN; 
contrast 'G 1 vs G2' drug 1 -1 0 0;
contrast 'G 1 vs G3' drug 1 0 - 1  0;
contrast 'G 1 vs G4' drug 1 0 0 -1;
contrast 'G 2 vs G3' drug 0 1 -1 0;
contrast 'G 2 vs G4' drug 0 10 - 1 ;
contrast 'G 3 vs G4' drug 0 0 1-1;




titlel 'Model: Adjust for Time and centre for Group 3';
title2 "&title";
proc mixed data=uni2 noclprint;
class patient centre time drug; 
model value=centre time drug drug*time; 
repeated/sub=patient type=UN;
lsmeans centre time drug drug*time / alpha=0.05 cl; 
make 'lsmeans' out=&out;
run;
titlel 'Model: Adjust for Time, Centre and Base for Group 3';
title2 "&title";
proc mixed data=uni2 noclprint;
class patient centre time drug;
model value=centre base time drug drug*time;
repeated/sub=patient type=UN;




titlel 'Model: Adjust for Time, Base for Group 3'; 
title2 "&title"; 
proc mixed data=uni2 noclprint; 
class patient time drug; 
model value=base time drug drug*time; 
repeated/sub=patient type=UN; 
contrast 'G 1 vs G2' drug 1 -1 0 0;
92
contrast 'G 1 vs G3' drug 1 0 - 1 0 ;  
contrast 'G 1 vs G4' drug 1 0 0 -1;
contrast 'G 2 vs G3' drug 0 1- 10;
contrast 'G 2 vs G4' drug 0 1 0 -1;
contrast 'G 3 vs G4' drug 0 0 1 -1;












titlel 'Model: Adjust for Time for Group 3'; 
title2 "Diet Data"; 
proc mixed data=uni3 noclprint; 
class subject time group; 
model value=time group group*time; 
repeated/sub=subject type=UN; 




titlel 'Model: Adjust for Base and Time for Group 3'; 
title2 "Diet Data"; 
proc mixed data=uni3 noclprint; 
class subject time group; 
model value=time base group group*time; 
repeated/sub=subject type=UN; 
contrast 'G 1 vs G2' group 1 -1 0;
contrast *G 1 vs G3’ group 1 0 -1;
contrast 'G 2 vs G3' group 0 1 -1;




PROGRAM: KMANAL.SAS PROGRAMMER: SHARAYD SHANBHAG DATE: 10-AUG-97








if high=l then event=l; 
else event=0;
if measure="&m“ and time ne 0 then output;
run;
proc sort data=all;




by drug patient descending event time; 
if event=0 then tos=24; 
else tos=time;




%kmplot(kmtest,surv_p,survtime,drug,treat..DRUG,Time on Study (Hours),0,24,1, 







PROGRAM: CATANAL.SAS PROGRAMMER: SHARAYU SHANBHAG DATE: 10-AUG-97
Produces cross tabulations of categorical data and tests using chisquared tests 
* • * * • • * • * • • • • • » * * * * • * * • • « • * * • • * • • * • * * • • * * * * * • • * * * • * * • • * * • * * • * * • • • * * • » * * • • * • • * * * * • • * » » * * * • * /
libname db '/home/sshanbha/Project/abp/SSDfiles' ; 
options pageno=l ps=66 ls=80 nodate;
INPUTTING THE DATA
%macro data(abn,cat,base,title);
proc sort data=db.&base out=base; 





TITLE1 “TESTS FOR RELATIONSHIP BETWEEN DRUG AND CATEGORIES AT BASELINE"; 
title2 "&title";
run;






















where measure in ('SBP','DBP');






where measure in ('HR');







/ • * » * • • * * * • • * * * • • • * * * • • * * * * • * • • * * * * * • * * * * * * * * * • * • • * * * * * * * * * * * • • * * « • • * • • * * * * • * « • * * * • * • * • * * * * -
PROGRAM: STIMEPLT.SAS 
PROGRAMMER: SHARAYU 
DATE: 10-JAN-Produces Plots of Mean, median, min and max over time for time(0 to 24) for original data and time 1 to 12 for average group 2 and time 1 to 8 for average group 3 for Vital sign data.
libname abp '/home/sshanbha/Project/abp/SSDfiles•; 
libname diet '/home/sshanbha/Project/diet/SSDfiles’; 




%macro graph(drg, lab, fig.app,no, title,data, 12,u2, value,summ, tit2,l,u,b,unit, foot) ;





if measure=“&value" then output;
run;
%end;

















symboll color=black interpol=spline width=0.5 value=dot height=l
symbol2 color=black interpol=spline width=0.5 value=circle height=l
symbol3 color=black interpol=spline width=0.5 value=sguare height=l
symbol4 color=black interpol=spline width=0.5 value=triangle height=l
axisl label=(h=0.2in "TIME &unit“) order=(&12 to &u2 by 1) offsets(2) width=3 csblack;
axis2 labels(hs0.2in angles90 "&title") orders( &1 to &u by &b ) offsets(2) widths3 csblack;
proc gplot datasgraphst;
* titlel csblack hs2.0 "Appendix &app";
* title2 csblack hs2.0 "Figure &fig";
titlel csblack hsl.5 "Plot Of &tit2 Over Time By
title2 csblack hsl.5
plot
/ haxissaxisl vaxissaxis2 hminorsO vminorsO caxis=black frame 







%if &dssl %then %do;
%graph(drug,l,4A,A,A10,HEART RATE (b/m) ,sumto,0,24,HR,mean.
Mean Response Profile,60,95,5, (mins),);
%graph(drug, 1,4B,A,All,HEART RATE (b/m) ,sumto, 0,24,HR,median.
Median Response Profile,60,95,5,(mins),);




%graph(drug, 1, 4A,B,B10,SYSTOLIC BLOOD PRESSURE (mmHg) , sumto, 0, 24, SBP,mean,
Mean Response Profile,115,165,5,(mins),);
%graph(drug, 1,4B,B,B11, SYSTOLIC BLOOD PRESSURE (mmHg) , sumto, 0,24, SBP,median,
Median Response Profile,110,165,5,(mins),);
%graph(drug,1,4C,B,B12,SYSTOLIC BLOOD PRESSURE (mmHg),sumto,0,24, SBP,min.
Minimum Response Profile,80,135,5,(mins),);
%graph(drug,1,4D,B,B13,SYSTOLIC BLOOD PRESSURE (mmHg),sumto,0,24, SBP,max.
Maximum Response Profile,140,205,5,(mins),);
%graph(drug, 1,4A,C,CIO,DIASTOLIC BLOOD PRESSURE (mmHg), sumto, 0,24,DBP,mean,
Mean Response Profile,70,105,5,(mins),);
%graph(drug,l,4B,C,Cll,DIASTOLIC BLOOD PRESSURE (mmHg),sumto,0,24,DBP,median,
Median Response Profile,65,110,5,(mins),);
%graph(drug, 1,4C,C,C12,DIASTOLIC BLOOD PRESSURE (mmHg) ,sumto, 0,24,DBP,min,
Minimum Response Profile,40,90, 5,(mins),);












%if &ds=2 %then %do;
%graph(drug,1,22A,A,A10_l,HEART RATE (b/m),sumtg3,l,8,HR,raean,
Mean Response Profile,60,85,5,GROUP,Mean of 3 hrs) ;
%graph(drug,1,22B,A,All_l,HEART RATE (b/m),sumtg3,1,8,HR,median.
Median Response Profile,60,85,5,GROUP,Mean of 3 hrs);
%graph(drug,1,22C,A ,A12_1,HEART RATE (b/m),sumtg3,1,8,HR,min,
Minimum Response Profile,40,75,5,GROUP,Mean of 3 hrs);
%graph(drug,1.22D,A,A13_l,HEART RATE (b/m),sumtg3,l,8,HR,max,
Maximum Response Profile,80,130,10,GROUP,Mean of 3 hrs);
%graph(drug,1,22A,B,B10_l,SYSTOLIC BLOOD PRESSURE (mmHg),sumtg3,1,8,SBP,mean.
Mean Response Profile,115,165,5,GROUP,Mean of 3 hrs);
%graph(drug,l,22B,B,B11_1,SYSTOLIC BLOOD PRESSURE (mmHg),sumtg3,1,8,SBP,median, 
Median Response Profile,115,165,5,GROUP,Mean of 3 hrs);
%graph(drug,1,22C,B,B12_l,SYSTOLIC BLOOD PRESSURE (mmHg),sumtg3,1,8,SBP,min, 
Minimum Response Profile,80,135,5,GROUP,Mean of 3 hrs);
%graph(drug,1,22D,B,B13_1,SYSTOLIC BLOOD PRESSURE (mmHg),sumtg3,1,8,SBP,max, 
Maximum Response Profile,140,195,5,GROUP,Mean of 3 hrs);
%graph(drug,1,22A,C,Cl0_1,DIASTOLIC BLOOD PRESSURE (mmHg),sumtg3,1,8,DBP,mean, 
Mean Response Profile,70,105,5,GROUP,Mean of 3 hrs);
%graph(drug,l,22B,C,Cll_l,DIASTOLIC BLOOD PRESSURE (mmHg),sumtg3,1,8,DBP,median. 
Median Response Profile,70,110,5,GROUP,Mean of 3 hrs);
%graph(drug,1,22C,C,C12_1,DIASTOLIC BLOOD PRESSURE (mmHg),sumtg3,1,8,DBP,min, 
Minimum Response Profile,45,90,5,GROUP,Mean of 3 hrs);
%graph(drug,1.22D,C,C13_1.DIASTOLIC BLOOD PRESSURE (mmHg),sumtg3,1,8,DBP,max, 
Maximum Response Profile,90,130,5,GROUP,Mean of 3 hrs);
%graph(group,2,22A, D,D10_l,DIETARY RESPONSE,sumtg3,1,3,HR,mean,
Mean Response Profile,0.4,1.0,0.1,GROUP,Mean of 3 hrs);
%graph(group,2,22B,D,Dll_l,DIETARY RESPONSE,sumtg3,1,3,HR,median,
Median Response Profile,0.1,1.0,0.1,GROUP,Mean of 3 hrs);
%graph(group,2,22C,D,D12_l,DIETARY RESPONSE,sumtg3,1,3,HR,min,
Minimum Response Profile,0.4,0.9,0.1,GROUP,Mean of 3 hrs);
%graph(group,2,22D, D,D13_l,DIETARY RESPONSE,sumtg3,1,3,HR,max,
Maximum Response Profile,0.5,1.1,0.1,GROUP,Mean of 3 hrs);
%graph(drug,1,42A,A,A10_2,HEART RATE (b/m),sumtg2,1,12,HR,mean,
Mean Response Profile,60,95,5,GROUP,Mean of 2 hrs);
%graph(drug,1,42B,A,A11_2,HEART RATE (b/m),sumtg2,1,12,HR,median.
Median Response Profile,60,95,5,GROUP,Mean of 2 hrs);
%graph(drug,1,42C,A,A12_2,HEART RATE (b/m),sumtg2,l,12,HR,min,
Minimum Response Profile,40,75,5,GROUP,Mean of 2 hrs);
%graph(drug,1,42D,A,A13_2,HEART RATE (b/m),sumtg2,l,12,HR,max,
Maximum Response Profile,70,180,10,GROUP,Mean of 2 hrs);
%graph(drug,1,42A,B,B10_2,SYSTOLIC BLOOD PRESSURE (mmHg),sumtg2,1,12,SBP,mean. 
Mean Response Profile,115,165,5,GROUP,Mean of 2 hrs);
%graph(drug,1,42B,B,B11_2,SYSTOLIC BLOOD PRESSURE (mmHg),sumtg2,1,12,SBP,median, 
Median Response Profile,115,165,5,GROUP,Mean of 2 hrs);
%graph(drug,1,42C,B,B12_2,SYSTOLIC BLOOD PRESSURE (mmHg),sumtg2,1,12,SBP,min. 
Minimum Response Profile,80,135,5,GROUP,Mean of 2 hrs);
%graph(drug,1,42D,B,B13_2,SYSTOLIC BLOOD PRESSURE (mmHg),sumtg2,1,12,SBP,max, 
Maximum Response Profile,140,195,5,GROUP,Mean of 2 hrs);
%graph(drug,l,42A,C,C10_2,DIASTOLIC BLOOD PRESSURE (mmHg),sumtg2,1,12,DBP,mean. 
Mean Response Profile,70,105,5,GROUP,Mean of 2 hrs);
%graph(drug,l,42B,C,Cll_2,DIASTOLIC BLOOD PRESSURE (mmHg),sumtg2,1,12,DBP,median, 
Median Response Profile,70,110,5,GROUP,Mean of 2 hrs);
%graph(drug,1,42C,C,C12_2,DIASTOLIC BLOOD PRESSURE (mmHg),sumtg2,1,12,DBP,min, 
Minimum Response Profile,45,90,5,GROUP,Mean of 2 hrs);
%graph(drug,l,42D,C,C13_2,DIASTOLIC BLOOD PRESSURE (mmHg),sumtg2,1,12,DBP,max, 






PROGRAM: ABNPLOT.SAS PROGRAMMER: SHARAYU SHANBHAG DATE: 10-JAN-96A set of plots are produced for all data of means and medians of actual data and change from baseline.The frequency of abnormal readings were plotted for each individual patient.
f t * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * /
libname db '/home/sshanbha/Project/abp/SSDfiles'; 




%MACRO PL0T(c,m,no,title,d,tit,n,tn,foot) ; 





























symboll color=black interpol=none width=0.5 value=dot height=l line=l; 
symbol2 color=black interpol=none width=0.5 value=circle height=l line=2;
symbol3 color=black interpol=none width=0,5 value=square height=l line=5;
symbol4 color=black interpol=none width=0.5 value=triangle height=l line=26;
axis2 label=(h=0.2in angle=90 "NUMBER OF &tn RESULTS") order=(0 to 24 by 1) offset=(2) width=3 
c=black;
axisl label=(h=0.2in "PATIENT") order=(l to 50 by 1) offset=(2) width=3 c=black; 
proc gplot data=abn; 
plot &n*id=drug
/ haxis=axisl vaxis=axis2 hminor=0 vminor=0 caxis=black frame ctext=black;
titlel c=black h=2.0 "Number Of &tn Results For Stitle";
title2 c=black h=1.5 "&tit: For Centre &c";
footnote j=l c=black h=1.5 "NOTE: &when &foot";
run;
footnote ' '; 






















1,HR,AAH1,HEART RATE (B/MIN),1,ORIGINAL DATA,nh,Abnormally High,missing data replaced); 
1, HR, AAN1, HEART RATE (B/MIN), 1, ORIGINAL DATA, nn, Normal, missing data replaced);
1, HR, AAL1, HEART RATE (B/MIN), 1, ORIGINAL DATA, nl .Abnormally Low,missing data replaced);
2,HR,AAH2,HEART RATE (B/MIN),1,ORIGINAL DATA,nh,Abnormally High,missing data replaced);
2, HR, AAN2, HEART RATE (B/MIN), 1, ORIGINAL DATA, nn, Normal, missing data replaced);
2, HR, AAL2, HEART RATE (B/MIN), 1, ORIGINAL DATA, nl .Abnormally Low,missing data replaced);
1, SBP, BAH1, SYSTOLIC BP (MMHG), 1, ORIGINAL DATA, nh, Abnormally High,missing data replaced); 
1,SBP,BAN1,SYSTOLIC BP (MMHG),1,ORIGINAL DATA,nn,Normal.missing data replaced);
1, SBP, BALI, SYSTOLIC BP (MMHG), 1, ORIGINAL DATA, nl, Abnormally Low,missing data replaced);
2,SBP,BAH2,SYSTOLIC BP (MMHG),1,ORIGINAL DATA,nh,Abnormally High,missing data replaced); 
2,SBP,BAN2,SYSTOLIC BP (MMHG),1,ORIGINAL DATA,nn,Normal,missing data replaced);
2,SBP,BAL2,SYSTOLIC BP (MMHG),1,ORIGINAL DATA,nl,Abnormally Low,missing data replaced); 
1,DBP,CAH1,DIASTOLIC BP (MMHG), 1,ORIGINAL DATA,nh, Abnormally High,missing data replaced) 
(MMHG),1,ORIGINAL DATA,nn,Normal.missing data replaced);
(MMHG), 1, ORIGINAL DATA.nl, Abnormally Low,missing data replaced); 
(MMHG), 1,ORIGINAL DATA,nh, Abnormally High,missing data replaced) 
(MMHG) ,1,ORIGINAL DATA,nn,Normal.missing data replaced);












PROGRAMMER: SHARAYO SHANBHAG 
DATE: 10-JAN-96Individual patient profiles before and after missing data generated.ft*******************.
libname abp '/home/sshanbha/Project/abp/SSDfiles'; 
libname diet '/home/sshanbha/Project/diet/SSDfiles'; 
options pageno=l;
%macro sub(m,title2);
%macro graph(drg, ther, tm,ds,app, fig, fig2, i,no,no2,m2,data,d, t,u2, t2,value, title, time,grp) ;
%if &ds=l %then %do; 





%else %if &ds=2 %then %do; 






array t{&u2} &t; 




















symboll color=black interpol=stdmj value=none line=l; 
symbol2 color=black interpol=stdmj value=none line=26; 
symbol3 color=black interpol=stdmj value=none line=2; 
symbol4 color=black interpol=stdmj value=none line=34;
axisl label=(h=0.2in "&time") order=(l to &u2 by 1) offset=(2) width=3; 
axis2 label=(h=0.2in angle=90 "&value");
proc gplot data=plot;
* titlel c=black h=2.0 "Appendix &app";
* title2 c=black h=2.0 "Figure &fig";
titlel c=black h=1.5 "Group means and standard errors Over &tm for &value data"; 
title2 c=black h=1.5 "&title"; 
plot value*time=&drg
/ haxis=axisl vaxis=axis2 hminor=0 vminor=0 caxis=black frame ctext=black; 
footnote j=l c=black h=1.5 "Note: &title2";
run;
footnote ' ' ; 





%if &m=l %then %do;
%graph(drug,Treatment,Time,1,A,3,,HR,a9,alO,,omult,l,_0-_24,25,26,Heart Rate (beats/min), Original 
Data,TIME+l (hours),);
%graph(drug,Treatment,Time,1,B,3,,SBP,b9,bl0,,omult,l,_0-_24,25,26,Systolic BP (mm/Hg), Original 
Data,TIME+1 (hours),);
%graph(drug,Treatment,Time,1,C,3,,DBP,c9,cl0,,omult,l,_0-_24,25,26,Diastolic BP (mm/Hg), Original 
Data,TIME+1 (hours),);
%graph(group,Therapy,Time,2,D,3,,,d9,dl0, ,omult, l,_0-_9,10,11,Dietary Response, Original Data,TIME+1 
(hours),groupl);
%end;
%if &m=2 %then %do;
%graph(drug,Treatment,Time,1,A,21,,HR,a9,al0,_1,mgrp3,1,grpl-grp8,8,9,Heart Rate (beats/min),
Average of 3 Time Points,TIME GROUP,);
%graph(drug,Treatment,Time,1,B,21,,SBP,b9,bl0,_l,mgrp3,l,grpl-grp8,8,9,Systolic BP (mm/Hg), Average of 3 Time Points,TIME GROUP,);
%graph(drug,Treatment,Time,1,C,21,,DBP,c9,cl0,_l,mgrp3,1,grpl-grp8,8,9,Diastolic BP (mm/Hg), Average 
of 3 Time Points,TIME GROUP,);
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%graph(group,Therapy,Time,2,D,21,, ,d9,dl0,_l,mgrp3,l,grpl-grp3,3,4,Dietary Response, Average of 3 
Time Points,TIME GROUP,groupl);
%graph (drug, Treatment, Time, 1, A, 38,, HR, a9, alO,_2,mgrp2,1, grpl-grpl2,12,13, Heart Rate (beats/min), 
Average of 2 Time Points,TIME GROUP,);
%graph(drug,Treatment,Time, 1,B,38,,SBP,b9,blO,_2,mgrp2,l,grpl-grpl2,12,13,Systolic BP (mm/Hg), 
Average of 2 Time Points,TIME GROUP,);
%graph(drug,Treatment,Time, 1,C,38, ,DBP,c9,cl0,_2,mgrp2,1,grpl-grpl2,12,13,Diastolic BP (mm/Hg), 
Average of 2 Time Points,TIME GROUP,);
%end;
%mend sub;
%sub(l,Before Missing Data Replaced);




PROGRAMMER: SHARAYU SHANBHAG 
DATE: 10-JAN-96
Box plots before and after missing data generated. 
* * * • • * * • * • * * * • • • » • * * * * • * * * • * * * • * • • * * * • • • * • * * • • • • • * * • • * * * * * • • * * * * • * * * * * • * * • * * * • * * * * » * * * * • * • /
libname abp '/home/sshanbha/Project/abp/SSDfiles'; 




%if &ds=l %then %do; 
data GRAPH1(keep=patient drug &t); 
set abp.&data._&m; 
where drug=&d and measures"&i";
run;
%end;
%else %if &ds=2 %then %do; 







array t{&u2} &t; 



















noprompt; * TO THE GIF FILE **;
symboll color=black interpol=join value=dot line=l;
axisl label=(h=0,2in "&time") order=(l to &t2 by 1) offset=(2) width=3; 
axis2 labels(h=0.2in angles90 "&value");
proc gplot datasplot;
* titlel csblack hs2.0 "Appendix &app";
* title2 csblack h=2.0 "Figure Stfig";
titlel csblack hsl.5 "Plot of Data Over &tm On &ther &d: &value"; 
title2 csblack hsl.5 “Sctitle"; 
plot value*times&drg
/skipmiss haxis=axisl vaxis=axis2 hminorsO vminorsO caxissblack frame ctextsblack nolegend; 
footnote csblack jsl hsl.5 "Note: &title2";
run;
title ' '; 
footnote ' ';
%if fimsl %then %do;












noprompt; * TO THE GIF FILE **;
axisl labels(hs0.2in -stirne") orders(l to &u2 by 1) offsets(i); 
axis2 labels(hs0.2in angles90 "&value");
proc gplot datasplot;
* titlel csblack h=2.0 "Appendix &app";
* title2 csblack h=2.0 "Figure &fig2";
titlel csblack hsl.5 "Box plot of Data Over &tm On &ther &d: &value"; 
title2 csblack hsl.5 "fctitle"; 
plot value * times&drg
101
/ haxis=axisl vaxis=axis2 hminor=0 vminor=0 caxis=black frame ctext=black nolegend; 
symbol ci=black interpol=boxtOO; 
footnotel j=l c=black h=1.5 "Box plots show range, quartiles and median"; 
footnote2 j=l c=black h=1.5 "Note: &title2";
run;
footnote ' '; 






%if &m=l %then %do; ** Original DATA **;
%graph(drug,Treatment,Time,l,A,lA,2A,HR,al,a5, ,omult,l,_0-_24,25,26,Heart Rate (beats/min), Original 
Data,TlME+l (hours),);
%graph(drug,Treatment,Time, 1,A,IB,2B,HR,a2,a6, ,omult,2,_0-_24,25,26,Heart Rate (beats/min), Original 
Data,TIME+1 (hours),);
%graph (drug, Treatment, Time ,l,A,lC,2C,HR,a3,a7,, omul t, 3, _0 -_2 4,2 5,2 6, Hear t Rate (beats /min), Original 
Data,TIME+1 (hours),);
%graph(drug,Treatment,Time, 1,A,ID,2D,HR,a4,a8, ,omult,4,_0-_24,25,26,Heart Rate (beats/min), Original 
Data,TIME+1 (hours),);
%graph(drug,Treatment,Time,1,B,1A,2A,SBP,bl,b5,,omult,l,_0-_24,25,26,Systolic BP (mm/Hg), Original 
Data,TIME+1 (hours),);
%graph(drug,Treatment,Time,1,B,IB,2B,SBP,b2,b6, ,omult,2,_0-_24,25,26,Systolic BP (mm/Hg), Original 
Data,TIME+1 (hours),);
%graph(drug,Treatment,Time,1,B,1C,2C,SBP,b3,b7, ,omult,3,_0-_24,25,26,Systolic BP (mm/Hg), Original 
Data,TIME+1 (hours),);
%graph(drug. Treatment, Time, 1,B, ID, 2D, SBP, b4, b8, ,omult, 4, _0-_24,25,26, Systolic BP (mm/Hg), Original 
Data,TIME+1 (hours),);
%graph(drug,Treatment,Time,1,C,1A,2A,DBP,cl,c5, ,omult,l,_0-_24,25,26,Diastolic BP (mm/Hg), Original 
Data,TIME+1 (hours),);
%graph(drug,Treatment,Time,l.C,IB,2B,DBP,c2,c6, ,omult,2,_0-_24,25,26,Diastolic BP (mm/Hg), Original 
Data,TIME+1 (hours),);
%graph(drug,Treatment,Time, 1,C, 1C,2C,DBP, c3,c7,,omult,3,_0-_24,25,26,Diastolic BP (mm/Hg), Original 
Data,TIME+1 (hours),);
%graph(drug,Treatment,Time,1,C,ID,2D,DBP,c4,c8,,omult,4,_0-_24,25,26,Diastolic BP (mm/Hg), Original 
Data,TIME+1 (hours),);
%graph(group, Therapy,Time, 2, D, 1A, 2A,,dl, d4,, omult, 1,_0-_9,10,11, Dietary Response, Original 
Data,TIME+1 (hours),groupl);
%graph(group,Therapy,Time,2,D,IB,2B, ,d2,d5,,omult,2,_0-_9,10,11,Dietary Response, Original 
Data,TIME+1 (hours),group2);
%graph(group,Therapy,Time,2,D,1C,2C,,d3,d6,,omult,3,_0-_9,10,11,Dietary Response, Original 
Data,TIME+1 (hours),group3);
%end;
%else %if &m=2 %then %do; ** After Data Replaced **;
%graph (drug, Treatment, Grouped Time, 1, A, 21A,, HR, al,,_2, mgrp3,1, grpl-grp8,8,9, Heart Rate (beats/min), 
Grouped Data: Mean of 3 hrs,TIME 
GROUP);
%graph(drug,Treatment,Grouped Time, 1,A,21B, ,HR,a2, ,_2,mgrp3,2,grpl-grp8,8,9,Heart Rate (beats/min). 
Grouped Data: Mean of 3 hrs,TIME 
GROUP);
%graph (drug,Treatment,Grouped Time, 1, A, 21C, ,HR,a3, ,_2 ,mgrp3,3,grpl-grp8,8, 9,Heart Rate (beats/min), 
Grouped Data: Mean of 3 hrs,TIME 
GROUP);
%graph (drug. Treatment, Grouped Time, 1, A, 21D, ,HR,a4, ,_2,mgrp3,4, grpl-grp8, 8,9,Heart Rate (beats/min), 
Grouped Data: Mean of 3 hrs,TIME 
GROUP);
%graph (drug, Treatment, Grouped Time, 1,B, 21A,, SBP,bl, ,_2,mgrp3 ,l,grpl-grp8, 8,9, Systolic BP (mm/Hg), 
Grouped Data: Mean of 3 hrs,TIME GROUP 
, ) ;
%graph( drug, Treatment, Grouped Time, 1,B, 21B,, SBP,b2, ,_2,mgrp3,2,grpl-grp8, 8,9, Systolic BP (mm/Hg), 
Grouped Data: Mean of 3 hrs,TIME GROUP .) ;
%graph( drug. Treatment, Grouped Time, 1, B, 21C, ,SBP,b3, ,_2,mgrp3,3,grpl-grp8,8,9,Systolic BP (mm/Hg), 
Grouped Data: Mean of 3 hrs,TIME GROUP 
. ) ;
%graph (drug. Treatment, Grouped Time, 1,B, 21D,, SBP,b4, ,_2,mgrp3,4,grpl-grp8, 8, 9, Systolic BP (mm/Hg), 
Grouped Data: Mean of 3 hrs,TIME GROUP 
, ) ;
%graph( drug. Treatment, Grouped Time,1,C,21A,,DBP,cl, ,_2,mgrp3,l,grpl-grp8,8,9,Diastolic BP (mm/Hg), 
Grouped Data: Mean of 3 hrs,TIME 
GROUP,);
%graph (drug, Treatment, Grouped Time, 1,C, 21B, ,DBP, c2, ,_2,mgrp3,2 ,grpl-grp8, 8,9,Diastolic BP (mm/Hg), 
Grouped Data: Mean of 3 hrs,TIME 
GROUP,);
%graph (drug, Treatment, Grouped Time, 1, C, 21C, ,DBP, c3, ,_2,mgrp3,3 ,grpl-grp8, 8,9,Diastolic BP (mm/Hg), 
Grouped Data: Mean of 3 hrs,TIME 
GROUP,);
%graph(drug,Treatment,Grouped Time,1,C,21D,,DBP,c4, ,_2,mgrp3,4,grpl-grp8,8,9,Diastolic BP (mm/Hg), 
Grouped Data: Mean of 3 hrs,TIME 
GROUP,);
%graph(group,Therapy,Grouped Time,2,D,21A,,,dl,,_2,mgrp3, l,grpl-grp3,3, 4,Dietary Response, Grouped 
Data: Mean of 3 hrs,TIME GROUP, 
groupl);
%graph(group,Therapy,Grouped Time, 2,D, 2IB,,,d2, ,_2,mgrp3,2,grpl-grp3,3,4, Dietary Response, Grouped 
Data: Mean of 3 hrs,TIME GROUP,
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group2);
%graph(group,Therapy,Grouped Time,2,D,21C,,,d3,,_2,mgrp3,3,grpl-grp3,3,4,Dietary Response, Grouped 
Data: Mean of 3 hrs,TIME GROUP. 
group3) ;
%graph(drug,Treatment,Grouped Time,1,A,41A,,HR,al,,_l,mgrp2,l,grpl-grpl2,12,13,Heart Rate 
(beats/min). Grouped Data: Mean of 2 hrs,TIME 
GROUP,);
%graph(drug,Treatment,Grouped Time,1,A,41B,,HR,a2,,_l,mgrp2,2,grpl-grpl2,12,13.Heart Rate 
(beats/min), Grouped Data: Mean of 2 hrs,TIME 
GROUP,);
%graph(drug,Treatment,Grouped Time,1,A,41C,,HR,a3,,_l,mgrp2,3,grpl-grpl2,12,13.Heart Rate 
(beats/min), Grouped Data: Mean of 2 hrs,TIME 
GROUP,);
%graph(drug,Treatment,Grouped Time,l,A,41D,,HR,a4,,_l,mgrp2,4,grpl-grpl2,12,13,Heart Rate 
(beats/min). Grouped Data: Mean of 2 hrs,TIME 
GROUP,);
%graph(drug,Treatment,Grouped Time,1,B,41A,,SBP,bl,,_l,mgrp2,l,grpl-grpl2,12,13,Systolic BP (mm/Hg), 
Grouped Data: Mean of 2 hrs,TIME 
GROUP,);
%graph(drug,Treatment,Grouped Time,1,B,41B,,SBP,b2,,_l,mgrp2,2,grpl-grpl2,12,13,Systolic BP (mm/Hg), 
Grouped Data: Mean of 2 hrs,TIME 
GROUP,);
%graph(drug,Treatment,Grouped Time,1,B,41C,,SBP,b3,,_l,mgrp2,3,grpl-grpl2,12,13.Systolic BP (mm/Hg), 
Grouped Data: Mean of 2 hrs,TIME 
GROUP,);
%graph(drug,Treatment,Grouped Time,1,B,41D,,SBP,b4,,_l,mgrp2,4,grpl-grpl2,12,13,Systolic BP (mm/Hg), 
Grouped Data: Mean of 2 hrs,TIME 
GROUP,);
%graph(drug,Treatment,Grouped Time, 1,C,41A,,DBP,cl,,_l,mgrp2,l,grpl-grpl2,12,13,Diastolic BP 
(mm/Hg), Grouped Data: Mean of 2 hrs,TIME 
GROUP,);
%graph(drug,Treatment,Grouped Time,1,C,41B,,DBP,c2,,_l,mgrp2,2,grpl-grpl2,12,13.Diastolic BP 
(mm/Hg), Grouped Data: Mean of 2 hrs,TIME 
GROUP,);
%graph(drug,Treatment,Grouped Time,l,C,41C,,DBP,c3,,_l,mgrp2,3,grpl-grpl2,12,13,Diastolic BP 
(mm/Hg), Grouped Data: Mean of 2 hrs,TIME 
GROUP,);
%graph(drug,Treatment,Grouped Time,1,C,41D,,DBP,c4,,_1,mgrp2,4,grpl-grpl2,12,13,Diastolic BP 




%sub(l,Before Missing Data Replaced);
%sub(2,After Missing Data Replaced);
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* * •
HISTPLOT.SASProgrammer: Sharayu Shanbhag Date: 06/JAN/97
Produces Histograms for Each variable mean, median, min, max, gl and q3. Also for overall summaries.
**«/











* format a &form; 
run;
%end;




















patternl value=13 c=black; 
proc gchart data=a;
titlel c=black h=1.5 "Block Charts of Overall &tit Values"; 
title2 c=black h=1.5 "&av";
block a / noheading ctext=black coutline=black caxis=black; 
label a="&tit“;
run;
footnote "Note: &when &f"; 
quit;
footnote ' '; 
title ' ';















titlel c=black h=1.5 "Block Charts of Overall &tit Values by &trt"; 
title2 c=black h=1.5 "&av";
block a / group=&drg noheading ctext=black coutline=black caxis=black ; 
label a= "&tit";
run;
footnote "Note: &when &f"; 
quit;
%mend hist; 
footnote ' '; 
title ' '; 
quit;
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%if &v=l %then %do;
%hist(Treatment,drug,hcl,hc2,sumpo.Base,DBP,Baseline Diastolic BP (mm/Hg),twoe..Missing Data 
Replaced,Original Data,);
%hist(Treatment,drug,hc3,hc4,sumpo,Change,DBP,Change in Diastolic BP (mm/Hg), twoe..Missing Data 
Replaced,Original Data,);
%hist(Treatment,drug,hc5,hc6,sumpo,Mean,DBP,Mean Diastolic BP (mm/Hg),twoe..Missing Data 
Replaced,Original Data,);
%hist(Treatment,drug,hc7,hc8,sumpo,Median,DBP,Median Diastolic BP (mm/Hg), twoe. .Missing Data 
Replaced,Original Data,);
%hist (Treatment,drug,hc9,hcl0,sumpo,Min,DBP,Minimum Diastolic BP (mm/Hg) .onete. .Missing Data 
Replaced,Original Data,);
%hist (Treatment,drug,hell,hcl2, sumpo,Max,DBP,Maximum Diastolic BP (mm/Hg), twote. .Missing Data 
Replaced,Original Data,);
%hist(Treatment,drug,hcl3,hcl4,sumpo,ql,DBP,Lower Quartile Diastolic BP (mm/Hg),twoe..Missing Data 
Replaced,Original Data,);
%hist(Treatment,drug,hcl5,hcl6,sumpo,q3,DBP,Upper Quartile Diastolic BP (mm/Hg),onee..Missing Data 
Replaced,Original Data,);
%hist(Treatment,drug,hcl,hc2,sumpg3,Change,DBP,Change in Diastolic BP (mm/Hg), twoe. .Missing Data 
Replaced,Average of 3 Time Points,_1);
%hist(Treatment,drug,hc3,hc4,sumpg3,Mean,DBP,Mean Diastolic BP (mm/Hg),twoe..Missing Data 
Replaced,Average of 3 Time Points,_1);
%hist(Treatment,drug,hc5,hc6,sumpg3,Median,DBP,Median Diastolic BP (mm/Hg), twoe. .Missing Data 
Replaced,Average of 3 Time Points,_1);
%hist (Treatment,drug,hc7,hc8, sumpg3,Min,DBP,Minimum Diastolic BP (mm/Hg) .onete. .Missing Data 
Replaced,Average of 3 Time Points,_1);
%hist (Treatment,drug,hc9,hcl0,sumpg3,Max,DBP,Maximum Diastolic BP (mm/Hg), twote. .Missing Data 
Replaced,Average of 3 Time Points,_l);
%hist(Treatment,drug, hell,hcl2,sumpg3,ql,DBP,Ql Diastolic BP (mm/Hg),twoe..Missing Data 
Replaced,Average of 3 Time Points,_1);
%hist(Treatment,drug,hcl3,hcl4,sumpg3,q3,DBP,Q3 Diastolic BP (mm/Hg),onee..Missing Data 
Replaced,Average of 3 Time Points,_1);
%hist(Treatment,drug,hcl,hc2,sumpg2,Change,DBP,Change in Diastolic BP (mm/Hg), twoe. .Missing Data 
Replaced,Average of 2 Time Points,_2);
%hist(Treatment,drug,hc3,hc4,sumpg2,Mean,DBP,Mean Diastolic BP (mm/Hg),twoe..Missing Data 
Replaced,Average of 2 Time Points,_2);
%hist (Treatment,drug,hc5,hc6, sumpg2,Median,DBP,Median Diastolic BP (mm/Hg), twoe. .Missing Data 
Replaced,Average of 2 Time Points,_2);
%hist(Treatment,drug,hc7,hc8,sumpg2,Min,DBP,Minimum Diastolic BP (mm/Hg) .onete. .Missing Data 
Replaced,Average of 2 Time Points,_2);
%hist (Treatment,drug,hc9,hcl0,sumpg2,Max,DBP,Maximum Diastolic BP (mm/Hg), twote. .Missing Data 
Replaced,Average of 2 Time Points,_2);
%hist(Treatment,drug,hell,hcl2,sumpg2,ql,DBP,Ql Diastolic BP (mm/Hg),twoe..Missing Data 
Replaced,Average of 2 Time Points,_2);
%hist(Treatment,drug,hcl3,hcl4,sumpg2,q3,DBP,Q3 Diastolic BP (mm/Hg),onee..Missing Data 
Replaced,Average of 2 Time Points,_2);
%end;
%if £cv=2 %then %do;
%end;
%mend perm;
%perm(l,abp);
%perm(2,diet);
%mend when;
%when(_l,Before);
%when(_2,After);
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